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Some practical considerations in the design of multi-arm multi-
stage designs
Jerome Wulff, Nikolaos Demiris
Cambridge Clinical Trial Unit, Cambridge, United Kingdom
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Introduction: In the design of cancer clinical trials, one is often con-
cerned with a number of options in the event that several treatments
are of interest.
Methods: We explore in this work the distinct possibilities when four
treatments are available, one acting as control and three as poten-
tially efficacious alternatives. This design may be embedded within
the context of multi-arm multi-stage (MAMS) trials where one may
select a two- or three-stage design.
Potential Results: We explore the application of such designs, in-
cluding trade-offs between potential gains in the number of pa-
tients with additional stages contrasted with patients “lost” due
to practical considerations such as patients randomised in
dropped arms while waiting for interim analyses and inspection
by an Independent Data and Safety Committee. In addition, in
cancer studies one may focus on the primary end-point using a
time-to-event analysis or a binary outcome by looking at the
probability of (potentially progression-free) survival at a specific,
clinically meaningful, time point. The effect of such choices is ex-
tensively investigated.
Potential Relevance & Impact: We conclude with a discussion of the
available software for MAMS designs and their advantages and dis-
advantages in terms of accuracy.© The Author(s). 2019 Open Access This artic
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The UK plasma based Molecular profiling of Advanced breast cancer
to inform Therapeutic CHoices (plasmaMATCH) Trial: A multiple
parallel-cohort, phase IIa platform trial aiming to provide proof of
principle efficacy for designated targeted therapies in patient
subgroups identified through ctDNA screening (CRUK/15/010)
Sarah Kernaghan1, Laura Moretti1, Lucy Kilburn1, Katie Wilkinson1, Claire
Snowdon1, James Morden1, Iain Macpherson2, Andrew Wardley3,
Rebecca Roylance4, Richard Baird5, Alistair Ring6, Nicholas Turner7,
Judith M Bliss1, on behalf of the plasmaMATCH Trial Management
Group
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Introduction: plasmaMATCH is a novel platform trial which assesses
the potential of circulating tumour DNA (ctDNA) screening to dir-
ect targeted therapies in advanced breast cancer (ABC) patients.
The trial recruited ahead of target and will report initial results
within 3years of first patient first visit demonstrating efficiency of
this design.
Methods: plasmaMATCH is an open-label, multi-centre phase IIa plat-
form trial, consisting of a ctDNA screening component and five paral-
lel treatment cohorts. Patients with an actionable mutation identified
at ctDNA screening are invited to enter Cohorts A-D to receive a tar-
geted treatment matched to the mutation identified (A: ESR1–ex-
tended-dose fulvestrant; B: HER2–neratinib+/-fulvestrant; C&D: AKT1
(or PTEN for Cohort D) –AZD5363+/-fulvestrant). Cohort E was addedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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mutation identified by ctDNA screening to receive olapari-
b+AZD6738. ~1150 patients will be screened, with 195 evaluable pa-
tients entered into cohorts (A–78; B–16; C–16; D–16; E–maximum 69).
Each cohort will be analysed independently. The primary endpoint
for Cohorts A–E is confirmed objective response rate by RECIST v1.1.
Secondary endpoints include clinical benefit rate, progression-free
survival, safety and frequency of mutations identified in ctDNA
screening.
Timing of potential results: Screening for Cohort A closed in March-
2019 and for B-D in April-2019. ctDNA screening and Cohorts A-D re-
sults will be presented in Q4-2019.
Potential relevance & impact: plasmaMATCH is a successfully recruit-
ing platform trial that seeks to determine the efficiency of the dy-
namic trial platform design in providing proof of principle efficacy
for designated targeted therapies. plasmaMATCH also seeks to dem-
onstrate utility of ctDNA as a screening tool for ABC patients, with
the aim of future integration into routine clinical practice. Details of
the novel trial design will be presented with illustrations of trial
innovation and efficiencies. Clinical outcome data will not be
presented.
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Optimising hypothesis tests of efficacy in external pilot trials using
Bayesian statistical decision theory
Duncan T. Wilson, Rebecca E. A. Walwyn, Julia Brown, Amanda J. Farrin
Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
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Introduction: External pilot trials of complex interventions are often
conducted in advance of a definitive trial to assess feasibility and to
inform its design. The efficacy of the intervention is rarely assessed
using a formal hypothesis test since it would have low power, given
the small sample size of a pilot and assuming a conventional type I
error rate (e.g. 0.05). An external pilot not testing efficacy will effect-
ively have a type I error rate of 1, suggesting an infinite preference
for type I errors over type II errors. As such a preference will never
occur in practice, we consider methods for finding the optimal bal-
ance of type I and II error rates in external pilots.
Methods: We consider the problem of determining the sample size
and type I error rate which maximise the expected utility of an external
pilot trial testing intervention efficacy. We introduce a utility function
which accounts for improvement in primary outcome, the cost of sam-
pling, treatment costs, and the decision-maker’s attitude to risk. We
apply the method to the re-design of a pilot trial with a continuous pri-
mary outcome with known standard deviation and where uncertainty
in the treatment effect is quantified using a normal prior distribution.
Timing of potential results: A study of the proposed method’s prop-
erties under a range of values for the utility function and prior distri-
bution parameters is to be completed by August 2019.
Potential relevance and impact: By viewing external pilot trial de-
sign from a Bayesian decision-theoretic viewpoint, we will provide a
method for finding the optimal balance of type I and II error rates in
external pilots. In particular, we will identify in which (if any) settings
the current approach of not assessing efficacy is the optimal course
of action.P-6
Rare Disease Clinical Trials: Using a continuous covariate to
allocate patients in a response-adaptive clinical trial
Holly Jackson
Lancaster University, United Kingdom
Trials 2019, 20(Suppl 1):P-6Introduction: The randomised controlled trial (RCT) is the conven-
tional method used in a clinical trial, as it produces large power.
However, the RCT gives no opportunity to change the treatment allo-
cation probability within the trial. In many rare disease clinical trials,
a large proportion of the patient population is entered into the trial.
Hence, a response-adaptive design can change the probability of
each patient receiving a treatment, to prioritise the health of those
patients within the trial. The aim of these trials is not just to deter-
mine if a new treatment is safe and effective, but also, to treat as
many patients as successfully as possible. Response-adaptive designs
are not often used as they produce a low power and many of them
do not consider the patient’s covariates.
Method: We present a response-adaptive method, using a continu-
ous covariate and a non-parametric regression procedure to allocate
patients to the best treatment for them with varying probability. This
method starts with 0.5 allocation probability to their estimated best
treatment, but increases to 0.9 for the last patient who enters the
trial. We evaluated the method against an RCT using simulations.
Results: This method produces more patient successes than the RCT
in all scenarios. A number of these scenarios involved the best treat-
ment changing depending on the patient’s covariate. In these sce-
narios, we split the trial depending on the patient’s covariate and
calculated the power. The power of this method is at least 82.7% of
the power of the RCT for all scenarios.
Discussion: Future work will include testing this method for many
more scenarios to see in which situations it works best. We would
also like to extend this method to involving multiple covariates (in-
cluding both continuous and binary) to make its use in clinical trials
more realistic.P-7
Introducing the Adaptive designs CONSORT Extension (ACE)
Statement to improve reporting of randomised trials that use an
adaptive design
Munya Dimairo1, Philip Pallmann2, James Wason3,4, Susan Todd5,
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Biggs1, Toshimitsu Hamasaki10, Michael A. Proschan11, John A. Scott12,
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Background: The reporting of adaptive designs (ADs) in randomised
trials is inconsistent and needs improving [1]. Incompletely reported
AD randomised trials are difficult to reproduce and are hard to inter-
pret and synthesise. This consequently hampers their ability to in-
form practice as well as future research and contributes to research
waste. Better transparency and adequate reporting will enable the
potential benefits of ADs to be realised.
Methods: We developed an Adaptive designs CONSORT Extension
(ACE) guideline through a two-stage Delphi process with input from
Trials 2019, 20(Suppl 1):579 Page 3 of 141multidisciplinary key stakeholders in clinical trials research in the
public and private sectors from 21 countries, followed by a consen-
sus meeting [1]. Delphi survey response rates were 94/143 (66%),
114/156 (73%), and 79/143 (55%) in round one, two and across both
rounds, respectively. Members of the CONSORT Group were involved
during the development process.
Results: The resultant ACE checklist is comprised of seven new items,
nine modified items, six unchanged items for which additional ex-
planatory text clarifies further considerations for ADs, and 20 un-
changed items not requiring further explanatory text. The ACE
abstract checklist has one new item, one modified item, one un-
changed item with additional explanatory text for ADs, and 15 un-
changed items not requiring further explanatory text. The ACE
guideline contains minimum essential reporting requirements and it
applies to both frequentist and Bayesian ADs in randomised trials.
Discussion: The intention is to enhance transparency and improve
reporting of AD randomised trials to improve the interpretability of
their results and reproducibility of their methods, results and infer-
ence. We also hope indirectly to facilitate the much-needed know-
ledge transfer of innovative trial designs to maximise their potential
benefits.
Reference
[1] Dimairo et al. Development process of a consensus-driven CONSORT ex-
tension for randomised trials using an adaptive design. BMC Med.
2018;16(1):210P-8
The PITHIA trial: a stepped wedge, cluster randomised, registry
based national trial with economic evaluation
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Introduction: The Pre-Implantation Trial of Histopathology In renal
Allografts (PITHIA) will assess whether a national, 24-hour, digital
histopathology service increases the number, and improves out-
comes, of kidneys transplanted in the UK from older deceased
donors.
Methods: PITHIA is a stepped-wedge cluster randomised study, in-
volving all UK adult kidney transplant centres. At 4-monthly intervals,
a group of randomly selected centres will be given access to urgent
histopathology: centres can request biopsies of kidneys from donors
aged over 60, as required. Biopsies are reviewed by specialist renal
histopathologists, who provide a Remuzzi score showing the extent
of chronic damage. The score provided may be used by centres to
decide whether and how the kidney may be used. The trial is open,
and it is anticipated that over 2000 kidneys will be eligible during
the 24-month trial duration.
Results: The trial has two primary end points: proportion of primary
kidney offers transplanted and kidney function 12 months post-
transplant. The trial will be analysed using mixed effects models
allowing for clustering within centres and adjusting for secular
trends. Results will inform a decision-model based economic evalu-
ation to determine whether it is cost-effective.
The trial is registry based; hence the majority of the data can be
drawn from the UK Transplant Registry (UKTR) held by NHS Blood
and Transplant. The UKTR collects survival and covariate data on all
patients undergoing transplantation. The design allows patients to
be followed up using only data that is collected routinely. Only oneadditional data collection form is required, to record and report the
histopathology information to the requesting centre.
Conclusion: The PITHIA trial is using a stepped-wedge design to in-
clude all centres in an evaluation of a new service. The registry based
design is novel in transplantation, and is low cost to implement with
high levels of data completeness.
P-9
Issues in the design, analysis, and reporting of factorial trials: a
review
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Jairath5, Douglas Altman6
1LSHTM, London, United Kingdom; 2Queen Mary University of London,
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4Schulich School of Medicine and Dentistry, Ontario, Canada; 5University
of Western Ontario, Ontario, Canada; 6Centre for Statistics in Medicine,
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Introduction: Factorial designs can allow efficient evaluation of mul-
tiple treatments within a single trial. We report the quality of the de-
sign, analysis, and reporting in a sample of factorial trials.
Methods: A 6-person team from the UK, Australia and Canada
reviewed 2x2 factorial trials evaluating health-related interventions
and outcomes in humans. Using MEDLINE, we identified articles pub-
lished between January 2015 and March 2018. We randomly selected
100 articles for inclusion.
Results: Few trials (22%) provided a rationale for using a factorial de-
sign. Only 63 trials assessed interaction for the primary outcome, and
only 39/63 (62%) made a further assessment for at least one second-
ary outcome. 12/63 trials (19%) identified a significant interaction for
the primary outcome, and 16/39 trials (41%) identified a significant
interaction for at least one secondary outcome. Inappropriate
methods of analysis to protect against potential negative interaction
effects were common, with 18 (18%) of trials choosing an analysis
method based on a preliminary test for interaction, and 13% (n=10/
75) of authors conducting a factorial analysis including an interaction
term in the model.
Conclusions: Reporting of factorial trials was often suboptimal, and
assessment of interactions was poor. Investigators often used in-
appropriate methods of analysis to try to protect against adverse ef-
fects of interactions. The CONSORT Group (Consolidated Standards of
Reporting Trials) has developed guidelines to alleviate problems aris-
ing from inadequate reporting of RCTs. The results of this review sug-
gest items of the CONSORT statement that can be extended for
factorial trials.
P-10
Designing a multi-arm multi-stage trial in progressive multiple
sclerosis
Baptiste Leurent1, Frederik Barkhof2, Olga Ciccarelli2, Arman Eshaghi2,
Emma Gray6, Vivien Li5, Jennifer Nicholas1, Nigel Stallard3, James Wason4,
Fay Cafferty, Jeremy Chataway2,5
1London School of Hygiene and Tropical Medicine; 2University College
London; 3University of Warwick; 4Newcastle University; 5University
College London Hospitals; 6MS Society
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Introduction: Multiple sclerosis affects more than 100,000 people in
the UK, with few effective treatments for the progressive stage of the
disease (PMS). Multi-Arm Multi-Stage (MAMS) trials may accelerate
treatment discovery in PMS, as done with success in other disease
areas. MAMS are adaptive trials characterised by multiple experimen-
tal arms, and multiple interim analyses, where treatments with insuf-
ficient indication of efficacy are discontinued. MAMS designs can
provide efficiencies, particularly in terms of duration and sample size,
but their preparation is more complex.
The aim of this research was to explore designs for a feasible and ef-
ficient MAMS trial in PMS.
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rophy) and final outcome (e.g. time to disability progression). Data
from earlier PMS trials were used to determine parameters such as
the association between the outcomes. We explored different design
options, including choices for interim and final outcomes, timing of
interim analyses, and stopping rules. Under each scenario, trials were
simulated and operating characteristics (sample size, duration, type-I
and type-II error rates) graphically displayed.
Timing of Potential Results: Simulations are ongoing and will be
completed by August 2019. Simulations have been informed by ana-
lysis of two-phase II trials but will be refined with results from on-
going analysis of several larger phase III trials. Preliminary results
suggest that multiple interim analyses could be beneficial to better
balance the trade-off between stopping ineffective treatments early
and the risk of missing effective ones.
Discussion: Designing a MAMS trial presents several complexities. To
date simulations are key to inform decisions such as the appropriate
outcome and time-point for the interim analyses. The findings will in-
form the optimum trial design to maximise the chance of identifying
effective treatments for PMS and should be instructive in trial design
in other neurodegenerative diseases such as dementia.P-11
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Protocol for a pragmatic cluster randomised controlled trial
assessing the clinical effectiveness and cost effectiveness of
electronic risk-assessment tools for cancer for patients in general
practice (ERICA)
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Antonieta Medina-Lara2, Martin Pitt2, Elizabeth Shepard2, Fiona Warren2,
Sarah Dean1,2, Willie Hamilton2
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Introduction: Compared with other developed countries, the UK has
poorer cancer outcomes. Early cancer diagnosis within general practice has
the potential to facilitate improvements. Paper and mouse mat Risk Assess-
ment Tools (RATs) for 18 cancers have been developed to support GPs in
identifying cancer. The RATs give precise estimates of the risk of an under-
lying cancer based on a single symptom or combination of symptoms.
Some of the RATs have been converted into electronic versions (eRATs)
and embedded into GPs’ clinical systems, delivering an automated prompt
to consider the possibility of cancer when a patient has at least a 2% risk of
cancer. Early pilot work suggests that the eRATs are acceptable to GPs.
There is no evidence to date of their clinical- or cost-effectiveness.
Methods: A pragmatic, cluster RCT with 530 practices across England ran-
domised 1:1 to receive either the intervention (access to the eRATs medical
device including: lung, oesophago-gastric, kidney, bladder, ovarian, colorec-
tal) or usual practice. There will also be embedded process and health eco-
nomics evaluations along with a parallel study modelling the impact of
eRATs on NHS service delivery. Clinical outcomes will be observed in rou-
tinely collected data exported from the cancer registry. The primary out-
come will be the proportion of the combined six cancers diagnosed during
a 2-year follow-up that were at Stage 1/2 (early – cure likely) versus Stage
3/4 (late – cure not likely) at the time of diagnosis. Ethics approval and trial
registration will be sought in the early spring 2019. Practice recruitment is
planned to launch in summer 2019 and close in winter 2019.
Results: Results will be available from winter 2023.
Discussion: The results of the RCT will provide a definitive assess-
ment of the clinical- and cost-effectiveness of the six eRATs being
studied and report their impact on patient care.P-13
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Introduction: Perinatal mental health problems affect up to 1 in 5
women worldwide and affect not only the mother but can also have
long-term adverse effects on her child. It is thus of high priority to
develop new low-cost, low-resource, non-stigmatising and culturally
appropriate approaches to reduce symptoms of anxiety and depres-
sion perinatally.
Methods: We have worked to test the feasibility of undertaking a
stepped wedge trial to examine how group singing could be benefi-
cial in alleviating perinatal mental distress in The Gambia. Women in
the intervention participated in weekly singing sessions, led by local
Kanyeleng singing groups, for six weeks while the control group re-
ceived standard care. Symptoms of anxiety and depression were
measured using self-report questionnaires. The feasibility of the de-
sign was assessed through recruitment, retention and attrition rates
of participants, clinic’s adherence to the schedule and completeness
of data by site. Qualitative interviews and video and audio recordings
were used to evaluate the acceptability of the intervention.
Timing of Potential Results: We will have the final results of this trial
by the end of May 2019.
Potential Relevance & Impact: When running a trial in a low re-
source context different challenges are present, such as lack of infra-
structure and technology, low literacy rates, and different cultural
expectations, as well as affordances, such as high levels of willing-
ness to help and the ability to quickly affect policy. In this presenta-
tion, we will discuss how the design of the trial was planned and
how the implementation of this design was achieved. This trial's find-
ings will allow us to investigate the use of music as a potential inter-
vention for perinatal mental health in The Gambia as well as discuss
different methodological techniques which can be applied to low
and middle-income countries.P-14
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Move-It動起來: Digital worksite exercise in China - outcome and
process evaluation
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Introduction: Developing strategies to promote exercise is a major
health priority in China. Integrating exercise within the working day
may benefit employee health, although workplace interventions are
less commonplace in China. We evaluate the outcomes and
Trials 2019, 20(Suppl 1):579 Page 5 of 141processes of a video and web-based worksite exercise intervention
for sedentary office workers in China.
Methods: Participants were recruited from an insurance information
technology service organisation with sites in two major cities in
China. A theoretically informed digital workplace intervention (Move-
It 動起) involving a 10-minute Qigong exercise session (video demon-
stration via website) was delivered twice a day at set break times
during the working day for 12 consecutive weeks. The outcome
study was a cluster-randomised wait-list control trial with outcomes
assessed in two groups (intervention, n = 143; wait-list control, n =
73). Process evaluation was conducted using the RE-AIM framework:
reach, effectiveness, adoption, implementation and maintenance.
Data from employee exercise logs, six focus groups with employees
and managers, and analysis of documents including employee pro-
files and promotional materials were examined.
Results: Employees’ physical activity increased from baseline to post-
intervention in both the intervention and control group, though the
magnitude of change failed to reach statistical significance. There
were no changes in job performance or weekday sitting hours.
Process evaluation showed that the intervention had wide reach and
was successfully marketed to all employees with good uptake. The
participatory approach increased perceived organisational support
and enhanced adoption. The intervention was implemented broadly
as planned, with employee enthusiasm for long-term maintenance
but no concrete plans in place at study sites.
Discussion: Qigong worksite exercise intervention can be successfully
delivered to sedentary office workers in China using video and web-
based platforms and may increase physical activity although further
outcome trials are required. The study highlights the complexity of
conducting health research in real-world organisational settings.
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Improving engagement in a health app: considerations in
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Introduction: Health systems are undergoing a digital revolution,
with recent developments seeing therapeutic apps emerging as pre-
scribed treatments. However, a common barrier to the therapeutic
app’s effectiveness is sustaining user engagement. One feature to in-
crease user engagement is with push notifications, which are mes-
sages sent to the user from the app.
This research focuses on Drink Less, a digital therapeutic app which
is a complex intervention that aims to help users reduce harmful and
hazardous alcohol drinking. The app includes five different thera-
peutic components and sends a daily push notification at 11am.
Methods: Observational data comprises of 25,083 users of 1,108,102 ses-
sions between May 2017 and January 2019. We are exploring patterns of
use and engagement with the app through descriptive statistics, graphical
summaries and cluster analyses. Results from this exploratory analyses will
inform the design of a Micro-Randomised Trial (MRT) which aims to under-
stand the effect of new push notifications as time-varying treatments.
The MRT objective is to optimise the delivery of notifications to increase
user engagement by tailoring the message content and timing of delivery
to baseline characteristics. Following the randomisation of a notification,
our outcome will be time spent on the app (seconds) during the next hour.
Timing of potential results: Exploratory analyses of current patterns of
use will be finalised at the end of May 2019. The Micro-Randomised Trial
protocol will be finalised by the end of August 2019.
Potential relevance and impact
The results will be generalizable to other behaviour change thera-
peutic apps. This reflects good practice of learning from real world
use and brings transparency to the app-developing process which is
often considered a ‘black-box’. To date, this will be the largest Micro-
Randomised Trial undertaken, providing insights to shared experi-
ences, challenges and solutions of clinical trials for developing digital
therapies.P-18
Issues with missing data in trials of complex interventions: Using
therapy non-compliance, we demonstrate a framework for
assessing how to deal with the potential bias caused by missing
data, a systematic way of determining which pre-/post-
randomisation variables predict missingness in final outcomes and
assess the need for multiple imputation
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Introduction: The ACTIB trial [1] followed 558 participants randomly
assigned to either telephone delivered CBT (TCBT), web-based CBT
(WCBT) in addition to treatment as usual (TAU) or TAU alone. Binary
compliance was defined differently for TCBT and WCBT and not
assessed for TAU. Therapy non-compliance (primary outcome com-
pletion) was for TCBT, WCBT and TAU respectively; 16% (73%) , 31%
(67%) and undefined (70%).
Methods: We intended to analyse the primary outcomes using longi-
tudinal linear mixed modelling, a method robust to missing data as-
suming that the mechanism driving missingness was missing at
random (MAR), and valid if all potential predictors of missingness
have been collected pre-randomisation and incorporated into the
analysis model.
Non-compliance with therapy, determined by an independent
statistician, was found to be predictive of missing data in both
therapy arms (Fisher’s exact tests p<0.001) invalidating the MAR
assumption. We therefore employed MI to accommodate MAR
process which includes a post-randomisation variable predicting
missingness.
We used a three-step framework (described in detail in [1]);
1.Assess empirically what baseline variables predict missingness
using a stepwise forward selection procedure to identify important
predictors
2.Empirically assess whether post-randomisation variables predict pri-
mary outcome missingness, e.g. therapy compliance. If true then do
step 3,
3.Use MI including all variables identified in steps 1 and 2 in the im-
putation step of the procedure.
Results: Imputation resulted in more conservative trial arm differ-
ences comparing therapy arms individually with TAU. The attenu-
ation was more pronounced in the WCBT arm which imputed more
missing values. This suggests that MI analyses allowing non-
compliance to predict later drop can help remove missing data
biases.
Discussion: MI can be used where post-randomisation variables such
as compliance predict missing outcomes. Variables allowed to drive
missingness under a MAR assumption should be assessed
systematically.
P-19
Outcome selection and reporting for innovative surgical
procedures and devices: a review of current practice in IDEAL/
IDEAL-D studies to inform the development of a core outcome set
Rhiannon Claire Macefield1, Nicholas Wilson1, Kerry NL Avery1, Shelley
Potter1,2
1Bristol Centre for Surgical Research, Bristol Medical School: Population
Health Sciences, University of Bristol, Bristol, United Kingdom; 2Bristol
Breast Care Centre, North Bristol NHS Trust
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Introduction: Evaluation and reporting of innovative surgical proce-
dures and devices has historically been poor. Development of a core
outcome set (COS); generic domains to be measured and reported in
all studies of surgical innovations, may help to improve safe and
transparent evaluation for their introduction into clinical practice.
Methods for identifying outcomes for COSs for effectiveness studies
are well established, however, these are unlikely to encompass out-
comes relevant to innovation.
Trials 2019, 20(Suppl 1):579 Page 6 of 141The IDEAL (Idea, Development, Exploration, Assessment and Long-
term monitoring) framework provides a pathway for evaluating surgi-
cal innovations. This targeted review examined outcome selection
and reporting in self-identified IDEAL studies to identify current prac-
tice and inform conceptualisation of domains for a COS.
Methods: Electronic database searches for articles citing key IDEAL
publications was undertaken. Records with ‘IDEAL’ in the title/ab-
stract were selected and screened for eligibility. Excluded were sys-
tematic reviews, secondary studies, letters/editorials and studies not
including humans or surgery. Data were extracted from full-text pub-
lications with outcomes extracted verbatim. Descriptive study charac-
teristics including detail on outcome selection and reporting were
summarised. Outcomes were reviewed by the study team and itera-
tively grouped into domains.
Results: of 786 records citing key IDEAL papers, 98 (12%) stated
‘IDEAL’ in the title/abstract. Some 29 (30%) eligible studies (24 re-
ports, 5 protocols) were included. Studies self-identified as IDEAL
stage 1 (n=10), 2a (n=8), 2b (n=5), 3(n=1), multiple stages (n=4) or
not stated (n=1). Detail on outcome selection and reporting varied
considerably across studies. Over 1000 verbatim outcomes were
grouped into 30 domains with several unique to innovation (e.g.
modifications to procedures/devices; surgeon’s experiences).
Conclusion: This review further highlights the need to standardise
outcome selection and reporting in studies of surgical innovations.
Findings have informed a Delphi survey to reach consensus on a
COS and reporting guidelines to promote standardised, transparent
outcome reporting for safe evaluation.P-20
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Background: Complexities associated with delivering surgical inter-
ventions, such as clustering effects, by centre or surgeon, and surgi-
cal learning, should be considered at trial design. This work aims to
provide insight into current practice in the management, and ac-
knowledgement, of these considerations during the development of
randomised surgical trials.
Methods: The cohort searched comprised funded applications, within
a four year period, from the National Institute of Health Research
Health Technology Assessment and Efficacy and Mechanism Evalu-
ation funding streams. Data were extracted on considerations for
learning and clustering effects and the driver, funder or applicant,
behind these.
Results: Fifty applications were eligible. Managing learning
through establishing pre-defined centre and surgeon credentials
was common. Few applications also planned exploratory analysis
of learning within centre (n=1), and surgeon (n=2) specifically.
Clustering, by centre and surgeon, was commonly managed
through stratifying randomisation, with the majority also planning
to subsequently adjust the main analysis (81% for centre strati-
fied and 60% surgeon stratified). One-third of responses to ref-
erees contained funder led changes in support of learning and/or
clustering consideration.
Discussion: This review indicates that researchers are familiar with
the need to do consider the impact of learning and clustering, by
centres and surgeon, at trial outset. Furthermore, the funder isidentified as a potential driver of considerations. Early consideration
of these complexities at trial design will ensure that future trials do
not have the same shortfalls as the past.
P-21
Successful collaboration between a Clinical Trial Unit (CTU) and the
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Introduction: PIVOTALboost is a multicentre phase III trial which tests
pelvic nodal irradiation and focused dose-escalation (with high dose-
rate brachytherapy (HDR) or intensity modulated radiotherapy (IMRT)
to a boost volume) in the treatment of localised prostate cancer. The
complex radiotherapy treatment requires close liaison between the
clinical investigators, CTU and the National RTTQA group to minimise
deviations from the trial protocol to ensure integrity of trial out-
comes. The radiotherapy techniques used within PIVOTALboost were
not routine standard of care for all centres and their implementation
required a change in practice.
Methods: Radiotherapy treatment was accredited using outlining
and planning benchmark cases for focal boost and pelvic node treat-
ment and radiotherapy quality assurance (RTQA) guidelines were
made available. The benchmarks were sent to participating sites for
completion prior to a pre-launch, face-to-face training workshop
where experience was shared and tailored feedback given. Agree-
ment was sought between the RTTQA group and CTU on a priority
list of centres to open, based on their trial approval progress. Tele-
conferences were held every 2 weeks between the CTU and RTTQA
group and issues or problems were escalated between each team
and the priority list amended as necessary.
Results: The workshop was well attended with 59 participants from
26 sites (21 sites had managed to submit their benchmark cases for
prior review). Regular communication between the CTU and RTTQA
group meant that resources were effectively managed with both
teams working on an agreed priority centre list. Within the 1st year
of PIVOTALboost opening to recruitment, 24 centres were open, and
237 patients had been recruited.
Discussion: It is proposed that to meet trial milestones close collabor-
ation between the CTU, RTTQA team and clinical investigators is needed.
This includes managing the pre-trial RTQA schedule and this should con-
tinue throughout patient recruitment, follow-up and analysis.
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Trials 2019, 20(Suppl 1):579 Page 7 of 141Background: In PIVOTALboost (ISRCTN80146950) localised prostate
cancer patients receive standard prostate intensity modulated radio-
therapy (IMRT) (A); standard IMRT plus pelvic node IMRT (B); standard
IMRT plus prostate boost (C); or standard IMRT plus pelvic node IMRT
and prostate boost (D). Allocation to boost arms C and D depends
on patient eligibility and having a suitable tumour volume, and boost
technologies being available at site. Power was therefore reduced for
the boost comparisons, so the overall population will be split 9:9:8:8
across arms. During design, recruitment simulations led to an initial
allocation ratio of 2:2:3:3 to counteract early imbalances, with plans
to change to 1:1:1:1 after 12-18 months. We assumed 80% patients
would have suitable tumour volume, 5% would be ineligible for
boost, and sites could open to 2-arm randomisation (AvB) but would
change to 4-arm randomisation once boost technologies were imple-
mented at site. Simulations indicated 30% patients would be allo-
cated via 2-arm randomisation by 18 months.
Methods: Design simulations assumptions are compared to data
available after 16 months of recruitment and updated to estimate
end of recruitment.
Results: To 1st May 2019, 386 patients have been randomised from
31 sites: 132 (A), 131 (B), 61 (C) and 62 (D). Overall, 66% had suitable
boost tumour volume, 31% were ineligible for boost, and 47% have
entered via the 2-arm AvB randomisation. Technical challenges such
as use of fiducials or new planning methods are reported to be de-
terring centres to allocate patients to the 4-arm randomisation.
Discussion: Changing allocation ratio to 1:1:1:1 is now not appropri-
ate, as it would increase imbalance between arms. Simulation of re-
cruitment is a useful tool both to design and monitor recruitment
projections. Assumptions and simulations should be updated as the
trial progress to optimise the likelihood of achieving target numbers
in an efficient manner.
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The HI-Light trial: facilitating at home self-delivery of narrowband-
UVB (NB-UVB) light therapy for people with vitiligo
Garry Meakin1, Rachel Haines1, Jonathan Batchelor2, Kim Thomas2,
Jennifer White1, Joanne Chalmers2, Paul Leighton2
1Nottingham Clinical Trials Unit, University of Nottingham, Nottingham,
United Kingdom; 2Centre of Evidence Based Dermatology, University of
Nottingham, Nottingham, University of Nottingham
Trials 2019, 20(Suppl 1):P-23
Introduction: Vitiligo is a dermatological condition causing loss of pig-
ment on affected areas of the skin. Management includes narrowband-
UVB (NB-UVB) light therapy, however this is reserved for widespread
vitiligo and is only available in secondary care, requiring regular hos-
pital visits.
The HI-Light trial evaluated handheld NB-UVB light therapy at home
for early/limited vitiligo. Treatment carried potentially severe adverse
events (AEs), including burns.
Methods: For safety, a training package was designed to ensure par-
ticipants were able to (1) administer the intervention (2) identify AEs,
(3) take appropriate action in response to AEs.
‘Train the trainer’ training took place at site initiation visits. Participant
training at baseline lasted on average 1 hour, focused on treatment ad-
ministration and AE detection and was further reinforced by a take-
home training DVD and participant handbook. The handbook included
(1) treatment instructions, (2) treatment schedule, (3) description of
AEs, (4) AE management guidance, (4) contact information.
Participants received a telephone call two weeks post-randomisation
and were encouraged to contact the research team at any time over
the 9 month treatment period with questions or concerns. Partici-
pants were reviewed face to face at 3, 6 and 9 months. Participant
interviews, part of a process evaluation, covered topics relating to
training and intervention use.
Results: 517 participants were randomised into the trial. There were
no treatment related serious AEs and all reported AEs were managed
effectively. Nurses were confident in delivering training. Participants
had a good understanding of how to use the light device, felt
confident and adhered well. The support from nurses when dealingwith side-effects was highly valued and no major issues with using
the devices were uncovered.
Discussion: With appropriate training, an intervention that carries a
high risk of side effects if not undertaken properly, can be adminis-
tered at home by the participant, safely and effectively.P-24
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Background: In cluster randomised trials, clusters of participants such
as practices are randomised rather than individuals, with the inter-
vention aimed at the cluster level. Blinding can be difficult, increas-
ing the risk of selection or performance bias or contamination
between arms.
The UK primary care landscape is changing, with cross-networking at
all levels from Clinical Commissioning Groups to practice federations.
The level and complexity of the networks varies from linked to fully
merged practices, sharing resources such as management, health
professionals and specialised services.
This changing landscape has implications for cluster definition and
strategies for managing blinding and contamination.
Methods: We will present the process of cluster selection in two
primary care trials. ASPIRE is an audit and feedback trial. PROSPER
is a feasibility study of an intervention aimed at supporting older
people, findings will be used to inform definitive trial design and
methods. General practice was defined as the unit of
randomisation.
Results: ASPIRE defined a practice as a cluster, unless a full merger
was planned. PROSPER undertook a more detailed assessment of
shared resources as part of site selection. Only 5/13 practices were
considered sufficiently independent to be a standalone cluster.
Reasons for grouping practices into clusters included a planned mer-
ger during trial period and sharing of practice managers. Sharing of
staff and training sessions across linked practices was common.
Discussion: The level and complexity of networking in primary care
has implications on the extent of blinding to allocation, but impact
depends on the nature of the intervention. The feedback interven-
tion in ASPIRE was less affected but PROSPER attempted to manage
potential contamination by adjusting the cluster size. Methods of
managing contamination in cluster trials may need to evolve with
networking arrangements in primary care and be tailored to inter-
vention characteristics.P-25
A review of the use of theoretical and implementation frameworks
in trials of complex interventions
Lorelei Jones, Paul Brocklehurst
University Of Bangor, Bangor, United Kingdom
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Introduction: Understanding how and why a complex intervention
works in a trial setting is crucial to determining if the results will be
replicated in a specific context. A number of theoretical frameworks,
such as Normalisation Process Theory, Theoretical Domains Frame-
work, and Promoting Action on Research Implementation (PARiHS)
have been developed that could potentially be used in intervention
and trial design to understand the range of factors that influence
adoption and impact. The aim of this study is to review the use of
theoretical and implementation frameworks in trials of complex
interventions.
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were sampled from guidelines produced by the UK National Institute
for Health and Care Excellence (NICE). The full text of journal articles
reporting the trial findings were retrieved and read to assess the ex-
tent to which the trial employed implementation frameworks or
theory.
Timing of potential results: The importance of context is widely ac-
knowledged, and both implicit and explicit theory is evident in inter-
vention design (e.g. by incorporating education for clinicians), however
so far, we have found no examples that use frameworks in the design
of the trial itself. In discussing trial results authors would speculate
about the influence of context, however evidence was restricted to in-
formal feedback from participants, or reference to findings from a small
number of qualitative studies in the broader literature.
Potential relevance and impact: Although largely absent from trial
design, understanding barriers and facilitators of implementation,
and using this evidence to make recommendations for practice, was
a key concern of NICE guideline development groups (and they used
theoretical frameworks to support this). Using theoretical frameworks
in trial design could help provide important evidence on what is
needed for interventions to be effective in real-world settings and
support the work of translating findings into recommendations for
practice.P-26
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How do we optimise approach and recruitment strategies for
inclusion of people with dementia in primary care clinical trials?
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Trials 2019, 20(Suppl 1):P-27
Introduction: The DPACT-Dementia Support Study aims to evaluate
the effectiveness of a primary care-based person-centred dementia
support intervention. One of the challenges is recruiting people diag-
nosed with a dementia, who may also be living with frailty and emo-
tional difficulties, and who live alone or lack an extended support
network into clinical trials. Previous primary care-based trials have
struggled to recruit such individuals, who may respond least well to
written material, yet have the potential to benefit most from the
intervention. Our aim is to test key uncertainties in relation to trial
science including recruitment issues and inclusion/exclusion criteria
in a Feasibility Study the learning form which will inform process for
larger cluster randomised control trial.
Methodology: Our strategy involves testing the applicability of clin-
ical research network staff in the identification of participants from
GP registers. Our recruitment process designed to be person centred
and flexible will then test the effectiveness of an Opt-In approach for
potential participants in response to invitation form GP practice. A
positive response initiates a pathway, with a series of exclusion
points, of combined letters, phone calls and face-to-face meetings as
appropriate. For those who do not respond to any opportunity along
the chain, clinical follow-up will be arranged through the GP practice,
to allow identification of hitherto unknown clinical or social needs.
The approach follows MCA 2005 recommendations where opinion
from personal or nominated consul tee would be sought should an
individual with dementia lack capacity to consent.
Timing of Potential Results: The results from Feasibility Study will in-
form cluster RCT due to commence in August 2020.Potential Relevance & Impact: Inclusion of clinical research network
staff and optimisation of recruitment strategies has the potential to
overcome practical implications of inclusion of under-served popula-
tions in primary care based clinical trials.
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Introduction: Randomised controlled trials (RCTs) in surgery are fre-
quently criticised because surgeon expertise and standards of sur-
gery are not considered or accounted for during study design. We
developed and tested quality assurance (QA) measures for use within
a predominantly pragmatic surgical RCT comparing minimally inva-
sive and open techniques for oesophageal cancer (the NIHR ROMIO
study).
Methods: Three types of QA measure were developed, and their
feasibility established during the study: (i) entry criteria for surgeons,
(ii) standardisation of operative techniques (by establishing key pro-
cedural phases) and (iii) monitoring of intervention fidelity during
the trial, using intraoperative photography to document adherence
to the key procedural phases.
Results: Surgeons each submitted two unedited video recordings of
oesophagectomy (n=64), which were each assessed by two surgeons
using the validated OSATS tool. Standardization of operative tech-
niques was undertaken by deconstructing oesophagectomy and con-
sideration of the components that should be delivered identically
(n=4) and differently (n=2) between minimally invasive and open sur-
gery. Monitoring of intervention fidelity was achieved by collecting
digital photographs (n=1710) onto a bespoke online platform devel-
oping a tool to assess whether the six key operative phases had
been delivered as intended.
Conclusion: The QA methods we have developed are practical to use
in surgical RCTs, to investigate standards of surgery and assess fidel-
ity to intervention protocols. Whilst the collection of large quantities
of anonymised video and photo data is feasible, more work is
needed to streamline the electronic assessment of videos.P-29
How should we proceed from local to national evaluation of
complex interventions: Overcoming challenges in scaling up a
local primary care prescribing feedback intervention to a national
trial – a consensus process
Sarah Alderson, Amanda Farrin, Robbie Foy
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Background: Cumulative meta-analysis of ‘Audit and Feedback’ (A&F)
trials have shown no improvement in effect sizes, suggesting a lack
of learning on how to improve effectiveness. The Campaign to Re-
duce Opioid Prescribing (CROP) provided 316 practices in West York-
shire with bimonthly evidence-based enhanced A&F reports on their
opioid prescribing for one year. The CROP intervention reduced pre-
dicted opioid prescription spending by £900,000 in West Yorkshire.
We are exploring feasibility and ethical challenges of scaling up the
CROP intervention for a national primary care randomised controlled
trial to reduce harmful opioid prescribing whilst adding significantly
to the wider evidence base on A&F.
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mary care medicines optimisation leads and members of our existing
Patient and Public Involvement Panel will identify solutions to the
ethical and feasibility issues of scaling up the CROP intervention,
drawing upon a state-of-the-science summary of recommendations,
on-going research and medicines optimisation expertise.
Timing of potential results: We will present the findings of the con-
sensus process, due to take place in May and June 2019 with results
due in July 2019. Results will be presented by panellist type and
overall results.
Potential relevance and impact
A key factor to the successful planning and delivery of a national pri-
mary care A&F intervention trial will be how well ethical and feasibil-
ity issues relating to consent (waive consent, practice or Clinical
Commissioning Group consent), unit of randomisation (practices,
Clinical Commissioning Groups or regional), and the source of pri-
mary care data (nationally gathered databases or electronic health
records) are resolved. We will present the consensus process recom-
mendations on how acceptable and ideal different core ethical and
feasibility options are for a national trial of different modifications to
A&F for primary care opioid prescribing that will add significantly to
the wider evidence base on A&F.P-30
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Introduction: In a randomised controlled trial consistent determin-
ation of the start of follow-up is critical. In many trials start of follow-
up is often the day of randomisation. However, in a cluster random-
ized trial, with a complex intervention, determination of the start of
follow-up may be problematic. Arrisa-UK is a two-arm multicentre
cluster randomised controlled pragmatic trial of a complex interven-
tion including practice staff training and creating an asthma at-risk
register. Before randomisation, GP practices identified at-risk asthma
patients, using trial-specific search criteria. Intervention practices’ “at-
risk” asthma patients are flagged electronically, with reminders trig-
gered when their Electronic Health Record is opened by practice
personnel. Follow-up commences on the day patient flags go “live”.
There is no equivalent date for control practices. Furthermore, time
between randomisation and “live” flags for intervention practices
ranged from 35 days to 619 days, due to delays with computerised
training. Practices randomised to intervention early in the trial experi-
enced longer delays than those randomized later.
Methods: We consider how to define start of follow-up for control
practices. One approach is the date of randomisation. Another is to
add the average number of days between randomisation and live
flagging of intervention practices to the randomisation date of con-
trol practices; the resulting date used to commence follow-up. Alter-
natively, as time between randomisation and flagging of intervention
practices decreased as the trial progressed, average delay between
randomization and live flags for intervention practices for each 3-
month period of randomization could be applied to control practices
randomized in the same period. These approaches will be explored.
Conclusion: in a cluster randomized trial of a complex intervention,
start of follow-up may be difficult to identify in control practices, and
possible solutions should be explored.P-31
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Central data monitoring in phase III RCTs in the UKCRC Registered
Clinical Trials Units: results from a survey
Sharon B. Love, Victoria Yorke-Edwards, Sarah Lensen, Matthew R. Sydes
MRC Clinical Trials Unit at UCL, University College London, United
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Introduction: The FDA and EMA each published guidelines in 2013
supporting the use of risk-based monitoring approaches in clinical
trials, including the wider use of central data monitoring. These ideas
were enshrined in an ICH GCP Addendum in 2016. However, there is
little explicit guidance or evidence for how best to achieve risk-based
monitoring. We surveyed the 50 registered clinical trials units (CTUs)
in the United Kingdom Clinical Research Collaboration (UKCRC), to
find out about current approaches in the UK.
Methods: A questionnaire about monitoring in phase III randomised
CTIMP trials was distributed to the UKCRC registered CTUs in Novem-
ber 2018. Questions focused on the relationship of central monitor-
ing to on-site monitoring, and included why central data monitoring
was used, how it was programmed, and how often run, what triggers
were used, process automation, and how often triggers were
assessed.
Results: 86% (43/50) of the CTUs responded. Five CTUs do not carry
out phase III randomized CTIMPs, and another stated that the spon-
sor conducted the monitoring. Therefore, the monitoring experiences
relate to 37 CTUs. 92% (34/37) used centrally available data to evalu-
ate site performance, with 97% (36/37) using it to guide, target or
supplement site visits. Only 6% (2/36) always used central monitoring
to replace on-site visits, whilst 17% (6/36) never did. 53% (19/36) did
not program the central monitoring explicitly and 56% (30/36) con-
duct central monitoring at least monthly. All 31 CTUs who used trig-
gered monitoring had a process that included human assessment of
whether a trigger should result in a site visit. Consent, protocol devi-
ations, suspected fraud, number of unanswered queries, AE/SAE inci-
dence and number of data queries were common triggers.
Discussion: These survey results demonstrate substantial variation in
approaches to central monitoring across UKCRC registered CTUs. This
finding encourages research for an evidence-based standard.P-33
Risk-based trial monitoring: Site performance metrics across time
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Introduction: Trialists need to ensure data integrity and patient
safety in each clinical trial. Often, the intensity of central and site
monitoring strategy is chosen based on the level of risk inherent in
the trial design or population. Many monitoring strategies involve
selecting metrics (e.g. number of protocol violations) and assessing
site performance based on these. If the metrics are poor (threshold
breach for several or one significant metric) for a site, then an on-site
monitoring visit is carried out. We will analyse three years of histor-
ical trial data to investigate changes in the metrics over time and
how these relate to site visits that were undertaken.
Methods: We will look at metrics in each trial across time and investi-
gate trends over time. In particular we will assess
a.whether there is an improvement in the metric score after a site
visit
b.whether change in the metric score is sustained over the following
year
c.if some metrics are more sensitive
d.interaction of the metrics
Timing of Potential Results: Data were received in April 2019. Re-
sults will be available in August 2019.
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lines advocating risk-based monitoring, more trials are now using site
performance metrics to assess if a site visit is required. Trialists need
to find out more about how site performance metrics normally be-
have. These forthcoming data will add to our knowledge and con-
tribute to discussions of which metrics to use.
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Wound Healing in Surgical Trauma (WHiST) RCT
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Introduction: In ‘closed’ high-energy fractures associated with major
trauma the surgical site infection (SSI) rate is an important outcome,
as SSI involves prolonged antibiotic use, delayed rehabilitation and
additional hospital admissions. To investigate the efficacy of inter-
ventions which might improve infection rates, robust methodology
to assess the presence of deep SSI is required.
Objective: To compare wound healing complications that define a deep
SSI on case report forms (CRFs) completed by patients and research nurses
with information extracted from patients’ medical notes.
Methods: This study was performed as part of the WHIST trial. Pa-
tients with a major trauma fracture requiring surgery were randomly
assigned to standard or negative pressure wound dressings. The rate
of deep SSI, defined by the Center for Disease Control criteria, was
the primary outcome. CRFs were completed 30 days post-surgery by
the participant and research nurse. An independent surgeon retro-
spectively reviewed a sample of participants’ medical records (includ-
ing all potentially infected and a random sample of non-infected
cases), for pre-specified wound complications.
Results: 308 participants had their medical records checked. For the
majority (83%), the CRFs and the routine medical record agreed on
the presence or absence of a deep SSI. However, four participants
with no deep SSI found on the CRFs, had a deep SSI according to
their medical records. Conversely, 49 deep SSIs were indicated ac-
cording to the CRFs, but not identified from the medical record. For
nearly half of these latter participants (49%), at least one wound
healing complication was identified in the audit. However, the
remaining participants had no wound healing complications.
Conclusions: This study suggests that a review of the medical record
alone is likely to lead to an underestimation of the rate of deep SSIs.
This could have implications for the interpretation of reports of infec-
tion using routinely collected data.
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Background: Pilot studies provide research teams with restricted time to
demonstrate that the trial would be feasible at full-scale, as well as limited
time to demonstrate that high quality outcome data can be collected for
this study. This demand for clean and accurate data in a short time frame
requires an efficient data cleaning process. Our objective is to assess an au-
tomated data cleaning approach versus a manual method.
Methods: The main method used for data cleaning within the EMmY
study comprised of a post-entry validation tool. Rules were created
in the database to detect discrepancies of interest, including missingfields, missing forms, and incongruent fields. Queries were then
raised directly through the database to study sites, for site users to
address and resolve electronically.
We compared this method against the manual approach used in pre-
vious studies within our unit. In this case, sites would receive a list of
data discrepancies to complete manually and return them to the re-
search team to update in the database.
Prior to final analysis, the study statistician raises further queries. To
compare the two data cleaning approaches, we will examine the pro-
portion of queries raised by the study statistician at the end of the
study, as an indicator of the level of data quality reached.
Timing of potential results: The EMmY study completed follow-up in
March 2019, and final data analysis will take place in May 2019.
Therefore, the above comparison in data cleaning approaches will be
made in August 2019.
Potential relevance and impact: While automated discrepancy rules
are more labour-intensive upfront, they yield potentially valuable
time savings, whilst also maintaining the high accuracy and quality
required in the short timeframe of a pilot study. Our analysis will pro-
vide insight as to whether this upfront effort is warranted over a
short study duration.
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The Validity of Setting Error Rates in Clinical Trials
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Introduction: Data entry errors in clinical trial databases are inevit-
able due to the complexity of the information and the manual nature
of the data collection process. The aim of this review was to evaluate
the applicability of pre-setting acceptable error rates in clinical trials.
As an indication of data quality, it is common practice to calculate
error rates as part of the database audit process. Based on the error
rate, decisions can be made if further data cleaning is required or if
the database is ready to be locked.
Methods: An assessment of current literature was performed. Scien-
tific publications, industry practices and standard operating proce-
dures from clinical trials units were examined to determine the
purpose and relevance of setting limits on error rates and how to
apply them for specific clinical trials.
Results and Discussion: Error rates limits are influenced by such fac-
tors as industry standard, personal choice and historical precedent,
with acceptable error rates ranging from 0.05% to 5%. They can also
vary within a single trial, with one limit being set for critical primary
outcome data and another less stringent limit for non-critical data.
This review suggests that auditing and monitoring of data from early
on in a trial leads to lower error rates and buys time for corrective
and preventative procedures to be put in place for the remainder of
the trial and for future trials. Also, in anticipation of more widespread
data sharing being part of future clinical trials, publication of quality
control measures such as error rates may become unavoidable.P-37
Improving trial eligibility criteria: new methods to enhance fitness-
for-purpose
William J Cragg1, Kathryn McMahon1, Jamie B Oughton1, Rachael
Selby2,3, Rachel Sigsworth1, Chris Taylor1, Vicky Napp1
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Introduction: Eligibility criteria (EC) are key in defining patient popu-
lations included in a trial. There are no widely used, detailed
Trials 2019, 20(Suppl 1):579 Page 11 of 141standards for writing clear criteria in line with trial objectives and
intended generalisability.
Inadequacies in criteria can lead to problems such as ineligible pa-
tients being recruited, patients being excluded from trials without
strong rationale, or trial results being unintentionally limited in gen-
eralisability. Such problems are known to occur and can affect trial
validity and jeopardise patient safety. Suboptimal criteria may need
to be corrected in later protocol amendments, therefore contributing
to research inefficiency.
In the context of trials at the Clinical Trials Research Unit (CTRU) at
University of Leeds, our aims are:
1)Develop standards for writing clear EC;
2)Design quality control procedures to ensure EC are fit-for-purpose;
3)Evaluate these new methods.
Methods: Intervention development: using examples from CTRU tri-
als of EC that have required amendment, we will develop a sug-
gested formula for writing EC and a quality control tool for assessing
them once drafted.
Evaluation: the new methods will be applied to at least two in-
development trials. We will review the criteria before and after the
process and qualitatively summarise the differences the new
methods have made. We will also collect qualitative feedback on use-
fulness from those involved.
We will conduct brief surveys of Chief Investigators, investigators and
other site staff to find out how they use EC and to help assess the
feasibility of our new methods.
Timing of potential results: Late summer 2019.
Potential relevance and impact: Our outputs will aim to help stand-
ardise the format and raise the quality of EC used in all kinds of trials.
This could reduce the number of errors relating to EC and random-
isation, and ensure criteria are appropriate to the aims and intended
generalisability of each trial.
P-38
Opportunities and experiences of accessing pharmaceutical
individual patient data for statistical research
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Introduction: We are living in the era of data sharing. In 2013, the
EMA released its draft policy on publication and access to clinical-
trial data including individual patient data (IPD). Although this policy
is not yet mandated, in 2014 the pharmaceutical industry committed
to share IPD from clinical trials in the US and EU upon request from
a suitably qualified scientific/medical researcher. In addition, many
funders (e.g. MRC and Wellcome) now mandate open access to IPD
on completion of the primary research.
The ClinicalStudyDataRequest.com resource set-up in 2013 to enable
such activity now has 19 collaborators including many major
pharmaceutical companies (e.g. GSK and Roche) and funders (e.g.
MRC and Wellcome). We present the key lessons learnt when apply-
ing for access to IPD via ClinicalStudyDataRequest.com and tips for a
successful application.
Methods: In late 2018 we began the process of applying for access
to IPD to conduct methodological research. In early 2019, our appli-
cation was approved and access to IPD from several clinical trials
was granted.
Results: What have we learnt?
i)How to prepare a successful application.
ii)How to identify relevant/appropriate studies (especially for
methods research where the disease and/or drug are not the focus).iii)How to prepare for receiving and storing the data.
iv)What is expected from you?
Discussion: IPD offers a valuable resource for statisticians and other
investigators to undertake methods research and platforms such as
the ClinicalStudyDataRequest.com provide access to such datasets.
Access to IPD enables an opportunity to better understand novel
methods when applied to real-world data in a timely manner. The
process of acquiring IPD from ClinicalStudyDataRequest.com is sim-
ple and can be relatively quick but careful consideration of several
key factors prior to submission can aid the process. We encourage
wider use of this valuable resource from the research community.P-39
Managing the paper mountain – systems and processes for
tracing, managing and transferring high volume trial data from
paper sources
Karolina Rusiak, Ian Woodrow
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Clinical data management systems and processes are an integral part
of collecting, capturing, combining, cleaning, validating, and extract-
ing high quality data for statistical analysis. This paper considers the
systems and processes for the collection, capture and management
of a high volume of paper source data from the IDEAL study.
IDEAL was a 5-year longitudinal multicentre study, which ex-
plored the experiences of people living with dementia. Data col-
lection was on validated TeleForm paper based case report forms
(CRFs) at three time points from 38 centres. In total, 15,943 paper
CRFs were received at the trials unit. The priority was to have ef-
fective and responsive processes and systems to trace, manage,
and transfer high volume data from paper to electronic database.
To minimise issues with large volume of data tracking and man-
agement, and to reduce the risk of human errors, unique scan-
able barcodes were created for each paper CRF, which were
traceable on a web-based system. The returned completed CRF
data were inputted into a MACRO system. Initially data were en-
tered manually but processes and tools were then developed to
allow for specific non-text data to be automatically scanned using
TeleForm, converted into MACRO format using a bespoke map-
ping tool and then uploaded into MACRO minimising manual
data entry and human errors. The bespoke mapping tool required
detailed definitions and extensive validation. A separate query
tracking system was used with MACRO to support data validation,
cleaning and verification prior to the locking of data sets and de-
livery for analysis. The large volume of paper source data gener-
ated by IDEAL required closely integrated digital systems with
use of established tools, bespoke conversion and tracking tools
allowing the trials unit to efficiently collect and manage the large
volume of data without the cost and risk of developing or pro-
curing new combined system.
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Case Report Form for collecting surgical data
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preventing parastomal hernia) developed an electronic CRF (eCRF) to
collect surgical data in the operating theatre about stoma creation.
An eCRF was chosen because: i) some data cannot be retrieved sub-
sequently; ii) some data items depend on preceding answers; iii) real-
time validation can be applied to minimise missing/invalid data. A
paper CRF was subsequently implemented, and sites chose to use ei-
ther method. We report changes in completeness, quality and timeli-
ness of data before/after implementing the paper CRF.
Methods: Recruitment started in January 2018 using the eCRF, which
takes 5-10 minutes to complete. Some sites reported difficulty com-
pleting the eCRF and developed informal paper CRFs. We issued a
formal paper CRF in January 2019. We describe numbers/% of partici-
pants (a) for whom each CRF type was used, (b) missing <=1 data
item and (c) missing <=1 data item and data entered <=1 day after
operation, before/after implementing the formal paper CRF.
Results: BEFORE (12 months, 48 sites, 355 participants): 3 sites (6%)
reported using informal paper CRFs for 31 participants (9%); for
eCRFs/paper CRFs, 86% vs 97% of participants had <=1 missing data
item and 69% vs 57% had <=1 missing data item with data entered
<=1 day after operation. AFTER (4 months, 57 sites, 329 participants):
45 sites (79%) used paper CRFs for 223 participants (68%); 98% vs
96% of participants had <=1 missing data item and 73% vs 61% had
<=1 missing data item with data entered <=1 day after operation.
Conclusion: About 20% of sites have successfully used the eCRF
throughout and report data entry works well. However, many sites
switched to paper, which is now used for most participants. Data
capture is faster with the eCRF. We will compare data values to inves-
tigate the validity of each method.
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AVATAR-AF: Getting to the heart of data management for analysis
(5 simple rules to follow to ensure data integrity)
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Introduction: AVATAR-AF - a three-arm, unblinded, randomised trial
had results presented at the EHRA in March 2019. To ensure a high-
quality dataset was available for analysis, a number of challenges
had to be overcome. Upon reflection and review, 5 simple rules were
subsequently developed to ensure the integrity of clinical trial data
for analysis.
Methods: Analysis for AVATAR-AF consisted of two treatment com-
parisons; one between AVATAR cryo-balloon ablation and a non-
invasive course of anti-arrhythmic medication, the other comparing
AVATAR and conventional ablation approaches. Primary endpoint
was time from initial intervention (index ablation/commencement of
drug therapy) to first hospital episode related to the treatment for
atrial arrhythmia. Two secondary endpoints alongside standard safety
output were also defined. Statistical analysis between arms comprised
of Kaplan-Meier statistics with log-rank testing and proportional haz-
ards models. A structured data-cleaning process was formulated be-
tween the trial manager and study statistician to ensure the integrity of
the analysis data whilst also allowing for a quick transition from last
subject visit to database lock (8 weeks). The plan enabled primary ana-
lysis to be completed, quality-controlled and prepared for abstract sub-
mission just 17 days following database lock.
Results: After reviewing the processes which allowed the trial team
to complete analysis within the 10-week time-frame, five key lessons
were produced and presented internally within the CTU. These were
based on the topics of Communication, Database Design, DMEC/
DSMB Reports, Post-Hoc Analysis and Escalation.
Discussion: Data quality is one of the key components to a success-
ful trial. However, with trials getting more ambitious and complex in
design, considerations to ensure data quality can easily get lost dur-
ing design, recruitment and follow-up. The five topics when com-
bined and considered throughout the trial process form a solid
framework that can be universally applied to ensure a high-quality
analysis dataset.P-42
Routine electronic health records used as participant data in UK
randomised trials: The BOSS trial as a case study
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Introduction: There is much discussion about the current usefulness
of electronic health records. In the UK, death data is nationally regis-
tered and for a fee is provided to support clinical trials. We will look
at the data provided from the registry and that amassed as trad-
itional trial data to look for patterns of data availability and to com-
pare the correctness of data from the two sources.
Methods: The BOSS trial (Barrett’s Oesophagus two yearly Surveil-
lance versus no Surveillance; ISRCTN54190466) is a 3400-patient ran-
domised controlled trial, in follow-up, designed to estimate
effectiveness and cost-effectiveness1. The primary outcome of the
trial is overall survival for which trial data is collected (CRF) and data
has been provided from the registry annually since 2013. We will
look at the death data for the whole trial across time collected by
the 2 methods and describe any discrepancies e.g. maybe the regis-
try data is available a year late or early.
Timing of Potential Results: Work is currently ongoing but will be
completed by August 2019
Potential Relevance and Impact: There are many efforts and re-
sources directed towards increasing the accessibility and quality of
“big data” in healthcare. However, trialists, regulators and commis-
sioners need to know more about the quality and timeliness of the
routine data. This project will show how routine death data and trial
death data compare over a 6-year period and can set a precedent
for other trials presenting this, and similar, information.
Reference
1 Oliver Old et al. Barrett’s Oesophagus Surveillance versus endoscopy at
need Study (BOSS): protocol and analysis plan for a multicentre
randomised controlled trial. Journal of Medical Screening 2015,22,158-
165
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Blinding in surgical trials: using bespoke online systems to
improve blinding
Elke Gemperle Mannion, Andrew Metcalfe, Jaclyn Brown, Chockalingam
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University Of Warwick, United Kingdom
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Introduction: START: REACTS is a participant and assessor blinded, adap-
tive, multi-centre randomised trial of up to 221 patients in 21 centres. The
study aims to assess the clinical effectiveness of arthroscopic debridement
with the insertion of an InSpace balloon to arthroscopic debridement alone.
In standard care, the medical records and particularly the operation note
contains all the information about the surgery, available to any healthcare
professional involved in the treatment of the patient. To ensure that the
participant, the assessor, and the nursing and physiotherapy teams who
provide post-operative care and rehabilitation remain blinded for the dur-
ation of the study, two bespoke electronic online systems were developed
to ensure the allocation the participant received remains hidden.
Methods: Randomisation is done online at the end of the arthro-
scopic debridement.
Blinded information is inserted into a secure online Operation Note
system which we have created, which contains the allocation. The
medical records will contain the information about the arthroscopic
debridement only and contain web links to the operation note sys-
tem and secure unblinding module.
Access to the participant’s trial allocation through the unblinding
module is granted only in case of emergency and available to any
NHS personnel at any time of the day.
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tion of the primary outcome, to see if the blinding procedure was
successful in this trial.
Findings: Initial findings indicate that both systems are robust, user
friendly and have had good acceptance by the Trusts.
Conclusion: Many challenges were encountered setting up a blinded
surgical trial. We believe that this new approach could make blinding
in surgical trials much more robust. Results from the success of the
blinding will be disseminated with the main trial results.P-44
Challenges in applying clinical trial standards to routine data. A
case study from a randomised controlled trial embedded in a
National Clinical Audit
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Introduction: The use of routine data can enhance the efficiency of a
clinical trial but presents methodological challenges. The AFFINITIE
programme (Enhanced audit and feedback interventions to increase
the uptake of evidence-based transfusion practice) embedded two
cluster-randomised, factorial trials evaluating enhanced feedback in-
terventions within the UK National Comparative Audit of Blood
Transfusion. This audit programme aims to promote the uptake of
evidence-based guidance and reduce the unnecessary use of blood
components within a rolling programme of audits with bespoke data
collection.
Methods: We used audit data, supplemented by other routinely col-
lected data, in trial design, intervention content, outcome assessment
and analysis.
Results: We encountered five main challenges. First, we had to link
data, collected by multiple data providers for different purposes, with
clusters randomised to trial interventions, where the definition of the
clusters varied by data source over time. Second, as we embedded
the trials in real time within ongoing audits, challenges arose in data-
set version control and from the desire to include sites falling behind
with data entry to maximise sample size. Third, as each audit ad-
dressed a new topic, organisational learning across audits was lim-
ited. A new database was constructed for each audit, not to clinical
trials standards, compromising data quality and demanding greater
data management. Fourth, the actual nature and complexity of the
data available for analysis was only apparent once the data were
available, after defining the primary outcome and agreeing the statis-
tical analysis plan. Fifth, staff changes posed a particular challenge,
as knowledge of the data was key.
Discussion: We will provide recommendations for future trials that
utilise data collected for purposes other than trial evaluations.P-45
Different data source, different regulatory and management
demands? The use of routinely collected data in a trials unit
setting
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Introduction: The use of routinely collected data (RCD) in a trials unit is in-
creasing rapidly. These data can be used to identify potential participants,
answer primary and secondary outcomes as well as provide longer-term
follow-up of participants. The response from a regulatory perspective ishowever, advancing at a less rapid speed and the understanding of how
RCD can satisfy regulatory requirements remains unclear.
The aim of this presentation will be to compare traditional trials
which are heavily curated, and audit trailed, to studies that use RCD
which are not, in terms of workflows, skill set and balance and also
how they may converge/diverge in terms of regulatory requirements.
Methods: Using an example trial that used RCD for two of the four
primary outcomes, this will be compared with another study using
only RCD as part of a large observational study. Building Blocks trial
accessed data from Primary Care (individual GP practices), Hospital
(via NHS Digital), Immunisations (PCTs) and Abortion (Department of
Health and Social Care). The POOL study is accessing data directly
from maternity records at hospital sites and from the National Neo-
natal Research Database.
Results: This presentation will compare and contrast how the use of
RCD in these studies have diverged from the standard operating pro-
cedures of the trials unit, the additional processes required to ensure
compliance with data provider, and regulatory requirements as well
as how such projects are and should be resourced. It will also com-
pare how the different studies might influence the approach to data
management and analysis.
Discussion: While RCD reduces burdens such recruitment, retention
and follow-up, the additional work required to ensure regulatory com-
pliance does need to be considered and resourced appropriately.P-46
The feasibility of using electronic medical record data in a trial
testing approaches to increasing uptake of self-management
education programmes for type 2 diabetes in a multi-ethnic
primary care setting
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Introduction: Self-management education (SME) for people with type
2 diabetes mellitus (T2DM) has been shown to be effective and cost-
effective. Yet uptake is low. An “Embedding Package” addressing bar-
riers and enablers to uptake at patient, healthcare professional and
organisational levels is being developed and will be evaluated in a
cluster RCT. The aim of this study was to test the feasibility of using
electronic medical record data in the RCT.
Methods: Six general practices were recruited. Pseudonymised data
were extracted from primary care medical records for all eligible pa-
tients. These data were supplemented by a questionnaire completed
by patients. Recruitment to the questionnaire was either by post or
opportunistically by the GP. Where consent was given the question-
naire and extracted data were linked. Descriptive statistics were used
to assess completeness and accuracy. Where data were linked the
two sources were compared.
Results: Data were extracted for 2877 patients. The primary outcome
for the RCT, HbA1c, had less than 10% missing data. 63% of patients
had no record of ever being referred to SME but using attendance re-
cords this dropped to 46%. 423 questionnaires were received, the sam-
ple was roughly similar to the total eligible population in terms of age
and sex, but not for ethnicity. More participants were recruited via the
postal invite (85%) than the GP (15%). 384 (90.8%) participants con-
sented to have their questionnaire and extracted data linked. Self-
reported and extracted data had poor agreement for HbA1c with mod-
erate agreement for SME referral and attendance data.
Discussion: It is feasible to extract data from primary care with reason-
able completeness and accuracy for the subsequent RCT. The question-
naire data provides additional outcomes not available in primary care,
such as SME preferences. Measures will be taken to further improve the
quantity and quality of the data collected for the RCT.
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Introduction: Using routine patient data is encouraged by funding bodies
to improve research efficiency. Routine data (e.g. Hospital Episode Statistics)
are available from national sources, however it can be a lengthy process to
obtain the information, which may also be incomplete.
Instead of collecting data from Case Report Forms (CRFs), which re-
search nurses manually complete via medical note review taking
considerable time, the UPSTREAM trial (ISRCTN56164274) utilised a
novel method directly obtaining resource use data from 26 NHS par-
ticipating hospitals in England. We estimated the informatics re-
source cost to hospitals of this method.
Methods: We requested two data downloads directly from hospital
informatics teams; an interim download 12-months from trial com-
pletion and a “top-up” download upon completion of trial follow-up.
We invited Information analysts to complete feedback question-
naires, which included the time taken to complete the work, from
coding to data verification, and the number of datasets queried.
Results: All 26 hospitals successfully returned diagnostic (ICD-10), pro-
cedure (OPCS-4) and currency codes (HRGs) for inpatient stays, outpatient
appointments and A&E attendances for 802 trial patients for whom we
had permission to access hospital records. Feedback requests were sent
by email, with two follow-up reminders. 58% of analysts responded; for
these sites, the average time taken for the initial data extraction was 187
minutes (95%CI: 121–241 minutes). Number of patients per site ranged
from 7–114 and number of datasets queried 2–7.
As NHS Information analysts and nurses follow the same salary struc-
ture, any time reduction using this method versus CRF completion
demonstrates cost saving.
Discussion: We demonstrated that it is possible to obtain, directly
from hospitals, a complete dataset of inpatient, outpatient and A&E
resource use. This method is likely to be cost saving over nurse com-
pleted CRFs and lower the potential for missing data.
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outcomes in NIHR HTA trials
Andrew J. McKay1, Andrew J. Farmer2, Carrol Gamble1, Ashley P. Jones1,
Paula R. Williamson1
1Clinical Trials Research Centre, University of Liverpool, Liverpool, United
Kingdom; 2Nuffield Department of Primary Care Health Sciences,
University of Oxford, Oxford, United Kingdom
Trials 2019, 20(Suppl 1):P-48
Introduction: The cost of later phase clinical trials have led to an in-
creased focus on methodology that will support innovative and efficient
delivery but still require the collection of consistent and reliable data.
Clinical trials usually require the development of bespoke data collec-
tion systems yet there are many Electronic Heath Records (EHRs)
available that may collect the same data. EHRs could potentially be
used more widely within the delivery of clinical trials.
National Institute for Health Research Health Technology Assessment
(NIHR HTA) are a major source of funding for investigator-led clinical
trials within the UK. The aim of this work is to review all protocols of
ongoing clinical trials funded by the NIHR HTA Programme to iden-
tify the types of EHRs currently being used for outcome data collec-
tion to identify lessons learnt.
Methods: We identified ongoing randomised controlled trials (RCTs)
by searching the NIHR journals library. Trials collecting at least one
outcome from an EHR were included. For this pilot review a randomsample were assessed for inclusion with data sources and outcome
types extracted.
Results: For the pilot, from reviewing a sample of 49/282 studies in
progress (01/05/2019), 35/49 are RCTs with 20/35 (57%) using rou-
tinely collected data for at least one clinical, health economic or
safety outcome. The most common EHR sources used are Hospital
Episode Statistics (n=6), Office for National Statistics (n=5), and dis-
ease registries (n=5).
Discussion: The pilot results show around half of ongoing RCTs used
routinely collected data for at least one outcome from various EHRs.
For the main review, we will extract data for all eligible studies and
contact their lead investigators to obtain detail from gaps in report-
ing. Once completed, we hope to increase awareness of potential for
using EHR data and explore factors that facilitate and offer barriers to
its use.P-49
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Introduction: Electronic health records (EHRs), used to record most
UK primary care consultations, are a potential key resource for those
conducting research. Data within EHRs are not collected for research
purposes, posing issues to researchers interrogating these data.
We will present challenges encountered during analysis in two pro-
jects using EHRs and discuss solutions adopted.
Methods: ResearchOne is a database of de-identified clinical and ad-
ministrative data drawn from the EHRs of UK GP practices using the
TPP SystmOne clinical system.
Funded by NIHR RfPB and Macmillan Cancer Support we conducted
two cross-sectional, observational studies, using ResearchOne data to
describe the population size, characteristics and healthcare resource
use of people with cancer and (1) dementia and (2) long-term health
conditions.
Patients aged over 50 with a cancer/dementia diagnosis consistent
with Quality and Outcomes Framework eligibility between 01/01/05
and 01/01/16 were included. The data covered 391 general practices
(5.1% of all English practices) across 18 datasets totalling 37,095,534
records.
Results: Obtaining data was challenging. We encountered difficulties
and delays in accessing ResearchOne data, affecting project time-
scales. We will present strategies to limit similar issues in future
research.
Managing data was also challenging. Lack of data dictionaries or
code-lists made data cleaning difficult and time-consuming. As GPs
can add codes locally, many data items required recoding into use-
able categories i.e. cancer type had 1946 distinct values. Missing and
inconsistent data also caused issues. We will share the methodolo-
gies employed in our analysis.
Discussion: Research utilising routine data is often perceived as more
efficient. Analysis of EHR data is, however, challenging and time-
consuming. Researchers should ensure they allocate sufficient time
for receipt and analysis of data. We encourage researchers working
with this data to share their methodologies and suggest data
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Background: Use of routine data in healthcare research is increas-
ingly prevalent, due to several advantages, including availability and
relatively low costs. The limitations of routine data are well described,
such as time-lag from collection to publication. We report on the ex-
perience of using a routine screening tool, the electronic frailty index
(eFI) to identify the target population.
Methods: The eFI was developed to identify categories of frailty and
facilitate planning and delivery of services for older people with
frailty. The eFI is automatically populated from routinely recorded
data contained within primary care electronic healthcare records
(EHR) and is embedded into SystmOne, EMIS, Vision and Microtest
EHR systems. PROSPER is a feasibility trial in older people with frailty
utilising a specific eFI score as defined by economic modelling, as an
inclusion criterion. Practices were asked to search EHRs to identify eli-
gible participants based on their eFI score and four other factors.
Results: Economic modelling of eFI data successfully identified an ap-
propriate eFI cut off of ≥0.21 as the target population for the clinical
trial. Using the eFI score to identify eligible participants provided
some challenges. The eFI is designed for use as a screening tool and
is coded into frailty categories: fit, mild, moderate and severe. The
eFI report is not integrated into the patient summary record, there-
fore not possible to search for patients with a certain eFI score and
other criteria. Additional resources were required to enable identifica-
tion of participants. These findings will inform the definitive trial.
Discussion: Use of routine data tools for purposes other than origin-
ally designed needs early consideration to ensure any limitations can
be addressed in advance. However, can be hugely valuable, as
shown by using the eFI to both define the target population and
identify participants.P-51
Preliminary analyses of anonymised UK hospital episode statistics
data to inform a research protocol on surgical management of
severe pressure ulcers
Barnaby Reeves1, Rosie Harris1, Maria Pufulete1, Jess Harris1, Jo Dumville2
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Introduction: In April 2018, the UK National Institute for Health Re-
search sought to commission an “efficient cohort study” to identify
patient groups in whom surgical interventions for severe pressure ul-
cers (SPU) may be indicated and to determine which interventions
may be suitable for evaluation of clinical effectiveness. In the ab-
sence of population data on rates of surgical intervention for SPU,
we analysed anonymised hospital episode statistics acute patient
care data (HES-APC) to inform a research plan. Specifically, we
wished to estimate numbers of hospital admissions with a SPU and
describe the characteristics of admitted patients, managed surgically
or not.
Methods: We requested anonymised HES-APC with an ICD-10 SPU
diagnosis code (L89.2, L89.3, L89.9) from 01/10/2014 to 30/09/2016,linked to HES-APC episodes for six months before and after the index
admission. Index patients were identified as continuous spells (ad-
missions), with an SPU diagnosis code in any episode during the
spell. Surgical intervention was defined as reconstructive surgery (Of-
fice for Population Censuses and Surveys, OPCS, codes S17-S27).
Results: Of 81,383 index admissions, 40%, 14% and 46% were coded
as L89.2, L89.3 and L89.9. Only 165 patients (0.2%) had reconstructive
surgery during the admission; 63 had reconstructive surgery in a sub-
sequent admission, including six who had reconstructive surgery dur-
ing the index admission. Reconstructive surgery (some multiple
operations) occurred in 37, 55 and 92 index admissions coded as
L89.2, L89.3 and L89.9. Surgical debridement only was more frequent
(OPCS code S57.1, 2013 patients, 2.4%). Patients who had recon-
structive surgery were about 20 years younger and had fewer comor-
bidities than those who did not; about half had paraplegia,
tetraplegia, spinal injuries or sequelae of transport accidents.
Conclusion: Our ability to identify SPU and reconstructive surgery in
HES-APC led us to propose a retrospective efficient cohort study
based on linked HES-APC and mortality data (NHS Digital).P-52
Efficacy, feasibility and acceptability of mHealth technology (SMS)
for promoting glycaemic status and self-management among low-
income earning adults in Eastern Cape, South Africa
Eyitayo Omolara Owolabi, Daniel Ter Goon
University Of Fort Hare, East London, South Africa
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Background: Diabetes persists as a significant public health and
socio-economic challenge in South Africa. There is a high level of
sub-optimal control, low level of knowledge and adherence to ther-
apy, which predisposes to poor health outcomes and complications
development. Adherence to lifestyle regimen, particularly dietary rec-
ommendations and activity pattern poses significant challenge to
achieving targeted health outcome. The study sought to assess the
impact of text-messaging on diabetes self-management and gly-
caemic control among low-income earning diabetic patients in East-
ern Cape Province of South Africa.
Methods: This was a multi-centre, two-arm, parallel, randomised-
controlled trial designed to compare the impact of daily text-
messaging to standard care to standard care on glycaemic control
and self-management. Study was conducted among diabetic patients
with uncontrolled glycaemic status in selected districts of the Eastern
Cape Province of South Africa. Participants were randomly assigned
into the intervention and control arm. Data was collected at baseline
data and six months post-intervention. Fasting blood glucose meas-
urement followed standard procedure. Self-management was mea-
sured using a pre-validated tool. A total of 216 participants were
included in the study. Mixed-model effect analysis was used to assess
the impact of the SMS on blood sugar. Linear regression was used to
assess for its effect on diabetes self-management. P-value of <0.05
was considered statistically significant.
Results: Majority were females and had Type 2 diabetes. Self-
management among the study participants was low. No significant
difference in the mean change in glycaemic status and self-
management following a six-month intervention, mean change was
0.26mmol/L (-0.81 to 1.32), p= 0.634 for blood glucose and -0.02
(-0.15 to 0.12), p=0.821 for self-management. Text-messaging was
highly acceptable and feasible among the study participants.
Conclusion: Text-messaging was highly acceptable and feasible
among low-income earning adults. However, its efficacy on improv-
ing glycaemic control and self-management remains doubtful.P-53
Abstract omitted
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The impact of alternative assumptions on QALY calculations in the
presence of missing data
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Bangor University, Bangor, United Kingdom
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Introduction: Quality-adjusted life-years (QALYs) are often derived
from responses to questionnaires administered to trial participants.
Questionnaire data, however, are prone to being incomplete, and
while multiple imputation (MI) is established as a robust approach to
dealing with values missing at random, a number of assumptions are
necessary to implement MI. This study aims to explore the impact of
alternative assumptions on the QALY, and consequently, the incre-
mental cost-effectiveness ratio.
Methods: We will simulate a data set representative of economic
data alongside an RCT. Missing values will be introduced for utilities,
under an MAR assumption. Each simulated patient will have either
complete, partial, or no utility data. Scenarios will simulate alternative
proportions of partial and complete data. For each simulated data
set, combinations of the identified alternative assumptions will be
modelled. Three assumptions will be considered:
1)Defining complete QALY data as requiring a minimum of two data
points, including baseline, or when all utility data is complete.
2)Imputing each utility or overall QALY.
3)How timing may be represented within the imputation model,
given non-exact timing in questionnaire return, and increased rigour
from using patient level data, over group means at time points.
Percent bias over 1000 replications for each scenario will be re-
ported, compared with analysis of complete data. Estimates will be
compared by Monte-Carlo 95% confidence intervals. We will draw
conclusions as to the most appropriate assumptions based on pro-
portions of missing data.
Timing of potential results: Results from the analysis will be avail-
able for the ICTMC conference in October.
Potential relevance and impact: These results could offer insight
and guidance as to the most robust assumptions in the imputation
of missing utility data in future economic evaluations alongside clin-
ical trials.
P-55
Preventing mental health conditions in children and young adults:
a review of the costs of complex interventions and their
components
Joanna C Thorn, Deborah Caldwell, Sarah R Davies, Jennifer C Palmer,
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Introduction: Mental health conditions such as anxiety or depression
are increasingly widespread amongst children and adolescents, and
commonly continue into adulthood; prevention has the potential to
realise long-term benefits to both patients and society. Many pre-
ventative interventions have been developed, tested and reviewed;
however, less is known about the costs of such programmes. This
study aims to assess current knowledge of the costs and cost-
effectiveness of interventions for preventing mental ill health in chil-
dren and young people and to apply it to component parts of the
interventions.
Methods: A systematic review covering MEDLINE, Embase, CENTRAL
and PsycINFO was conducted to identify randomised controlled trials
of school-based interventions to prevent anxiety or depression in
children and young people. Included interventions were categorised
as targeted or universal, and broken down into relevant components
(e.g. psychoeducational, physiological). The initial search strategy was
extended to the NHS Economic Evaluation Database and all results
were further restricted with terms to identify costing studies (e.g.
“economic evaluation”, cost). A narrative review describing cost-
effectiveness analyses is in preparation. Based on detailed microcost-
ing of ‘representative’ interventions for combinations of interventioncomponents, we are developing a novel method for assigning costs
to the individual components.
Timing of potential results: Preliminary results on intervention effi-
cacy are already available; more detailed results on efficacy by inter-
vention components are expected by June 2019, with economic
analysis results expected by September 2019.
Potential relevance & impact: Preliminary examination of relevant
studies indicates substantial heterogeneity in terms of interventions,
outcomes and economic analyses. Breaking complex interventions
down into components could potentially explain some of this hetero-
geneity to allow more meaningful conclusions to be drawn. The re-
sults could inform the design of interventions that draw on the most
effective and potentially cost-effective combinations of components,
and the work will inform costing methodology in future trials.P-56
Implementation of an almost paperless trial in the Emergency
Setting: The SCIENCE Study (Surgery or Casts for Injuries of the
Epicondyle in Children’s Elbows)
Duncan Appelbe, Louise Spoors, Juul Achten, Matt Costa, Dan Perry
NDORMS, University of Oxford, Oxfrord, United Kingdom
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The SCIENCE Study is a multi-centre prospective randomised equiva-
lence trial of a soft bandage and immediate discharge versus current
treatment with rigid immobilisation for acute torus fractures of the
distal radius in children. We plan on recruiting a minimum of 334
participants from over 70 sites. The aim of this trial is to evaluate the
clinical and cost-effectiveness of soft bandage immobilisation and
immediate discharge, compared to rigid splint immobilisation.
Patient information for the trial is entirely electronic using online
multimedia encompassing animations, videos and web-content. Data
collection for the study is electronic with patient reported outcomes,
consent and baseline data entered directly into the data collection
system. Follow-ups are completed by the participant at home, follow-
ing an automated reminder sent via E-Mail or SMS.
Management of the study is facilitated by the studies electronic sys-
tems to collect delegated duties, training, prompt for sign-offs and
alerts, thereby minimising the Trial Managers workload and allowing
tasks to be more easily prioritised. Communication with large num-
bers of sites is facilitated by a bespoke communication system, which
is able to personalise e-mails (including attachments).
We present the processes, and solutions that have been imple-
mented to make the study as efficient as possible using a generalis-
able approach based on the REDCap data collection system and a
small amount of bespoke programming.
P-57
EudraCT Safety Data Input Software Tool
Simon Bond1,2
1Cambridge Clinical Trials Unit, Cambridge, United Kingdom; 2Medical
Research Council Biostatistics Unit, Cambridge, United Kingdom
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Introduction: The remit of the European Clinical Trials Data Base
(EudraCT) is to provide open access to summaries of all registered
clinical trial results; thus, aiming to prevent non-reporting of negative
results and provide open-access to results to inform future research.
The amount of information required and the format of the results,
however, imposes a large extra workload at the end of studies on
clinical trials units (CTU). In particular, the adverse-event-reporting
component requires entering:
•each unique combination of treatment group and safety event
•for every such event above, a further 4 pieces of information (body
system, number of occurrences, number of subjects, number ex-
posed) for non-serious events, plus an extra three pieces of data for
serious adverse events (numbers of causally related events, deaths,
causally related deaths).
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efficient / innovative delivery of NIHR research” has developed tools
using standard statistical software to:
•prepare the required statistics needed by EudraCT
•format them into the precise requirements to directly upload an
XML file into the web portal, with no further data entry by hand.
Timing of Potential Results: The project will be completed by Octo-
ber 2019, and we will present the tools, explain how they may be
accessed and provide routes to further training.
Potential Relevance and Impact: The tool should remove the work-
load on CTUs of manually entering a large amount of data points
(e.g. over 1000 datum points for a recent oncology study) using the
web-interface, which is expensive and error-prone. It should also pre-
vent the alternative and lower quality practice of uploading pdf files
with safety summaries, which are difficult to amalgamate with any
other data sources, nor subject to any controls regarding content.P-58
Development of a web-based investigational medicinal product
management (IMP) system to track and account for an IMP in
clinical trials: IMP-Track
Abby Willcox, Samir Bellani, Jonathan Evans, Lucy Culliford, Chris Rogers
Clinical Trials and Evaluation Unit, Bristol Trials Centre, University Of
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Introduction: Efficient management of a clinical trial of an investiga-
tional medicinal product (CTIMP) requires robust systems to track the
IMP throughout the trial. Not all investigators and clinical trials units
(CTUs) have systems available, which can make management of the
IMP difficult and time-consuming. The aims of this project were to
scope CTUs’ requirements for an IMP management system and de-
velop a secure web-based application to meet the requirements.
Methods: A survey was designed to determine the number of CTIMPs
run through CTUs, IMP management systems used, and the key
features required. Survey responses and a focus group with representa-
tives from four CTUs formed the basis of the design of a web-based ap-
plication, IMP-Track, which can be used to centrally manage an IMP in
CTIMPs. The application was validated and systematically tested for use
in a range of trial designs and a user manual was prepared.
Results: Twenty-seven CTUs participated in the survey; 92% were del-
egated the task of managing the IMP by the sponsor. Current sys-
tems included paper or spreadsheet based; in-house IT solution; IT
solution provided by a third-party. Eighteen (72%) respondents were
interested in a CTU-developed system. Top requirements were the
ability to track batch numbers, confirm receipt of the IMP, record the
return of used/unused IMP, order the IMP from the manufacturer,
record temperature monitoring data and inclusion of a central moni-
toring function. CTEU Bristol developed IMP-Track and accompanying
user manual.
Discussion: IMP-Track supports parallel-group, factorial and cross-
over designs, includes a randomisation facility and has a full audit
trail. It can manage IMP across multiple sites, communicate with ex-
ternal databases, send email notifications, operate in masked and
unmasked modes, and unmask participant allocations. All functions
are restricted by user permission settings. IMP-Track is currently in
use in three multi-centre CTIMPs and is available to all CTUs.P-59
Ox-PRiME - Oxford Primary trial Management Environment
David Dyson, Emma Ogburn, Ly-Mee Yu
University of Oxford, Oxford, United Kingdom
Trials 2019, 20(Suppl 1):P-59Introduction: In recent years, clinical trials have become more auto-
mated and complicated in terms of data collection and investigation
process. Although clinical database software is becoming increasingly
feature-rich to keep up with these trends, the background trial man-
agement and site monitoring can often be overlooked. Commercial
trial management software is often inaccessible to developing coun-
tries and academic organisations due to restrictive pricing models.
In academic settings, trial management is often performed using
standard off-the-shelf software and data files stored on secure net-
work drives. Although this method is easy to setup and use, it is
often slow to update and susceptible to mistakes throughout the life-
time of the trial.
Using off-the-shelf software can mean that collating recruitment data,
safety reports and data return rates from each of the participating GP
recruitment sites can become a substantial drain on the management
team’s time. These situations are where a centralised database would
enable the management team to work far more effectively.
Methods: We developed a reliable and accessible web-based app,
the Ox-PRiME System (Oxford Primary trial Management Environ-
ment) to manage multiple multisite trials efficiently. The system has
been developed combining key aspects of trial management while
keeping an adaptable database structure that can meet the specifica-
tions of many trials.
Key features of Ox-PRiME include:
* Secure user management and permissions.
* Participant management including secure remote storage of identi-
fiable information.
* Form progress tracking.
* Recruitment site management and approval.
* Management of user training and access logging.
* Custom page layouts and database tables for each trial (editable
with no system downtime).
* Interfacing with REDCap to track completed forms.
* Custom regular email reporting on stored data.
Results: We will demonstrate the functions of Ox-PRiME using The
HABIT (Health professional Administered Brief Insomnia Therapy) trial
as a case study.
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Development of an ‘eSource Storage System’ for capture and
storage of electronic source data for large-scale, international,
randomized clinical trials
Michelle Nunn, Alex Baxter, Michael Lay
Clinical Trial Service Unit (CTSU) and MRC Population Health Research
Unit, Nuffield Department of Population Health, University of Oxford,
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Introduction: It is increasingly common to use computerised systems
to collect clinical trial data via an electronic Case Report Form (eCRF).
However, there is a need for the development of a system that can
be used to fulfil the FDA & EMA guidance on the electronic collection
and storage of participant source data.
Methods: We have developed an ‘eSource Storage System’ (ESS)
using a publicly available ‘Platform as a Service’ (PaaS) solution from
a trusted third-party provider.
Trial data is entered via a Web Application and saved as source
data on the ESS. A copy is created simultaneously onto the in-
house Trial Data System database for subsequent analysis. This
approach ensures that data entry and validation are done in real-
time and enforces compliance with the protocol. Participant Iden-
tifiable Data is not saved to the ESS. Security measures are in
place to protect data, including HTTPS connectivity for in-transit
security.
Discussion: Advantages of the ESS are that data can’t be overwritten
or deleted although updated data can be appended to an existing
form. All saved data is signed off by users and timestamped by the
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Authorised users e.g. Investigators & Regulatory Authorities can ac-
cess site appropriate data as required during the trial and for many
years after completion.
Potential drawbacks include reliance on users having a good internet
connection to be able to save data.
Conclusions: The eSource Storage System allows the current regula-
tory requirements for electronic collection and storage of clinical trial
source data to be met. The initial set-up process is somewhat time-
consuming and there are additional project costs and complexity.
There may be more efficient ways to ensure that trial results are
credible, particularly in an era of expanding technology and trial
designs.
P-61
Enabling Blinded Independent Central Review of medical images
for the RAMPART trial, with a bespoke, cloud-based, Picture
Archiving and Communication System
Brendan Mauger, Dominic Hague, Benjamin Smith, Carlos Diaz-Montana,
Angela Meade
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Methodology, London, United Kingdom
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Introduction: Clinical trials may require blinded independent central
review (BICR) of medical images to assess or confirm outcome mea-
sures obtained from such images, especially in licensing settings.
BICR is costly and may not be needed until a positive result. How-
ever, in a multi-site trial, images would preferably be collected cen-
trally on an ongoing basis rather than retrospectively. The RAMPART
trial (NCT03288532) required a cost-effective system that would allow
trial sites to remotely upload and anonymise medical images to a
central repository, making the trial ready to undertake a BICR, if and
when required.
Methods: We have developed a Picture Archiving and Communica-
tion System (PACS) for RAMPART, a cloud-based solution consisting
on a web application, used to upload and manage images and gen-
erate reports, and cloud storage. The system aims to provide access
to medical images at crucial time points from the beginning of a
trial, to archiving and future analysis. It has been designed with the
capacity for future trials to use, if required.
Results: The first phase of the system went live in October 2018, and
it is currently accessible by the RAMPART trial team, who upload im-
ages centrally, allowing further testing and fine-tuning of the remote
uploading functionality. The system will be available for sites’ use in
the second phase release, which is currently under development. Ap-
proximately 25 scans have been uploaded to date.
Discussion: We have implemented a cloud-based solution that lever-
ages the full security, cost and accessibility that is coincident with a
modern cloud-based system architecture. Current development is un-
derway to add to the existing system functionality, as well as to
make it easily configurable for other trials. This will provide the op-
portunity for large-scale storage of medical images at a low cost, fa-
cilitating the future proofing capabilities of clinical trials.
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Identifying factors limiting accrual and facilitating improvements:
experience of using an EDC system to capture screening data
Loretta Davies, Jonathan Cook, Heidi Fletcher, Beverly Shirkey, Akiko
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Introduction: Collection of screening data on patients considered for
trial participation has been indicated as a potential means of identify-
ing problems and facilitating improvements to recruitment.Collecting screening data, however, can be challenging and detailed
data on reasons for ineligibility and non-consent often difficult to ob-
tain. This paper describes the development and use of a bespoke on-
line electronic data capture (EDC) system, which was used to help
monitor and identify potential factors limiting accrual during the 12-
month pilot phase of an NIHR HTA funded trial: ACL SNNAP.
Methods: The bespoke online EDC system was developed in collab-
oration with Fr3dom Limited. A screening case report form captured
data on patients considered for trial participation and enabled docu-
mentation of specific reasons for non-inclusion (i.e. reasons patients
were ineligible or declined to participate). The form was completed
electronically and automatically populated an electronic screening
log, enabling immediate review of the collated screening data.
Results: Detailed screening data was available from 15/16 sites dur-
ing the pilot phase of this trial. Feedback from sites was positive with
main difficulties reported to be related to occasional online access is-
sues. The system enabled prompt review of data and collection of
consistent terminology for reasons for non-inclusion. Specific factors
contributing to recruitment difficulties were identified, such as, pa-
tients’ strong preference for particular treatment.
Discussion: Implementing an EDC system to capture screening data
enabled a more immediate review of the collated screening data
than potentially would occur with traditional paper recruitment logs.
The data permitted early identification of important factors limiting
accrual and enabled the implementation of specific changes to the
protocol and site training. Consideration of the use of EDC systems
to capture screening data should be made in future studies to sup-
port the timely identification of factors limiting accrual, and poten-
tially inform more effective trial conduct.P-63
Making performance metrics work: Developing a triggered
monitoring management system
Carlos Diaz-Montana, Lindsey Masters, Sharon B Love, Sarah Lensen,
Victoria Yorke-Edwards, Matthew R Sydes
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Introduction: Risk-based monitoring (RBM) strategies are encouraged
by regulators; ICH GCP E6(R2) guidelines recommend that trialists
should “develop a systematic, prioritised, risk-based approach to moni-
toring clinical trials”. The use of technology and in particular computer
systems are crucial in implementing efficient, systematic RBM ap-
proaches, such as triggered monitoring, where centrally monitored trig-
gers observing performance metrics, drive monitoring activities.
We explore the possibility of using a bespoke computer system to
help the implementation of a standard, systematic and adaptable
triggered monitoring strategy in the MRC Clinical Trials Unit (CTU).
Methods: Building on the experience gained in developing the RBM
system for the TEMPER study (Diaz-Montana et al 2019), we are de-
veloping a prototype of a triggered monitoring management system
which will offer trial teams the ability to program bespoke triggers,
set thresholds to highlight concerning behaviour, generate and
visualize data to inform monitoring actions, and collect data on find-
ings from monitoring visits. Triggers could evolve throughout the
trial by adjusting thresholds and other properties, adding triggers
with different performance metrics, while triggers that do not appear
to discriminate could be dropped.
Timing of Potential Results: A system prototype will be released and
trialling of the first triggers will start before October 2019.
Potential Relevance & Impact : We envision this type of system will
play a key role in implementing a more standard and efficient RBM
strategy across the CTU; we expect it will also allow us to collect trig-
ger usage data, identify temporal trends and patterns across triggers,
and observe correlations between triggers and visit findings;
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Moreover, we are designing the system to facilitate the implementa-
tion of methodological projects to identify standard triggers and best
practice in triggered monitoring, by providing a technological plat-
form where different approaches can be tested.P-64
Using study websites for more than just electronic data capture:
gaining trial management efficiencies
Seonaidh Cotton, Karen Campbell, Karen Innes, Mark Forrest, Graham
Devereux
University Of Aberdeen, United Kingdom
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Introduction: There are many commercial data capture solutions
available for both trials management and electronic data capture,
but an advantage of building bespoke software is the inclusion of
added functionality. In this abstract, we describe some administrative
tools and functionality that can be included in our study websites.
Site administration: With this functionality we register a site on the
study website as soon as they express interest. The regulatory and
greenlight processes required prior to opening the site are then cap-
tured within this functionality, eg REC approval for the site, progress
of the site agreement (to signature), SIV training and R&D approval.
People administration: With this functionality we register the people
working at the recruitment site and can then link them to that re-
cruitment site. We record names, contact details, dates working on
the study, date of GCP training, date of CV etc.
Greenlight checklist: From the information entered into the site and
people administration, the greenlight checklist for the site (docu-
menting all the agreements are in place and documents available)
can be generated automatically for confirmatory signature.
Contact lists: The email contact details entered into the people ad-
ministration are used to generate email lists for study updates; these
lists can be generated by site, by role or for everyone involved in the
study.
Reporting: From the information captured, we generate progress re-
ports on site opening and metrics describing time between, for ex-
ample expression of interest to greenlight. We can also run regular
reports in relation to GCP training that might need to be repeated.
Discussion: This website functionality has been implemented in a
large multi-centre drug study. The efficiencies gained have helped
the two part time trial managers greenlight 52 sites over a seven-
month period and to start the regulatory and greenlight process for
a further 100 sites.
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Predicting serious adverse events in cardiac surgery patients using
real-time vital sign monitoring
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An early warning score (EWS) is a worldwide guide for healthcare
practitioners to expedite medical decisions that help prevent the oc-
currence of serious adverse events (SAEs). The national early warning
score (NEWS) is the EWS currently recommended by the Royal Col-
lege of Physicians and has been in use for the routine clinical assess-
ment of adults in many UK hospitals since 2012. However, this guide
has not been derived for particular patient populations. In addition,
its additive feature based on categorised continuous physiological
parameters, may undermine its ability to predict the onset of a SAE.
This reasons lead us to investigate NEWS for cardiac patients and de-
velop a potential early warning score system.In our work we evaluated the predictive performance of a selection
of statistical and machine learning methods (such as logistic regres-
sions, tree-based methods, neural networks) as well as NEWS. The
dataset used is confidential and composed of the vital sign observa-
tions of cardiac patients admitted to Royal Papworth Hospital in
Cambridgeshire from 2014 to 2017. The composite SAE we used con-
sists of ICU re-admission, Cardiac arrest or death. The primary out-
come is whether an observation captures a SAE in 24 hours before
the onset. We mainly used two validation protocols for evaluating
predictive performance. In addition, we adopted area under receiver
operator curve, sensitivity and specificity as performance measures.
We not only prove that NEWS may be inadequate to be utilised for
cardiothoracic patients, but also provide evidence of the superiority
of other predictive modelling methods. In particular, multi-level logis-
tic regression showed the greatest improvement in predictive power
when compared to NEWS due to the increased level of personalisa-
tion and information included in the model.
We conclude that future methods should take patient-level informa-
tion into account when making predictions.P-66
The MRC HTMR recruitment working group: Driving recruitment
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Introduction: The Hubs for Trials Methodology Research (HTMR)
were set up by the UK Medical Research Council (MRC) in 2009 to
create a UK-wide resource to improve the design, conduct, analysis,
interpretation, and reporting of clinical trials. Collaborations and net-
working were fostered through working groups focusing on key pri-
ority areas for the UK trials community.
Methods: The remit of the Recruitment Working Group (RWG) is to
develop, implement, and evaluate recruitment interventions in clin-
ical trials and promote/cultivate new ideas and studies to improve
the efficiency of recruitment research through collaboration.
Potential relevance and impact: Two landmark studies in recruit-
ment research were reported in 2017, specifically the ORRCA online
resource for recruitment research (a RWG collaborative project) and
the PRioRiTy study that identified the top ten questions for recruit-
ment research. These, along with systematic review evidence, were
discussed by 20 RWG members, in a face-to-face meeting, and future
RWG activities prioritised.
Three key research areas were identified by the RWG: the core in-
formation needs of clinical trial participants (PRioRiTy question 5),
core training activities for health professionals working on a clinical
trial (PRioRiTy question 6), and the inclusion of under-represented/
minority groups within clinical trials (PRioRiTy question 8).
Sub-working groups for each of the three research questions have
been established representing cross HTMR collaboration. Research
proposals are in development that will address the research ques-
tions prioritised by the RWG and to develop SWAT protocols for fu-
ture evaluation across multiple trials. The RWG has enabled a
collaborative, innovative, cohesive, efficient network of researchers
interested in trials methodology consolidating efforts to achieve
more than the sum of the parts and built a solid foundation for fu-
ture growth and expansion as the network develops.
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Introduction: Around 5,000 people are waiting for a kidney transplant in
the UK. Half of UK potential deceased donors are over 60 years old, but
only 28% of kidneys are eventually transplanted from this pool.
The PITHIA (Pre-Implantation Trial of Histopathology in Renal Allo-
grafts) trial is now open and will assess whether introducing a na-
tional, 24-hour digital pathology (biopsy) service increases the
number, and improves outcomes, of kidney transplants from donors
aged over 60 in the UK. The stepped-wedge, registry-based design is
a pragmatic and cost-effective approach, but logistically, this trial
was complex to implement.
Methods: For the trial to work, it needed to be fully embedded into many
teams within NHS Blood and Transplant. This included the Organ Donation
and Transplantation Hub who coordinate donor organ allocation, the 200+
Specialist Nurses in Organ Donation and the ten abdominal retrieval teams.
Biopsy processing is provided by six NHS Histopathology Laboratories,
which use digital slide scanners to send biopsy microscopic images re-
motely to one of twelve on-call Specialist Histopathologists.
Results: Embedding the trial required extensive relationship building,
training and the development of a range of Standard Operating Pro-
cedures and logistical tools. To illustrate the complexity: the first bi-
opsy was requested for a donor in the Isle of Wight. The Cambridge
Organ Retrieval team attended the donor and performed a biopsy,
which travelled with the team for processing by the Cambridge la-
boratory. The on-call Histopathologist in London reviewed the bi-
opsy, with the report then relayed to the Belfast transplant team
who were implanting the kidney.
Discussion: Collaboration across this unique community, utilisation
of existing networks and the development of supportive tools has
enabled this trial to be implemented on a UK-wide scale. The PITHIA
trial provides a template by which future introductions of large-scale
services can be assessed effectively.P-68
Recruitment rates vary when recruiting outside of the UK versus
within the UK: Data from the international Tranexamic acid for
hyperacute primary IntraCerebral Haemorrhage (TICH-2) study
Nikola Sprigg, Lisa Woodhouse, Diane Harvard, Lee Haywood, Philip M
Bath, on behalf of the TICH-2 Investigators
Stroke Trials Unit, Division of Clinical Neuroscience, University Of
Nottingham, United Kingdom
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Background: TICH-2 was an international randomised controlled trial of
tranexamic acid after intracerebral haemorrhage. Here we assess whether
recruitment rates were affected by recruiting country.
Methods: TICH-2 was performed in 12 countries (Denmark, Georgia,
Hungary, Ireland, Italy, Malaysia, Poland, Spain, Sweden, Switzerland,
Turkey, and the UK). Ethics and regulatory approval was achieved ineach country before recruitment to the study could commence. Re-
cruitment rates were calculated as mean number of participants re-
cruited per site or country per month. Rates were compared between
UK and non-UK sites.
Results: In total 149 sites were set up for recruitment, 109 UK and 40 non-
UK; 15/109 UK sites (14%) and 10/40 non-UK sites (25%) failed to recruit
any patients.
2,325 participants were recruited over 54 months (11 March 2013 to 30
September 2017) from 124 sites in 12 countries. 1910 (82%) were recruited
within the UK (first participant 11 March 2017) and 415 (18%) were re-
cruited outside of the UK (first non-UK participant 11 Dec 2013).
Overall the mean recruitment rate was 42.5 participants per month,
the maximum monthly recruitment was 43.3 participants. For the UK,
the maximum monthly rate was 35.9 participants per month, re-
cruited at a mean rate of 34.9 participants per month (range 0.01
-2.2 participants/site/month).
In a direct comparison, there were 415 non-UK participants, recruited
at a mean rate of 7.6 participants per month. For non-UK countries,
the maximum monthly rate was 9 participants per month (range 0.06
– 3.28 participants/country/month). 3 countries recruited their first
participants more than 36 months after the opening of the trial.
Conclusion:
The majority of sites recruited participants, but recruitment rates var-
ied widely. Regulatory approval took longer in Non-UK sites. Future
studies should allow longer set up time for international sites. Mea-
sures to ensure all sites enrol participants should be explored.P-69
Compensation for trial related injuries: what are we waiting for?
Ayat Ahmadi, Ehsan Shamsi
Tehran University of Medical Sciences, Tehran, Iran
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Introduction: Trial Related Injuries (TRIs) are the occurrence of injur-
ies for participants in trials that would not have happened if they
had not participated in that trial. This study mapped evidence about
compensation for TRIs and analyzed the situation of Iran, as a case of
developing country with a high number of RCTs. A manual for TRIs
compensation was developed as well.
Methods: a mixed method study including a comprehensive review
of related literature and a qualitative study consisting of 3FDGs and
16interview, was conducted. Quantitative data was gathered from 50
academic members of ethic committees.
Results: Academic-Initiated vs. industry-initiated RCTs, casual rela-
tionship between the injury and the study, study costing, and in-
crease in the induced demand for participation in RCTs were the
most frequent challenges pointed out in literature. In qualitative
section, drug companies stated that insurance companies are not
interested to taking part in this topic. Insurance companies were
worried about how to measure the study attributes risk for an in-
jury and who is responsible for making the final decision. Regula-
tory bodies were interested in ways to determine high risk
studies and trial protocol considerations. Researchers were agreed
on considering TRIs compensation in industry initiated studies,
but they though it increases the cost of academic studies. In the
quantitative part, participants mentioned to the contribution of
insurance companies is the best solution for industry initiated
studies(42%) but not for academic studies. There were agreement
on the ethic committees as the en-charge entity to approve
protocols(63%).
Discussion: Consideration for TRIs compensation in trial protocols
brings advantages for various stakeholders. It prevents civil causes
and increase authenticity and confidence around the study results. It
also prevents unjustified trials. In this study we provided a guideline
in 4 seasons,45 articles and 4 appendix concerning definitions, injur-
ies, risk assessment and compensation process.
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Establishing the International Prediction of Pregnancy
Complication (IPPIC) collaborative network – Harmonising an
international database
John Allotey, Shakila Thangaratinam
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Introduction: Pre-eclampsia, stillbirth, fetal growth restriction, and
spontaneous preterm birth are all adverse pregnancy outcomes sus-
pected to follow similar pathophysiology. Over a hundred systematic
reviews have been published to date, to identify factors for predict-
ing these outcomes and even more risk prediction models devel-
oped. We set out to establish the IPPIC Collaborative Network of
global researchers to access individual participant data (IPD) from
existing studies and large databases, to reach a consensus towards
well developed, and externally validated prognostic models.
Methods: We identified primary studies, and large birth or
population-based cohorts studies with information to assess the
accuracy of clinical characteristics alone or in combination with bio-
chemical and ultrasound markers for the prediction of various ad-
verse pregnancy outcomes, through systematic review of reviews
and reviews of existing prediction models. Strict range and
consistency checks ensure data quality and the PROBAST Tool was
used to assess dataset quality. Missing data over a pre-specified limit
or inconsistencies between pre-identified variables were queried and
rectified with original author input.
Results: The network brings together more than one hundred re-
searchers, clinicians, and epidemiologists from over 25 countries. The
collaborative group agrees the minimum data to be requested, and
authors of the primary studies/datasets are contacted to share their
IPD. All requested data including those not reported in the published
studies are obtained. The database is set-up as a living database, so
can be added to as new studies or datasets become available.
Discussion: Standardizing and harmonizing IPD from various
sources for analysis requires committed involvement and partici-
pation by the original study team. A pre-defined harmonization
process is required, with clear definitions of predictors and out-
comes to aid standardization. A living database such as the IPPIC
repository with >3M pregnancies provides unique opportunities
to answer research questions related to the prediction of various
pregnancy outcomes.P-71
Identifying and learning from non-commercial trials submitted in a
pivotal role in a licensing submission to the European Medicines
Agency
Andrew Embleton, Matthew Sydes, Rick Kaplan, Mahesh Parmar
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Isolated case studies of non-commercial trials being used in market-
ing authorisation applications are known to experienced researchers
but are rarely published in the academic literature. As a conse-
quence, little formal knowledge exists of the experience gained from
these attempts to increase the number of approved medicines avail-
able for patients.
A literature search for published case studies uncovered extremely
limited results, so other sources were sought. The European Medi-
cines Agency (EMA) publish abbreviated assessment reports online
for all applications. From 1417 submissions, we identified 109 with
non-commercial trial involvement. Defining major involvement as a
pivotal trial which would require extensive evaluation of the trial byEMA, 25 (23%) were major uses, 42 (39%) minor and 42 (39%) were
micro.
Several products were assessed together by the EMA due to their
similarity, leaving 22 unique appraisals. 17 of these 22 (77%)
reviewed were given a positive opinion. Of those approved, 7 were
initial-evaluation applications and 10 were extensions. 9 initial-
evaluation applications were submitted in total, with the 78% ob-
served approval rate similar to the all-encompassing 2018 85%
initial-evaluation approval rate. Five applications were withdrawn/re-
fused, with two being initial-evaluation applications and the rest ex-
tensions. Four of these had major objections due to the GCP conduct
of the pivotal non-commercial trial. The volume of applications in
rare diseases was much higher in our subset than observed gener-
ally, arguably an illustration of non-commercial trials being con-
ducted in neglected populations.
The use of non-commercial trials in regulatory submission is more
widespread than the academic literature would suggest. Review-
ing EMA applications, we highlight that, while there are clear les-
sons to be learnt with respect to GCP conduct, the approval rate
of non-commercial trials compares well with those utilising only
company-led trials. Marketing approval on the basis of a non-
commercial trial is an opportunity to expand patient choice.
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Background: Iran has been encountering a sharp growth in the num-
ber of industry and academic initiated clinical trials during recent
years. It brought intense demands to meet regulatory and methodo-
logical standards. Therefore, new requirements in term of regulatory
demands and ethical considerations, that could not be accomplished
in university departments, have come up. In 2012, Tehran University
of Medical Sciences (TUMS) with active collaboration from Iran FDO
established a clinical trial center (CTC) aiming to institutionalize Good
Clinical Practice (GCP) as an ethical and scientific international stand-
ard in clinical trial in Iran.
Activities: Iran’ FDO recognizes CTC as the academic entity to train
and accredit researchers based on GCP principles over the country.
In doing so, number of face-to-face or online courses has been hold-
ing by CTC. It includes RCT-GCP introductory courses(n=20) , GCP ad-
vanced courses(n=18); GCP monitoring courses(n=8), short courses
on special topics such as project management, biostatistics, special
designs, ethical consideration(n=8), customized courses based on re-
quests and participant eligibilities and study specific courses in order
to empower clinical trial staff of a specific study(n=12).
CTC participates in performing high quality trials through consultant
meetings, developing protocols and SOPs, carrying out site visits and
site monitoring, statistical advocacy and promoting studies in respect
to ethical and regulatory considerations. Furthermore, CTC supervises
high risk academic initiated trials in TUMS. It also provides special
services to initiate and perform trials in the university.
CTC initiated the first private Knowledge-based Clinical Research
Organization (CRO) in Iran that works closely with Iran’ FDO to en-
hance standards of conducting industry-initiated clinical trials by pro-
viding functional services to the pharmaceutical, biotechnology and
medical device industries.
Perspective: CTC is aiming to enhance international collaboration to
preserve and promote its national capacity for high quality services
and to develop capacity to stabilize international collaboration.
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Development of a resource to guide set-up and conduct of
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Increasingly clinical trials research needs to adapt to the changing
health environment as we move to personalised health approaches,
a greater awareness of the need to inform global health and to ad-
dress generalisability across cultures and health service structures.
This leads to the requirement for international collaboration in clin-
ical trial conduct. International trial conduct is however more com-
plex which can cause significant time delays, hinder efficient delivery
and hence delay the potential for patient benefit.
The Clinical Trials Research Unit (CTRU) at the University of Leeds, UK,
has experience of running a number of international surgical trials, all of
which faced varying challenges during set-up and implementation resulting
in significant delays. With these issues in mind, the CTRU successfully bid
for funding from a call issued by the UK’s National Institute for Clinical Re-
search (NIHR) which focussed on supporting efficient/innovative delivery of
clinical trials. The funding enabled the development of an international tri-
als toolkit for use by UK researchers, to guide the efficient set-up and con-
duct of international surgical trials and therefore improve the delivery of
research.
This project was led by the Leeds CTRU and brought together expert-
ise from other UK based clinical trials units with experience of run-
ning international surgical trials. The toolkit content is based on the
obstacles and successes encountered by these CTUs in coordinating
and delivering international trial collaborations from the UK.
The toolkit includes suggested collaborative models for trials running
internationally, case studies, links to existing resources and key con-
siderations. Areas for considerations covers sponsorship, finance, con-
tracts, insurance, research governance, protocol, monitoring, trial
supplies, data collection, sample collection, health economics/PROMS
and data ownership/publication. Each section also covers different
models of working along with key issues and practical advice on
how to approach the difficulties that currently hinder the delivery of
international surgical trials.
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Impact of a Collaborative Clinical Trials Methodology Course on
Trainees’ Funding and Clinical Trials Activity
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Introduction: Clinical trials are challenging, and many junior investigators
lack the skills to move through phases in a coherent way. To address this,
the National Institute of Neurological Disorders and Stroke Clinical Trials
Methodology Course (CTMC) was created through cross university collabo-
rations to provide junior investigators with relevant training to promote
well-designed clinical trials. This study aims to explore the impact of CTMC
by determining the trajectory of U.S. National Institutes of Health (NIH)
funding and clinical trials activity in trainees after completion of the course.
Methods: The online databases NIH RePORTER and ClinicalTrials.gov
were searched respectively to determine NIH funding and clinical tri-
als activity of each CTMC trainee between 2014-2017. Data wascollected on the Project Start Date of the first NIH grant and the
Study Start Date of the first non-withdrawn clinical trial each trainee
had after taking CTMC. Grants or trials prior to CTMC were noted.
The date of a trainee’s CTMC was designated as January 1st of the
year following course completion. Time until grant or clinical trial
was calculated as the difference between the Project/Study Start
Date and the trainee’s CTMC date.
Results: There were 131 CTMC trainees between 2014-2017. As of
early 2019, 23.7% of these trainees received a NIH grant and 43.5%
became involved in a clinical trial after the course. Excluding those
with prior experience, 11.5% of all trainees received their first-ever
NIH grant and 27.5% became involved in their first-ever clinical trial
following completion of CTMC. For all trainees who received a NIH
grant or became involved in a clinical trial after the course, the me-
dian times to these achievements were 1.1 years (IQR 0.5-1.9 years)
and 1.2 years (IQR 0.6-2.2 years), respectively.
Discussion: These results suggest that completing CTMC may help
promote successful funding and clinical trials by junior investigators.P-75
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Introduction: Trials to prevent or ameliorate frailty are in their in-
fancy. A range of different outcome measures have been proposed,
but current measures require either large sample sizes, long follow-
up, or do not directly measure the construct of frailty.
Methods: We propose a composite outcome for frailty prevention
trials, comprising progression to the frail state, death, or being
too unwell to continue in a trial. To determine likely event rates,
we used data from the English Longitudinal Study for Ageing,
collected 4 years apart. We calculated transition rates between
non-frail, prefrail, frail or loss to follow up due to death or illness.
We used Markov state transition models to interpolate one- and
two-year transition rates and performed sample size calculations
for a range of differences in transition rates using simple and
composite outcomes.
Results: The frailty category was calculable for 4650 individuals at
baseline (2226 non-frail, 1907 prefrail, 517 frail); at follow up, 1282
were non-frail, 1108 were prefrail, 318 were frail and 1936 had
dropped out or were unable to complete all tests for frailty. Transi-
tion probabilities for those prefrail at baseline, measured at wave 4
were 0.176, 0.286, 0.096 and 0.442 for non-frail, prefrail, frail and
dropped out. Interpolated transition probabilities were 0.159, 0.494,
0.113 and 0.234 at two years, and 0.108, 0.688, 0.087 and 0.117 at
one year. Required sample sizes for a two-year outcome were be-
tween 1000 and 7200 for transition from prefrailty to frailty alone,
250 to 1600 for transition to the composite measure, and 75 to 350
using the composite measure with an ordinal logistic regression
approach.
Conclusion: Use of a composite outcome for frailty trials offers re-
duced sample sizes and could ameliorate the effect of high loss to
follow up inherent in such trials due to death and illness.
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Assessment of outcomes for inflammatory bowel disease in
routine clinical practice: an ethnographic study
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Introduction: There is growing interest in utilising routinely collected
outcome data to support efficient, pragmatic trials. In the area of in-
flammatory bowel disease (IBD), there are initiatives to standardise
outcomes for trials (Core Outcome Sets) and routine health records
(e.g. ICHOM) . Our aims were to explore variability in outcome assess-
ment in clinical practice and the use of two common symptom-
based indices promoted for routine use by the UK Biologics Audit
(Harvey-Bradshaw Index [HBI] and Simple Clinical Colitis Index
[SCCAI]).
Methods: We performed ethnographic observations of 76 IBD clinic
consultations conducted by 19 IBD clinicians (9 consultants, 7 IBD
nurses and 3 trainees) in five acute hospitals in the North West re-
gion of England. Consultations were audio-recorded, transcribed and
analysed for pre-defined IBD outcomes elicited by clinicians and/or
volunteered by patients during patient-physician encounters, includ-
ing those items required for HBI and SCCAI.
Results: Most commonly elicited outcomes were general wellbeing
(76 [100%]), abdominal pain (61 [80%]), stool frequency (56 [74%]),
blood in stool (54 [71%]), and stool consistency (46 [61%]). HBI and
SCCAI were collected in only 14 (18%) consultations. In the remaining
62 consultations, items of HBI and SCCAI were discussed in variable
detail. Complete HBI coverage: 5/33 (15%) consultations. Symptom
components of HBI (wellbeing, liquid stools, abdominal pain): 10/33
(30%) consultations. Complete SCCAI coverage: only 1 consultation.
Partial coverage (5 out of 6 SCCAI items): 5/29 consultations (17%).
Selected symptoms were elicited significantly more often by nurses
compared to doctors.
Discussion: There is significant variability in the breadth, depth and
quantification of outcomes during routine clinical assessments. Al-
though most items of clinical disease activity indices were elicited,
formal scoring and assessment over fixed time periods was rare. In-
terviews explored barriers and facilitators to capturing structured
outcomes in routine records.P-77
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Introduction: Infants born with a cleft palate can suffer from delayed
speech development when compared to non-cleft infants. Whilst
speech development during early years is paramount, assessing
speech both accurately and efficiently to ensure the validity and reli-
ability of results requires careful consideration.
Methods: TOPS is an international two-arm randomised controlled
trial aiming to determine whether it is better to perform primary cleft
surgery at age six or twelve months. Infants with cleft palate were re-
cruited from 23 centres in the United Kingdom, Scandinavia and
Brazil. Speech outcomes are assessed at age twelve months, three
and five years by thirty international speech and language therapists.
Spontaneous speech recordings of each infant were taken at eachtime point for independent assessments of trial outcomes. Prior to
twelve-month speech outcome assessment, extensive calibration and
training was undertaken to ensure reliability of the outcomes and a
good level of agreement within and between assessors.
Results: The trial recruited 558 infants, of which 485 (87%) had
speech recorded at twelve months. Pre-outcome assessment cali-
bration and training indicated that outcomes assessed by three in-
dependent assessors were equivalent to four. Assessors
independently classified the infants as the same ability in at least
85% of infants when assessing both binary and continuous speech
outcomes. Speech recordings were considered representative of
day-to-day ability, with parents’ assessment of ability agreeing with
the independent therapists in 87% of infants. A good level of inter-
and intra-rater agreement was identified for common sounds pro-
duced by the infants, although agreement varied across languages.
Discussion: Accurate and efficient speech outcome assessment re-
quires careful planning. Further considerations may be required for
assessments across languages. We present the steps taken to ensure
valid and reliable speech assessments within the TOPS trial.P-78
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A core outcome set for seamless, standardised evaluation and
reporting of outcomes throughout the surgical device innovation
lifecycle
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Introduction: Development of new surgical procedures and devices
(e.g. pacemakers, implants) is not well regulated; rigorous evaluation
is uncommon and reporting unstandardised. Detailed guidance on
selecting and reporting outcomes at different developmental stages
is lacking. Development of generic core outcome sets (COS) with a
minimum set of outcome domains to be reported at each phase of
device development is one strategy to promote safe and transparent
evaluation.
Methods: A modular COS is being developed according to COMET
(Core Outcomes Measures in Effectiveness Trials) and COS-STAD
(Core Outcome Set - Standards for Development) guidelines. The
study has three phases:
1.Generation of an outcome long-list identified from: (i) published
studies of innovative procedures and devices, (ii) NHS new proce-
dures committee policies, (iii) regulatory documentation, (iv) qualita-
tive interviews with surgeon-innovators. A conceptual framework for
outcome domain categorisation is being iteratively developed. Out-
come domains identified will be formatted into questionnaire items
for a Delphi consensus survey.
2.Key stakeholders, including 50 patients and 150 professionals (sur-
geon-innovators, device manufacturers, regulatory representatives,
journal editors), will complete the survey to rate the importance of
including outcomes in a COS.
3.Stakeholder consensus meeting(s) to discuss and agree the final
COS(s) and accompanying guidance.
Results: A long-list was generated comprising 7,302 verbatim out-
comes identified from 141 published studies (40 devices) and 17
Trust policies. Outcomes were categorised into domains and format-
ted into questionnaire items. Following internal piloting with sur-
geons and academics the survey consists of 47 and 27 items for
reporting guidelines and COS inclusion respectively. The survey com-
mences in May 2019.
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standardised, outcome evaluation throughout the surgical device life-
cycle are being developed. This will promote safe and transparent
evaluation of innovative devices by reducing outcome reporting bias,
improving the detection of emerging signals of promising or harmful
innovationsP-81
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Ascertainment bias: accounting for differential STI screening
frequency in a HIV prevention trial
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Background: Ascertainment bias is a phenomenon whereby the
more screening that is conducted, the larger the number of out-
comes detected. PROUD, a pragmatic trial, investigated the effective-
ness of pre-exposure prophylaxis (PrEP) in preventing HIV acquisition.
A key secondary outcome was sexually transmitted infection (STI)
diagnoses. However, clinic attendance, and therefore STI screening
frequency, was higher amongst participants receiving PrEP. We de-
scribe the impact and relevance of adjusting for the number of
screens in an analysis.
Methods: PROUD randomised participants to receive PrEP immedi-
ately (IMM) or after a twelve-month deferral period (DEF). The out-
come was defined as the total number of STIs (chlamydia,
gonorrhoea, or syphilis) detected during the randomised phase.
Negative binomial models were used to allow for heterogeneity be-
tween participants. Unadjusted models and models adjusting for the
number of STI screens (as a linear term) were compared.
Results: There was a significant difference in the number of screens
between IMM and DEF (mean 4.1 vs. 3.6, P<0.001). STI incidence was
higher amongst the IMM group (114.7 vs. 94.3/100PY). After adjust-
ment, the incidence rate ratio (IRR) shifted towards the null (IRR=1.2
(95% CI:1.0-1.5), P=0.08 to aIRR=1.1 (95% CI:0.9-1.4), P=0.28).
Conclusions: Adjusting for the number of screens has been used in
several PrEP studies to account for ascertainment bias. However, it
can be seen as an external confounder (e.g. additional screening
driven by clinic attendance for PrEP - which we want to adjust for) or
a variable that lies on the causal pathway (e.g. clinic attendance
driven by symptoms, which we do not want to adjust for). Simple
statistical adjustment that does not discriminate between reasons for
screening is likely to over-adjust for factors related to STI risk. There-
fore unadjusted analyses provide a more clinically relevant insight
into the PrEP effect on STIs.P-83
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accelerometry in e-coachER - a randomised controlled trial of web-
based support in exercise referral schemes
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Introduction: Adult patients referred to an exercise referral scheme
(ERS) were recruited from primary care to the e-coachER trial
(ISCRTN15644451). Participants were randomised to usual ERS +/-
web-based support. The primary outcome was physical activity (PA)
level at 12 months, objectively measured using a GENEActiv™ Ori-
ginal accelerometer. This wrist-worn accelerometer is scientifically
validated for clinical trials and designed for 24-hour wear.Methods: Participants (N=450) were asked to wear an accelerometer
continuously over 1 week at baseline, 4 and 12 months, returning
the accelerometer to CTU by post on each occasion.
On return, participants received a £20 shopping e-voucher. The ac-
celerometer was physically cleaned, re-charged, raw data extracted,
and the accelerometer returned to the pool.
PA was analysed according to pre-defined thresholds for wear-time
and activity, to derive parameters of interest (e.g. wear-time ≥16
hours per day, activity in ≥10 minute bouts).
Results: At 12 months, 329/356 (92%) participants returned the accel-
erometer. Once the thresholds were applied, data were available for
primary analysis for 243/356 (68%) participants. 67% of the e-
vouchers issued were claimed. 165 accelerometers were required
(costing c£150 each) to deliver the trial; 66 were never returned to
the CTU.
Discussion: Learning points on use of accelerometry:
•When pre-defining thresholds for accelerometer-derived PA out-
comes, potential attrition of primary outcome data and the impact
on assumptions for the trial’s power calculation, should be assessed.
•Unlike commercially available wearable fitness trackers, activity level
is not visible or accessible to the wearer of the GeneActive™ Original
accelerometer; the accelerometer is not useful to a participant be-
yond use in the trial. Even so, accelerometers were not returned to
CTU, at considerable cost.
•A bespoke database, built and maintained by the CTU, was critical
to managing accelerometer stock versus demand across multiple
sites, and enabled automatic issuing of e-vouchers to participants.
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Background: The win ratio approach has been proposed and applied
in analysis of composite endpoints (e.g. cardiovascular death and
heart failure hospitalisation) and continuous non-normal outcomes in
clinical trials. The win ratio method has the advantages of easy-to-
use for reporting composite endpoints and giving appropriate prior-
ity to the more clinically important event. However, no literature is
available on sample size estimation based on the win ratio approach,
which has limited its application in the design of clinical trials.
Methods: This study will provide a sample size estimating procedure
based on the win ratio method. The statistical power of win ratio
method will be compared with other statistical methods such as Cox
model, Anderson-Gill model and Poisson model for dealing with the
composite endpoints using some real trial datasets as well as simu-
lated datasets. By simulations, we will generate a series of sample
size tables under various scenarios.
Timing of Potential Results: We have three trial datasets available.
The literature review, statistical analysis and simulations are un-
derway, and the results will be ready by the end of September
2019.
Potential Relevance & Impact: We expect that the sample size esti-
mation procedure and the sample size tables can be used as guide-
lines for making informed decisions on the sample sizes required in
designing a trial with a composite endpoint as its primary endpoint.
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Introduction: Personalised medicine is advancing at an ever-
increasing pace, with the possibility of routine genetic testing to
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sential that the views of the public are included in this advancement.
We are designing an experiment to measure the general public’s
opinions about genetic testing to prevent adverse drug reactions.
This will take the form of a discrete choice experiment (DCE), a sur-
vey design which allows us to quantify preferences.
Methods: A DCE requires participants to ‘trade-off’ different aspects
of genetic testing. For example, we may find that people are willing
to wait an extra month to receive results if the accuracy of the test
was higher. Using this design allows us to provide quantitative an-
swers to the question of public preferences.
To ensure the generalisability, relevance, and accuracy of results,
qualitative work to inform DCE development is essential. We are
planning to use online questionnaires with a patient group and with
clinicians, followed up with focus groups with the general public. We
are hoping to use a market research company to administer the sur-
vey, as they have access to a UK-representative panel and can return
results within 48 hours.
Timing of Potential Results: At the time of abstract submission, we
are awaiting ethical approval to begin the study. Once this is re-
ceived, we anticipate spending 3 months on qualitative work, and 2
months for data analysis.
Potential relevance and impact: We are doing this to ensure that
the views of the general public are heard and can inform future
developments in personalised medicine. Quantifying using a DCE
provides clear results to policy-makers and clinicians. This in-
creases the likelihood of public acceptance of personalised medi-
cine interventions.P-86
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Background: Public involvement as advisors in health research stud-
ies is becoming an established norm. However, scrutiny of the litera-
ture indicates that public involvement is predominantly described in
clinical evaluation studies, such as trials of medical interventions. The
value and role of public involvement in studies which are theoretical
or methodological, such as the development of new statistical
methods, are less well reported. We aimed to explore the value of
having public advisors on these types of studies where, in contrast
to clinical studies, their input is not drawing on patient experience.
Methods: A qualitative study, using focus groups with members of
the public and with researchers, was used to explore the perceived
role and value of public advisors in types of health research which
are not clinical research studies. Focus groups were recorded, and
transcribed, and qualitative data analysis software was used to sys-
tematically store and retrieve data during thematic analysis.
Results: Fifteen public and nine researcher participants took part in
the study. Examination of the data suggested themes relating to po-
tential benefits from public involvement; challenges to involvement;
and opportunities provided. The data indicated potential for public
involvement at different stages of the research cycle in all studies, in-
cluding those which are more theoretical or methodological in na-
ture, such as methods development in clinical trials.
Discussion: Involving the public as advisors in all forms of research
adds value, and the study confirms that involvement should not be
confined to research evaluating clinical interventions. The study pro-
vides information for health researchers in areas where public in-
volvement may be less established, such as methods development in
clinical trials. Involvement in these research areas has the potential
to add diverse forms of knowledge, provide legitimacy, and aid
impact.P-87
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Introduction: Involving service users in the design and conduct of re-
search has been encouraged in government policy, but it is rarely
achieved, especially at trial initial stages. Co-design implies genuine
partnership in the generation of knowledge between service users
and researchers. This paper shows a step-by-step co-design approach
used to adapt an existing manualised social cognition intervention
for people with a first episode of psychosis to a virtual world
environment.
Methods: Clinical researchers, IT programmers and a group of young
people who have used mental health services were invited to partici-
pate in the design of a virtual environment to deliver an accessible
social cognition intervention to a hard to engage service user group.
An iterative process between service users and the design team was
set up and included developing initial ideas, creating a prototype
and testing the virtual world.
Results: Twenty young service users of local mental healthcare ser-
vices participated in the design and planning of intervention deliv-
ery. Young people felt the virtual environment should be familiar,
urban spaces, akin to therapy rooms or classrooms they have used in
real-life situations rather than non-traditional therapy spaces that
were initially proposed. Findings reflected the demographic makeup
of the sample.
Discussion: After the co-design process, the specific design, ap-
proach and protocol was tested in a proof-of-concept trial with
young people who experienced a first episode of psychosis. Young
service users were integral to an agile and iterative design. Techno-
logical innovations should be routinely co-designed and coproduced
if they are to realise their potential to deliver acceptable and afford-
able mental health interventions.
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Introduction/Aims: This trial is investigating Transcranial Magnetic
Stimulation (TMS) as a treatment for patients with moderate to se-
vere treatment resistant depression. From the outset the research
team were keen to involve service users or carers with lived experi-
ence of managing depression, in order to optimise engagement with,
and retention of participants.
Methods: Throughout the trial set up and current phase of recruit-
ment we have imbedded LEAP in all activities by: -scheduling on-
going quarterly (LEAP) meetings; involving members who either
have received TMS treatment, participated in previous TMS trials, or
have experience of treatment resistance depression, all local to the
Trials 2019, 20(Suppl 1):579 Page 26 of 141research sites; including LEAP members in reviewing trial documents;
completing a practice run-through of trial assessments; inviting LEAP
members to sit on the interview panel for recruitment of trial staff.
Findings: LEAP feedback was invaluable in the development of this
trial and enabled the research team to make key changes, e.g. avoid-
ing medical jargon within participant facing trial documents, specific-
ally the information sheet, consent form and advertising materials.
LEAP members also advised on visit structure, suggested changes to
outcome measures, and highlighted the importance of consistency
in patient-staff relationships. Following this advice, the treatment
period was extended to allow participants more flexibility for attend-
ance. Additionally, LEAP members’ inclusion in the interview process
ensured that empathetic trial staff were appointed.
Conclusion: By involving patients with lived experience from the out-
set, several changes were made to the trial design to improve patient
experience. The outcome has been promising thus far and we will
continue these strategies, involving LEAP members in all dissemin-
ation activities. Using this approach throughout the trial has the po-
tential to improve the experience of participants, and therefore has
implications for participant retention in future clinical trials into
depression.
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Introduction: Previous studies show that participants want to be in-
formed of the overall results of trials they have taken part in, but that
this often does not happen. Anecdotal reports suggest even when
trials do attempt to communicate results to participants, it is often
not done well. Show RESPECT tests three approaches, identified and
developed through extensive PPI, to communicating trial results to
UK participants of ICON8, a phase III ovarian cancer chemotherapy
RCT.
Methods: Show RESPECT is a mixed methods cluster randomised fac-
torial Study Within A Trial (SWAT), run within ICON8. Over 40 ICON8
UK centres (hospitals) are being randomised to communicate results
to participants using combinations of:
-Link to a basic webpage (text only) vs enhanced webpage (including
diagrams, video, links to further support and information, and the
option to submit questions)
-Printed summary vs no printed summary
-Invitation to join an email list vs no invitation
The primary outcome measure (OM) of Show RESPECT is participant
satisfaction with how the results are communicated. Data are col-
lected from participants, site staff and CTU staff by questionnaires,
and qualitative interviews are being carried out with site staff and
participants.
Secondary OMs include uptake of the interventions, which is mea-
sured using analytic data from customised links (for webpages and
email list) and data collected on logs by site staff (printed
summaries).
Timing of potential results: The final sites will be randomised in May
2019. We will present data on the PPI process and intervention up-
take (available from August). Results from the primary outcome will
be presented at a later date.
Potential relevance and impact: These data have the potential to in-
form future approaches to better communicate overall results to
similar participant populations in other trials, helping trialists meet
their ethical obligations to offer results to patients in accessible ways.P-90
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Introduction: There is a lack of evidence/consensus amongst sur-
geons on optimum frequency or duration of follow-up including
mammography for breast cancer patients aged 50 years and older at
diagnosis. Mammo-50 RCT has the opportunity to gather patient re-
ported outcomes and patients’ perspectives on follow-up.
Methods: Mammo-50 trial has recruited over 5235 women in a ran-
domised trial assessing duration of mammographic surveillance for
women over 50 years old at diagnosis and 3 years post curative sur-
gery. 91% of women agreed to participate in a quality of life sub-
study (QoL) and 75% of women consented to enter the Qualitative
sub-study (QSS). In addition, a national patient-led survey on follow-
up was developed by the Independent Cancer Patients’ Voice (ICPV)
to gather patients’ experience of follow-up.
Results: Mammo-50 patient questionnaires indicated that 28% of pa-
tients had high levels of distress due to concerns about fatigue,
sleep, worry/anxiety, memory/concentration, hot flushes and pain.
Mammo-50 focus groups (6 at multiple sites) and individual inter-
views (32 telephone interviews) indicated that patients in general
were satisfied with their care and happy to be in a trial. The inter-
views reached saturation quickly with patients being concerned
about early discharge from hospital follow-up and the fear of recur-
rence. The ICPV survey indicated that over 2/3rds of respondents said
they had some unmet needs during their follow up period; these
were varied and included both physical and psychological needs.
Discussion: In summary, focus groups and individual interviews sug-
gest that patients, when followed-up by the trial team, are happy with
their care. When given the opportunity to report unmet needs through
questionnaires/surveys, patients often report things which could be
causing them distress, but which may go unnoticed in routine follow-
up. Clinical trials have the opportunity to collect patient reported expe-
riences alongside the standard QoL booklets, providing a rich source of
additional data.
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lenges to the successful delivery of surgical trials. Patient and public
involvement (PPI) has the potential to improve both but there have
been few attempts to formally investigate this. We aimed to develop
an evidence-based PPI Intervention to enhance Recruitment and Re-
tention In Surgical Trials (‘PIRRIST’).
Methods: Four stages: (1) Online survey to identify current PPI prac-
tice in UK surgical trials; (2) Stakeholder focus groups and interviews
to explore PPI needs and challenges, issues with participant recruit-
ment and retention, and how PPI might address these; (3) Two on-
line surveys to estimate the frequency and importance of the
identified issues with recruitment, retention and PPI in surgical trials;
(4) Stakeholder workshop to determine key features of the final PPI
intervention.
Results: 393 individuals took part across four stages of data col-
lection. Based on the findings, we made recommendations for
PPI in surgical trial design including: use a two-tier model of PPI
(ongoing partnership with individuals plus consultation with the
wider patient population); involve patients/carers with personal
experience of the target health condition; budget for staff time
on PPI. We held eight events with surgical trial staff and patient/
public contributors across the UK to review these recommenda-
tions and plan next steps. From this we developed succinct, prac-
tical guidance to aid Chief Investigators (CIs) in planning PPI in
surgical trials. We involved a professional graphic designer, user-
tested the guidance with CIs and consulted many stakeholders
including PPI contributors and trial managers.
Discussion: Our evidence-based guidance will help CIs to plan PPI
that should boost participant recruitment and retention (evaluation
needed). Although based on evidence gathered from surgical trials,
the guidance could be applied to other clinical trials within the UK.
The guidance will be available online from June 2019 via
www.phc.ox.ac.uk/pirrist
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Introduction: The UK National Institute for Health Research ‘Breaking
Boundaries’ review of patient and public involvement (PPI) in re-
search highlighted the need for a more strategic approach to PPI,
recommending that PPI leads should have opportunities to network
and share best practice. Furthermore, there is increasing emphasis
on public engagement within clinical trials, including public dialogue
about the need for and design of trials.
The UK Clinical Research Collaborative (UKCRC) Registered Clinical
Trials Unit (CTU) Network established a Patient and Public Involve-
ment and Engagement (PPI&E) Task and Finish Group to conduct a
scoping exercise to:
•Identify different approaches for delivering PPI&E within CTUs•Map existing PPI&E resources during the course of clinical trials
•Develop more effective collaborative PPI&E working across regis-
tered CTUs.
Methods: We conducted an e-survey with registered CTUs to investi-
gate the current PPI&E landscape and challenges. Responses were
discussed at a workshop with targeted activities to explore PPI&E
practices. 4 public contributors also attended the workshop, sharing
their perspectives on how CTUs should involve and engage patients
and the public.
Results:
•46/51 registered CTUs completed the survey, 39 attended the work-
shop. Findings included:
•15/46 CTUs reported one person with overall PPI &E responsibility
•11 CTUs had PPI guidance for trial staff, 2 CTUs had PE guidance. 6
CTUs used PPI standard operating procedures
•No CTUs stated they would be unwilling to collaborate in PPI&E
activity.
Discussion: This scoping exercise illustrated that PPI&E is evolving,
with involvement currently more advanced than engagement. Re-
sources to support PPI&E varied amongst CTUs. There is duplication
of activities, suggesting a need for a formal sharing mechanism
across the Network. The UKCRC PPI&E group will be developing a na-
tional communication strategy and central repository for resources
and training for PPI&E to address the findings of this scoping
exercise.P-94
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Introduction: In recent years there has been a significant increase in
the use of novel trial designs increasing statistical efficiency, particu-
larly in the early phase setting. Little work has been done to assess
how these designs impact patients and research nurses. We set out
to develop an understanding of their views on novel early phase de-
signs including Continual Reassessment Method, exploring if trial de-
signs can be more patient-centred.
Methods: We conducted a joint interview with two research nurses
working in early phase oncology trials (RN) and held a group discus-
sion with nine representatives from a Patient and Public Involvement
group (PPIgroup) to identify the aspects of trial design that mattered
most. An interactive session was held at the NIHR Statistics - Early
phase trials meeting, February 2019 (EPmeeting).
Results: 78% (7/9) in the PPIgroup and 48% (20/42) of EPmeeting felt
that increased trial design complexity would have no impact on pa-
tient recruitment. Members of PPIgroup felt that an increase in logis-
tical complexity would discourage trial recruitment but that trial
design complexity would not. 39/44 delegates at the EPmeeting felt
that patients would feel less secure joining a first –in-man trial how-
ever RN reported no concerns with recruiting to these trials; 1 mem-
ber of the PPIgroup commented “We were clutching at straws and
would have done anything”. When asked about dose selection in a
dose-finding trial, EPmeeting gave mixed responses across dose
ranges however; the PPIgroup felt that patients would be reluctant
to receive the highest dose due to potential toxicities.
Discussion: Trialists understanding of patients’ needs may not ne-
cessary be in line with patients’. In order to ensure that innova-
tive designs achieve benefits that matter most to patients, they
need to be designed with patients as co-developers. Further work
is required to identify how to encourage a more patient-centred
approach.
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Focus groups are widely used in health services research. They en-
able participants to speak freely about concerns and offer views on
existing and proposed evaluation of new approaches to surgical
treatment. A qualitative study was conducted using focus groups to
elicit the views of stakeholders on the acceptability and feasibility of
a randomised trial to evaluate the effectiveness of patches in aug-
menting rotator cuff repair. Stakeholders’ opinions on various trial
design options were also sought. This was part of a larger, multi-
method project (the PARCS feasibility study) to assess the overall, ac-
ceptability and design of a trial of this surgical innovation.
Participants were recruited to separate focus groups reflecting each
of the key stakeholder groups: patients/carers; industry; research
regulatory representatives. The focus groups were facilitated by a
trained member of the PARCS study team. Discussions were audio re-
corded and transcribed verbatim. Transcripts were analysed by two
members of the PARCS team, alongside data collection and using
thematic analysis. Themes from discussions were grouped according
to whether they related to: patient population to include; the compo-
nents of intervention and control arms; the outcomes to measure;
and practical considerations in trial set-up.
A total of 24 people participated in the focus groups. There was
widespread stakeholder support for patch use in rotator cuff surgery.
There was discrepancy among some stakeholders about whether a
trial was even needed. They had varied perspectives on timing of
patch use and also what patches would be compared to in a trial set-
ting (e.g. patch vs no patch, or patch A vs patch B).
The focus groups allowed us to elicit and understand views of a
broad range of stakeholders. The findings were used to inform the
subsequent stages of the PARCS study including a survey of surgeon
trialists, a Delphi process and final consensus meeting.P-96
What methods are used to involve patients and the public in
numerical aspects of research? A scoping review
Beatriz Goulao, Marion Campbell, Katie Gillies, Craig Ramsay
Health Services Research Unit, University of Aberdeen, Aberdeen, United
Kingdom
Trials 2019, 20(Suppl 1):P-96
Introduction: Patient and public involvement (PPI) in clinical trials
may improve research, but the best way to achieve its full potential
is unclear. One challenge is the lack of methodology to involve pa-
tients and the public in numerical aspects of trials (ie design, data
collection, analysis and interpretation). We aimed to review methods
to involve the public or elicit their opinions about numerical aspects
of research and draw lessons applicable to PPI in trials.
Methods: We conducted a scoping review using EMBASE (1946-April
2019) focused on stakeholder involvement and participatory re-
search. We included primary research and case studies. The public in-
cluded citizens or research end-users (ie farmers in veterinary
medicine or patients in healthcare).
Results: 97 abstracts were identified, 38 full texts assessed, and 19
papers included. Studies were published between 2006 and 2018
and focused on environmental research (n=7), veterinary (n=6), pol-
icy (n=3), health research (n=2) and trials (n=1). Ten studies involved
the public in the analysis; six in data collection; three in research de-
sign and one in the interpretation of findings. The main methods
used were participatory modelling (n=9), participatory epidemiology
(n=6), participatory mapping (n=1), questionnaire (n=1), focus group(n=1), discrete choice experiments (n=1). Nine studies involved mul-
tiple stakeholders (like researchers, politicians and the public). The
studies discussed two main reasons to elicit the public’s opinions on
numerical aspects: to make research more relevant to stakeholders,
increasing their sense of ownership; to gather information from
stakeholders, when relevant data is unavailable.
Discussion: There are methods available to incorporate the public’s
opinions on numerical aspects of research. These methods have
been successfully implemented in other fields and have the potential
to improve current PPI practices in trials, but their acceptability and
feasibility needs to be investigated.
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Introduction: New musculoskeletal (MSK) care models are required
that are patient-centred and better reflect patients’ individual needs.
The Arthritis Research UK Musculoskeletal Health Questionnaire
(MSK-HQ) is a recently validated outcome measure to evaluate an in-
dividual’s MSK health-status across the care pathway. The aim of this
paper is to describe how people with MSK conditions have been in-
volved in a study to test the feasibility and impact of implementing
the MSK-HQ using an innovative IT platform, the MSK-Tracker.
Methods: As part of the study team and in advisory groups, people
with MSK conditions contributed to the co-design and delivery of
the study, including:
•a stakeholder workshop to determine the MSK-Tracker’s require-
ments within a clinical setting
•study design, including recruitment methods and outcome measures
•co-design and informal testing of the MSK-Tracker platform
•development of participant information
•project management
•interpretation of results
Results: Public contributors actively shaped this project at every
stage. For example, by identifying the MSK-Tracker's potential to
give patients a “start-point for the consultation” by providing “an
opportunity to discuss the things important to you”. They also
suggested having a secondary outcome to examine how the na-
ture of the consultation conversation changed with the platform’s
introduction. Through co-design and informal testing, public con-
tributors have been instrumental in improving the MSK-Tracker’s
usability and functions. Public contributors have actively sup-
ported the troubleshooting of difficult recruitment issues and are
helping to explore the wider value of the MSK-Tracker to patients
in the future.
Some challenges existed with public co-applicant involvement in
project management meetings and sustaining regular feedback with
other public contributors.
Discussion: People with MSK conditions made important contribu-
tions throughout this study. Future activities will focus on ways to
share findings with patients and the wider public and how other
studies can similarly embrace public involvement.P-98
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vance, acceptability, and quality of patient-reported outcome mea-
sures (PROMs) in clinical trials. Guidance exists on PROMs
development which includes the use of qualitative research with pa-
tients to establish the content and face validity of PROMs. However,
there is no specific guidance for PI roles throughout PROMS develop-
ment. This paper proposes a new framework for embedding mean-
ingful PI in this process. Working collaboratively with the research
team, PI can have important roles alongside the research activities
throughout all stages of PROMs development, as follows:
Scoping-
Research: i) Literature review to identify existing PROMS and relevant
outcomes, ii) Expert opinion
PI: i) Review the quality and acceptability of existing PROMs; ii) Iden-
tify the need for a new PROM; iii) Advise on research plan (e.g. re-
cruitment, interview topic guide)
Conceptual Framework & draft PROM-
Research: Qualitative interviews with patients to identify outcomes of
importance
PI: i) Conduct interviews; ii) Analyse and interpret findings; iii) De-
velop conceptual framework; iv) Draft PROM content
Iterative development-
Research: Cognitive interviews to verify face and content validity of
the draft PROM
PI: i) Analyse and interpret findings; ii) Finalise PROM wording and
format; iii) Support translation and cultural adaptation for use in
other countries
Assessment of psychometric properties-
Research: Observational or experimental study
PI: Contribute to the interpretation of the psychometric properties
from and patient and public perspective (e.g. missing data issues,
minimal clinical important difference)
Dissemination and implementation-
Research: Publish
PI: i) Support dissemination to the general public; ii) Encourage up-
take and use of the PROM in clinical practice
Conclusion: A framework for embedding meaningful PI throughout
the PROMS development process is proposed. Previous studies have
implemented individual elements of this framework. Future work will
test all elements of the framework together to assess added value
and impact.P-99
Raising the Standards of Public Involvement in Clinical Trials
Steven Blackburn1, Carol Rhodes1, Adele Higginbottom1, Laura
Campbell1, Research User Group1, Nadine Foster2, Krysia Dziedzic1
1Research Institute for Primary Care and Health Sciences, Keele
University, Keele, United Kingdom; 2Keele Clinical Trials Unit, Keele
University, Keele, United Kingdom
Trials 2019, 20(Suppl 1):P-99
Introduction: The UK National Standards for Public Involvement in
research have recently been launched to improve the quality of
public involvement. Keele University is one of the ten test sites
nationally developing ways to put the six National Standards into
practice. This paper presents some of the approaches and re-
sources developed to implement the National Standards for use
with clinical trials.
Methods: In partnership with Keele Research User Group (RUG), we
used the Standards to audit current trial processes and co-produce
new resources to improve public involvement practices. Over 12
months, we adopted a Plan-Deliver-Review-Act approach to implement
each Standard across the Research Institute and Clinical Trials Unit.
Results: The audit highlighted areas for improvement in how we de-
liver public involvement. We have developed new resources and
practices for the six Standards, including:
Standard 1 (Inclusive Opportunities): A Diversity and Inclusion policy and
new recruitment plan to ensure fair opportunities for public involvementStandard 2 (Working Together): Clear role descriptions for all public
involvement roles (Trial Steering Committees, Public Co-applicants,
Advisory Groups)
Standard 3 (Support and Learning): Induction sessions for new public
contributors and a ‘RUG-Buddy’ peer-mentoring scheme with more
experienced members supporting new members
Standard 4 (Communications): a brief guide for researchers to en-
courage clear, two-way communication with public contributors, in-
cluding improved feedback
Standard 5 (Impact): Tips on capturing and evaluating the impact of
public involvement in trials
Standard 6 (Governance): A developing Public Involvement and En-
gagement Strategy, and Funding formula to ensure appropriate pub-
lic involvement budgets.
Discussion: We have used the National Standards to reflect on
current practices and develop new resources to improve public in-
volvement in research. They are helping to drive a culture change to-
wards doing better public involvement. More is to be done on
encouraging wide-spread awareness and adoption of the Standards
across studies.
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Linking involvement and engagement in clinical trials research: a
year in the life of a public involvement partnership
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Introduction: We have focused on maximising public engagement,
to drive better and more meaningful involvement in our research
and worked with public partners to develop engagement activities
about clinical trials. This presentation will highlight key learning
points of setting up and running a public involvement partnership
within a health services research unit and clinical trials unit (CTU) to
link involvement and engagement.
Methods: We set up an independent Public Involvement Partnership,
led by a dedicated PPIE coordinator (KB). Individuals within the group
were recruited through a number of mechanisms, with involvement in
projects varying across activities. Regular opportunities for feedback
from the group contribute to a cycle of ongoing improvement, with op-
portunities for reflection at the end of the first year.
Results: A total of eight local public partners were recruited to
the group. Over the year, the group’s activities were based on
improving the accessibility of information about trials, shaping
trial questions and methods, and dissemination of trial results to
the public.
The group valued face-to-face meetings and being part of a team.
They enjoyed the opportunity to visit the CTU and see researchers in
their day-to-day jobs. A bonus of the face-to-face format was the
sharing of ideas and perspectives which was harder to facilitate by
individual emails.
At the end of year review, the group were extremely positive about
the group itself, the research they contributed to, and their enthusi-
asm for continuing. They are proud of what they have achieved.
Discussion: By linking involvement and engagement, we have pro-
moted reciprocal sharing of ideas to improve the way we involve the
public meaningfully in our research.
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and Public Involvement (PPI) into all aspects of trial design, running
and oversight. This research explored the induction and training of
PPI Contributors joining trial oversight committees and was used to
update the Medical Research Council Clinical Trials Unit at University
College London’s (MRC CTU at UCL) induction pack for new PPI
Contributors.
Methods: Published and unpublished materials on training for PPI
Contributors on oversight committees were reviewed, with themes
then triangulated to identify the most common topics covered in in-
duction training. A face-to-face workshop with PPI Contributors from
the MRC CTU at UCL reviewed a draft updated Induction Pack. Find-
ings from these discussions were incorporated into a revised induc-
tion pack which was then re-reviewed by the workshop attendees.
Results: No published literature on this subject was found. However,
several common themes were identified from unpublished materials.
Workshop attendees agreed with most of the themes suggested in
the initial draft pack based on the literature search and also provided
a number of additional topics for discussion.
Discussion: There is very little consistency in the induction of PPI
Contributors on oversight committees. Whilst most local guidance
explains the general role of a PPI Contributor, more context and
background of the particular trial needs to be provided to allow for
adequate induction of new committee members. The Induction Pack
created provides a framework upon which trial managers can build a
full picture of their study.P-102
Hard to reach or easy to ignore - the use of social media and
community engagement in ROSHNI2
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Background: There is under-representation of ethnic minorities in
clinical research. British South Asian women are considered ‘hard to
engage’ due to multiple factors including language, culture and
stigma. Social media and community engagement have the potential
to play a pivotal role in bridging this gap in research participation.
Design: ROSHNI-2 means light in Urdu/Hindi language is a Rando-
mised controlled trial (RCT) to compare culturally adapted Positive
Health Programme (PHP) based on the principles of CBT with Treat-
ment as Usual (TAU) in BSA women with postnatal depression. The
study aims to recruit 720 mothers.
Community engagement:
•Social media: We have used well-known platforms such as Facebook,
Twitter, Instagram to disseminate information. We have connected
with ethnic channels and with popular social media influencers to
raise awareness about maternal health.
•Chai with ROSHNI2: Inviting GPs & Health Visitors to meet the
women and encourage conversation around mental health.
•There a many languages spoken throughout South Asia, the main
ones being; Urdu, Hindi, Punjabi, Gujarati, Bengali and Tamil. Each re-
searcher is able to speak English and one of the study languages flu-
ently. Participants are able to communicate in the language that
they feel most comfortable in and all study materials have been
translated.
Results: In comparison to recruitment rates prior to the social media
campaign, increased activity on our pages resulted in much higher
rate of recruitment.
Feb-March 2019: 6400 post reached (575% increase from previous
months) 2000 post enjoyments (168% up from previous months)
April-May 2019: 13,600 post reach (213% increase) 2063 engage-
ments (7% increase)
Conclusions: The ethnic minorities are considered “hard to reach”
though the feedback from the community tells us that they thinkthey may be “easy to ignore”. This may be because there is a lack of
innovative and culturally sensitive recruitment strategies in place.
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Introduction: STAR is a phase II/III, UK multicentre, randomised con-
trolled, non-inferiority trial evaluating the use of treatment breaks
compared with continuous treatment for patients with renal cancer.
Quality adjusted life-years (QALYs) are a co-primary endpoint of STAR
with overall survival. They are calculated using the utility index de-
rived from the patient reported EQ-5D-3L questionnaire, which is col-
lected during trial treatment and follow-up, encompassing both
time-on and time-off trial treatment.
Missing EQ-5D-3L data occurs in STAR. We will describe and justify
how this limitation has impacted on how QALYs will be derived and
analysed.
Methods: Missing EQ-5D-3L data during the follow-up period will be
imputed using multiple imputation by chained equations at the util-
ity level. QALYs for each participant will be derived within each im-
puted dataset.
QALYs are hypothesized to display a bimodal distribution thus mix-
ture models, with two normal components, will be fitted within each
imputed dataset, regressing QALYs on randomisation allocation and
the minimization factors of the trial. A marginal treatment effect will
be obtained, and the results combined using Rubin’s rules.
Results: The trial will conclude non-inferiority in terms of QALYs, if
the lower bound of the 95% confidence interval around the com-
bined marginal treatment effect corresponds to a ≤10% difference in
the mean QALYs between the two arms.
Discussion: The statistical analysis planned for QALYs within STAR is
the result collaboration between statisticians and health economists.
This considered: the level of imputation (question or utility); whether
the missing data pattern would be consistent over time; which pe-
riods to impute (on or off trial treatment, or both); the form and type
of imputation model; how to account for withdrawal and death; how
to model the assumed bimodal distribution of the QALYs and finally
how to assess the decision related to the primary research question
of non-inferiority.P-104
Measuring patient reported outcomes in the POSNOC trial:
strategies employed to promote high quality data return
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Introduction: POSNOC is a multi-centre RCT to determine whether
axillary clearance/radiotherapy can be avoided safely in women with
early breast cancer and one or two involved sentinel nodes. It is cen-
trally coordinated at Nottingham CTU (NCTU) with patient reported
outcomes (PROs) on quality of life and long-term side effects of axil-
lary treatment managed by Sussex Health Outcomes Research & Edu-
cation in Cancer (SHORE-C).
Methods: PRO measures are FACT B+4, EQ-5D-5L, STAI Y1/Y2, LBCQ,
and QuickDash questionnaires. All are completed in clinic at baseline,
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Dash which are administered by site staff in clinic or by telephone.
Site staff are trained in PRO procedures at trial initiation. Further
training is provided at individual site level and via regular trial
memos/newsletters. SHORE-C, NCTU and site staff liaise closely to en-
sure participant health status and contact details are kept up to date
and as many PROs as possible are completed by patients. PRO data
are monitored in real time to permit swift resolution of any
problems.
Results: 1172 UK patients were randomised to 28/02/2019; seven did
not commence PRO measures and a further 81 (7.5%) discontinued
postal questionnaires. Key reasons by 12 months for stopping were
patient decision and withdrawal from the trial. At 24 and 36 months
questionnaires were discontinued if not returned at 3 previous time-
points. Thirteen patients had died. Postal (clinic) questionnaire
returns, calculated as a percentage of the number expected at each
timepoint were: 98% (97%), 92% (-), 93% (90%), 92% (90%), 87%
(86%), and 90% (88%) respectively.
Discussion: A recent review on strategies to reduce missing PRO data
concluded this can be minimised by implementing thoughtful design
and methodology strategies. POSNOC has employed several of these
strategies and achieved high PRO data return.P-105
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Introduction: Eczema has an episodic nature and in clinical trials, re-
peated measures are often used to give more precise estimates of
between-group differences. The Harmonising Outcome Measures in
Eczema (HOME) collaboration has recommended that outcomes be
measured at least at baseline and follow-up but, where repeated
measures planned for a trial, it is unclear how many measures would
be optimal.
From a statistical standpoint, more measures are better because add-
itional measures reduce intra-patient variation and can decrease the
required sample size. But for researchers and trial participants, fewer
measures minimises burden.
This study explores whether there is an optimal number of measure-
ments beyond which there are few statistical gains.
Methods: The statistical efficiency can be calculated from the correl-
ation within and between repeated measures. We used the correl-
ation matrices from 4 published clinical trials to explore the marginal
gains in statistical power from including additional repeated mea-
sures. All trials used the Patient Orientated Eczema Measure (POEM),
the HOME recommended instrument for the symptoms domain,
weekly over a 12-16 week period.
Results: Four or five measures seem to be optimal. On average, the
sample size required with 4 follow-up measure was 64% of that re-
quired for a single follow-up measure, 61% for 5 measures and 60%
for 6 measures. Few marginal gains in sample size were made be-
yond 5 measures.
There is no statistical requirement for the measurements to be
evenly spaced but, if they are, this equates to approximately monthly
measurements for a 12-week trial.
Discussion: For eczema trials, measuring outcomes around 4-5 times
is likely to be most efficient, which is consistent with results for other
conditions. This represents the statistical view and will be shared
with the HOME collaboration.
However further discussion is needed to incorporate the views of pa-
tients, clinicians and researchers before recommendations can be
made.P-106
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Do study participants complete electronic questionnaires?
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Introduction:
Electronic capture of patient reported outcomes (PROs) is increas-
ingly utilised in clinical research. Resources are required to develop
and maintain electronic PRO tools, but this is offset with savings in
printing and postage costs and data entry of paper questionnaires.
Personal computers and smart phones have made the internet more
accessible. However, if participants prefer paper questionnaires, or if
data quality is compromised with electronic data capture, resources
may not be optimally used. We present data from two large studies
offering postal and online questionnaires to assess participant prefer-
ences and data completeness.
Methods: The studies: OMACS – Outcome Monitoring After Cardiac
Surgery (ISRCTN90204321), a cohort study in cardiac surgery, collect-
ing Quality of Life (QoL) data for 1y and By-Band-Sleeve (BBS;
ISRCTN00786323) – a multicentre RCT of bariatric surgery collecting
QoL data at multiple timepoints over 3y.
Results: OMACS: 642 participants, 12% of whom opted for online
completion of the PRO. Compared to the “paper completion” group,
the “online completion” group contained proportionally fewer fe-
males (26% vs 23%) and were on average 3 years younger (median
age 69 vs 63y). Completion rates were lower in the “online comple-
tion” group (3 months 97% vs 93%; 12 months 86% vs 63%)
BBS: 1296 participants, 34% of whom opted for online completion of
the PRO. Again, the “online completion” group contained fewer fe-
males (81% vs 69%) and were younger (median 52 vs 49y). Overall,
280 of ~5700 (~5%) questionnaires were completed online, with the
remainder completed by post or in clinic.
Discussion: Uptake of the electronic PRO completion option is low
and completion rates were lower than when paper was used. Many
BBS participants who opted for online data capture have in practice
completed questionnaires by post or in clinic. Reasons for these
choices need investigation.
Both studies were funded by the NIHR.P-108
Variation and poor reporting on the measurement of patient-
reported outcomes can hinder the interpretation of study findings:
a case study using the WOMAC measure
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Introduction: A lack of consistency in how outcome measurement
tools are used and reported in clinical research can hinder its inter-
pretation and limit its usefulness. We explored this issue using a case
study of the WOMAC, a patient-reported outcome commonly used in
osteoarthritis research. The WOMAC is made up of multiple items
across 3 subscales: pain, function and stiffness. A number of import-
ant variations in how the items can be measured and combined
have been proposed. It is unclear what current practice is and
whether these variations are used in practice. This study aims to re-
view how the WOMAC tool is being used in a specific clinical area.
Methods: A cohort of randomised trials in hip or knee osteoarthritis
that used the WOMAC measure were reviewed. Data were extracted on
the version used, how it was implemented, use of subscales and total
score, and how scores were analysed and reported.
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was unclear for one-third of studies (35%, n=22/62), although half used
a Likert scale version (50%, n=31/62). The total (66%, n=41/62),
pain or function subscales (63%, n=39/62) were reported in most
trials. The stiffness subscale was reported less often (48%, n=30/
62). Of trials that reported the WOMAC total score, only one-third
reported the results for all three individual subscales (pain, func-
tion and stiffness) (37%, n=15/41). The range of the total score
was unclear for 20% of trials (n=8/41) and, where reported,
spanned from 0-10 to 0-2400.
Discussion: The measurement and calculation of the WOMAC score
were highly variable. Furthermore, the reporting of the WOMAC
methods and results was often poor. This hinders the interpretation
of study findings. Clear, consistent and complete reporting of the
WOMAC measurement methods is needed.P-109
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Introduction: Participants of trials managed by the Clinical Trials and
Statistics Unit at The Institute of Cancer Research (ICR-CTSU) currently
complete patient reported outcome (PRO) questionnaires on paper.
We are now considering implementing electronic capture of PROs.
We summarise here our requirements for an ePRO system, together
with plans for implementation and impact assessment.
Methods: System requirements:
•Secure access and data storage
•User friendly interface and password management
•Two step identity verification
•Scheduling and reminder facility
•Basic compliance reporting
•Statistical analysis data output facility
•Compliance with applicable regulations
Implementation plans: Following identification of a potential system,
patient and public focus groups will assess user acceptability. Should
this be successful, the system will be piloted within an appropriate
trial. A study within a trial (SWAT) will be implemented with the aim
of comparing paper and electronic questionnaire responses to inves-
tigate whether questionnaire modality impacts PRO data. Response
rates to both modalities will also be compared. Participants will also
complete user feedback surveys to capture qualitative data on their
experience using the system. A statistical analysis plan will be devel-
oped prior to initiation of the pilot.
Challenges: ePRO system use has resulted in non-compliance find-
ings during several MHRA inspections, related to lack of validation,
poor audit trail and lack of source data. Regulators are currently de-
veloping further guidance on ePRO which will need to be taken into
account if implementing ePRO in a trial which falls under the MHRA.
Any system implementation requires comprehensive pre-
implementation testing and user acceptability prior to rollout, neces-
sitating dedicated resource investment.
Discussion: Anticipated benefits
We hope that the introduction of an ePRO system will improve par-
ticipant experience over completing questionnaires on paper and
may therefore improve response rates. The planned SWAT will aim to
identify whether this is the case.P-110
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Background: Cancer-related major abdominal surgery is associated
with lengthy recovery and complications. Concerning symptoms can
go undetected as clinical follow-up after hospital discharge is not
standardised. Electronic patient-reported outcomes (ePRO) systems
can enhance symptom monitoring and detection of complications
and improve patient outcomes. Evidence for the use of ePRO sys-
tems in surgical oncology is lacking. This prospective pilot study eval-
uated the feasibility of a hospital-integrated electronic symptom
monitoring system for patients after discharge following cancer-
related major abdominal surgery.
Methods: The ePRO surgery system is an online questionnaire inte-
grated into hospital electronic records that provides patients with tai-
lored self-management advice or automated alerts to a clinician
depending on symptom severity. Participants recruited from Univer-
sity Hospitals Bristol and University Hospitals Birmingham completed
the ePRO questionnaire weekly post-discharge. Aims included exam-
ining barriers to using the ePRO system, questionnaire completeness,
symptom severity-dependent actions generated by the system and
technical performance. Interviews with participants and clinicians ex-
plored perceptions of the usefulness and acceptability of the ePRO
system.
Results: Thirty-one participants were recruited to the study and ques-
tionnaire response rates typically exceeded 60% (range 50-100%). Of
197 ePRO completions analysed, most triggered self-management
advice (39%) or advice to contact a clinician (37%), and 4% triggered
email alerts to clinicians. Participants reported that they found the
ePRO system reassuring and relevant to symptom management dur-
ing recovery. Clinicians described the system’s usefulness for under-
standing patients’ experiences of recovery and monitoring symptoms
in the context of their ongoing recovery.
Discussion: The use of the ePRO system to monitor patients during
recovery after cancer-related surgery is feasible and acceptable to pa-
tients and clinicians. A future randomised controlled trial will evalu-
ate the effectiveness of the ePRO system for improving the detection
of symptoms, complications and patient outcomes after hospital dis-
charge following major cancer-related surgery.P-111
Chronic Headache Education and Self-management Study (CHESS)
– Smartphone Application
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Study (CHESS) is a multi-centred randomised controlled trial comparing
an education and self-management program with a relaxation control
arm. We required frequent data collection for headache outcomes, and
therefore aimed to develop and pilot a system for this using a smart-
phone app.
Methods: The app was developed by Clinvivo Ltd, a University of
Warwick spin–out company, who worked closely with the CHESS
team. Using the existing literature, the team’s clinical expertise and
input from our lay advisory group three questions were developed
to capture headache frequency, duration and severity.
Once eligibility was confirmed, participants were asked to complete
the smartphone app (or a paper alternative for those without a
smartphone) and given detailed instructions on how to install and
use. The app is completed weekly for six months then monthly for
six months. For each question a calendar is displayed indicating the
recall period of seven days, and participants receive app notifications
when responses are due. Participants who never downloaded the
app or haven’t completed the app for at least three weeks are sent
reminders via post or email. At 12 months, participants are provided
with a summary of their responses should they wish to receive this.
Results: During feasibility, eight participants downloaded the app
and completed for up to 11 weeks. Completion rates varied, partici-
pants did not report any difficulties downloading or using the app.
In our ongoing RCT the average completion rates for all app users is
currently 62%, with 67% of participants completing at least 3 re-
sponses between randomisation and the 4 month questionnaire.
Discussion: The app data is still being completed by participants. We
will have final results at the end of 2020.P-112
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Introduction: PERSEPHONE is a Phase 3 randomised non-inferiority
trial comparing 6 months of trastuzumab to the standard 12 months
in patients with HER2 positive early breast cancer. Patients consented
to a quality of life sub-study where information was collected about
their experiences. Collecting ‘quasi-qualitative’ data via open-ended
questions adds depth and complements quantitative quality of life
data. It allows patients to report experiences that may otherwise re-
main unknown.
Methods: Alongside the toxicities reported on the trial case report
forms (CRF) and patient booklets being collected, including quality of
life (QoL) and Health Care Resource Usage, patients were invited to
record any other comments they had about their treatment. Experi-
ences were recorded prior to commencement of trastuzumab, then
3-monthly for a year, then every 6 months up to year 2. Within a
mixed methods framework, both the trial researcher and patient rep-
resentatives explored the information collected using thematic con-
tent analysis.
Results: Between October 2007 and July 2015, 4088 patients were
randomised. In total, 5542 experiences were recorded from 2456 pa-
tients across the 6 time-points. Patients offered information on all as-
pects of the study, including their views on the treatment, their care,
the QoL questionnaire and the research. Most often mentioned was
the impact the treatment had on participants personally - physically,
psychologically or socially. Most frequently cited were aches, pains
and fatigue; for many, these did appear to be particularly distressing
and intractable. In parallel, CRFs reported 20% of patients reporting a
grade 3/4 toxicity during treatment (23% 12 month, 18% 6 month,
p=0.004), with significantly higher rates of cough, pain, fatigue, chillsand palpitations reported by patients having 12 months trastuzumab
(p<0.05).
Conclusions: Patients’ experiences during and beyond trastuzumab
highlighted the long-term cumulative effects of their treatment and
confirm that patients do suffer from burdensome toxicity, which af-
fects their QoL.
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Introduction: Several methods for collecting follow-up data from par-
ticipants who take part in research studies have been cited in the lit-
erature and these include the use of the postal questionnaires, face-
to-face interviews, telephone interviews, and use of the Internet. The
postal questionnaire is the most frequently used and is considered to
be the most cost effective but is often associated with the lowest re-
sponse rate. Poor response to questionnaires is known to reduce the
statistical power of the study as the effective sample size is reduced.
It can also introduce bias if the nonresponders are systematically dif-
ferent on outcomes of interest to those who respond to the ques-
tionnaires. Lall et al (2012) reported that collecting data by
telephone on patients who had not responded to questionnaires sig-
nificantly increased the response rate and enhanced the treatment
difference on one trial of back pain (Back Skills Training Trial).
Methods: We have taken a range of clinical trials within the rehabili-
tation and critical care fields (CHESS, I-WOTCH and BREATHE) and
analysed the primary and secondary outcomes that were collected
by postal questionnaire and if missing using this mechanism of data
collection, were then collected by telephone. We have aimed to as-
sess whether the additional information increases response rates, in-
creases the patient representation and enhances the treatment effort
across and within all the clinical trials.
P-114
Abstract omitted
P-115
Priority safety data issues in late phase clinical trials: A qualitative
approach from an academic clinical trials unit
Genevieve Helen Wills, Alejandro Arenas-Pinto, David Dunn, Ruth
Goodall
MRC Clinical Trials Unit at UCL, London, United Kingdom
Trials 2019, 20(Suppl 1):P-115
Introduction: Collection, reporting and analysis of efficacy outcomes
are the main focus for late phase clinical trials. These aspects have
been relatively neglected in relation to safety data and this study
aims to identify areas in need of improvement.
Methods: Interviewees were employees of the MRC CTU at UCL with
experience working with safety data in clinical trials (analysis, collec-
tion, oversight of trial management). Potential interviewees were
contacted via email, sent a protocol and information sheet, and in-
vited to join. In-depth, semi-structured interviews were conducted on
all participants, lasting between 30-60 minutes. Verbatim transcripts
were produced, and content analysis was used to identify common
themes.
Results: In total, 9/13 (69%) people responded favourably and were
interviewed; 4 statisticians, 3 clinicians and 2 senior staff within trial/
study management. Multiple areas were raised during interviews and
flagged in analysis; four areas were identified in over half of the
interviews.
Relatedness assessments:Collected to fulfil a regulatory requirement
but not in themselves a useful measure. Subjectivity in assigning re-
latedness between and within assessor.
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tiple places, particularly SAEs, recurrent events and those with associ-
ated symptoms. Over counting of events is a concern. Hard to define
unique events.
Collection: Too much safety data is collected in general (seen as det-
rimental). Some trials could collect less safety data than others e.g. if
using licensed drugs, phase III, in an academic trial setting.
Chronic/genetic/pre-existing conditions:Not well documented at ran-
domisation and no consensus on how to handle these events in
analysis
Discussion: Experienced trialists working on late phase clinical trials
identified four key areas related to the collection, analysis and report-
ing of safety data which would benefit from further research. These
findings reflect the general practice at one CTU and the experience
of those interviewed but are likely to be applicable in a wider
setting.
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Background: We embedded a qualitative study within a feasibility
trial of non-operative treatment versus appendicectomy for acute ap-
pendicitis in children (aged 4-15 years), with the aim of optimising
trial recruitment. Previous optimisation work has focussed mostly on
trials for adult patients in non-urgent care settings. Here we identify
distinctive challenges and lessons for children’s urgent care surgical
trials.
Methods: Across three UK children’s hospitals we audio-recorded 85
recruitment consultations from 58 families, and interviewed 35 health
professionals, 34 parents and 14 children. Thematic data analysis in-
formed training for recruiters and helped refine trial information for
families.
Results: Following recruiter training, recruitment rates increased from
38% to 62%. Training focussed on presenting the trial arms in a bal-
anced way, exploring family treatment preferences and refining com-
munication about the trial’s pathways. Recruiters’ presentation of the
trial became increasingly balanced following training, but training on
preference exploration was only partially implemented. Few re-
cruiters elicited the reasons underlying families’ treatment prefer-
ences and when families volunteered reasons, recruiters rarely
responded with tailored counterbalancing of preferences. Time con-
straints and concerns about coercion curtailed such counterbalan-
cing. However, parents and recruiters were also concerned about
children being exposed to conversations about treatment risks –
which is often part of counterbalancing – and this further compli-
cated treatment preference exploration. Lessons for further refining
communication about children’s trials in the urgent care settings in-
clude clarity about the timing of treatments, and sensitivity in the
communication of treatment allocation, and in post-surgery discus-
sions with families.
Conclusions: This qualitative study helped recruiters to present the
trial in more balanced ways to families and led to increased recruit-
ment, despite partial implementation of the training. We identify dis-
tinctive complexities in exploring treatment preferences in children’surgent care trials, but also distinctive opportunities to enhance com-
munication and recruitment to similar trials in the future.
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Introduction: Digital tools are increasingly being used to identify, re-
cruit and retain participants. While these tools are being used, there
is a lack of quality evidence to determine their value in trial recruit-
ment and retention. Given the lack of certainty around the evidence-
base, there is a need to improve and sustain the evidence related to
the use of digital tools.
Methods: The aim of the main study was to identify the benefits and
characteristics of innovative digital recruitment and retention tools
for more efficient conduct of Randomised Controlled Trials (RCTs).
The qualitative study was conducted to identify the benefits of in-
novative digital recruitment and retention tools for more efficient
conduct of RCTs from the perspective of five stakeholder groups (in-
cluding research participants).
A purposive sampling strategy was used to identify 16 participants
from the five stakeholder groups. A theoretical framework was devel-
oped from results of a UK Clinical Research Collaboration (UKCRC)
registered Clinical Trials Units (CTUs) survey. Semi-structured inter-
views were conducted and analysed using an inductive approach. A
content and thematic analysis was used to explore stakeholder’s
viewpoint and the value of digital tools.
Results: Content analysis revealed that ‘barriers / challenges ‘and
‘awareness of evidence’ were the most common areas across all
stakeholders. The five themes were security and transparency, inclu-
sivity and engagement, human interaction, obstacles and risks, and
potential benefits. Three emergent themes were present across all
groups: ‘security and transparency’, ‘inclusivity’, and ‘human inter-
action’. Interesting similarities and differences were also noted be-
tween practitioner and participant groups.
Discussion: The qualitative study outcomes show that there is a
common use of digital technology for the recruitment and retention
of participants in trials. Developing the evidence base in this area will
be important for future research and raises important questions
around the potential value for participant involvement in trials.
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Introduction:
Traditional pre-specified clinical outcome measures cannot fully cap-
ture participant experience of complex interventions; thus some ben-
efits or unintended consequences of an intervention may remain
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although few process evaluations attempt to contextualise and ex-
plain outcomes. This paper illustrates the explanatory value of
process evaluation within a RCT of abdominal massage for neuro-
genic bowel dysfunction (NBD) in people with multiple sclerosis (MS).
Methods:
This paper draws on longitudinal semi-structured interviews with 20
intervention participants, interviewed twice. Analysis explored partici-
pant contexts and the process of change, linking participants’ bowel
diaries to experiences of self-massage and reported changes in
bowel habits over time.
Results:
Fifteen of the twenty participants reported improvements that
they attributed to the intervention, and the intention to continue
with the massage after the trial. Investigating the lack of im-
provement in five participants revealed important insights includ-
ing the lack of sensitivity of the outcome measures to detect
change, increasing severity of MS symptoms that either affected
the ability to effectively conduct the self-massage, or led to new
drugs that exacerbated constipation. NBD scores (the primary
outcome measure) did not always reflect perceived impact of
self-massage reported during interviews; some interviewees who
reported no improvement nevertheless showed an improved NBD
score; and the reverse was also true. Some reported benefits
were not captured by primary or secondary measures.
Discussion:
Process evaluation findings contextualised trial results within partici-
pant experiences. The trial primary outcome finding favoured the
intervention group, but the effect size was small and neither clinically
nor statistically significant (p = 0.0558). However, we demonstrated
positive benefits in the process evaluation subgroup that would not
otherwise have been detected, suggesting that the impact of NBD is
such that even small improvements not detected by outcome meas-
urement may be important to patients.
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Introduction: Cancer symptom awareness is lower in disadvantaged
communities resulting in delayed help-seeking, late stage diagnosis,
and poorer long-term outcomes. Evidence suggests that tailored
community-based cancer awareness interventions can be successful
at engaging low sociodemographic groups. We tested a tailored
health-check intervention delivered by trained lay advisors in disad-
vantaged communities. The health-check assessed cancer symptoms,
risk and screening behaviours and summarised results in a traffic
light system with behaviour change advice delivered by the advisor.
This paper presents participants’ views of taking part in the
intervention.
Methods: Participants were purposefully sampled from the ABACus3
trial to take part in semi-structured telephone interviews at 4-6
weeks or 6 months post-randomisation. Sampling criteria included
trial allocation, recruitment setting, gender, age and geographical lo-
cation. Interviews were audio-recorded, transcribed and analysed
using thematic analysis supported by NVivo11.
Results: Fifteen interviews were completed 4-6 weeks post-
randomisation and to date thirteen interviews have been completed
6 months post-randomisation. 6-month interviews will be completed
by August 2019.
Some participants reported being very knowledgeable about spe-
cific cancers/symptoms before taking part based on directpersonal experience or caring for someone with cancer. Tailored
behaviour change advice was taken on board by some who re-
ported changing behaviour to reduce their cancer risk; however,
many described being limited by factors outside of their control
such as disability and accessing services. Participants showed
some awareness of national campaigns, although were often un-
able to name them or specify what cancer/symptom they were
raising awareness for.
Discussion: Preliminary results suggest that a tailored community-
based intervention could be a successful method for raising aware-
ness of cancer symptoms to people from low socioeconomic groups
and in supporting them to identify how best to reduce their risk. Fur-
ther work is needed to understand how any change implemented
supports long-term awareness and risk reduction in this population.
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Introduction: Recruiting participants for research in the intensive
care setting (ICU) is challenging, yet there is little evidence on stake-
holder perspectives to inform consent practices. Our objectives were
to investigate the experiences of stakeholders - patients, relatives,
and health care professionals (HCPs) - with the overall aim of inform-
ing good practice guidance on consent to ICU studies.
Methods: Mixed methods study comprising surveys and in-depth
qualitative interviews were conducted in 14 English ICUs.
Results: Surveys included in the analysis were from patients (n=115)
and relatives (n=157) who had been approached about participating
in a research study. HCPs with a research role (n=69) and HCPs with
no research role (n=477). A total of 55 patients, relatives and HCPs
were interviewed. Survey responses from patients and relatives indi-
cated that most had enough time to consider participation (78%/
80%), did not find it hard to take-in information about a study (55%/
55%), or make a decision about participation (66%/58%). In contrast,
most HCPs believed that patients/relatives found it hard to take-in in-
formation (63%) and to make a decision about participation (53%).
Interviews indicated that these contrasting perspectives arose from
differences in what patients/relatives and HCPs perceived was
‘enough’ time and information to understand what is being asked of
them, and to make a decision. Some HCPs doubted that patients/rel-
atives reached a sufficient understanding of a study, whereas pa-
tients/relatives prioritised acquiring enough information to discern
what activities a study involved, and its impact on the patient.
Discussion: Patients and relatives held more favourable views of as-
pects of recruitment and consent to ICU research than HCPs antici-
pated. Interviews indicated that stakeholders also had different
priorities regarding information provision, with patients/relatives
emphasising the potential implications of participation for the pa-
tient. Centring information provision on the priorities of patients/rela-
tives could minimise confusion and concern, and in turn, optimise
recruitment.
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Introduction: Involving members of the public in designing trials
helps to improve recruitment and retention, but we also need a way
of measuring participant experience. Most trials collect process and
outcome measures, yet few routinely measure patient experience;
measures that do exist have not been psychometrically tested.
Aims:
(1)To understand participant experience in trials;
(2)To understand advantages and challenges of using participant ex-
perience data to improve trial design and delivery.
Methods: Eleven professional stakeholders involved in trials were
interviewed about their views on measuring participant experience,
and what should be measured. Twelve trial participants were asked
about their experience of participation. Six members of our Patient
and Public Involvement Group (PPI) met to discuss what should go
into a participant experience measure.
Results: Experience involved nine domains (Information provision;
deciding to take part; trial logistics; treatment preferences; engaging
with staff; knowing results; enabling future research; participant out-
comes; and overall satisfaction) covering the participant ‘journey’; PPI
members gave insights of topics to cover in relation to each stage of
the journey.
Trial participants described contributing to something worthwhile,
yet they seek support throughout their journey to avoid feeling
‘abandoned’. Trial logistics (e.g. flexibility of appointments), and trial
processes (e.g. capturing expectations around participating), have a
role in determining future participation.
Professional participants highlighted the importance of understand-
ing how trial design impacts experience to inform future delivery; be-
ing able to compare data over time; and unravelling the experience
of intervention and trial processes. Common concerns of using ex-
perience data included a potential workload burden among partici-
pants and professionals, and negatively impacting on relationships.
Discussion: Our work outlines the domains needing measurement,
and the challenges of using experience measures in trials. We will
discuss the implications for the development of our participant ex-
perience measure and share learning from our pilot study.P-125
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Background: Recruiting patients to randomised controlled trials
(RCTs) can be challenging. Recruitment research often involves either
analysis of observations of doctors and nurses explaining the trial to
patients during ‘recruitment appointments’, or elicitation of patients’
experiences through qualitative interviews. However, little research
has compared recruitment as observed with recruitment as experi-
enced. This project aims to understand patients’ decision-making
about RCT participation by comparing what is communicated to
them during recruitment appointments with patients’ interpretationsof this communication. This is achieved by linking audio-recorded ap-
pointments with follow-up patient interviews from three UK-based
multicentre RCTs.
Methods/Potential Results: Data from 18 interviews with 17 patients
(14 consented, 3 declined) and 10 audio-recorded appointments (for
7 patients) have been collected for RCT 1, which compares routine
treatment (arm 1), with routine treatment plus additional interven-
tion (arm 2) for a life-limiting condition. Data are being analysed the-
matically. Preliminary findings suggest that patients’ motivations for
participation were often linked to their hope to benefit from the add-
itional intervention and reported altruism. Observations of appoint-
ments revealed that the uncertainty around the benefits of the
intervention were not always clearly communicated by recruiters, al-
though further analysis of these data is ongoing. As such, most pa-
tients had a preference for arm 2 and many misunderstood the
study design. Data collection is ongoing for RCTs 2 and 3.
Potential Impact: This work will address the knowledge gap between
the information that is provided to patients during an RCT consult-
ation and how that relates to a patient’s decision-making about trial
participation. Findings will inform training and resources for re-
cruiters to optimise trial recruitment and informed consent. By syn-
thesising findings from audio-recordings and patient interviews
collected across three RCTs, this work will identify considerations for
patient recruitment that may be transferable across RCTs.P-126
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Introduction: Vitiligo is a condition resulting in white patches on the
skin. It is a condition that is often poorly managed, partly due to lack
of high-quality evidence to inform clinical care. People with vitiligo
can suffer from low self-esteem, psychological disturbance and di-
minished quality of life.
The HI-Light Vitiligo Trial is a clinical trial involving 440 participants
aged 5 years and over with vitiligo. The purpose of this study is to
test the effectiveness of home-based light therapy using hand-held
units and topical steroid for the treatment of vitiligo.
The HI-Light Vitiligo Trial includes a nested process evaluation.
Methods: The process evaluation includes: interviews with trial par-
ticipants (incl. adults, young people (aged 12-17) and the parents of
children included in the trial); interviews with NHS commissioners; an
online survey of recruiting sites; and, discussion groups with clini-
cians and nurses involved in delivering treatments as part of the trial.
Results: Participants understood the treatments provided and had
realistic expectations of improvements that might be achieved. Ad-
herence to treatment was good, despite complicated regimens.
Healthcare professionals were positive about the potential treatment
options and were supportive of recommendations for NHS delivery
of home-based, hand-held light therapy for vitiligo. Healthcare pro-
fessionals demonstrated some concerns about safety issues, about
the complexity of treatment, and consequently suggested that any
clinical service might have precise criteria for patient eligibility.
Discussion: Clinical data demonstrated a statistically significant differ-
ence in treatment options, with combination therapy (incorporating
both light therapy and topical steroids) better than any individual
treatment. However, wide confidence intervals suggest some uncer-
tainty in the clinical significance and interpretation of these findings.
The process evaluation might offer a critical lense to re-interpret the
clinical significance of these findings: that new treatments are badly
needed for this population; that a well-managed service might have
positive impact.
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Introduction: Informed consent forms an integral part of modern
healthcare and is a critical step in supporting patient autonomy. Re-
search exploring informed consent for surgery has generally centred
on understanding consent in the context of established surgical pro-
cedures or randomised controlled trials. Consequently, very little is
known regarding consent processes for innovative surgical proce-
dures delivered in the context of early phase evaluation studies or as
part of everyday routine clinical practice.
Aim: To explore stakeholders’ views on information provision and in-
formed consent in the context of surgical innovation.
Methods: In total, 43 one-to-one interviews with surgeons and gov-
ernance representatives were conducted. Purposive and snowball
sampling methods were used to ensure participants were from vary-
ing geographical locations and surgical specialities. Interviews were
digitally audio recorded before being transcribed verbatim and trans-
ferred to data management software for thematic analysis.
Results: Personal accounts of informed consent discussions suggest
innovative surgeries are commonly introduced as part of routine
practice, outside of a formal research framework. Data indicates regu-
latory oversight of consent processes in this context is lacking and
varies between trusts. While all interviewees felt information that ex-
tends beyond that provided during for standard surgery should be
communicated, there are uncertainties surrounding the content and
volume of information needed. Generally, interviewees felt that pa-
tients are receptive to innovative surgery, however, many perceive
patients to have a poor understanding of information when provid-
ing consent.
Discussion: While participants valued the importance of consent,
perspectives on what information is required during consultations for
innovative surgery vary. More consistent and stringent regulation
within trusts may help to improve patient information provision and
consent processes. Collectively, findings suggest a need for standar-
dised approaches to information provision and consent for innova-
tive surgical treatments.
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Introduction: Sarcopenia in older people, though common, is rarely
diagnosed and recorded electronically, posing challenges to recruit-
ment. We describe strategies to efficiently recruit participants to a
factorial trial of perindopril and leucine for sarcopenia.
Methods: Primary care recruitment screened lists from collaborating
primary care practices, and sent mailshots to patients aged 70 and
over, not taking ACE inhibitors. Secondary care recruitment took
place via inpatient and outpatient geriatric medicine services. Local
research nurses screened clinic notes and approached potentiallyeligible patients. Telephone pre-screening, using the SARC-F ques-
tionnaire, was conducted either by research nurses at site or centrally
by Tayside Clinical Trials Unit. De-identified recruitment information
was held on an electronic tracking system run by Dundee Health In-
formatics Centre and analysed using SPSS.
Results: Thirteen UK sites undertook screening. From primary care,
13808 invitations were sent. 2955 (21.4%) responded positively
and 557/2897 (19.2%) participants eligible at pre-screening were
sent study information. 282 attended a screening visit, and 138
(1.0% of total contacted) were randomised. 633/2897 primary care
respondents were pre-screened centrally with the mean number
of calls per respondent 2.3. The conversion rate from pre-
screening to randomisation was 18/633 (2.8%) for centralised
calls, compared to 120/2264 (5.3%) for local pre-screening calls
(p=0.01). A weak relationship was seen between higher (worse)
SARC-F score at screening and lower likelihood of progression to
randomisation (r=-0.07). In secondary care, 1202 sets of notes
were screened at sites with 160 potential participants offered in-
formation. 24 agreed to attend screening visits, and 7 (0.6% of
total notes screened) were randomised.
Discussion: Primary care recruitment led to higher response rates
and overall numbers randomised than secondary care recruitment.
Centralised pre-screening saved local research nurse time but may
have been less effective. SARC-F was of limited help in targeting
screening activity in this sarcopenia trial.
P-129
SWAT: Can social media advertising enhance trial recruitment?
Fay Chinnery1, Nick Francis2, Gareth Griffiths1, Paul Little3, Ingrid Muller3,
Jacqui Nuttall1, Matt Ridd4, Beth Stuart3, Tracey Sach5, Irene Soulsby6,
Karen Thomas6, Kim Thomas7, Alison Layton8, Miriam Santer3, Louise
Stanton1
1Southampton Clinical Trials Unit, University of Southampton, UK;
2Division of Population Medicine, Cardiff University, UK; 3Primary Care
and Population Sciences, University of Southampton, UK; 4Population
Health Sciences, University of Bristol, UK; 5Health Economics Group,
Norwich Medical School, University of East Anglia, UK; 6PPI contributor,
UK; 7Centre of Evidence Based Dermatology, University of Nottingham,
UK; 8Hull York Medical School, University of York, UK
Trials 2019, 20(Suppl 1):P-129
Introduction: The SAFA (Spironolactone for Adult Female Acne) RCT
is aiming to determine the clinical effectiveness of spironolactone
compared with placebo in addition to standard care in the treatment
of moderate-severe persistent facial acne in adult women.
The trial recruits participants at 5 UK hospital sites. But potential par-
ticipants are approached via a number of other routes including:
local General Practices acting as Participant Identification Centres
and community advertising. Social media advertising is being used
to supplement these strategies.
Methods: The social media campaign consists of 2 approaches:
1.Targeted Facebook adverts. Facebook can target people by demo-
graphics and search history and geographical location. People on
Facebook who have shown an interest in acne or relevant organisa-
tions linked with the condition and who fit the profile demographic
are shown adverts for SAFA. If interested, they are directed to the
trial website.
2.Google AdWords campaign. This approach targets people search-
ing Google for acne drugs and treatments and directs people to the
trial website. The trial website provides more information about the
study and explains how to contact the local site study team.
Timing of potential results: SAFA opened in May 2019 and sites will
recruit without using social media for the first 3 months. The Face-
book adverts will be used first and their effect assessed after 3
months. If the Facebook adverts have not sufficiently boosted recruit-
ment, or the trial team thinks the trial will benefit from broader ad-
vertising, the Google AdWords campaign will start. Impact will also
be assessed after 3 months.
Potential relevance and impact: We will see if social media advertis-
ing can augment trial recruitment. Given that recruitment can be
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be of interest to anyone involved in clinical trials.
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Introduction: Recruitment for health intervention trials in socioeco-
nomically deprived areas is often difficult due to issues like poor en-
gagement, distrust, uncertainty and poor communication.
This paper reports on the recruitment strategies used in the Aware-
ness and Beliefs about Cancer (ABACus3) trial, which tested the ef-
fectiveness of a tailored health check to raise awareness of cancer
symptoms in areas of high deprivation of Yorkshire and South-Wales.
Methods: Participants (aged 40+) were recruited from healthcare (GP
surgeries, pharmacies) or community (libraries, community-hubs, job-
shop) settings using an opportunistic or appointment-based ap-
proach. Lay advisors identified and approached suitable venues. Re-
cruitment methods varied by setting type and were regularly
reviewed and adapted according to need. Site logs were kept to
track the interest of venues and recruitment logs recorded numbers
of individuals approached and recruited. Lay advisors were inter-
viewed before and after recruitment to gain an understanding of the
recruitment methods used.
Results: A total 113 venues were contacted to take part in the study
via email, phone and personal visits, of which 42 venues became re-
cruitment sites (n=13 Healthcare, n=29 Community). Recruitment
strategies were adapted based on-site availability, study needs (i.e.
achieving participant balance) and geographical spread. This allowed
for a broad range of participants (n=234/448) to be recruited across
all target areas. Recruitment maps depicted good reach within each
area. Community setting recruitment was more successful than
healthcare settings (n=174 community, n=60 healthcare). Lay advisor
interviews indicated that this was due to high staff engagement and
support.
Discussion: Building positive relationships between lay advisors and
recruitment site staff were vital to ensure positive recruitment out-
comes. Focusing on community settings and arranging planning
meetings in advance was key to successful engagement. In turn, this
facilitated high recruitment with members of the public who were
more likely to engage with trusted site staff.
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Introduction: Study recruitment can be affected by a number of is-
sues with evidence to show that only around 55% of studies achieve
their target sample size. Not being able to recruit to target can
undermine the entire study but for external pilot/feasibility studies
this reduces the precision of any further estimates that can be gener-
ated. Prediction of recruitment timeframes for external pilot/feasibility studies have the additional complexity of having limited
prior knowledge and data.
Could prediction techniques in the literature have improved the esti-
mates and expectations of external pilot/feasibility studies run in
North Wales Organisation for Randomised Trials in Health (NWORTH)
clinical trials unit (2006-2018)?
Methods: Data from all randomised external pilot/feasibility studies
completed between 2006 and 2018 was extracted. The predictions
made using the unconditional model and the actual recruitments
achieved are compared. Subsequently whether the predictions could
have been improved using a conditional model or homogenous and
non-homogenous Poisson processes were all examined using mea-
sures of expected time to recruit and recruitment rates.
Results: Data was extracted for 17 studies. Only 24% managed to
achieve their target sample size, increasing to 47% for those which
achieved >80% of their target. The planned recruitment rate was
overoptimistic in 88% of studies with only one study achieving re-
cruitment in the time planned. Predictions for the planned recruit-
ment period varied very little between the four prediction methods
tested.
Discussion: Recruitment predictions for the NWORTH studies during
2006-2018 would not have been altered significantly using any of
the proposed methods. Intuitively modelling using a non-linear re-
cruitment process is more reasonable allowing for uncertainty and
set-up. With external pilots being used to optimise recruitment strat-
egies it would be sensible to consider a longer recruitment window
to allow the testing of alternative strategies and assessment of im-
pact rather than solely aiming for a target.
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homes. Findings from the ELECTRIC trial pilot
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Introduction: Urinary incontinence (UI), is highly prevalent in resi-
dential and nursing care homes (CH), and profoundly impacts on
residents’ dignity and quality of life. UI affects physical and cog-
nitive functioning, disturbs sleep, and increases risk of falls, frac-
tures, and pressure ulcers. Currently, CHs predominantly use
absorbent pads to contain UI rather than active treatment. Trans-
cutaneous posterior tibial nerve stimulation (TPTNS) is a non-
invasive, safe, low-cost intervention that has demonstrated effect-
iveness for reducing UI in adults. However, the effectiveness of
CH staff delivering TPTNS to residents is yet to be established.
ELECTRIC is a multicentre, placebo controlled, randomised parallel
group trial that aims to compare effectiveness of TPTNS with pla-
cebo stimulation, to reduce UI in CH residents (protocol available
at www.nihr.ac.uk).
Methods: A 6-month internal pilot aimed to test feasibility before
proceeding to full trial using pre-determined progression criteria
addressing: 1) recruitment rates; 2) adherence to stimulation
programme; 3) completion of primary outcome measure; 4) fidelity
to stimulation group. Data for each criterion
were assessed against targets using a traffic light system.
Results and Discussion: The ELECTRIC pilot achieved green (progress
to full trial) for criteria 1-3 (recruitment = 97 residents randomised,
target >90; adherence = 77% received >8/12 stimulations, target
>70%; primary outcome = 88% completeness of 24 hour pad collec-
tion, target >70%). Criterion 4 was amber with >2 fidelity checks cor-
rect (for time, positioning, intensity) in 69% residents, target >70%.
To improve fidelity, checks are now made by trial implementation
support facilitators not CH PIs, with first checks made soon after stim-
ulations start, so errors can be rectified early. Progression to full
ELECTRIC trial was confirmed; final results due June 2020.
ELECTRIC is funded by the National Institute for Health Research.
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Assessing the impact of site engagement on patient recruitment
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Introduction: Participant recruitment is crucial to the success of a
study. One TCTU-led multi-centre trial currently has varying levels of
recruitment across sites: 2 sites recruiting and randomising above
their target and 2 sites unlikely to reach their randomisation target
before the end of the recruitment period. The objectives of this
Study within a Trial (SWAT) are two-fold. 1. To establish whether
using real-time email updates of trial-wide recruitment acts as posi-
tive encouragement on recruitment across all study sites. The hy-
pothesis being that keeping sites aware of each instance of
recruitment may have a positive effect on recruitment, possibly by
showing that recruitment is achievable or by introducing competi-
tiveness across sites. 2. To determine if site engagement, i.e. attend-
ance at monthly teleconferences, has an impact on recruitment.
Methods: 1. At the beginning of the trial, congratulatory emails were
sent to individual sites each time they randomised a participant. As a
result of the intervention, email notifications are now sent to all sites
after each randomisation. The randomisation rate for 6 weeks prior
to the intervention will be compared with the rate in the 6 weeks fol-
lowing the intervention 2. Teleconference attendance by site staff
during the recruitment period will be monitored and recruitment
numbers vs teleconference attendance at each site compared.
Timing of Potential Results: June 2019 (end of recruitment period).
Potential Relevance & Impact: Improving recruitment using email-
based recruitment updates as motivational techniques for site staff
and increasing participation of site staff in teleconferences may
prove to be powerful tools for boosting recruitment at under-
performing sites throughout the recruitment phase of a study. This
in turn may change the way in which trial management responds to
participant randomisation notifications and lead to improvements in
the randomisation notification procedure for future trials.P-135
Common problems recruiting to trials or specific challenges? A
qualitative evaluation of factors affecting recruitment into a
randomised controlled trial of foster care training
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Jonathan Scourfield, Jeremy Segrott
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Introduction: Randomised controlled trials (RCTs) are comparatively
rare in UK social work but can offer distinct advantages. Confidence
in Care (CiC) is an RCT with embedded process evaluation evaluating
Fostering Changes (FC), a 12-week training programme for foster and
kinship carers to increase skills and coping strategies. A challenge in
most trials is participant recruitment. We designed an engagement
strategy and tailored our approach to maximise carer recruitment,
and target sample size was surpassed. To better understand setting-
specific issues in recruitment we undertook a process evaluation in-
corporating key study stakeholder groups.
Methods: Focus groups were conducted, two with field-based
recruiting staff (n=7), one with carers who attended the FC
programme (n=8). Five interviews were conducted with facilitators
who delivered FC. Transcribed audio-recorded data were inductively
coded, double-coded by a second researcher, and thematically
analysed.
Results: Six themes were identified. The first addressed aspects of
the intervention affecting recruitment (e.g. committing to a 12-week
training programme). A second focused on accuracy of communica-
tion between provider agencies and carers. A third concerned theability of recruiting staff to contact carers, a particular challenge in
group-based recruitment. A fourth addressed trial-related aspects
(e.g. the relationship between trial team and recruiting staff). A fifth
explored the lack of differentiation by carers between the roles of
the various professionals (e.g. FC facilitators and provider agencies).
The sixth addressed observations by stakeholders of differences be-
tween recruitment into social care and health studies.
Discussion: Recruitment challenges in this social care setting were
similar to those in healthcare. Some (e.g. gatekeeping by professional
staff) may be rooted in randomisation anxiety, or unfamiliarity with
research methods. Researchers more familiar with healthcare recruit-
ment were however encouraged about the experience of working in
this care setting. The original recruitment strategy and adaptations
form the basis of further recommendations for research practice.
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Introduction: The 2015 Nuffield Bioethics report states ‘the time has
come to protect Children and Young People(CYP) through research
not from research’[1]. However low enrolment is common, notably
this decline after age 14 [2] [3]. UK Children’s Research Networks, in
collaboration with Primary Care and disease-specific Research Net-
works, have transformed CYP research access; evidenced by a two-
fold increase in CYP enrolment between 2009-2019 [4]. Recruitment
challenges are common across all age-groups; between 2002-2008,
only 55% of non-commercial trials met recruitment target, further-
more 45% were extended with the majority continuing to fail [5].
Key CYP challenges relate to informed consent/assent [1].
The evaluation of prescribing asthma controller medication according
to beta2 receptor gene status, to improve quality of life in 12-18 year
olds with asthma required 240 participants. Predominantly recruited
from asthma research databases, supplemented by primary and sec-
ondary care recruitment; within 23 months (including 8-month no-
cost extension).
Methods: Commencing January 2016, PACT invitations were sent to
471 potentially eligible CYP identified from 3500 patients consenting
to contact on BREATH and PAGES databases; 259 reminder mailings.
Results: After 8 months only 19/240 participants (8%) were recruited:
6 from the main recruitment method; 13 from primary/secondary
care (4 sites). A novel wide-reaching primary-care recruitment strat-
egy and 6-month funded extension was implemented. The rescue-
plan, netted 16 CRNs and 441 GP practices. After implementation, re-
cruitment increased by more than 100% in the preceding 8 months
(60/240 – 25%) but remained behind projected target. Escalated en-
rollment (>300%) in the final 12 months added 187 participants.
PACT exceeded target ahead of schedule: 241/240.
Discussion: Engagement with the Kent Surrey and Sussex NIHR Clin-
ical Research Network [6] was fundamental to PACT achieving target.
Despite regulatory challenges (new HRA approvals process, cross-
border sponsorship and CYP consent processes) a UK-wide primary-
care recruitment net was successfully implemented to recruit CYP.
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The RAINDroP study is a pilot randomised clinical trial investigating
the possible benefits of replacing oral iron therapy with intravenous
iron in the treatment of iron deficiency anemia. One of the primary
outcomes is recruitment rates, and the aim is to use multiple chan-
nels to maximise the pool of potential participants.
Method: Recruitment to the study is running in parallel in primary
and secondary care utilising support from both primary care and
ageing research networks to facilitate screening. Broad inclusion/ex-
clusion criteria have been applied, to include co-morbidities that
would be expected within the eligible population. Four sites have
been selected for the study, two in Scotland and two in England.
Study posters, a website and local press will also be used to boost
recruitment
A secure Patient Management System (PMS) incorporating central
mailing designed by the Health Informatics Centre at Dundee Univer-
sity is core to the administration of this multiple recruitment strategy.
Where potential participants are identified their details will be se-
curely uploadedto the PMS which can then be accessed by study
staff at the relevant site.
Timing of Potential Results: The trial is due to end in January 2020,
with a review of recruitment carried out in May 2019.
Potential Relevance and Impact: There is a significant population
prescribed oral iron for iron deficiency anaemia but there is a lack of
evidence to show the benefit of this intervention. The RAINDroP
study aims to identify the most effective methods of recruitment and
inform the design and sample size calculation for a future definitive
trial.
The impact for patients with Iron deficiency anaemia could be a
change to the treatment pathway which will include improved qual-
ity of life and physical outcomes along with reduced side effect pro-
file should IV iron prove to be the best intervention.P-138
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Introduction: Participant recruitment is often challenging when con-
ducting randomised trials. If recruitment targets are not met, re-
search questions are left unanswered, wasting money and
participants’ time. Strategies such as training and education for trial
recruiters are often implemented to improve recruitment processes.
Conducted as part of a wider study (Training Recruiters-An educa-
tional Intervention (TRAIN)), this paper presents the findings of a
qualitative content analysis of previous education and training inter-
ventions for trial recruiters.
Methods: We carried out a systematic search of published studies
reporting on education and training interventions for recruiters to tri-
als. Of the 31 full-text records assessed, 24 met the inclusion criteria
for our content analysis. A directed qualitative content analysis ap-
proach was implemented using deductive categorisation, which in-
volved four main stages: decontextualisation (data familiarisation and
coding), recontextualisation (identifying un-coded text and assessing
for inclusion), categorisation (grouping the codes), and compilation
(presenting the results).Results: We found that the training methods included mostly didac-
tic teaching, individualised support and role play. Most of the inter-
ventions were delivered face-to-face (n=23), with few incorporating
an online format (n=4). The content of the training was grouped into
three main categories: contextual information (about the trial and/or
the training approach), trial management (about managing the trial
team and recruitment challenges/pathways/materials) and the re-
cruitment consultation (such as informed consent and communicat-
ing randomisation).
Discussion: This content analysis offers a useful resource for the
planning and development of education and training interventions
for recruiters to trials, either in advance of a trial or in response to re-
cruitment issues within an in-progress trial. It highlights a number of
factors to consider including the format of intervention delivery,
training components, content, timing and duration.
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Introduction: CALIBER (NCT02070120) is a phase II study investigat-
ing intravesical chemoablation as an alternative to surgery for recur-
rent low risk non-muscle invasive bladder cancer. The primary
endpoint is complete response (CR) following chemoablation. A con-
trol group was included to assess acceptance of randomisation. Par-
ticipants were randomly allocated to chemoablation or standard
surgical management (2:1 ratio).
Original design: CALIBER aimed to exclude a chemoablation CR rate
<45%. Simon’s 2-stage optimal design with α=0.05, 90% power, p0=
0.45, p1=0.60, required 51 chemoablation patients in the first stage.
If <26 CRs were seen, recruitment would cease. If ≥26 CRs were seen,
recruitment would continue to 110 chemoablation patients. If at least
58/110 chemoablation patients (60%) had CR then chemoablation
would warrant phase III evaluation. With a control group and inflat-
ing for 5% non-compliance/drop-out, 174 participants were required:
116 chemoablation, 58 control.
Recruitment: CALIBER opened in February 2015. To March 2017, 48
chemoablation and 26 control participants had been recruited, with
projected completion of recruitment (174 participants) in 2020. CALI-
BER’s independent oversight committees therefore recommended
sample size reduction to allow trial completion and suggested drop-
ping the control group in stage 2. They stipulated that any redesign
of stage 2 should be implemented prior to analysis of stage 1, to
avoid outcomes influencing the design.
Methods & results: Adapted design
The design was amended such that:
1)The surgical control arm was dropped for stage 2
2)The power was reduced to 85% and type I error increased to 10%,
with a success criterion of 31/60 chemoablation CRs. The revised tar-
get sample size (including stage 1 controls and 5% non-compliance)
was 89 patients.
Discussion: Recruitment to trials is challenging, however collabor-
ation with oversight committees and creative adaptations to trial de-
sign can enable trials to be completed rather than abandoned due
to poor recruitment.
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Monitoring changes in recruitment rate over time
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Introduction: Recruitment rates for grant applications are estimated
before detailed information is available about relevant care path-
ways, times at which potential participants can be screened for eligi-
bility, approached to provide study information, consented and
randomised, and how these timings vary across participating sites.
Also, in studies recruiting rare patients or over a long period, recruit-
ment fatigue can occur. Consequently, it may be helpful to monitor
changes in recruitment rate over time from site opening.
Methods: We analysed accruing data about dates of first contact
with potential participants and consent/randomisation, and time
since site opening, to generate graphs showing the average monthly
recruitment rate per site for successive months since site opening, ir-
respective of the calendar months when sites opened. Hence, all
open sites contribute to the estimate of recruitment rate for month
one, but only sites open for longest contribute to the estimate for
the month furthest from first recruitment into the study. We imple-
mented these graphs as part of central monitoring in two NIHR-
funded studies, one trial and one cohort study.
Results: In the trial, when seeking a recruitment extension, we
sought reassurance that the rate of recruitment of rare patients was
not declining; the graph provided the reassurance sought. In the co-
hort study, we wanted to understand why recruitment was slower
than anticipated; the graph showed that the recruitment rate in-
creased over the first six months open, by about 1.5 times, due to
delays between first approach (time of consultant appointment) and
consent (admission for surgery) and initial lack of familiarity with
study processes.
Conclusion: In both instances, the graphs underpinned discussions
with the funder. We recommend the approach as part of central
monitoring, especially when constancy of recruitment rate over time
since site opening is uncertain and is important for projecting future
recruitment.
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Introduction: Recruitment is crucial for any study. Due to its import-
ance a considerable amount of research has addressed barriers to
successful recruitment. Less attention has been given to how re-
cruiters manage participants who decline participation. As part of
good clinical practice, it is important that potential participants feel
reassured that they receive the best available care regardless of their
decision to participate in research or not. This paper draws on evi-
dence about recruitment that was gathered as part of a nested
process evaluation within the TOPSY trial (a multi-centre randomised
controlled trial that compares self-management to standard care in
terms of quality of life outcomes for women using a vaginal pessary
for prolapse).
Methods: This paper draws upon two data sources from the process
evaluation: 1) audio-recordings of recruitment sessions between re-
cruiters and potential participants (n=13); and 2) semi-structured in-
terviews with recruiting pilot centre healthcare professionals (n=7research nurses, specialist nurses or consultants). Data was tran-
scribed verbatim and analysed using Framework Analysis.
Results: Data analysis resulted in identification of three themes:
highlighting participation is voluntary; reassurance that decision does
not affect care provision and emphasising patient care and wellbeing
is paramount. All themes are representative of good clinical practice
and how-to best support patients in their decision to decline trial
participation and alleviating any concerns.
Discussion: As recruitment is a vital part of research it is important
to address all aspects of it to ensure participant wellbeing and en-
courage informed decision about participation. We will contribute to
the discussions surrounding recruitment by extending the focus to
successfully dealing with patients declining trial participation in a
sensitive manner. This allows potential research participants to feel
secure in their choice to not participate while retaining a positive at-
titude for potential research participation in the future.
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Introduction: TARS is a definitive, multi-centre RCT of tailored sup-
port as an aid to reducing smoking, recruiting participants from GP
practices across four England cities (ISRCTN47776579). The preceding
pilot RCT used invitation letters sent out by practices and reported a
recruitment rate of 5.1%. However, six months into the TARS trial, re-
cruitment was 1-2%. This study assessed the efficiency of three differ-
ent GP practice invitation methods.
Methods: This was a randomised study within a trial (SWAT) and in-
cluded six GP practices in one city. The TARS protocol described
three different general practice invitation methods: (a) full invite pack
(~£1/invite); (b) single-page invite (~£0.55/invite); (c) text message in-
vite (£0 research cost). Postal invites were sent via DOCMAIL, a se-
cure online mail management system used by GP practices. Practices
searched electronic records to identify potentially eligible patients,
who were then individually randomised (1:1:1). Patients allocated to
receive text invite but who had no mobile number or had requested
not to be contacted by text were excluded. The number of expres-
sions of interest received, number recruited, and costs attributed to
each method were captured.
Results: Of ~40,000 patients, 1377 were identified as potentially eli-
gible for TARS. 459 were randomised to receive the full pack; 459 the
brief invite; and of 459 randomised for text invite, 349 were eligible
and sent the text invite. The full invitation pack resulted in the high-
est recruitment rate (2.8%), followed by the single-page invite (1.5%).
One individual was recruited by text (0.03%). Initial invite costs per
recruited participant were £35.31 and £36.06 for the full and single-
page postal invite methods, respectively.
Discussion: Despite being the most expensive invitation method, the
full invitation pack was the most efficient recruitment method. If cost
is not an issue, the full invitation pack method is recommended for
recruiting from GP practices.
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challenge in conducting clinical trials. We sought to recruit 138 pa-
tients with early stage Dupuytren’s disease, a benign hand condition,
to determine the efficacy of a novel treatment in delaying disease
progression which results in impairment of hand function.
There is no approved treatment for early stage Dupuytren’s disease
and patients are only referred to secondary care when they have im-
paired hand function and the finger joints are bent to 30 degrees or
more.
Recruitment of people with early Dupuytren’s disease to our clinical
trial, the RIDD trial, via their existing care pathway was therefore not
possible. Consequently, we used alternative strategies to ensure re-
cruitment to target.
Methods: A number of strategies were used, including a website, so-
cial media and posters in GP practices. Data were collected on how
people became aware of the trial to refine our ongoing recruitment
strategy.
Results: Our most successful strategy was the provision of waiting
room posters to GP practices, with accompanying information sheets
for GPs. A notable number of enquiries were also received from
people whose family/friends had seen our posters.
Discussion: We completed recruitment on schedule and our strategy
could be applied to other studies where patients are not in a care
pathway. In addition to recruiting such patients, this methodology
could also be applied in other scenarios such as recruitment of pa-
tients at high risk of developing a disorder or to raise awareness of
research projects prior to diagnosis of a condition.
Practical consideration including some of the challenges we encoun-
tered will also be presented.P-145
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Introduction: Regulatory bodies, funders and the pubic widely
accept the obligation of registration and timely reporting of clinical
trials. In addition, as a condition of consideration for publication, the
International Committee of Medical Journal Editors (ICMJE) requires
registration of clinical trials in a public trials registry at or before the
enrolment of the first trial participant. Ambiguity in anchoring partici-
pant recruitment/enrolment, and the trial start/end date, temporally
to trial processes (e.g. invitation, consent, randomisation), however,
has the potential for variation in how recruitment and enrolment are
reported and understood in trial registries, protocols and reports.
This research aims to theoretically define and operationalise ‘trial re-
cruitment’ for purposes of reporting through a concept analysis.
Methods: A concept analysis using the Hybrid Model will be per-
formed, involving three phases; i) the theoretical phase aims to gain
an understanding of how ‘trial recruitment’ has been defined, used
and measured in the literature; based on a systematic search of trial
reports, their protocols and register details of trials published during
2018-2019 in the top five healthcare journals, and a review of these
journal’s policies/publication guidelines; ii) the fieldwork phase will
refine the concept through focus group interviews with trial re-
cruiters and individuals who have been previously invited to take
part in a trial; iii) the analytical phase integrates the findings from
the previous phases to provide theoretical and operational defini-
tions, as well as enhanced understanding of ‘trial recruitment’.Potential results: We will present the final findings from the theoret-
ical phase (complete: 08/2019) which will highlight how ‘trial recruit-
ment’ is currently defined, used and measured.
Potential impact: Standardised reporting of completed trials is im-
portant to ensure unbiased assessments of evidence to inform health
care decisions. This concept analysis will potentially enhance and
standardise the reporting of trials by disambiguating the concept of
‘trial recruitment’.
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Introduction: SAILOR was a multi-centre, feasibility trial to determine
whether post-surgery outcomes at three months were better for pa-
tients with low rectal cancer who had early surgery compared with
the standard method of treatment.
Participants were randomised on a 1:1 basis to receive either the
intervention (early surgery alone) or standard care (pre-operative
radiotherapy then surgery).
Methods/recruitment issues:
All eight sites reported significant recruitment issues relating to the
narrow inclusion criteria, a lack of equipoise amongst consenting cli-
nicians and, most importantly, patients’ treatment preference. At one
site, 9 out of 13 eligible patients cited treatment preference as the
reason for declining the trial.
A modified Zelen design was introduced for the final 3 months of re-
cruitment to determine whether it would increase the likelihood of
patients consenting to the trial. The design involved two stages of
consent; 1) participation and randomisation, then 2) acceptance of
the randomisation result. If second stage consent was refused, the
patient was offered whichever treatment they wanted and remained
in the trial.
Results: We only consented one patient following the design change
due to time constraints. This patient consented to both randomisa-
tion and the treatment they were allocated. The patient had a treat-
ment preference at the point of consent but was randomised to that
treatment anyway.
Discussion: Whilst no further insight could be gained into the value
of the Zelen design, we believe that allowing patients the freedom
to know that they can have the treatment they prefer and still be in-
volved in research will lead to them consenting to trials.
We would suggest that other trials consider adopting the Zelen de-
sign where a treatment preference is likely and recruitment is likely
to be poor due to strict eligibility or rare conditions should be
considered.
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able, yet fewer men engage in weight loss interventions and disad-
vantaged men are under-represented. The aim was to examine the
acceptability and feasibility of a men-only weight management inter-
vention consisting of text messages, with and without an endow-
ment incentive, compared to waiting list control.
Methods: Men with obesity were recruited through community out-
reach and general practitioner obesity registers in two disadvantaged
communities in Scotland. Participants were randomised to receive a)
narrative text messages for 12 months (SMS), b) financial endowment
incentives plus narrative texts messages for 12 months (SMS+I), or c)
to a waiting list control. Acceptability and feasibility of recruitment,
retention, engagement, and weight outcome verification were
assessed by analysing quantitative and qualitative data at three, six
and 12 months. A priori full trial progression criteria were set for re-
cruitment and retention.
Results: 105 men from across the socioeconomic spectrum were re-
cruited within four months, 60% from more disadvantaged areas.
Fewer participants from the SMS+I group (64%) completed at 12
months compared to SMS only (79%) and control (83%). Compared
to community recruits, men recruited via GP obesity registers were
more likely to live in deprived areas (community=56% vs GP=64%),
were older (community=48 years vs GP=57 years), more likely to re-
port having a co-morbidity (44% community vs 87% GP) and had
lower mean BMI (community=36.2 kg/m2 vs GP=35.0 kg/m2). Partici-
pants completing 12-month assessments differed slightly by recruit-
ment route: community 43/60 (71%); GP 36/45 (80%). Retention was
higher for participants from disadvantaged areas in the SMS+I and
control groups, but not in the SMS group. Interventions were accept-
able and all groups lost some weight.
Conclusions: Men from disadvantaged areas were engaged. Baseline
characteristics and retention differed according to recruitment strat-
egy, which has potential implications for preventative medicine trials
and health inequalities.P-148
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Introduction: For results of trials to be valid and rigorous trial teams
need to recruit and retain an adequate sample size to reach statis-
tical power. Recruitment and retention of people with dementia in
research is challenging due to increased frailty, morbidity, cognitive
change, social isolation, the language of research, capacity issues and
gatekeepers, such as family members, acting on behalf of the person
with dementia. Research into complex interventions present an add-
itional challenge for this population as there is often a requirement
to commit to a structured programme.
Journeying through Dementia is a NIHR HTA funded randomised
control trial investigating the clinical and cost effectiveness of a com-
plex psychosocial intervention for individuals with early-stage de-
mentia. The intervention aimed to improve quality of life by
promoting self-management and independence. The trial recruited
and randomised 480 participants from 13 sites.
Aim: To understand the factors impacting recruitment and retention
of people with dementia in the Journeying through Dementia trial.
Objectives:
•To identify barriers and enablers to recruiting to, and retaining people
with dementia in, a trial of a complex psychosocial intervention.•To disseminate the lessons learnt from a large randomised control
trial to improve recruitment and retention in the future.
Methods: A retrospective descriptive analysis of 480 participants’
recruitment and retention rates along with bivariate analysis
against demographic data. Additionally, semi-structured telephone
interviews were conducted with a purposive sample of re-
searchers, selected to include researchers who had experience of
recruitment and retention in the trial. Interviews are analysed
through thematic analysis.
Timing of Potential Results: The potential results will be available by
the end of June 2019.
Potential Relevance & Impact: The results of this study aim to iden-
tify effective recruitment and retention strategies in trials of complex
interventions involving people with dementia and other hard to
reach groups.P-149
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Introduction: Recruitment into clinical trials is difficult to predict with
just 56% recruiting to target (Walters et al., 2017). Barriers often in-
crease for complex interventions and more so when they are
dependent on the availability and expertise of small professional
groups such as Speech and Language Therapists.
The PD COMM trial compares two types of speech and language
therapy (SLT), for people with Parkinson’s and communication prob-
lems, to a no intervention control in 42 sites across Britain. One inter-
vention is an intensive therapy programme (16 one-hour sessions
over 4 weeks). Sites start SLT within 4-7 weeks of randomisation. PD
COMM is recruiting more slowly than predicted. Here we identify
and review reasons for delays to aid future site selection.
Methods: A series of risks to recruitment were identified. These in-
cluded: staffing levels; working patterns (full or part-time); and train-
ing /expertise of individuals in delivering Lee Sliverman Voice
Treatment (LSVT). We reviewed delays in recruitment including initi-
ating recruitment, slower recruitment than expected including
planned temporary pauses in recruitment.
Results: Forty out of 42 open sites have recruited to the trial. 27
sites needed LSVT training for therapists, delaying the start; the
average time to open was 5 months, and to first recruitment was
2 months; although three sites took 6 or more months. Of the
combined 862 months open, there have been 32 pauses of at
least 6 months, including 7 sites that have had 2 pauses. The
most common reason reported by research nurses is lack of ther-
apist availability due to staff changes and periods of leave. We
will further explore the impact therapist numbers and working
patterns have on these delays and the implications for complex
interventions of this type.
Discussion: Recruitment has been affected by the lack of therapists’
availability for delivering the intensive intervention.
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Introduction: Thoracolumbar fractures are the most common spinal
fracture. Where the fracture is not obviously stable or unstable, and
despite the seriousness, there is no current consensus on the best
treatment. There are variations between surgeons, treating centres
and within the evidence base as to whether surgical or non-surgical
approaches should be used. A Cochrane review (Abudou et al., 2013)
identified the need for a RCT investigating treatments for these frac-
tures and prompted an NIHR commissioning brief.
The PRESTO study aims to determine the feasibility of undertaking a
full-scale trial to evaluate cost and clinical effectiveness of surgical
versus non-operative management for thoracolumbar fractures with-
out neurological deficit.
Methods: The study consists of three elements: a two-arm rando-
mised feasibility study which will explore the size of the population
and completeness of follow-up; a qualitative study where both pa-
tients and staff will be interviewed to determine views and experi-
ences of the intervention and trial processes and a national survey of
surgeons to explore methods of establishing spinal stability, surgical
fixation and non-operative management that are currently used in
the UK. At least 60 patients will be recruited to the study via three
secondary care centres, and followed-up using paper questionnaires,
or data submitted online to the British Spine Registry.
Timing of potential results: Recruitment ended 31st March 2019,
with final follow-up 3 months later. Results will be available in August
2019 and presented at the conference.
Potential Relevance and Impact: The study elements will be com-
bined to give an overview of current practice in management of
these fractures, the views of clinicians and patients on facilitators
and barriers to a definitive trial, and feasibility of trial conduct. It will
also provide information on using British Spine Registry data within a
trial setting; of relevance for future trials in this population.P-151
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Introduction: Feasibility studies play an important role in designing
randomised controlled trials (RCT), especially in identifying and ad-
dressing challenges in primary care where rapid recruitment of large
numbers of participants can be needed.
SuMMiT-D is a feasibility RCT testing the impact of SMS text-
messages for behaviour change using a digital trial platform for re-
cruitment, screening, e-consent, data collection, randomisation, inter-
vention delivery and trial monitoring. It aims to recruit 200 patients
with type 2 diabetes in three months.With a narrow recruitment window and progression to a main trial
dependent on recruiting to target, close monitoring by the trial team
of set-up, and practice and patient recruitment, is needed.
Methods: The trial is being carried out in 16 practices in four clinical re-
search networks.
Recruitment metrics, including set-up time, number of invitations
sent, methods of identifying eligible patients and response rates
were monitored weekly to assess the recruitment performance of
each site. Resource use data for the study are also collected.
Results: A total of 8196 patients were identified across 16 practices
and 7372 invitations to take part in the trial were sent out. The mean
number of screened patients per practice was 20 (5% of those in-
vited). Conversion from screening to randomisation was high (73%).
Data from the digital trial platform identified stages in the enrolment
process where participants found difficulties, and these were modi-
fied in real-time during recruitment.
In total, we recruited 209 participants. The average number (range)
of days from site setup to permission for recruitment was 66 (7 to
134) days and between site opening to first randomisation was 40
(12 to 80) days.
Discussion/Conclusion: Close monitoring and quick resolution of is-
sues causing delays was key in quickly recruiting to target. The re-
sults collected will inform the design and recruitment plan of the
subsequent main trial.P-152
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Introduction: A common challenge in mental health trials occurs during
recruitment, where one or all the interventions involve group therapy. Typ-
ically, there is a therapeutic constraint on the minimum number of partici-
pants needed for the group therapy and it is necessary to recruit a group
of participants before the intervention can start.
Methods: There are two approaches to randomising in this situation, by
sequential randomisation, or by randomising once enough participants are
recruited to ensure the minimum therapy group size (“block randomisa-
tion”). We will describe our experiences using both approaches.
Results: In either approach, many of the challenges arise from the
need to delay the start of therapy. For sequential randomisation
there is a potential delay between randomisation and start of the
therapy and for block randomisation, a potential delay between
baseline and randomisation. In either case, this can affect the validity
of baseline measurements (which can become “outdated”), result in
loss of participants during delays and lead to variability in time from
baseline to commencement of therapy.
For one trial using “block randomisation” with a large block size, loss
of participants prior to randomisation often resulted in a “block”
never reaching the required number to be randomised. However, se-
quential randomisation possibly only delays this issue until after ran-
domisation and losses post-randomisation result in missing data for
the intention-to-treat analyses.
There are other design challenges. In another trial, including multiple
strata within a “block” required randomising additional participants
to ensure the minimum therapy group size was achieved.
Discussion: In our experience, “block randomisation” can be overly
restrictive especially for large groups and can lead to under-
recruitment. Sequential randomisation should be considered but
may require flexibility in group sizes and/or relaxing the definition of
the intervention (e.g. by having a “rolling” group where individuals
start at different times).
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Introduction: Many clinical trials fail to reach their planned sam-
ple size within the planned timeframe and budget. The pre-
dicted recruitment rate is based on both the sample size
calculation and an estimated timeframe for recruitment. Various
sources of information (e.g. recruitment data from previous re-
search, clinician estimates, audit data) may be used to inform
these estimates at the design stage, usually whilst applying for
funding. It is unclear which sources are most reliable for esti-
mating recruitment rates. We are conducting a survey of trial
managers in the Bristol Trials Centre (BTC) to identify which in-
formation sources are used to calculate predicted recruitment
rates, how often studies meet these targets and reasons why
they may fall short.
Methods: We created a short online survey (SurveyMonkey) to collect
information about (i) study design, budget and funder; (ii) sample
size and planned timeframe (recruitment rate); (iii) information
sources used to estimate the recruitment rate; (iv) actual recruitment
rate; (v) details about why the study was/ was not on target. The sur-
vey will initially be circulated to the trial managers in the BTC (at
least 60 studies) in the pilot phase. The survey respondents will be
asked to answer questions about clinical research studies they man-
age that are in set-up, currently recruiting or have finished recruit-
ment in the past three years.
Timing of potential results: We expect the results of the pilot phase
of the survey in July 2019.
Potential relevance and impact: The results will provide evidence
about information sources used for estimating recruitment rates
and whether some sources provide more realistic targets than
others. We plan to refine the survey, based on the pilot results,
before circulating it as a national survey, via the UK Trial Man-
agers’ Network.P-154
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Introduction: Optimal fever management in critically ill children is
unknown. We explored parent and practitioner views on the feasibil-
ity of a trial investigating temperature thresholds (37.5°C v 39.5°C) for
the administration of paracetamol in children with fever and sus-
pected infection.
Methods: 1) Pre-trial focus groups with practitioners and interviews
with parents to inform the pilot trial design. 2) Embedded study
within the pilot trial involving focus groups and surveys withpractitioners and interviews and questionnaires with parents of ran-
domised children. Data analysis drew on Sekhon et al’s (2017) theor-
etical framework of acceptability.
Results: 1) Parents (n=25) were interviewed and practitioners (n=56)
took part focus groups. Overall parents found the proposed trial ac-
ceptable. However, parents and practitioners raised concerns regard-
ing proposed thresholds and not using paracetamol for pain or
discomfort. Findings informed changes to the pilot trial protocol, par-
ticipant information and site training. 2) Sixty parents of 57 rando-
mised children took part in interviews and/or questionnaire; and
practitioners (n=98) took part in either a focus group or survey. Both
groups found the pilot RCT acceptable, with pre-trial research assist-
ing practitioner ‘buy-in’. However, concerns about children being in
pain or discomfort when weaned from ventilation led to cases of
withdrawal and protocol non-adherence. Nevertheless, n=87/100 par-
ents provided consent and supported the trial. Practitioners had
polarised views on the acceptability of the higher temperature
threshold; those trained by the Fever team found it more acceptable
than those trained by site colleagues.
Discussion: Challenges to delivering proposed trial included con-
cerns about the acceptability of the protocol. Pre-trial research and
experience of pilot trial conduct augmented views, providing insight
into how challenges may be overcome; such as changing the inclu-
sion criteria and delivery of site training. All seven constructs of the
framework of acceptability would then be met. The Fever trial was
deemed feasible.
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Introduction: Run-in periods, whereby participants take trial drug(s)
for a period prior to randomisation, are common in cardiovascular tri-
als, but their use is often debated. By selecting participants for ran-
domisation on the basis of compliance or tolerability, statistical
power may be increased, but careful interpretation of results is
needed. Run-ins generally have less relevance in oncology where
duration of therapy may be short and/or compliance less of an issue.
The Add-Aspirin trial is assessing aspirin for preventing recurrence following
cancer diagnosis and treatment. Evidence suggests that aspirin must be
taken for several years to see an effect and, since it is available over-the-
counter, non-compliance is a concern. Additionally, tolerability is not well-
documented in this setting. We evaluate use of a run-in period in the trial.
Methods: Add-Aspirin is a phase III, double blind, placebo-controlled,
basket trial assessing daily aspirin (100mg or 300mg for 5 years) follow-
ing treatment for an early stage cancer (breast, colorectal, gastro-
oesophageal, prostate; total n=9920). An active run-in, whereby partici-
pants take 100mg aspirin daily for 8 weeks, was incorporated to select
those most likely to tolerate and comply with the intervention.
Run-in data from a planned feasibility phase lasting 2 years will be used
to evaluate use of the run-in period, considering: randomisation rates;
reasons for not proceeding to randomisation; and differences (in demo-
graphics, disease, adherence and tolerability) between rando-
mised and non-randomised participants. Feedback from recruiting
teams on implementation of the run-in will also be incorporated.
Timing of potential results: The feasibility stage is complete (n=
3194, of which 2719 (85%) were randomised). Analyses will be fina-
lised in Summer 2019.
Potential Relevance & Impact: Add-Aspirin demonstrates successful
implementation of a run-in period in a late-phase cancer clinical trial.
Evaluation of this design element, in terms of both statistical and
practical aspects, will have relevance beyond the oncology setting.
P-156
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Introduction: Emergency Departments (EDs) benefit from high pa-
tient numbers and a wide demographic to allow potential recruit-
ment to clinical trials, however it is a challenging setting for research.
EDs are crowded and patients may have prolonged waits to be seen.
LoDED (Limit of Detection of Troponin and ECG Discharge Strategy)
is a pragmatic randomised trial to assess clinical effectiveness of a
novel discharge process for patients with chest pain. We describe
several aspects considered in the trial to ensure recruitment to target
and high-quality data.
Methods: We selected eight UK sites with a track-record in recruiting
to ED trials and established research teams. We engaged clinical
teams through bespoke teaching sessions to identify potentially
eligible patients at the time of triage. To increase recruitment effi-
ciency, pre-prepared participant packs were provided which con-
tained necessary study documents.
Participants were given a two-page participant information sheet
(PIS). Time taken for usual care laboratory processing of blood sam-
ples and time waiting to be assessed by a doctor allowed sufficient
time to consider the PIS prior to being approached for consent.
Randomisation was undertaken using simple bespoke online soft-
ware and efficient clinical data collection undertaken following par-
ticipant discharge using electronic patient records. Follow-up of
participants at 30 days was facilitated by using multiple methods of
contact (texts, e-mail, post and phone).
Timing of potential results: In nine months 632 participants were re-
cruited; 106.4% against a target of 594, with follow-up rates of ap-
proximately 95%. Results are anticipated in mid-2019.
Potential Relevance and Impact: This trial benefited from a high
number of potentially eligible patients presenting with chest pain.
Clinicians reported that participants were very engaged with the trial
and appreciated the simple processes involved, and staff found the
study easy to recruit to. This led to recruitment over target in a hos-
tile clinical environment.
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Introduction: Reaching recruitment targets in randomised controlled
trials is a challenge. Media tools such as video clips are increasingly
used to engage participants, yet there is a paucity of research into
the use of video to optimise recruitment. We therefore tested
whether adding a participant information clip to a standard partici-
pant information sheet following a screening phase improved recruit-
ment into a parenting trial.
Methods: A study within a trial was embedded within a randomised
controlled trial of a parenting intervention to improve child behav-
iour problems. Potential participants were randomised to receive ei-
ther a standard participant information sheet (PIS) or a participant
information clip (PIC) as part of an email contact following a screen-
ing phase; all participants went on to receive the PIS as part of the
existing recruitment procedure.
Results: During the study within a trial period 107 eligible partici-
pants entered screening for the main RCT and were randomised to
either the PIC condition (N=56) or to the PIS condition (N=51) on a
weekly basis. The PIC condition did not increase the odds of recruit-
ment into the trial (OR = 0.82, CI = 0.31 – 2.14, p = 0.68). Qualitativeinterviews indicated that participants perceived both the PIS and PIC
to be useful, comprehensive and accessible, while researchers found
the use of an initial email contact helpful in promoting participant
interest in the study irrespective of the PIS/PIC condition.
Discussion: The introduction of a PIC into a parenting trial did not
lead to an improvement in recruitment, however the small sample
size precludes definitive inferences regarding group differences.P-159
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ELECTRIC is a multicentre, placebo controlled, randomised trial aim-
ing to determine the effectiveness of non-invasive transcutaneous
posterior tibial nerve stimulation (TPTNS) to treat urinary incontin-
ence (UI) in care home residents. This paper discusses challenges
and successes encountered in recruiting to the ELECTRIC trial and en-
gaging nursing and residential care homes in research.
Two elements of recruitment are considered: i) Identifying and recruiting
care homes as research sites ii) Identifying and recruiting care home resi-
dents to participate in ELECTRIC. The planned approach to recruitment of
care home sites, how and why the actual strategies differed from the ori-
ginal plan will be described. Reflections on successes and challenges in-
clude involving the ENRICH (Enabling Research In Care Homes) network,
fostering group partnerships, care home manager meetings, targeted re-
cruitment and snowballing methods of introduction. The relative success
of strategies specifically designed to foster enthusiasm and early uptake
of the opportunity to engage with the trial will be discussed.
The crucial roles of the care home manager, delegated ELECTRIC lead
and care home staff are highlighted for resident recruitment and the
influence of organisational and individual care home culture ex-
plored. Lessons learned during the early stages of ELECTRIC trial re-
cruitment and applied to later recruitment and engagement
activities will be described. Details of resident recruitment and ran-
domisation rates will be provided for i) Overall care home size and
number of residents; ii) number of eligible residents iii) number of
eligible residents for whom consent is available.
Conclusion: Recruitment to trials from nursing and residential care
homes presents a number of context-specific challenges and oppor-
tunities for success that are not routinely encountered when recruit-
ing through NHS services. Exploring the influencing factors, based on
experiences of recruiting from forty care homes, may expedite the
application of successful recruitment strategies in such research con-
texts in the future.P-160
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Trials 2019, 20(Suppl 1):579 Page 47 of 141Introduction: Recruitment and retention of participants are the big-
gest challenges to successful delivery of trials. Many interventions
are used by trial teams to improve recruitment and retention; how-
ever, few have been rigorously evaluated. A Study Within A Trial
(SWAT) is a robust method to evaluate the effectiveness of interven-
tions for improving trial conduct. PROMoting THE USE of SWATs
(PROMETHEUS) aims to make embedding SWATs standard practice
across UK Clinical Trials Units (CTUs), by pump-priming and facilitat-
ing trial teams to start at least 25 SWATS of recruitment or retention.
Methods: We established a network of CTUs committed to starting
at least two SWATs of recruitment and/or retention interventions. We
identified promising recruitment and retention interventions from a
variety of sources including Cochrane systematic reviews and exist-
ing prioritisation exercises. We created a priority list of 7 recruitment
and 8 retention interventions, and developed template SWAT proto-
cols for testing them. We are inviting trial teams to apply for funding
of up to £5,000 to test one of our prioritised interventions or their
own. Successful applicants are given funding, methodological and
process support to embed and report the SWAT.
Results: 26 trial teams from 11 CTUs have been funded to undertake
30 SWATs of recruitment and retention strategies, exceeding our ini-
tial target of 25 SWATs ahead of schedule. Each recruitment and re-
tention intervention is being evaluated in up to five host trials, and
will be evaluated for its effectiveness in the context of individual tri-
als, as well as across different trial populations and contexts.
Discussion: The RCT community has shown that with enough finan-
cial and methodological support, many are willing to engage with
and implement SWATs to build rapidly the evidence base. This will
help to deliver trials in a timely manner, patients to receive better
treatments and funders to deliver on their objectives.P-161
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The past 15 years have seen an exponential rise in published studies
in health research described as pilot or feasibility studies. Many of
these published studies are in preparation for larger randomised con-
trolled trials evaluating efficacy or effectiveness. The vast majority of
these studies are external pilot or feasibility studies conducted separ-
ately from the future larger randomised trial, andthe data they pro-
duce is used only to make decisions about whether and how to go
on to a larger study. However, there has also been a rise in the num-
ber of effectiveness or efficacy randomised controlled trials in which
the first part of the trial is a pilot phase used to test out the feasibil-
ity of trial processes such as recruitment and retention. These pilot
phases are usually called internal pilot studies.
A pilot or feasibility phase for trials of complex interventions is widely
recommended, for example by the UK MRC framework for the develop-
ment and evaluation of complex interventions and is expected by fun-
ders such as the UK NIHR. However, researchers still face the question
about whether and what sort of external pilot work is needed in rela-
tion to their own research area. In this talk, we will use some examples
of external pilot and feasibility studies to reflect on when external pilot
studies are particularly useful, and how to make judgements about
their objectives, design and conduct. The examples cover a range of
different health issues. We suggest that the usefulness of an externalpilot study in advance of a larger randomised controlled trial may be
best assessed on a case by case basis.
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Introduction: The Prioritising Recruitment in Randomised Trials Prior-
ity Setting Partnership Study (PRioRiTy PSP), identified and prioritised
unanswered questions around trial recruitment research. We utilised
qualitative research methods to answer Question 5 ‘What are the
barriers and enablers for trial recruiters?’ within the maternity care
setting.
The aim of this Qualitative Evidence Synthesis (QES) was to explore
the evidence on the recruiter’s experience and perceptions of recruit-
ing women during pregnancy & childbirth to trials. We were specific-
ally interested in exploring;
1)The recruiter’s perception and awareness of how their own role
(e.g. clinical or non-clinical) might influence recruitment.
2)The recruiter’s perception and experience of how the ‘type of trial’
(i.e. pharmaceutical, non-pharmaceutical,) might influence recruitment.
3)Explore the setting and environment in which recruitment is
undertaken.
Methods: Using SPIDER, a broad search of electronic databases
(Pubmed, CINAHL, Embase, PsycINFO) & grey literature (Scopus, for-
ward & backward citation searches) returned 13,401 citations. Ab-
stracts were independently screened by two reviewers, of these, 29
citations progressed to full text screening, resulting in 8 eligible pa-
pers. We designed a data extraction tool and critically appraised
using CASP checklist. A thematical approach to coding & synthesis
was undertaken, applying CERQual for confidence in review findings.
Timing of Potential Results: We have preliminary results and expect
the QES will be submitted for publication in December 2019.
Potential Relevance & Impact: The review will, for the first time, sys-
tematically synthesise existing research on factors associated with re-
cruitment to RCTs in maternity care from the recruiters perspective.
The findings will provide the basis and direction of an exploratory
qualitative study seeking to develop a statement of recommendation
(in collaboration with stakeholders) for successful recruitment of
women during pregnancy & childbirth to RCTs.
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Introduction; The Topic 2 randomised controlled trial (RCT) (NIHR-
HTA- 16/111/111) was set up to compare the effectiveness of thor-
acic epidural and paravertebral blockade in reducing chronic post-
thoractomy pain. Recruitment was anticipated to be difficult and the
QuinteT Recruitment Intervention (QRI) was integrated into the trial
design to optimise recruitment.
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vided to assist recruitment from the outset. In-depth semi-structured
interviews were conducted with healthcare professionals, TMG mem-
bers and sites declining trial participation. Monthly screening logs
were scruitinised and recruitment consultations and interviews ana-
lysed, using thematic and constant comparative methods. In phase 2,
we provided confidential and supportive feedback to recruiters and
collaboratively developed and implemented plans to optimise
recruitment.
Results: (Recruitment and qualitative data collection is ongoing).
We conducted 12 interviews with surgeons, anaesthetists and re-
search nurses, audio-recorded 9 recruitment consulations and carried
out individual and group feedback sessions. Randomisation rates var-
ied between 43 to 100 per cent (randomised/ eligible patients
approached). Specific training was given to convey equipoise, to gen-
tly explore patient preferences and balance the description of the
treatment arms. Despite centres exceeding recruitment targets, ac-
crual may lag due to problems opening the target number of recruit-
ment centres, owing to a sharp decline in the number of planned
thoracotomies, a shift away from thoracic epidurals and limited cap-
acity to deliver high-dependency unit nursing care.
Potential relevance and impact
This is the first anaesthesia RCT to embed qualitative methods to op-
timise recruitment. Findings may be of interest to trialists initiating
RCTs when community equipoise challenges clinician preferences for
routine local practice.P-164
Recruitment strategies and screening yields in the Hypertension
Approaches in the Elderly: a Lifestyle Study (The HAEL Study)
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Introduction: The identification and recruitment of research partici-
pants for clinical trials is a common challenge across studies, being
considered a key determinant for adequate trial completion. Since
several recruitment strategies may be implemented to enhance re-
cruitment rates, we aimed to describe the recruitment strategies and
preliminary results for the Hypertension Approaches in the Elderly: a
Lifestyle Study (HAEL).
Methods: The HAEL Study is a 12-week randomised controlled trial
(NCT03264443) that aims to assess blood pressure effects of a prag-
matic combined training program (1:1 allocation ration) in compari-
son with a health education program. The sample size will be
composed by 184 older adults, divided in two implementation cen-
ters. In the two sites, recruitment strategies include five main
sources, as follows: press media, word-by-mouth, lists generated by
electronic health records, professional referrals, and flyers. Descriptive
statistics are used to monitor characteristics of study participants, dis-
tribution of sex across sites. Data are expressed as absolute and rela-
tive frequencies.
Results: From September/2017 to April/2019, four recruitment waves
have been conducted in both, totalizing 289 and 200 monitored
screening calls in coordination and field sites, respectively. The
screening yields were consistent across site for word-by-mouth (62
[21.4%] of total screenings), flyers (8 [1.6%]), and professional refer-
rals (7 [1.4%]). However, important discrepancy has been observed
across sites for press media, which is the source of 154 (53.3%)
screenings at the coordination site, and lists generated by electronic
health records, which is the source of 104 (52.0%) screening at the
field site.
Discussion: The observed discrepancies in recruitment strategies
have yielded differences in distribution of women and men in differ-
ent sites, suggesting that active monitoring of recruitment yields
from different sources might be useful to avoid non-random distor-
tions in screened and included subjects.P-165
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Background: Randomised clinical trials (RCTs) provide the most trust-
worthy evidence when evaluating a medical intervention. However, it
can be difficult to appraise the true effect of an intervention due to
publication bias, i.e. the frequent non-publication of studies with un-
favourable results. Clinical trial registries are supposed to give a com-
prehensive overview of all ongoing RCTs which helps to estimate
and control publication bias and to avoid duplication of research.
There is little evidence on what proportion of approved RCTs (pub-
lished and unpublished) was actually registered. This study aimed to
close this knowledge gap.
Methods: We had access to a total of 555 RCT protocols that were
approved by a research ethics committee in 2012 or 2016 in
Switzerland, Canada or Germany. For each RCT we systematically
searched if it was registered in a clinical trial registry, and if it was
registered before patient enrolment. We present results separately
for 2012 and 2016 to assess if there was an improvement over time.
In addition, we stratified the analysis by industry and non-industry
sponsored RCTs.
Results: From the 555 RCTs, 491 (88%) were registered and 447
(81%) were prospectively registered. We did not find an increase in
registrations over time (2012: 91% registered, 81% prospectively reg-
istered; n=262; 2016: 88% registered, 81% prospectively registered;
n=293). Industry trials seemed to be more often registered (96%; 257
of 269) and prospectively registered (90%; 241 of 269) compared to
non-industry RCTs (82% registered; 234 of 286; and 72% prospect-
ively registered; 206 of 286). Data collection on publication status of
RCTs approved in 2012 is ongoing and will be present at the
conference.
Conclusion: Registration of RCTs is still incomplete, especially for
non-industry RCTs. Our study will provide a first estimate of the pro-
portion of unpublished RCTs that can be found in a registry.P-166
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Introduction: Underpowered trials risk contributing to research waste
through the production of inaccurate results. Stroke rehabilitation
RCTs can experience recruitment challenges and limited sample sizes.
Simulations have been used successfully in other fields to explore
sample size adequacy and provide recommendations for future RCTs
recruitment targets.
Aim: To examine the adequacy of stroke rehabilitation RCT sample
sizes in the context of BI or mRS.
Trials 2019, 20(Suppl 1):579 Page 49 of 141Method: We secured 2,350 anonymised individual participant data
(IPD) on the BI or mRS from 18 stroke rehabilitation RCTs archived
within VISTA-Rehab (www.virtualtrialsarchives.org/vista-rehab). Com-
puter simulations were conducted using typical experimental event
rates (EER) and control event rates (CER) for both outcome measures
in order to determine appropriate sample size boundaries. Event
rates were defined as clinically relevant improvements (BI 1.85; mRS
1). We examined numbers needed to treat (NNT), estimated how ac-
curate these NNTs were for differing sample sizes, and estimated the
RCT sample sizes required in order to achieve an NNT within clinic-
ally acceptable boundaries (+/- 1 of the true NNT value).
Result: For a 75% chance of a stroke rehabilitation RCT being able to
accurately determine statistical advantage over control when using
the BI (assuming a CER of 0.36 and EER of 0.43) 702 participants per
group would be required and for accurate interpretation of effect
sizes 1000s would be required. Simulations were not possible for the
mRS as there was a higher CER (0.13) than EER (0.12).
Discussion: The BI when used as an outcome measure for stroke re-
habilitation RCTs requires unfeasible sample sizes for effect size inter-
pretation. The mRS appears to lack the sensitivity to detect change
and is therefore unlikely to be a useful outcome measure for stroke
rehabilitation. Therefore, the current use of these outcome measures
for stroke rehabilitation RCTs is contributing to research waste.P-167
Incorporating estimated correlation between baseline and follow-
up measurements into sample size calculations in randomised
trials: Efficient design or type 2 error risk?
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Introduction: Adjusting for baseline measurements in the analysis of
randomised trials increases efficiency, but this is often neglected
from sample size calculations. We aim to explore the utility of incorp-
orating estimated correlation between baseline and follow up mea-
surements into sample size calculations.
Methods: Using data from trials coordinated by York Trials Unit
(YTU), we obtained estimates of the correlation between baseline
and follow up for three outcomes; body weight, Patient Health Ques-
tionnaire (PHQ-9) score and Hospital Anxiety and Depression Scale
(HADS) score. We identified trials funded by the Health Technology
Assessment (HTA) programme using one of these measures as a pri-
mary outcome and featuring a sample size calculation that did not
account for repeated measurements. This yielded five trials using
body weight, two using PHQ-9 and one using HADS.
Timing of Results: YTU data suggests correlation between baseline
and follow up of around 0.9, 0.4 and 0.7 for body weight, PHQ-9 and
HADS respectively. Using these values in a power calculation would re-
duce the sample size by 81% for body weight, 16% for PHQ-9 and 49%
for HADS. For the five HTA trials using body weight, failure to account
for correlation between repeated measurements in their sample size
calculations may have led to unnecessarily large trials, increasing the
chance of finding statistically significant differences, which are not clin-
ically significant, while also being potentially inefficient. Of these five
trials, two found statistically significant differences, although the point
estimate was not clinically significant in one of these.
Potential Impact: Trials using outcomes with substantial correlation be-
tween repeated measurements, such as body weight, could be made
more efficient if they incorporated this information into their sample size
calculation. However, trials planning to use outcomes, such as the PHQ-9,
with relatively poor correlation between repeated measurements, might
consider using appropriate alternatives to improve efficiency.P-168
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Introduction: One of the challenges we faced while undertaking a
systematic review assessing the effectiveness of interventions to
manage non-respiratory sleep disturbances in children with neurodis-
abilities was the diversity of outcomes assessed across included stud-
ies. We therefore undertook further analysis of the extracted data to
assess whether a core outcome set is required for studies evaluating
interventions for this population.
Methods:
We undertook a survey of outcome measures used in primary
studies identified by the systematic review which searched seven-
teen electronic databases and other sources including ASSIA,
CENTRAL, MEDLINE, and PsycINFO. Studies evaluating pharmaco-
logical or non-pharmacological interventions for children with a
neurodisability and experiencing non-respiratory sleep disturbance
were included. Outcomes were listed from each study and cate-
gorised into core outcome areas and domains.
Results: Five core outcome areas were identified across 39
studies: child sleep, other child outcomes, parent outcomes, ad-
verse events and process measures. 54 different measures of
child sleep were used (across the domains of global assessment
of sleep; sleep initiation; maintenance; scheduling; and other).
Total sleep time was most commonly used in pharmacological
studies (92%) and parent-reported Child Sleep Habits Question-
naire (58%) in non-pharmacological studies. Fifteen non-
pharmacological (58%) and four pharmacological studies (31%) re-
ported child outcomes other than sleep across the domains of
child behaviour, quality of life, ADHD symptoms, cognition,
school-related, and other. 14 non-pharmacological (54%) studies
reported parent outcomes (17 different measures) compared to
one pharmacological study. Most melatonin studies (85%) re-
corded adverse events compared to one non-pharmacological
study. Process measures, related to adherence, feasibility of deliv-
ery, acceptability of the intervention were used.
Discussion: There was a lack of consistency between studies in the
outcome measures used. A minimum core outcome set, with inter-
national consensus, should be developed in consultation with par-
ents, children and young people, and those involved in supporting
families.P-169
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Excellence Framework Assessment (REF)
Catherine Hanna1, Lauren Gatting2, Rob Jones1, Katie Robb2
1CRUK CTU, University of Glasgow, Glasgow, United Kingdom; 2Institute
of Health and Wellbeing, University of Glasgow, Glasgow, United
Kingdom
Trials 2019, 20(Suppl 1):P-171
Introduction: Millions of pounds are spent annually on cancer re-
search [1] and many thousands of patients participate in this re-
search. Clinical trials are a significant component of these
investments making it important that cancer trials have real life im-
pacts for patients and wider society. Our aim is to improve the im-
pact of cancer trials in the UK by better understanding the impact of
current trials, and identifying how future trials can have greater
impact.
Methods: In 2014, higher education institutions submitted case stud-
ies outlining the wider impact of their research to the UK govern-
ment in a funding allocation exercise (REF2014). After identifying
case studies that focused on cancer trials, a content analysis was per-
formed to understand the types of impact described and methods
used to evidence them.
Results: In total, 46 case studies were identified, mentioning 106 in-
dividual trials. The majority were phase III (89%) and those investigat-
ing breast cancer were most common (35%). The most widely
described benefits were on policy (93% of case studies), specifically
national guidelines, and on the health sector (87%), for example, im-
plementation of infrastructure, shorter waiting times and clinical
practice change. Impact on individuals’ health was less common
(67%) and was usually predicted rather than evidenced through mea-
sured outcomes. Finally, half of the case studies mentioned economic
impact.
Methods used to demonstrate impact included expert testimony,
policy citation, surveys and interrogation of patient or population
level data. There was minimal documentation of researchers making
active attempts to improve impact.
Discussion: A content analysis of case studies submitted to
REF2014 identified limitations in describing and evidencing of im-
pact for cancer trials. We suggest that trialists consider the wider
impact of their research early and make active efforts to evaluate
and maximise a broad range of impacts, not only those that are
easy to measure.
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Introduction: Feasibility studies are described by the National Insti-
tute for Health Research (NIHR) as a means of testing if a trial ‘can be
done’ before investing in the full trial [1]. Feasibility studies typically
aim to describe parameters useful to planning future studies such as
estimating measures of variability and characteristics of outcome
measures, availability and willingness of participants or clinicians and
likelihood of success and completion of trial procedures and follow-
up. Feasibility studies have gained popularity in recent years as they
promise to minimise uncertainties surrounding the conduct of a fulltrial whilst minimising resources and duration thereby reducing risk
to funders. However, it isn’t clear if feasibility studies are able to suc-
cessfully deliver within these constraints.
Aim: To assess the question ‘Can feasibility studies successfully de-
liver the research questions within the constraints of the funding en-
velope awarded to conduct them’.
Objectives:
1.Identify and describe research studies conducted within LCTU as ei-
ther feasibility or full (phase II or III);
2.Assess the relative impact of conducting studies in terms of de-
sign/preparation, conduct, and outcomes/deliverables to LCTU;
3.Assess the implications for the design of future feasibility trials.
Setting: Trials conducted via LCTU since 2013.
Methods: RCTs described as either feasibility or full studies with
LCTU statistical support will undergo review of grant application,
protocol and end of trial report. Parameters associated with demon-
strating a trial’s resource use will be extracted and findings sum-
marised by trial type.
Timing of results and potential impact: The review of 28 trials is cur-
rently underway and the results will be presented. The review will ex-
plore if feasibility studies currently being undertaken by the LCTU
are successfully delivering outcomes within the planned constraints
of the awarded funding and any impact this has on the trials unit.P-173
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Introduction: Diabetic retinopathy (DR) is one of the major causes
of blindness worldwide. National systematic screening pro-
grammes for sight threatening DR (STDR) are established in sev-
eral countries with many involving annual screening intervals.
Extending the interval for people at low risk is expected to re-
duce the economic burden of annual screening on health sys-
tems without compromising efficacy. A randomised controlled
trial was conducted to assess the safety, efficacy and cost-
effectiveness of individualised variable interval risk-based screen-
ing for DR in Liverpool.
Methods: This RCT required data from multiple sources. Demo-
graphic and clinical (primary care) data were obtained from GPs
across Liverpool (EMIS) and retinopathy data came from an externally
held database (OptoMize). Randomisation was 1:1 to either annual or
individualised screening (6, 12, 24 months). Screening interval alloca-
tions for the individualised arm were calculated using a risk engine.
The primary analysis focuses on equivalence in attendance at 1st
follow-up between the two arms. Development of STDR within 24
months (secondary outcome) was analysed across the arms using a
non-inferiority approach.
Timing of Potential Results: The trial has now been completed. Re-
sults of the main analyses (attendance at 1st follow-up, STDR within
24 months) are expected to be available in June 2019. These will be
presented along with a description of methodology and processes
required throughout the data collection period.
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of an individualised risk based approach to varying screening inter-
vals for diabetic retinopathy. As a large trial with data obtained from
multiple sources, our experience may be helpful for the design and
conduct of similar trials in the future.
This abstract presents independent research funded by the NIHR UK
(RP-PG-1210-12016). The views expressed are those of the authors,
not those of the NHS, NIHR or Department of Health.
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Introduction: Trial populations need to reflect those in the commu-
nity who may benefit from the treatment being tested if the results
of the trial are to maximise patient health gains.
The European Union defines a rare disease as one affecting fewer
than 5 in 10,000 of the general population. With over 8,000 known
rare diseases, almost 6% of the population will be affected by a rare
disease. This equates to approximately 3.5 million people in the UK
and 30 million people across Europe.
Consequently, one would expect 6% of those recruited to clinical tri-
als to have a rare disease; however this is at best unknown and likely
to not be the case. This study will investigate the representation of
rare disease participants within clinical trials and possible reasons for
under-representation of these participants, including (i) lack of
reporting that a participant has a rare disease, (ii) potential exclusion
due to the recruitment criteria to the clinical trial and/or (iii) lack of
awareness of rare diseases.
Methods: A sample of clinical trials for anti-hypertension medica-
tions, listed on ClinicalTrials.gov, will be investigated. Representation
of participants will be considered by analysing the reporting of par-
ticipants’ rare disease and the inclusion/exclusion criteria from proto-
cols, reports and publications of the clinical trials. Awareness of rare
diseases will be explored through a network analysis of the citation
of rare disease literature using CitNetExplorer, specifically citation of
the European Union definition of a rare disease.
Timing of Potential Results: Expected August 2019.
Potential relevance and impact: The aim of the UK Strategy for Rare
Disease is to ‘ensure no one gets left behind just because they have
a rare disease’. Clinical trials are pivotal to the improvement of pa-
tient health, and require representation of all patients, including and
inclusion of rare disease patients in clinical trials.
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Introduction: Missing data (MD) can compromise the power, preci-
sion, generalisability and validity of trial findings. To minimise the im-
pact of MD, it is essential that MD are reduced as much as possible.
Despite this, very little evidence has been developed on how to re-
duce MD. To ensure effective interventions to reduce MD are devel-
oped and evaluated it is important that these are based on evidence
and theory. Assessment of factors that are associated with missing-
ness will help to inform the design of such interventions.Methods: Individual participant-level data from 10 phase 3 palliative
care trials were used to assess the association between participant
and site-level factors and MD. Multi-level cross-classified models were
developed. Missing values for the participant and site-level factors
were handled according to the most plausible assumptions about
the mechanism of covariate MD and compared in MD sensitivity
analyses.
Results: Participants with MD at the previous time-point and poorer
performance status were more likely to have MD for the primary out-
come and quality of life (QoL) outcome, at both the primary follow-
up point and end of follow-up. At the end of follow-up, sites who
randomised more participants and those with two research
personnel (compared to 1) were more likely to have MD. Sites with
four research personnel were significantly less likely to have MD. Trial
duration and the number of research personnel explained most of
the variance at the trial and site level respectively.
Discussion: Participants with poorer performance status and those
with previous MD are at high risk of MD in palliative care trials and
should be identified early and provided with further support to en-
able the provision of complete data. Site-level factors should also be
addressed to reduce MD at the end of follow-up.P-176
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Introduction: Participant newsletters are commonly used to maintain
participant engagement and boost retention in clinical trials. How-
ever, there is little evidence to guide this trial activity, and an ap-
proach based on theories of human behaviour could improve
newsletter engagement. We conducted a study within a trial (SWAT
#91), nested within the T4DM diabetes prevention trial, to evaluate
the impact of theory-based enhancements to an emailed participant
newsletter on participants’ engagement with the newsletter.
Methods: T4DM participants are Australian men aged 50-74 years. All
participants (on-treatment and completed treatment) receive quar-
terly email newsletters from the central coordinating centre. In this
evaluation, participants were randomised to receive a one-off email
newsletter with one of eight possible variations using a 2x2x2 factor-
ial design. Factors were subject line (standard wording versus en-
hanced competency-based wording), sender (trial name versus site
nurse’s name), and salutation line (no salutation versus personalised
salutation). Enhancements were designed to influence competence
and relatedness, based on self-determination theory. The primary
outcome was email open rate. Analysis was by logistic mixed-effects
regression modelling. Three-way factorial interaction was tested, and
backward stepwise elimination performed to identify the optimal
model.
Results; Of participants (n=931) randomised to an email option, 511
(55%) opened the email. After backwards variable elimination, the
optimal model included sender and subject line only (OR=1.8,
95%CI=[1.1, 3.0], p=0.02), but not salutation. Participants who re-
ceived an email with an enhanced, competency-based subject line
sent under their site nurse’s name were more likely to open the
email compared to those who received the other combinations (ap-
proximately 10% higher absolute open rate).
Discussion: Using a theory-based approach, combining enhanced
subject line and nurse’s sender name, engagement with an emailed
participant newsletter was modestly increased. Although requiring
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Introduction: Participant drop-out affects the credibility of findings
from randomised controlled trial (RCT) and reduces their potential to
influence clinical practice. Several aspects of trial retention can be
thought of as a behaviour e.g. returning a questionnaire or attending
a clinic. Most existing retention interventions have no theoretical
basis, do not explicitly target behaviour change, and have little evi-
dence to support acceptance by participants. Our research develops
theoretically informed, participant-centred, behaviour change inter-
ventions to improve retention in RCTs. This presentation will intro-
duce the potential benefits of using insights from behavioural
science (specifically the Theoretical Domains Framework (TDF) and
behaviour change techniques (BCTs)) to consider how to improve re-
tention in RCTs.
Methods: Sixteen telephone interviews were conducted using a TDF-
based topic guide with participants who had either failed to return a
follow-up questionnaire and/or attend a follow up clinic. Participants
were invited from a range of RCTs with poor retention identified
from clinical trial unit portfolios, UK. Theory based content analysis
was conducted. Domains were prioritised based on frequency and
content and then mapped onto BCTs. Crucially, retention specific in-
terventions were co-designed with trial participants using these
BCTs.
Timing of Potential Results and Potential Relevance and Impact:
We will know the form (i.e. content, mode, timing) of our interven-
tions in September 2019. This is one of the first studies to apply a
theoretical lens to the development of participant-centred interven-
tions to improve trial retention. These findings provide a new meth-
odology to develop interventions in clinical research trials to target
participant retention using a behaviourally focussed approach that
can be applied across trials in different contexts and ultimately lead
to more reproducible, participant centred, interventions.P-178
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Introduction: Aims: It is sometimes assumed that collecting data
electronically is less staff resource-intensive than collection on paper,
and that follow-up will be more complete. Evidence to support this
is lacking. Our aims were to assess the impact of switching from datacollection via postal paper questionnaires (paper-data) to electronic
data collection (e-data) on follow-up rates.
Objectives: To report on the effectiveness of e-data compared to
paper-data.
Setting: In the UKSTAR trial, we switched data collection from paper-
data to e-data during follow-up. UKSTAR is an RCT comparing treat-
ments for patients with Achilles tendon rupture.
Methods: 540 adult participants were invited to complete question-
naires 3, 6 and 9 months post-randomisation. Questionnaires were
sent by post, during the first 15 months of follow-up. Data collection
then switched to e-data for a further 13 months, with invitations sent
via email and/or text. Relevant data collected for this sub-study in-
cluded: patient demographics and follow-up rates.
Results: 1577 invitations were sent (732 postal, 845 electronic). Re-
sponse rate after the initial invite was lower at all time-points with e-
data than postal invitations (combined over time 59% vs 81% re-
spectively). Both sexes had higher response rates to paper-data than
to e-data (men 79% vs 56%; women 89% vs 70% respectively). Partic-
ipants aged 55 and over responded better to a first invite by post
than by edata (82% vs 60% respectively), as did younger participants
(78% vs 59% respectively).
Discussion: In this study we showed that e-data collection has lower
response rates than paper-data collection in an adult population that
includes people of working age. Results of this study could have
been limited by the study design; randomisation of patients to the
data collection method could have provided more robust data.
P-180
Trial questionnaire response rates - Is bigger better?
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Retention in randomised controlled trials (RCT) can often seem like
the poor cousin in comparison to the time and effort that is put into
recruitment. Trial managers and data coordinators/administrators
often spend inordinate amounts of time and effort collecting partici-
pant reported outcome (PRO) data using different strategies (e.g.
postal questionnaires, reminders etc.). This can be a large burden
upon both the trial budget and time for the trial team.
Within the NIHR HTA-funded SIMS Trial (a pragmatic multi-centred
surgical RCT in female stress urinary incontinence) we evaluated
whether sending A4 or A5 sized questionnaires with identical con-
tent, layout and pagination to participants affected questionnaire re-
tention/response rates.
Objectives: The aim of the study was to determine if the physical
size of the questionnaires affected response rates. We will also con-
sider economic aspects (cost of questionnaires, postage etc.).
Methods: Participants were randomised to receive either A4 or A5
sized postal questionnaire at 15 months post randomisation.
Results: There was no statistically significant difference in response
rates between the A4 and A5 sized questionnaires. 58.70% of partici-
pants receiving an A4 questionnaire responded compared to 52.10%
of those receiving an A5 questionnaire. N = 562, P-value = 0.116
In addition to discussing this result, economic aspects, by question-
naire size, will be presented at the Conference.
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Managing follow-up among parents of very pre-term infants:
methods to improve questionnaire response rate
Madeleine Hurd1, Ursula Bowler1, Jon Dorling2, Samantha Johnson3, Ed
Juszczak1, Oliver Hewer1
1NPEU Clinical Trials Unit, Nuffield Department of Population Health,
University Of Oxford, Oxford, United Kingdom; 2IWK Health Centre,
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Introduction: In randomised controlled trials it is important to maxi-
mise outcome ascertainment to minimise bias. SIFT (ISRCTN76463425)
Trials 2019, 20(Suppl 1):579 Page 53 of 141was a multicentre randomised controlled trial run in neonatal units in
the UK and Ireland, investigating two speeds of increasing milk feeding
in 2804 infants with gestational age at birth <32 weeks and/or birth
weight <1500g. Primary outcome was the proportion of infants surviv-
ing without moderate or severe neurodevelopmental disability at 24
months of age, assessed via parent-completed questionnaire.
Methods: Questionnaires were posted 17 days before participants
reached 24 months of age corrected for prematurity. Lack of parental
response triggered two postal reminders and one by phone, with
two weeks between each.
Measures introduced to improve response included contacting par-
ents prior to the questionnaire being posted; offering online ques-
tionnaire completion; a second reminder being accompanied by a
phone call and text message; promotion by Bliss (third sector stake-
holder); sending posters to sites for display in outpatient clinics; and
ultimately an incentive voucher (described elsewhere). Outcome data
were also sourced from routine clinical follow-up appointments at
sites for infants whose parents did not complete the questionnaire.
Results: Response rate prior to all interventions was 51.0%; at data
lock in April 2018 it was 76.5% (p<0.01). The largest increases (6%)
following a single intervention were seen after introducing pre-
questionnaire phone calls (p=0.07) and online completion (p=0.04).
Recruiting sites supplied additional data from 351 routine clinical
follow-up appointments. Primary outcome could be determined for
88.5% of the cohort.
Discussion: Multiple methods of contact, especially phone contact
prior to dispatch of questionnaire and availability of the question-
naire online, may improve response rate to postal questionnaires
among parents of very preterm infants. Over time, promotion by
sites and on social media may also play a role. Missing data can be
supplemented by information from routine sources.P-182
Conditional versus Non-Conditional Incentives to Maximise Return
of Postal Questionnaires in Clinical Trials: A Randomised Study
Within a Trial
Johanna Cook, Christopher Butler, Jonathan Cook, Emily Bongard, Carl
Heneghan
University of Oxford, Oxford, United Kingdom
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Background: High levels of retention in clinical trials is essential to
gain robust evidence to guide care. Many approaches have been
used to improve participant retention, but few have been evaluated.
The addition of a monetary incentive has been shown to increase re-
tention, but it is not known whether the point at which an incentive
is given matters. We aimed to determine whether there was a differ-
ence in follow-up trial questionnaires returned when a monetary in-
centive given to trial participants at recruitment (non-conditional),
and when patients were informed at recruitment that the incentive
would be given only once a questionnaire had been returned
(conditional).
Method: This was a sub-study within the Antivirals for influenza-Like
Illness, An rCt of Clinical and Cost effectiveness in primary CarE Trial.
Sites were matched according to previous recruitment or practice list
size. Practice pairs were randomised to giving either a non-
conditional or conditional incentive. Analyses were conducted ac-
cording to randomised group irrespective of compliance. Statistical
significance was assessed at the two-sided 5% level. The primary
analysis was regression adjusted for practice pair with various sensi-
tivity analyses.
Results: Only 28 out of the 42 sites recruited at least one participant
(range 1 to 56) with 10 practice pairs recruiting one or more partici-
pants at both constituent sites. There was no evidence of a differ-
ence in the proportion of questionnaires returned, time taken to
return questionnaires, nor proportion of pages completed, by inter-
vention group (all p>0.05). Findings of the sensitivity analyses yielded
similar findings. The conditional incentive cost approximately £23
less per diary returned.Discussion: There was no evidence of a difference in questionnaire
returns, nor the time to questionnaire return or completeness. There
was low precision, given the small number of sites which recruited,
and variability between sites in recruitment performance. The condi-
tional approach cost less.
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Pen and Social Incentive Letter Retention Study within a Trial
(SWAT) - An embedded, factorial design randomised controlled
trial to investigate whether the inclusion of a pen and/or social
incentive text cover letter included with the 12-month postal
questionnaire improved response rates
Sophie James, Adwoa Parker, David Torgerson
York Trials Unit, University of York, York, United Kingdom
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Introduction: Poor return of questionnaires in randomised con-
trolled trials (RCTs) affects retention rates. This can introduce bias
and thus affect generalisability and validity, with an associated
reduction in statistical power. The objective of this study within a
trial (SWAT) was to assess whether a pen and/or social incentive
text cover letter sent with the 12-month questionnaire increased
postal questionnaire response rates for participants in an RCT. We
aimed to compare the inclusion of a pen in questionnaires with
no pen; and the use of a social incentive text cover letter com-
pared with no cover letter.
Methods: A 2x2 factorial SWAT within the ‘Occupational therapist
home assessment and modification for prevention of falls trial (OTIS)’
host trial. Participants due their 12-month follow-up questionnaire
were randomised to be sent a pen; a social incentive text cover let-
ter; both; or neither. Primary outcome was the proportion of partici-
pants in each group who completed and returned the questionnaire.
Secondary outcomes were time to return and completeness of the
questionnaire, number of reminder letters sent and the cost effect-
iveness. To date 624 participants have been randomised.
Timing of Potential Results: By the time of the conference we will
present findings on questionnaire response rates, time to return and
completeness of the questionnaire, number of reminders and cost ef-
fectiveness. Odds ratios will be calculated and reported, along with
confidence intervals and p values. Adjusted hazard ratio results will
be presented for time to return the questionnaire, and the need for
a reminder.
Potential Relevance and Impact: Our SWAT will add to evidence for
improving retention rates in RCTs. Findings of the pen SWAT will be
combined with results of other SWATs in a meta-analysis to detect
small but cost-effective differences. Evidence for the social incentive
cover letter will need to be replicated in further SWATs.P-184
Factors that affect attrition in RCTs for the treatment of depression
Saleema Selwiyn Rex1, David White2, Robin Chatters2, Mike Bradburn2
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Introduction: Attrition is a common feature in clinical trials; higher
attrition rate can affect the statistical power of an RCT and can
undermine the external validity of the study. Therefore, it is import-
ant to evaluate and understand the factors that could affect attrition
so that informed decisions can be made when planning a trial. We
undertook a systematic review and meta-analysis of randomised
studies treating depression to determine attrition, and predictors of
attrition in these RCTs.
Methods:A comprehensive search was undertaken to identify RCTs
of interventions to treat depression. Firstly, Cochrane reviews with
“depression” in the title, abstract or keywords were identified and
were eligible if were published in or after 2005; their scope matched
our review’s eligibility criteria; and their inclusion criteria did not
Trials 2019, 20(Suppl 1):579 Page 54 of 141require another co-morbidity to be present (e.g. Bipolar disorder). We
then screened both included and excluded trials from these reviews
to identify eligible trials.
As well as estimating attrition rates overall, we hypothesised these
may depend on year of the study, blinding, burden of the outcome
measures, follow-up schedules, intervention burden, target sample
size, recruitment setting, number of arms, type of intervention, type
of control and participant characteristics.
Results: Many studies did not report their target sample size, number
screened or drop out details. The average attrition rate was 22% but
ranged from 0% to over 70%. Our results suggest that trials that had
combinations of intervention types (i.e. behavioural and drugs) had
lower attrition rate than trials with interventions that were purely
drugs or behavioural therapy.
Discussion: Although a review cannot identify and quantify the true
relationship between trial design and attrition, this review provides
some insight into what levels of attrition may be expected in a future
trial. It also highlights the lack of reporting of key factors.P-185
Methods to improve follow up procedures in a sexual health study
[safetxt]
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Introduction: Almost half of trials fail to achieve their follow up tar-
get. Follow up in young people and on sensitive topics is particularly
challenging, with less than 50% return rate of postal STI samples sent
to young people in previous trials. Effective evidence-based strat-
egies to increase follow up rates were used.
safetxt, a study of a sexual health intervention, recruited 6252 partici-
pants aged 16-24 from 52 UK sexual health sites. Participants were
required to return two postal questionnaires and an STI test kit at 12
months. We used evidence-based strategies to increase follow up
rates through contact by post, telephone, text message and email.
In May 2018, follow up return rates were 88.7% for the four week
questionnaire, 74.7% for the one year questionnaire and 67.75% for
the test kit. We aimed to further increase follow up rates.
Methods: Retaining participants that regularly changed address and
phone number was challenging, but contact was achieved through
various approaches. Sites were encouraged to emphasise the import-
ance of follow up to participants at the time of consent and provided
participants with pocket cards with a reminder of follow up dates.
Mail outs were developed to improve communication with partici-
pants and simplify return methods.
Additional evidence based methods were implemented, including
the use of postage stamps on return envelopes and a cash prize
draw for returned test kits.
Results: By April 2019, follow up rates of the four week questionnaire
were maintained. At one year, follow up rates were 76.8% for the ques-
tionnaire and 71.7% for the test kit.
Follow up rates for the one-year questionnaire and test kits returns
have continued to increase since introducing strategies from May 2018.
Discussion: Even when evidence based methods are already being
used, developing new approaches and employing additional evi-
dence based strategies improved follow up rates.P-186
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Background: Addressing attrition in clinical trial design is an import-
ant priority. Despite availability of statistical methods for missing
data, prevention is preferred. The development of effective retention
interventions needs to be based on improved understanding of attri-
tion risk factors. We aimed to identify attrition risk factors.
Methods: Two-arm, parallel, RCTs reported in JAMA, NEJM, BMJ and
The Lancet during 2013 and the first quarter of 2018 were identified
using MEDLINE(Ovid). The number of randomised participants with-
out observed primary outcome data were dual extracted. Associa-
tions with intervention type, primary outcome characteristics and
trial setting were assessed using univariate analysis.
Results: 141/159 (89%) of 2013 trials had missing data equating to 5.4%
[1.5, 10.7] of randomised participants per trial. This was lower in 2018 with
38/46 (83%) reporting a median 2.6% [0.3-15.4]. In 2013, increased attrition
was associated with outpatient data collection, studies within chronic condi-
tions, smaller trials (recruitment target and number randomised), shorter re-
cruitment and longer follow up. Data collection by clinicians and recruitment
in acute settings was associated with lower levels of attrition. The 2018 co-
hort generally supported these observations although in some areas the
numbers were too small for comparison. Data extraction was challenging
and the CONSORT often did not provide an effective trial summary: A fifth
of all diagrams were in the supplementary material; 19% did not report the
numbers analysed for the primary outcome and for a further 6% this did
not match the results; Imputed data was not clearly reported in 27%.
Discussion: Levels of missing data were lower than anticipated, but
this still equated to wasting an average of one month of participant
recruitment. Poor reporting may underestimate the extent of missing
data. Improvements to the CONSORT are recommended, in particular
explicit reporting of imputed primary outcome data.P-187
Generating collaborative relationships for a successful trial follow-
up
Alpana Ghadge, Rebecca Brown, Karen Bracken
NHMRC Clinical Trials Centre, University of Sydney, Camperdown,
Australia
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Introduction: Collection of developmental follow-up outcomes is crit-
ical to demonstrate long-term effects of interventions in neonatal
trials.
The Benefits of Oxygen Saturation Targeting (BOOSTII) trial enrolled
1135 infants born less than 28 weeks gestation, to investigate the
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mary outcome was death or major disability at 2 years of age. A high
rate of 2-year follow-up was therefore crucial. Maintaining contact
with families during follow-up presented numerous challenges, as
families were no longer under the care of the hospital and frequently
moved. We aim to describe various strategies implemented that
achieved a high follow up rate for the BOOST II trial.
Method
1.Interactions with recruiting centres: The central coordinating team
fostered positive and supportive relationships with the recruiting
hospitals through regular (but not overwhelming) contact using mul-
tiple modes of communication, such as email, telephone contact, sat-
ellite meetings at annual conferences and celebration of trial
milestones.
2.Interactions with families involved: Multiple tools were provided to
recruiting hospitals to support their contact with families, such as
personalised Christmas cards, trial newsletters, celebration of birth-
days with nominal surprise baby gifts, and transport assistance for
families suffering financial hardship.
Results
The 2-year follow up rate on the BOOSTII trial was over 96%.The
strategies we introduced have been widely taken up by our study
sites and implemented in other similar trials.
Discussion: One of the challenges with long term follow-up is main-
taining effective communication. Establishing positive relationships
promoted high follow-up rates through ongoing engagement with
families. We suggest that small positive interactions with site re-
search staff and families will alter perceptions of clinical trials and
create a sense of shared ownership.P-188
Maximising follow up rates of patient reported outcome measures:
a study within a trial (SWAT) - results from the LoTS2Care
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Background:
Ensuring satisfactory follow-up rates in trials, where primary out-
comes are patient-reported measures obtained via postal question-
naires, can be challenging. This challenge intensifies in populations
with communication or cognition problems, as minimising measure-
ment burden is key.
Methods:
LoTS2Care, a NIHR-funded Programme, included a feasibility cluster
randomised trial, assessing a self-management intervention address-
ing longer-term health and social care needs for stroke survivors. Par-
ticipants were followed-up at three, six and nine months using postal
questionnaires, containing various self-reported outcome measures,
alongside a resource use questionnaire.
A study within a trial (SWAT) was conducted to determine the most
acceptable questionnaire format to maximise follow up rates for a
future definitive trial. Stroke survivors (and available carers) were ran-
domised (1:1) to receive one of two alternative questionnaire for-
mats: a single comprehensive booklet containing all measures (19
pages) or two shorter booklets: one containing the outcome mea-
sures (12 pages); the other containing the resource use questionnaire
(7 pages) at the six and nine month follow-up time points.Results:
The study recruited 269 stroke survivors and 85 carers. At six months
follow-up, 227 stroke survivors were randomised in the SWAT; with
212 still available for follow-up at nine months. Participants were
more likely to complete all questionnaires at nine months when ran-
domised to the single booklet group (97.2% vs. 91.3%, OR=3.32, 95%
CI (0.87 – 12.61)). This trend was also observed at six months, but
not for the carer completion rates.
Relevance & Impact:
Postal follow-up is common in many trials; strategies to maximise re-
turn rates are essential. This SWAT demonstrated that return rates
are maximised when all study questions are contained within a sin-
gle, but lengthier, postal booklet, contrary to prior expectations. This
result is particularly pertinent to stroke and older populations, where
communication and cognitive issues are common.
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Maximising participant retention in a randomised prevention trial
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Introduction: We explored strategies to enhance retention within a
pragmatic, multicentre, randomised controlled eczema prevention
trial (BEEP Study). The study randomised 1394 newborns from high
risk families. The primary outcome of eczema was collected at 24
months.
We surmised that retention in a prevention trial of young families
with healthy babies, having no face to face contact between consent
and 24 months, would be challenging. Our sample size estimated
20% attrition and retention strategies were incorporated into the trial
design.
Methods: Strategies for enhancing retention included: chasing ques-
tionnaires by post, text and phone (3, 6, 12, 18 months), sending
birthday cards, small gifts (12 and 18 months), newsletters, appoint-
ment letters (21 months), and flexible visit scheduling at participant
homes. An online scheduling system, monthly updates of upcoming
appointments and retention league tables were provided to sites.
After 6 months of follow-up, retention was 76% and there were con-
cerns this would drop further. Additional retention strategies initiated
by the Trial Management Group (TMG) included: simplified appoint-
ment letters, handwritten notes to participants lost to follow-up and
development of an alternative data collection process via post or
through the participant’s GP. Sites were offered additional support
through teleconferences and an incentive scheme.
The TMG continued to monitor upcoming appointments and reten-
tion by site to allow for issues to be effectively and quickly managed.
Results: The final retention rate at 24 months was 1212/1394 (87%).
Retention was balanced between groups but varied between the 14
sites (70% to 97%). Primary outcome collection was face to face for
1123 participants (81%) and remote for 89 (6%).
Discussion: Little evidence for targeted retention strategies exists; in
this trial a combination of proactive and reactive retention strategies
was required. Future trials with little direct participant contact may
need to budget for similar multifaceted and resource-intensive reten-
tion strategies.
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Introduction: A matched nested case-control study is an efficient de-
sign, conventionally used within a cohort study where there is a cost
associated with measuring the exposure. We demonstrate how this
study design can be embedded within a randomised trial and illus-
trate its potential for answering important research questions
through the secondary analysis of prospectively collected trial data.
We also highlight the advantages of this method over the conven-
tional case-control design.
Methods: We applied this study design to a secondary analysis of
the Abnormal Doppler Enteral Prescription Trial (ADEPT;
ISRCTN:87351483). We investigated the role of milk feed type and
changes in milk feed type (exposures) in the development of severe
necrotising enterocolitis (NEC, outcome) in a group of 399 high risk
growth-restricted preterm infants. We matched cases (infants with
NEC) with up to four controls (infants without NEC) of the same sex
and smallest Mahalanobis distance based on gestational age and
birthweight. Conditional logistic regression was used to calculate an
adjusted odds ratio between the exposure and outcome, adjusted
for trial allocation.
Results: Using matching, we were able to generate a comparable
sample of controls for the cases, and thereby reliably investigate the
temporal relationship between feed type and NEC. Advantages of
this method over the conventional case-control design were that
controls were selected from the same population, exposure status
was collected prospectively, and compared between cases and
matched controls at the point at which an outcome event occurred.
Conclusions: A matched nested case-control study can be used to
identify credible associations in a secondary analysis of clinical trial data
where the exposure of interest was not randomised, and has several
advantages over a standard case-control design. This method offers the
potential to make reliable inferences in scenarios where it would be un-
ethical or impractical to perform a randomised clinical trial.P-193
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Introduction: Hot flushes and night sweats (HFNS) are problematic in
women after treatment of breast cancer. Cognitive Behavioural Ther-
apy (CBT) is known to be effective for the alleviation of hot flushes.
However, it is not currently offered within the NHS for women with
breast cancer, and it is not known whether it can be effectively deliv-
ered by breast care nurses (BCNs) in the NHS context.
This study’s aim was to assess the impact of HFNS at 26-weeks post-
randomisation to determine whether BCNs can be trained to effect-
ively deliver CBT.Methods: MENOS4(Breast Cancer Now:2015CR_004) is a multicentre
phase III individually randomised trial of BCN delivered group CBT
versus Usual Care and recruited 130 participants across six UK sites.
Mixed models for partially clustered data were intended to be used
for all primary and secondary outcomes to account for the therapist
effect. However, for some secondary outcomes, the residuals were
not normally-distributed and no sensible data transformations could
be found, and quantile regression was therefore incorporated. All
models adjusted for baseline score, and stratification factors of co-
hort and site.
Results: Mixed models were used to assess the primary outcome and
all secondary outcomes in which the residuals were found to be
normally-distributed, and quantile regression was used for all other
secondary outcome measures. Both models found statistically signifi-
cant improvements for CBT compared to Usual Care.
Discussion: Mixed models allowed us to adjust for the baseline ques-
tionnaire responses, site and cohort, and therapist effect with a par-
tially clustered data design. Quantile regression was a valuable
alternative model when no sensible transformations could be found
as it continued to allow for the comparison of outcomes with an ad-
justment for baseline score, cohort and site. However, utilising this
method resulted in no longer being able to adjust for the therapist
effect in the nested design.P-194
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Background: In a randomised trial, direct comparison of duration of
remission between treatments could be biased when it only includes
patients who respond. The issue, however, has not been much of a
concern, as remission rate rather than duration of remission is com-
monly used as the primary outcome measure, with comparison of re-
mission rates an intention-to-treat (ITT) analysis.
Methods: Current treatments for nephrotic glomerulonephritis
have serious limitations: although glucocorticoids are effective for
the majority of patients, repeated courses are normally required,
and the side effect of cumulative steroid exposure itself results in
high morbidity and mortality in patients, just as in other auto-
immune diseases where immunosuppression is required; steroid
sparing regimens, that is, ultimately, a long remission duration
treatment is needed. The TURING study is a randomised, two-
arm, double blind, placebo controlled phase III trial to assess the
efficacy of rituximab in treating nephrotic syndrome in patients
with minimal change disease or focal segmental glomerulosclero-
sis. The primary outcome measure is the duration of remission.
As an extension of the Kaplan-Meier survival curve method, the
probability of a patient being in remission, will be used as a
means of estimating the expected duration of remission across
all randomised patients (ITT), given as the estimated remission
rate times mean duration of remission for responding patients.
This approach can be considered as a stochastic process in which
a patient must start in state 0 (that is at start of treatment) and
eventually progress to an absorbing state, 2 (progression, death
in the absence of progression, treatment failure, relapse (or died
from disease)), possibly passing through a transient state 1
(remission).
Conclusions: The TURING trial is ongoing. Simulation results with
underlying time to response, duration of response and time to re-
lapse from exponential, Weibull and log-normal distributions will be
reported and discussed.
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Introduction: In clinical trials, intercurrent events such as use of res-
cue medication are often unavoidable. Typically for primary analysis
the use of rescue medication will be ignored as a treatment-policy
estimand, which estimates the effect of treatment assigned at base-
line, will be of interest. A treatment policy estimand will be estimated
by performing an Intention-to-treat analysis. But in trials where res-
cue medication is made available it can also be of value to conduct a
supplementary analysis to establish the treatment effect that would
have been obtained if rescue medication had not been taken. The re-
cent publication of the ICH-E9 addendum has brought the estimation
of such alternative ‘hypothetical’ estimands
into sharp focus. However, guidance is not provided on how these
estimands may be statistically estimated.
Methods: We demonstrate the use of controlled multiple imputation
procedures for estimating hypothetical estimands in the absence of
rescue medications, using data from the Atopic Dermatitis Anti-IgE
Paediatric Trial. This includes delta-based imputation and last mean
carried forward imputation. Data collected post rescue medication
initiation is set missing, then imputed under a contextually relevant
assumption that reflects the hypothesised value of the outcome in
the absence of rescue medication.
Results: The treatment policy estimand for the Children’s Dermatol-
ogy Life Quality Index was -3.6, 95% CI -6.5 to -0.6, p=0.018 (favour-
ing Anti-IgE). When the rescued were assumed to have a mean
outcome ranging from 0 to 7 Index points worse (greater) than the
observed non-rescued, the average treatment effect ranged from
-4.0 to -4.6. The treatment effect following last mean carried forward
multiple imputation was -4.0, 95% CI -7.1 to -0.9, p=0.012.
Discussion: Supplementary analysis revealed Anti-IgE is an effective
treatment for severe atopic dermatitis in the absence of rescue medi-
cation. Controlled multiple imputation provides a flexible accessible
tool for estimating hypothetical estimands.
P-196
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Use of time-varying covariate in assessing disease remission in the
early and late phases of treatment with application to RITAZAREM
trial
Marianna Nodale
Cambridge Clinical Trials Unit, Cambridge, United Kingdom
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Introduction: In a randomised trial, we are interested in assessing
whether overall improvement in relapse-free survival is sustained be-
yond a treatment period.
The RITAZAREM trial aim is to assess the efficacy of rituximab com-
pared to the current standard of care (azathioprine or methotrexate
and glucocorticoids) in the prevention of disease relapse in ANCA-
associated vasculitis (AAV). Rituximab is an established induction
agent in AAV, however the trial aims to demonstrate its efficacy as a
maintenance agent given that a large majority of patients relapses
within 2 years of a course of treatment.
Methods: Patients are recruited at the time of relapse and initiated
on a 4 months induction regimen of rituximab. Those achieving dis-
ease control are then randomised to either maintenance treatment
with rituximab lasting 20 months or standard therapy with azathio-
prine. Patients are followed up to between 36 and 48 monthsfrom enrollment. The primary outcome measure is time to dis-
ease relapse from randomisation. A secondary objective is to
demonstrate disease remission beyond the 24 month treatment
period. The primary intention-to-treat analysis will be based on a
Cox proportional hazard model. Firstly we plan to test the null
hypothesis for a hazard ratio of 1 at all time points. If rejected at
a global level, we will employ time-varying covariates to investi-
gate the two further sub-hypotheses of a hazard ratio of 1 pre-
and post- 24 months. This will elucidate whether rituximab over-
all efficacy in maintaining disease remission is achieved during
the active treatment phase of the trial and also sustained in the
post-treatment phase.
Potential Relevance & Impact: The RITAZAREM trial is ongoing, with
expected completion in November 2019. Simulations will investigate
operational characteristics of our model under a variety of assump-
tions. Alternative methods of assessing efficacy at varying time
points will also be considered.
P-198
Defining protocol deviations in a pragmatic non-inferiority trial of
potassium control after Coronary Artery Bypass Grafting
Elizabeth Allen1, Diana Elbourne1, Joanna Sturgess1, Richard Evans1, Ruth
Canter1, Matthew Dodd1, Ben O'Brien2
1Lshtm, London, United Kingdom; 2St Bartholomew's Hospital & Barts
Heart Centre, London, United Kingdom
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Introduction: Intention to treat (ITT) analysis is the analytic method
of choice for superiority trials as it adheres to the randomisation
process and is conservative. However, the ITT analysis may not be
conservative for non-inferiority trials as including non-compliers may
bias towards equivalence. Whilst a per-protocol (PP) analysis, is more
likely to identify differences it can also bias results. Therefore, the
recommended approach for non-inferiority trials is to carry out both
an ITT and PP analysis. A clear definition of compliance with the
intervention is therefore needed.
The Tight K trial is a randomised non-inferiority trial investigating the
impact of maintaining serum potassium ≥3.6mEq/L vs ≥4.5mEq/L on
the incidence of new onset atrial fibrillation after isolated elective
Coronary Artery Bypass Grafting. A pilot trial was carried out.
Defining compliance with the potassium protocols in each arm is cru-
cial for the analysis of the trial; however, is not straightforward.
Whilst the protocols specify maintaining levels of potassium, supple-
mentation generally occurs when a patient falls below the level re-
quired. Therefore, compliance cannot be based on all, or even most
measurements being above the required thresholds. Additionally, pa-
tients’ potassium levels vary differently by patient, with greater vari-
ability observed in some.
Methods: Here we use data from the pilot trial to explore possible
definitions of compliance using statistical process control.
Timing of Potential Results: Initial Control Charts suggest that they
could help define algorithms to identify patients who have not com-
plied with their assigned protocol. Work is ongoing and results will
be available by October 2109.
Potential Relevance & Impact: Many medical protocols are adminis-
tered in the belief that they will have the desired effect with little
evidence that they do. There is currently no accepted way of asses-
sing protocol deviations in these situations such and the proposed
approach shows promise.
P-199
Error rate control in perpetual platform trials
David S Robertson1, James M S Wason1,2
1MRC Biostatistics Unit, University of Cambridge, Cambridge, United
Kingdom; 2University of Newcastle, Newcastle, United Kingdom
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Introduction: Platform trials allow the evaluation of multiple ex-
perimental treatments under a single master protocol and are
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be seamlessly added to the trial in the future. In a perpetual
platform trial, controlling the family-wise error rate (FWER) leads
to a low statistical power, as vanishingly small significance levels
must be used for the later hypotheses being tested. An alterna-
tive error rate is the false-discovery rate (FDR), which controls the
expected proportion of recommended treatments that are actu-
ally ineffective. In this work, we apply recent methodological re-
search to show how to control the FDR in the perpetual platform
trial setting.
Methods: We investigate various rules for controlling the FDR in per-
petual platform trials, and propose a simple modification to the pro-
cedures for when there is an upper bound on the number of
hypotheses to be tested. The number of ultimately evaluated treat-
ment arms and proportion of treatments that are truly effective are
varied.
Results: We show that the FDR can be controlled in perpetual plat-
form trials, even under the dependence induced by a common con-
trol arm. Furthermore, controlling the FDR in perpetual platform trials
results in a uniformly higher power compared with controlling the
FWER.
Discussion: In perpetual platform trial settings, we recommend that
sponsors and trialists consider controlling the FDRP-200
Options and challenges of analysing data from recruitment
intervention studies A lesson from MRC START Hi-Light data
analysis
Wei Tan, Trish Hepburn
University of Nottingham, nottingham, United Kingdom
Trials 2019, 20(Suppl 1):P-200
Background: Achieving high participation in RCTs has traditionally
been difficult and there is a need to develop and test interventions
to improve recruitment. Embedded randomised trials of recruitment
interventions within in ongoing host RCTs have been growing
recently.
MRC START Hi-Light is embedded within the H-Light study to test
whether addition of multimedia resource (MMI) impacts on rate of
recruitment, in comparison with standard host trial website.
Methods: The primary outcome was the proportion of patients ran-
domised to the main trial, which was calculated and compared be-
tween the two arms. Various statistical methods were tested to find
the most appropriate model to analyse the data and answer the re-
search question.
Results: Linear model assumptions were violated for the original and
the log-transformed data.
Negative binomial model was then tested to compare mean number
of patients recruited, the assumptions of which were again not met.
A zero inflated negative binomial was proposed however due to the
single source of zero value in this study this model was deemed
inappropriate.
As around 80% recruitment units recruited either 0 or 1 patient,
we estimated the effect of MMI website using a binary outcome
variable, where 0=recruited none and 1=recruited at least 1. Re-
sults from binary measure (risk difference = -1.6%, 95% CI -18.6%
to 15.4%) indicate no evidence of effect of MMI. Results from
other methods were not presented but in support of the
estimates.
Conclusion : Recruitment intervention studies may result in data very
similar to this study where the choice of primary analysis model must
be carefully scrutinized. In this study various methods have been
tested to best analyse the data which all support no evidence of
intervention effect in improving recruitment. Better planning on the
most appropriate analysis model is recommended to produce more
reliable and robust results.P-201
Effect-based traffic light progression criteria for pilot studies
Gareth Mccray, Martyn Lewis, Kieran Bromley, Gillian Lancaster
Keele University, United Kingdom
Trials 2019, 20(Suppl 1):P-201
Introduction:
In the CONSORT guidelines for pilot and feasibility trials, formal hy-
pothesis testing of effectiveness or efficacy is not recommended as it
is likely that a study will have insufficient power to supply robust evi-
dence (and this is the aim of the main trial). However, particularly for
larger pilot studies and/or studies with a large assumed MCID/effect
size, the results of a pilot may carry valuable information about the
likely outcome of any follow-up trial. This presentation suggests a
method that uses the pilot sample size and observed effect size to
provide a traffic-light indication of the likely fruitfulness or futility of
any follow-on trial.
Methods:
The traffic-light designation is based on the simulated sampling dis-
tributions of the effect size under both null and specified alternative
hypotheses. The designation of “green”, “amber”, or “red” depends
on the likelihood of the observed effect size given the sampling dis-
tributions. At smaller sample/effect sizes, an “amber” is most prob-
able, but as sample/effect size increase, either “red” or “green”
designations increase in probability, reflecting the additional informa-
tion about the true effect from the data.
For “red” we recommend not to go to a full trial, for “amber” we rec-
ommend focusing more on the process outcomes to inform progres-
sion, while for “green” we recommend progression and there may be
less need to focus on other process outcomes.
Results:
Look-up tables of critical values are presented for the cases of a dif-
ference between two independent means and two independent pro-
portions (exact values). Worked examples from authentic studies
illustrate the utility of the methodology.
Discussion:
While we strongly discourage potential efficacy/effectiveness being
the primary feasibility outcome considered in a pilot study, we do
however think that it warrants consideration in the ‘proof of efficacy’
debate and we present a reasoned method of doing so.P-202
A simulation study to compare longitudinal methods for the
analysis of randomised trials and the implications for sample size
calculation
Bethan Copsey, Susan J Dutton, Ray Fitzpatrick, Sarah E Lamb, Jonathan
A Cook
University of Oxford, United Kingdom
Trials 2019, 20(Suppl 1):P-202
Introduction: The majority of randomised trials collect outcome data
at multiple follow-up time points. Reviews have shown that analysis
methods vary across different trials, such as mixed effects methods
or repeated single time point analyses. The use of these different
methods can have implications for the credibility of trial results,
impacting on the type I error, level of power and bias of the treat-
ment effect estimate.
This simulation study aims to compare the performance of different
methods to analyse longitudinal data from a randomised trial.
Methods: Simulated datasets were generated for 240 different sce-
narios with different sample sizes (100, 200, 400, 600, 800), numbers
of follow-up time points (2, 3, 4, 5), maximum level of treatment ef-
fect (0, 4, 8, 12) and different patterns of treatment effect. For each
scenario, 1600 datasets were produced. Distributional parameters
were based on the WOMAC measure and informed by a previous
randomised trial of medications for knee osteoarthritis.
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1.Repeated analysis of covariance (ANCOVA) at each follow-up time
point.
2.Generalised estimating equations, and
3.Mixed effects.
The performance measures used to compare the methods were con-
vergence, power, type I error, and coverage. Stata IC 14 software and
the University of Oxford Advanced Research Computing (ARC) facility
are being used to conduct this work.
Timing of Potential Results: It is anticipated that this study will be
completed during the summer of 2019.
Potential Relevance & Impact: The results will provide evidence to
inform the choice of longitudinal analysis methods in randomised tri-
als. This could allow trialists to select the methods that will provide
the highest statistical power for the anticipated pattern of treatment
effect and could result in reducing the required sample size whilst
maintaining adequate statistical power.P-203
Allowance for learning and clustering effects in the design and
analysis of multicentre randomised trials: current practice and
experiences
Elizabeth J Conroy1, Jane M Blazeby2, Girvan Burnside1, Jonathan A
Cook3, Carrol Gamble1,4
1Department of Biostatistics, University of Liverpool, a member of
Liverpool Health Partners, Liverpool, United Kingdom; 2Centre for
Surgical Research, Population Health Sciences, University of Bristol,
Bristol, United Kingdom; 3Centre for Statistics in Medicine, University of
Oxford, Oxford, United Kingdom; 4North West Hub for Trials
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Introduction: Patient outcomes can depend on the treating centre,
or health professional, delivering the intervention. Differences in
treatment delivery can be more prominent in trials investigating a
complex intervention, such as surgery. Considering any potential dif-
ference in delivery at trial outset will ensure that any adjustments, as
appropriate, can be made. The objective of this work was to establish
current practice for the allowance of learning and clustering effects
in the design and analysis of randomised multicentre trials.
Methods: A ten question survey was developed by the study team
comprising open and closed questions that drew upon quotes from
existing guidelines, references to relevant publications, and example
trial scenarios. All registered UK Clinical Research Collaborative regis-
tered Clinical Trials Units were invited to participate.
Results: Completed surveys were obtained from 44 of 50 registered
Units. Adjusting for learning by design through defining a minimum
level of expertise for treatment provider was common (89%), al-
though one third of units also had experience of expertise based de-
signs. Managing clustering by design through stratification by centre
was universally most common across the various trial types pre-
sented, and by treatment provider less so. Analysis of learning was
rarely performed for the main analysis (n=1), although many units re-
ported approaches to complement such analyses, such as sensitivity
analyses. The majority of responders had indicated experience in
adjusting during analysis for clustering, by centre or treatment pro-
vider, although approaches to doing so varied. Responders provided
insight behind the approaches used within their unit and reasons for,
or against, alternative approaches.
Discussion: This survey identifies widespread awareness of the po-
tential methodological challenges associated with the design and
analysis of multicentre trials, although approaches used and opinions
on these vary.P-204
An Independent Patient Data Meta Analysis to compare adjuvant
therapies in patients suffering with Pancreatic Cancer
Rebecca Griffin1, Eftychia-Eirini Psarelli1, Paula Ghaneh1, John
Neoptolemos2, Richard Jackson1
1Liverpool Clinical Trials Unit, Liverpool University, Liverpool, United
Kingdom; 2University of Heidelberg, Heidelberg, Germany
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Introduction: Pancreatic Cancer is a disease with particularly poor
prognosis with approximately 5% of patients surviving 5 years or
more. Only 20% of patients are eligible for surgery and adjuvant
therapy, but for those who do, prognosis improves with reported 5
year survival rates of 30% or more. A number of trials have explored
the use of radiotherapy and chemotherapy although the best ap-
proach is still a matter of much discussion.
Methods: An independent patient data meta analysis of randomised
controlled trials was performed using 3553 patients from 10 rando-
mised controlled trials. Data are analysed using a Hierarchical Bayes-
ian Network Meta Analysis incorporating frailty terms for patient
nationality, modelling the baseline hazard function using a Piecewise
Exponential Model and adjusting for trials with more than two ther-
apies evaluated. Sub groups analysis are performed on consistent
prognostic factors.
Results: An established network allows for comparisons of radiother-
apy vs Chemotherapy Vs Observation only using direct and indirect
evidence. Furthermore, networks allow direct and indirect compari-
sons of various types of chemotherapy. Subgroup analysis shows that
the effect of therapy does depend on reported prognostic factors.
Discussion: IPD meta analysis improves the knowledge base of the
effect of adjuvant therapies for resectable pancreatic cancer and
identifies consistent prognostic factors which can help direct treat-
ment decisions.P-205
Joint Modelling for longitudinal measures of marker CA19-9 and
survival data in patients with pancreatic cancer
Silvia Cicconi1, Paula Ghaneh1, John Neoptolemos2, Ruwanthi
Kolamunnage-Dona1, Richard Jackson1
1University Of Liverpool, Liverpool, United Kingdom; 2University of
Heidelberg, Heidelberg, Germany
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Introduction: Diagnosis of pancreatic cancer is increasing worldwide
but its prognosis remain extremely poor even after resection. The
ESPAC-4 trial showed that the adjuvant combination of gemcitabine
and capecitabine improves overall survival compared to gemcitabine
alone after resection for pancreatic ductal adenocarcinoma. CA19-9
concentration is a post-operatively established prognostic marker but
little is known of its role in providing predictions of survival probabil-
ities over time.
Methods: The relationship between longitudinal and time-to-event
data was explored on 431 patients from the ESPAC-4 trial by means
of joint modelling technique. A Cox proportional hazard regression
was used for modelling survival data while linear mixed model was
applied for CA19-9 follow-up measurements, incorporating random
intercept and slope components.
Results: Joint modelling describes the evolution of the CA19-9
marker in time and provides an estimate of its association with time
to death. Results show that CA19-9 decrease after surgery, reaching a
plateau for the following months. However, the marker concentration
spikes again with proximity to death.
Discussion: Joint modelling analysis improves the understanding of
the latent association between CA19-9 marker and survival outcome,
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to allow updated survival prediction of patients who undergone pan-
creatic ductal adenocarcinoma at any time following surgery.
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Joint modelling of multiple primary outcomes in clinical trials with
missing data
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Introduction: Multiple primary outcomes are sometimes specified in
clinical trials. The outcomes may be of different types, say a mixture
of survival and continuous outcomes. For example, in a trial investi-
gating the effect of a health intervention on cannabis users, the pri-
mary outcomes may be the time to psychiatric relapse and the level
of cannabis in the urine. These outcomes are typically associated and
it’s likely that at least one of the outcomes has missing values.
Joint models can be used to link survival outcomes with continuous
outcomes and may provide better estimates of the intervention ef-
fect. The survival and continuous outcomes may be analysed using a
survival model and a longitudinal model, respectively, which are
linked by shared parameters. Another approach to link the models is
to use joint random effects. This study evaluates the performance of
joint models in terms of bias and efficiency of the estimated treat-
ment effects. The results are compared to the estimates obtained
when analysing the outcomes separately.
Methods: Several scenarios were investigated using simulation by
varying the size of the association parameter joining the models and
the level of missing data. Joint models which share parameters or
have joint random effects were implemented using the R packages:
JoineR, jointModel and FrailtyPack.
Results: The results show that when the outcomes are analysed sep-
arately, parameter estimation for the survival outcome is typically
biased. The bias is reduced when using joint models. The joint
models had increased standard errors for the estimated treatment ef-
fect on the survival outcome compared to analysing the outcomes
separately.
Discussion: The joint random effects models and the models that uti-
lised shared parameters performed best. These models produced the
smallest mean square error of the estimated intervention effects on
the survival outcome.
P-208
Real Time Continuous Glucose Monitoring in Neonatal Intensive
Care (REACT): statistical challenges from the REACT trial
Annabel Allison1, Simon Bond1, Kathryn Beardsall2, Catherine Guy2,
Beatrice Pantaleo1, Lynn Thomson2
1Cambridge Clinical Trials Unit, Cambridge, United Kingdom;
2Department of Paediatrics, School of Clinical Medicine, University of
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Trials 2019, 20(Suppl 1):P-208
Introduction: Increasing numbers of infants are being born preterm,
requiring intensive care and with a high risk of mortality and morbid-
ity as well as longer term health problems. Treatable neonatal causes
of long term health problems have been difficult to establish but it isthought that early postnatal glucose control may be an important
risk factor for clinical outcomes. In utero, glucose levels are main-
tained between 4-6mmol/l, but preterm infants are at risk of both
hyperglycaemia (>8mmol/l) and hypoglycaemia (<2.6mmol/l).
The REACT trial aims to evaluate the efficacy, safety, utility, and cost-
effectiveness of real time continuous glucose monitoring (CGM) in
Neonatal Intensive Care.
Methods, Timing of Potential Results: REACT is an open-label, multi-
centre, parallel group, randomised controlled trial comparing CGM
with paper based algorithm to standard clinical management (con-
trol). The control group are managed according to standard practice
using point of care blood glucose monitoring. These patients also
have a sensor inserted and glucose data collected continuously but
the clinical team are blinded to this data.
Sensor glucose (SG) is recorded every five minutes for up to one
week. The primary outcome is the percentage of time that SG is in
the target range of 2.6-10mmol/l within the first six days of life. The
primary analysis is a linear regression model adjusted for randomisa-
tion strata (gestation and site). Results of the primary analysis, and a
range of pre-specified secondary analyses, will be presented.
Results will be available in August 2019.
Potential Relevance & Impact: The secondary analyses will explore
some of the statistical issues that are present in the data: varying
amounts of data between patients due to sensor insertion and cali-
bration issues (leading to different observation periods), within-
patient correlation due to the time series nature of the data, and po-
tential measurement error of CGM compared to blood glucose
monitoring.
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Review of reporting of time to event analyses and the
proportional hazards assumption in meta-analysis
Ashma Krishan1, Nicky Welton2, Catrin Tudur-Smith1
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Introduction: The most commonly used approaches for the analysis
of time-to-event (TTE) outcomes impose an assumption of propor-
tional hazards (PH), such that the hazard ratio (HR) is assumed to be
constant over time. It is currently unknown what impact non-PH can
have on overall conclusions and clinical decisions in meta-analysis.
The objectives were to (i) review the reporting of meta-analysis of
TTE outcomes that have assumed PH; (ii) describe the reporting of
the PH assumption in meta-analysis of TTE outcomes and (iii) assess
how often PH was valid or invalid in a sample of studies.
Methods: Eligible studies included systematic reviews (SRs) that in-
cluded meta-analyses of randomised controlled trials (RCTs) of TTE
outcomes which were included as a primary and/or secondary out-
come, where SRs included phase II/III studies and RCTs were analysed
using a PH model and where SRs were published between 2005 and
2015 in order to capture the most recent methods and allow the re-
view to be manageable.
Results: 123 SRs including 956 RCTs were eligible for inclusion in our
review. 35 (28%) of the reviews included aggregate data, 81 (66%) in-
cluded individual patient data (IPD) and 7 (6%) included both IPD
and aggregate data. Although all of the included SRs used methods
that assume PH, only 33 (27%) SRs examined whether this was a rea-
sonable assumption to make.
Discussion: Findings of this review demonstrate the poor reporting of
the investigation of the PH assumption in meta-analyses of TTE out-
comes. 73% (90 out of 123) SRs failed to adequately describe methods
and results of appropriate approaches to assess the validity of the PH
assumption. The poor reporting confirms that further work is needed
to assess what impact the violation of the PH assumption can have on
the statistical conclusions and clinical decisions in meta-analysis.
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Simulation study of the impact of including hypothesis tests for
differential biomarker cohorts in a comparative clinical trial in
oncology
Marion Procter
Frontier Science Scotland (Ltd), Kincraig, Kingussie, United Kingdom
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Introduction: Suppose in the context of metastatic breast cancer, the
initial sample size calculations indicated 380 events at the primary
analysis would provide 80% power to detect a hazard ratio (HR) of
0.75 at the 0.05 significance level. There would be 600 patients re-
cruited 1:1 to active and control. Suppose external evidence sug-
gested that there is a differential biomarker effect in the active arm,
and therefore there will be hypothesis testing in the biomarker co-
horts. Simulation was used to investigate the impact of the differen-
tial biomarker effect on the hypothesis testing.
Methods: Consider the following scenario for the HRs:
Overall cohort 0.75
Biomarker present cohort (40% of patients) 0.65
The null hypothesis for the biomarker present cohort (H01) and the bio-
marker absent cohort (H02) are tested at the 0.01 significance level.
Alpha recycling applies to the null hypothesis for the overall cohort
(H03), and H03 is tested at the 0.03, 0.04 or 0.05 significance level.
Simulation of 1000 datasets was used to estimate the impact if the
primary analysis:
i)was at 420 events and the sample size was 600 patients (case 1)
ii)was at 450 events and the sample size was 700 patients (case 2)
Results: Under case 1, there were 162 events expected in the bio-
marker present cohort and the estimated power to reject H01 was
54%. The estimated power to reject H03 at the 0.04 significance level
was 83%. Under case 2, the corresponding figures were 172 events,
an estimated powers of 61% and 85% respectively.
Discussion: When designing a trial where there may be a noticeable dif-
ferential biomarker treatment effect, consider taking this into account in
the alpha-spending function and sample size decisions. Simulation can be
used to investigate the impact of the differential biomarker effect.
P-211
Outcome assessment by central adjudicators in randomised stroke
trials: simulation of differential and non-differential
misclassification
Peter J Godolphin1, Philip M Bath2, Alan A Montgomery1, NA on behalf
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Background: Central adjudication of the primary outcome in randomised
trials is thought to control misclassification. We investigated the amount of
differential and non-differential misclassification needed before central adju-
dication alters the primary trial results.
Methods: We included data from five randomised stroke trials. Differ-
ential misclassification was introduced for each study until the confi-
dence interval for the ratio of treatment effects (RTE, adjudication vs
no-adjudication) did not include one. This was simulated 1000 times.
We calculated the between-simulation mean proportion of partici-
pants that needed to be differentially misclassified before the RTE
differed from one. In addition, we simulated hypothetical trials with a
binary outcome and varying sample size (1000-10000), overall event
rate (10-50%), and treatment effect (0.67-0.90). Non-differential mis-
classification was introduced until the true treatment effect was
missed for each scenario.
Results: For the five trials, unweighted kappa was reduced from 0.89-0.97
to 0.65-0.85 before the RTE differed from one. This corresponded to 2.1%-
6% of participants misclassified differentially for trials with a binary out-
come. For the hypothetical trials, those with a larger sample size, stronger
treatment effect and overall event rate closer to 50% needed a higherproportion of events non-differentially misclassified before a real treatment
effect was missed.
Discussion: Central adjudication is important to control for differential mis-
classification in a clinical trial. However, for large blinded studies, extensive
random noise is required before adjudication changes conclusions.P-212
A better method to analyse modified Rankin Scale in the out-of-
hospital cardiac arrest patients
Yujin Lee, Chen Ji
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Introduction: Modified Rankin Scale (mRS) is a clinically preferred 7-
level ordinal scale to measure neurological status post cardiac arrest.
Multiple methods have been developed to analyse this ranked out-
come. Ordinal logistic regression is commonly used to provide an in-
terpretable estimate for clinical audience. However, the proportional
odds assumption is not always satisfied, rendering the conclusions
from this model to become somewhat limited. Partial proportional
odds regression overcomes this issue but leads to difficulty in inter-
pretation. Alternative methods include 1) shift analysis: it tests the
ranking of the scores, 2) binary regression: it breaks the levels into 2
categories using a clinically meaningful cut-off point. 3) sliding di-
chotomy dichotomises the score by accounting for patients’ baseline
prognostic risk, 4) multinomial regression ignores the orders and
treats the score as nominal data and 5) linear regression.
Method: The aim of this analysis is to demonstrate the application of
these methods using data in the PARAMEDIC-2 trial. Paramedic-2 is a
multicentre double-blinded controlled trial of adrenaline versus pla-
cebo in the treatment of out-of-hospital cardiac arrest patients. The
statistical methods will be applied to the mRS data collected at hos-
pital discharge, 3 and 6 months post randomisation. The model fit
and clinical interpretability of these methods will be compared along
with the discussion of other advantages and disadvantages.P-213
A weighted Cox model for the identification of predictive markers
in oncology
Richard Jackson, Trevor Cox
Liverpool Cancer Trials Unit, Liverpool, UK
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Background: The current trend towards personalised medicine has led
to greater emphasis being placed on the ability to identify predictive
bio-markers which can inform treatment decisions and aid in trial de-
sign. Methods for identifying predictive markers are often carried out
on small populations and either rely on direct interaction effects be-
tween biomarkers and treatment or use dichotomisation to categorise
continuous markers into clinically meaningful groups. The results of ei-
ther approach can be misleading and have the problem of either mis-
representing the underlying relationship between a biomarker and a
treatment effect or not making efficient use of limited resources.
Methods: We developed a method based on weighted cox regression
models. Here, for each individual marker value, a vector of weights are
generated based on marker proximity and ‘local’ hazard ratios compar-
ing treatment arms obtained. Repeating across all marker values gives
a continuous profile giving a clear description of how treatment effects
differ based on biomarker information. Further, as the approach is
based on Cox modelling, estimates of predictive markers are obtained
which adjust for other prognostic factors.
Results: Applied to a dataset of patients with advanced Pancreatic
Cancer, the weighted Cox model was able to identify a single marker
which could be considered predictive in showing that the effect of
randomised treatment varied depending on the biomarker value.
Further, it also identified markers as having little impact which had
previously thought to be predictive. Simulations show this approach
less likely to identify spurious markers as being predictive.
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markers has the following benefits, makes efficient use of all data,
can incorporate other pertinent prognostic information, allows for a
visualisation of the direct relationship between treatment effects and
marker values and is less likely to identify spurious markers than
other approaches.
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Maximising detection of mediated effects: information
incorporation via Bayesian and Longitudinal mediation models
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Introduction: Many trials include mediation and moderation analyses
to inform refinement and targeting of treatments. One example is
the ACTIB trial of cognitive behavioural therapy (CBT) for irritable
bowel syndrome (IBS) (1), which collected potential mediators and
moderators in a repeated measures design. An earlier pilot trial of
CBT for IBS was designed similarly (2). These studies provide an ideal
opportunity to apply rarely employed mediation methods: Bayesian
and fully longitudinal mediation models.
Methods: Trial outcomes and mediators were measured at baseline
and three post-randomisation time points both in the pilot CBT for
IBS and ACTIB trials. We fitted Bayesian mediation models using bla-
vaan in R calling the Just Another Gibbs Sampler (JAGS) software
and longitudinal latent change mediation models using Mplus (3).
Negative illness perception was explored as a mediator of the effect
of CBT on the work and social adjustment outcome.
Results: Incorporation of prior/pilot information provided similar me-
diated effect estimates as compared to those using the ACTIB trial
data alone (indirect/mediated effect estimates -2.1 vs -2.5), but these
estimates were more precise (95% credible intervals -1.1 to -3.2 ver-
sus -1.4 to -3.6). Similarly, fully modelling longitudinal mediator and
outcome processes, and assuming equal mediator – outcome esti-
mates at all points, gave 2-fold and more than 3-fold more precise
estimates as compared to modelling a single measure each of the
mediator and outcome.
Conclusions: The availability of pre-main trial pilot data and repeated
measures designs help provide robust answers to the question: does
the treatment work? Such designs also allow us to flexibly and more
precisely address important secondary mediation questions, provid-
ing good quality empirical treatment refinement guidance. We will
explore whether combining Bayesian and longitudinal methods
brings further gains.
References
1. Everitt et al, 2019; 10.1136/gutjnl-2018-317805.
2. Moss-Morris et al, 2010; 10.1017/S0033291709990195.
3. Goldsmith et al, 2019; 10.1037/met0000154.
P-216
Comparisons of different concentration–response models in the
thorough QT studies
Huanyuan Luo1, Jorg Taubel2,3, Tao Chen1, Duolao Wang1
1Liverpool School of Tropical Medicine, Liverpool, United Kingdom;
2Richmond Pharmacology Limited, London, United Kingdom; 3St
George's University of London, London, United Kingdom
Trials 2019, 20(Suppl 1):P-216Background: The concentration–response modelling has been used
a primary analysis tool in the thorough QT (TQT) studies to detect
“threshold of regulatory concern”, a drug-induced effect on the QTc
(QT interval corrected by heart rate) beyond a limit of 10 msec. Dif-
ferent statistical methods have been used to model the concentra-
tion–response relationship. In this study, we aim to compare those
models in terms of their statistical performances and parameter
interpretations.
Methods: The commonly used concentration–response/effect models
include linear mixed-effects models, Emax models, sigmoidal Emax
models, log-linear models, and polynomial models (power function).
This study will compare those models using real TQT studies as well
as simulated datasets and assess the statistical performances in terms
of model convergence, predictive accuracy, type I error and power,
and sensitivity to model mis-specifications, as well as the interpret-
ation of parameters.
Timing of Potential Results: We have the real TQT studies datasets
so far. The literature review, statistical analysis and simulations
are ongoing. The results will be ready by the end of September
2019.
Potential Relevance & Impact: Advantages and disadvantages of ap-
plications of different concentration–response models in TQT studies
will be explored and relevant recommendations will be discussed re-
garding the design, analysis and reporting of TQT studies in the drug
development.P-217
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Introduction: Typically, subgroup analyses in clinical trials are con-
ducted by comparing the treatment effect in each subgroup by
means of an interaction test. However, trials are rarely, if ever, ad-
equately powered for interaction tests, so clinically important interac-
tions may go undetected. Within a Bayesian framework, expert
opinion can be used to inform the characterisation of the interaction
parameter. The motivating example for applying this methodology is
the VeRDiCT trial investigating the effect of preoperative volume re-
placement therapy (VRT) in diabetic patients undergoing cardiac sur-
gery. Two subgroup effects were of clinical interest: a) preoperative
blood glucose control (oral medication and/or insulin) and b) pre-
operative renal function (high vs low risk of renal failure).
Methods: Clinical experts (cardiac surgeons and cardiac anaesthe-
tists) were identified within one of the two trial centres. Question-
naires, designed to elicit opinions on the impact of VRT on early
outcome (time until medically fit for hospital discharge post-surgery)
in the different subgroups, were delivered face-to-face and as part of
a routine research meeting. The main and interaction effects were
elicited using unconditional and conditional questions respectively. A
‘community of priors’ as well as a robustness of results to various
variance derivations are investigated in a Bayesian Cox proportional
hazard model using the STAN software in R.
Timing of Potential Results: Analyses will be undertaken when the
collection of clinical opinions ends in May 2019. The results should
be available by July 2019.
Potential Relevance & Impact: The study results will quantify the ef-
fect of VRT for specific subgroups of patients, providing estimates of
the probability of benefit or harm while accounting for expert views
on the intervention (e.g. optimistic, sceptical, interaction priors) and
the trial data. The methodology applied in this example could be ap-
plied in other trials with planned subgroup analyses.
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Introduction: Clinical trials are the preferred method in the evalu-
ation of medical interventions. However, missing data causes loss of
power and may introduce biases, potentially leading to researchers
over- or underestimating intervention effects. This is a particular issue
in studies where data are correlated, such as in longitudinal cluster-
randomised controlled trials (LCRCTs). Despite advances in statistical
methods, many researchers choose to simply exclude cases with any
missing values from the analysis (complete case analysis).
Multiple Imputation (MI) and Structural Equation Modelling (SEM) are
two sophisticated statistical techniques that may provide unbiased
corrections in compensating for missing data. The aim of this re-
search was to compare the performance of MI and SEM in compen-
sating for missing data in LCRCTs using computer-simulated datasets.
The performance of these methods was also compared to a common
method used to analyse longitudinal data, mixed linear modelling
(MLM).
Methods: Simulated datasets were generated to imitate data from a
real LCRCT. Data from the outcome measures were deleted at 5%,
10%, and 20% and then analysed using the three aforementioned
methods, in addition to complete case analysis (CCA). Missingness
was introduced by three mechanisms: missing completely at random
(MCAR); missing dependent on covariate x (MAR); and missing
dependent on outcome value (MNAR).
Results: Regardless of missingness mechanism, MI, SEM, and MLM
provided similar, unbiased results. SEM and MLM produced the least
biased results, though the SEM generated the smallest standard er-
rors, therefore recovering more of the lost sample size. CCA produces
the largest standard errors and most biased results.
Conclusions: From the results of these simulations, MLM and SEM are
the preferred methods to compensate for missing data in LCRCTs. These
two techniques are able to recover most of the lost sample size, and
therefore researchers are less likely to miss important intervention effects.
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Introduction: In early phase often we have single arm trials with
small patient population to generate evidence for treatment effect. A
common approach in lack of randomized control arm is to compare
outcome from treatment arm with potentially similar historical con-
trol arm adjusting for baseline covariates. Although we can minimize
bias coming from the list of covariates at hand we may have un-
wanted factors which can potentially bias the treatment effect.
Methods: We will look into a case study from a Phase 2 trial. Treat-
ment effect adjusting for baseline covariates using propensity scores
and using adjusted Cox regression model will be demonstrated. Sub-
sequent analysis with other factors in the model will be provided.
Results; Adjusted covariate analysis suggests significant treatment ef-
fect and potential planning for Phase 3 trial. However, subsequent
analysis including other covariate in the model has raised questions
about the magnitude of treatment benefit.
Discussion: Exploratory data analysis with statistically sound method-
ology can generate evidence of treatment effect from single arm tri-
als. However, safeguarding against potential confounders is an issue.
At the end we have to make decision based on risk benefit ratio. But
questions should be raised and explored thoroughly to kill a drug
before a fully planned Phase 3 trial is initiated.P-220
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Introduction: RNA expression data are very common in clinical re-
search. In cancer, tissue samples, e.g. bone marrow aspirates, are usu-
ally a mixture of healthy and cancerous cells. The proportion of both
types of cells varies across individuals. Downstream analyses are
therefore affected by this source of error contributing to a reduction
in power and increase in bias of parameter estimation. A simple
tumor content correction is proposed to render RNA values more
highly correlated with true levels of gene expression in cancer.
Methods: Assume the following simple admixture model:
E ¼ pE cþ 1−pð Þ E n
,where E is the total RNA level for a given gene, e.g. log2(TPM*), Ec is
the expression among cancer cells, and En is the expression among
normal cells, and p is purity or cancer content in a 0-1 scale. A re-
arrangement of the equation above leads to:
E ¼ E nþ E c−E nð Þp ¼ aþ bp
, which is equivalent to a simple linear regression with intercept a
(expected expression in normal cells), and slope b (expected differen-
tial expression –DE-); which after adding a model error e (residuals
after regressing E onto p) would render E=a+bp+e. The proposed
correction is:
E c≅aþ bþ e
Results: Simulation work showed that power to detect DE is reduced
when sample purity decreases, but that power remained high after
adjusting for purity differences. The method corrects equally well re-
gardless of the levels of DE. There is some prediction bias that can
reduced by selecting only samples with higher purities.
Discussion: All downstream analyses using RNA data, e.g. DE, gene
signatures, prognostic modelling etc, would experience an increase
in power and reduction in bias after using this correction in admixed
cancer samples.
P-221
Abstract withdrawn
P-222
A new instrument to assess the credibility of effect modification
analyses (ICEMAN) in randomized controlled trials and meta-
analyses
Stefan Schandelmaier1,2, Matthias Briel1,2, Ravi Varadhan3, Christopher H
Schmid4, Niveditha Devasenapathy5, Rodney A Hayward6, Joel Gagnier7,
Michael Borenstein8, Geert JMG van der Heijden9, Issa Dahabreh4, Xin
Sun10, Willi Sauerbrei11, Michael Walsh2, John PA Ioannidis12, Lehana
Thabane2, Gordon H Guyatt2
1University Hospital Basel, Basel, Switzerland; 2McMaster University,
Hamilton, Canada; 3Johns Hopkins University, Baltimore, USA; 4Brown
University, Providence, USA; 5Indian Institute of Public Health - Delhi ,
New Delhi, India; 6University of Michigan School of Medicine, Ann Arbor,
USA; 7School of Public Health, University of Michigan, Ann Arbor, USA;
8Biostat Incorporation, Englewood, USA; 9University of Amsterdam,
Amsterdam, The Netherlands; 10Chinese Evidence-Based Medicine
Center, Sichuan University, Chengdu, China; 11University of Freiburg,
Freiburg, Germany; 12Meta-Research Innovation Center, Stanford
University, Stanford, USA
Trials 2019, 20(Suppl 1):P-222
Introduction: Most randomized controlled trials (RCTs) and meta-
analyses examine effect modification (also called subgroup effects or
Trials 2019, 20(Suppl 1):579 Page 64 of 141interaction) in which the effect of an intervention varies by another
variable (the effect modifier). Assessing the credibility of an apparent
effect modification presents challenges. Therefore, we aimed to de-
velop an instrument for assessing the credibility of effect modifica-
tion analyses (ICEMAN) in an RCT or meta-analysis of RCTs.
Methods: Following a stepwise process, we 1) developed a detailed
concept; 2) identified candidate credibility considerations in a sys-
tematic survey of the literature; 3) together with leading experts, per-
formed a consensus study to identify key considerations and develop
them into instrument items; and 4) refined the instrument based on
feedback from trial investigators, systematic review authors, and jour-
nal editors who applied drafts of ICEMAN to published claims of ef-
fect modification.
Results: The final instrument consists of a set of preliminary consider-
ations, core questions (five for RCTs, eight for meta-analyses) with
four response options, one optional item for additional consider-
ations, and a credibility rating on a visual analogue scale ranging
from very low to high credibility. An accompanying manual provides
rationale, detailed instructions, and examples from the literature.
Seventeen potential users tested the instrument. Implementing their
suggestions improved the user-friendliness of the new instrument.
Discussion: ICEMAN is a rigorously developed instrument to assess
the credibility of apparent effect modification. The instrument may
aid trial investigators, systematic reviewers, journal editors and others
who are interpreting or considering making a claim of effect
modification.P-223
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Introduction: Recent advances in tumour biology and targeted ther-
apies have led to clinical trials considering treatment effects in mul-
tiple subgroups of a patient population. These can lead to efficiency
gains by testing several hypotheses in the same clinical trial. Pro-
posed approaches include adaptive enrichment, umbrella and basket
trial designs. Although much of the development of novel designs
has been in exploratory phase II trials, there is growing interest in
the application of such methods in confirmatory randomized con-
trolled trials.
In a confirmatory trial setting, as the multiple hypothesis tests can
lead to statistical error rate inflation, questions arise regarding the
need for correction for multiplicity. The recent US FDA draft guidance
on Master Protocols notes the risk of “potential overinterpretation of
findings”, but offers no clear suggestions as to when statistical cor-
rection for multiplicity should be implemented.
Methods: We survey novel master protocol designs and explore the
resulting multiplicity issues. A basic principle is that correction for
multiplicity is needed in confirmatory trials if testing of multiple hy-
potheses increases the opportunity to claim of effectiveness for an
experimental treatment.
Results: Based on consideration of when subgroups result in multiple
opportunities for a claim of effectiveness for a treatment, we make a
proposal for when multiplicity corrections are needed. Wedifferentiate between different master protocol designs on the basis
of the role of the subgroups included.
Discussion: Conventionally, correction is required when multiple hy-
pothesis tests are conducted in a trial, but not when they are con-
ducted in separate trials. This position has arisen mainly in simpler
settings than those now being developed, and the use of innovative
trial designs requires a reconsideration of multiplicity issues. There
seems to be little current consensus on this question and this work
provides a contribution to ongoing discussion.
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Introduction: Usual statistical methods for evaluating prediction
models are based on assessing their performance by discrimination
and calibration. These do not incorporate information on model util-
ity, so a precise model is not always a clinically useful model. The
EMPiRE model was developed to predict risk of seizures in pregnant
women taking antiepileptic drugs at any time in pregnancy and until
6weeks postpartum. We also evaluated the clinical utility of the
model using DCA.
Methods: We fitted the model using LASSO regression and used
datasets of the prospective EMPiRE cohort study of 527 pregnant
women with epilepsy to develop and validate the prediction model.
We evaluated the net benefit of using the model with various prob-
ability thresholds to aid in clinical decision-making for individualized
patient ‘treatment’ options, where the preferred strategy is the one
with the highest net benefit at any given threshold.
Results: The EMPiRE model showed good performance in terms of
discrimination 0.79 (95% CI 0.75,0.84) and calibration 0.93 (95% CI
0.44,1.41). The highest net benefit was observed between predicted
probability thresholds of 12% and 99%. We did not recommend a
specific decision threshold as this would likely vary with the user
(healthcare professional or pregnant woman), intervention offered,
potential adverse effect associated with the intervention and the
intervention cost. Use of the model would reduce the number of
women incorrectly offered the intervention by at least 2, and up to
54 of every 100 woman when the decision threshold is high.
Discussion: The EMPiRE model can be used to predict seizure risk in
pregnant women with epilepsy on medication at any time during
pregnancy and up to 6weeks postpartum. It has good predictive per-
formance, and usefulness in clinical practice. Use of the model will fa-
cilitate decisions about the optimal management of these women
customized to their risk profile.
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Introduction: The use of prediction models in healthcare aims to im-
prove clinical decision-making by providing patient-specific risk of fu-
ture outcome. The PREP study developed and externally validated
prediction models for complications in early-onset pre-eclampsia. To
Trials 2019, 20(Suppl 1):579 Page 65 of 141improve health outcomes, model predictions need to affect the
decision-making of clinicians. Draft NICE guidelines for Hypertension
in pregnancy recommend the PREP model for use in clinical practice,
however it is important to assess whether the model will likely be
used by healthcare professionals and patients and if its use is likely
to have a positive effect on clinical decision and patient outcome.
Methods: Our mixed method study interviewed healthcare profes-
sionals and women with previous pregnancies complicated by pre-
eclampsia to understand how predicted risks were perceived and
how these influenced their decision-making. This information was
also used to arrive at thresholds for various treatment options based
on predicted risk probabilities, and decide on the format of predic-
tion model results and its interpretation when being assessed in a
large-scale impact study.
Results: The predicted threshold for admission to hospital set by
NICE in the draft guideline (≥30%) was conservative, compared to
that identified by healthcare professionals (>40%) and women
(>45%). The knowledge obtained on the perspective of the health-
care professionals and women, will influence the best way to present
the model when incorporated in the design of an impact assessment
study.
Discussion: A phased approach is needed to assess the impact of a
prediction model (such as the PREP model) in clinical practice. Deci-
sion Curve Analysis should first be performed to identify the clinical
utility of the model, before progression to a large-scale cluster ran-
domized impact study. This will at least indicate the potential effect-
iveness of the model. Results from phases of this research process
can help in optimizing the design of any future impact study.
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Introduction: In a Cluster Randomised Controlled Trial (CRCT), ran-
domisation units are “clusters” such as schools or GP practices. This
has implications for design and statistical analysis, since clustering
often leads to correlation between observations which, if not
accounted for, can lead to spurious conclusions of efficacy/effective-
ness. Bayesian methodology offers a flexible, intuitive framework to
deal with such issues. This review aimed to explore and quantify the
use of Bayesian methodology in the design and analysis of CRCTs
and appraise the quality of reporting against relevant published
CONSORT guidelines.
Methods: The protocol for this systematic review was prospectively
published (https://osf.io/2azrc/). We sought to identify all reported/
published CRCTs incorporating Bayesian methodology, as well as pa-
pers reporting developments of new Bayesian methodology. We
searched Medline, Embase and the Cochrane Library Central Register
of RCTs. The initial sift of titles and abstracts, full text reviews and
data extraction were undertaken twice, independently.
Results: Twenty-seven publications were included, six from an add-
itional hand search. Eleven (40.7%) were reports of CRCT results:
seven (25.9%) were primary results papers and four (14.8%) papersreported secondary results. Thirteen papers (48.1%) reported Bayes-
ian methodological developments, the remaining three (11.1%) com-
pared different methods. All eleven results papers used Bayesian
methodology in analysis, none did so in design/sample size calcula-
tion. Of the seven primary results papers, none clearly accounted for
clustering in sample size calculation, but six (85.7%) clearly did in the
analysis.
Discussion: The popularity of the CRCT design has increased in the
last twenty years and whilst there has been some effort to develop
Bayesian methodology for the design and analysis of CRCTs, uptake
of these modern methods remains low. There is an opportunity to
further develop Bayesian methodology in the context of CRCTs in
order to expand the accessibility, availability and, ultimately, use of
this approach.
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Introduction: The use of rescue medication is often allowed in tri-
als in chronic disease to aid recruitment and retention of partici-
pants in addition to ethical considerations. Use of rescue
medication in addition to study treatment will impact the treat-
ment effect estimate, especially if there is unequal use between
arms. It can therefore be of value to obtain a treatment effect es-
timate adjusted for the use of rescue medication. There are no
existing best-practice approaches recommended to calculate ad-
justed estimates. We aimed to identify what approaches are cur-
rently employed to describe and adjust for rescue medication
use. We undertook a systematic review of randomised controlled
trials (RCTs) in asthma and eczema to ascertain this.
Methods: We searched for original phase II-III monoclonal antibody
drug RCTs in asthma and eczema. A standardised, pre-specified
checklist was used to extract data on trial characteristics, reporting of
rescue use, and methods of analysis to adjust for rescue medication
on the primary outcome.
Results: We identified 59 trials and ascertained that 57 (97%)
allowed for rescue medication in the trial but only 28 (47%) arti-
cles reported its use. Twenty six (44%) articles summarized rescue
use by arm and 9 (15%) included an analysis on the primary out-
come adjusting for rescue medication. Eight of these 9 trials used
a sub-optimal approach of single imputation, such as last obser-
vation carried forward (LOCF) after setting post-rescue data to
missing, 4 (44%).
Discussion:: Rescue medication use is not commonly reported. There
is evidence of sub-optimal statistical practice that could lead to bias
being employed when undertaking rescue adjusted analyses. Guid-
ance on accessible statistical approaches to adjust for post-
randomisation variables, such as rescue use, would support better
practice.
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Introduction: BRAINTRAIN was a European consortium study de-
signed to develop and test the feasibility and efficacy of neurofeed-
back for the treatment of mental and behavioural disorders.
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single-centre trials but under an overarching conceptual and design
framework. A total of 7 small individual feasibility studies were com-
pleted in 5 countries. Four of the studies were randomised and three
were single group studies for proof of principle. Since the trials were
in 5 different clinical conditions (Alcohol dependence, PTSD, Autism,
Anxiety and Obesity) and had differing clinical outcomes, standar-
dised effects from each trial were compared. Common psychometric
outcome measures to assess depression, mood and anxiety across
disorders, and measures to predict neurofeedback success were
agreed with study teams. A common data platform designed with in-
put from the consortium members facilitated data sharing. Two
stage, random effects IPD MA across trials was carried out for the
randomised studies. The studies in Autism and Anxiety used a single
arm design, therefore within group change effects calculated from
each trial were used to carry out an aggregate data (AD) meta-
analysis.
Results: Feasibility criteria were met by all studies for recruitment, re-
tention and intervention uptake (>50% approached eligible; 50-80%
of those eligible recruited; 50-80% retention at the primary end-
point; 60-90% uptake). There were positive effects of neurofeedback
on PTSD symptom scores and for depression scores in the Alcohol
Dependence trial. Change scores indicated promising effects in the
Autism and Anxiety studies.
Conclusions: Meta-analysis is usually only carried out on completed
definitive randomised trials, however it has been used here, by de-
sign, to combine and synthesise the results of small feasibility studies
to give an overview of the potential effects of neurofeedback in vari-
ous clinical con
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Introduction: Loss to follow-up compromises the validity of trial re-
sults by reducing statistical power, negatively affecting generalisabil-
ity and undermining assumptions made at analysis, leading to
potentially biased and misleading results. Evidence exists that incen-
tives are effective at improving response rates, but there is little evi-
dence as to the best approach, especially in the perinatal field. The
NIHR-funded SIFT trial (ISRCTN76463425) follow-up of infants at two
years of age provided an ideal opportunity to resolve this remaining
uncertainty.
Methods: Participants: all infants from participating neonatal units in
the UK and Ireland followed up for SIFT (multicentre RCT investigat-
ing two speeds of feeding in babies with gestational age at birth <
32 weeks and/or birthweight <1,500g). Interventions: parents were
randomly allocated to receive incentives (£15 gift voucher) before or
after questionnaire return. The objective was to establish whether of-
fering an unconditional incentive in advance, or promising an incen-
tive on completion of a questionnaire (conditional) improved the
response rate in parents of premature babies. The primary outcome
was questionnaire response rate. Permuted block randomisation wasperformed (variable size blocks), stratified by SIFT allocation (slower/
faster feeds) and single/multiple birth. Multiple births were given the
same incentives allocation. Parents were blinded to their incentives
allocation, however this was not possible for the SIFT office staff.
Results: 923 infants were randomised: 459 ‘infants’ allocated to re-
ceive incentive before, 464 ‘infants’ allocated to receive incentive
after; analysis was by ITT. An incentive before led to a significantly
higher response rate, 83% (381/459) compared to the after group,
76.1% (353/464); adjusted absolute difference of 6.8% (95% CI 1.6%
to 12.0%).
Conclusions: An unconditional incentive in advance led to a signifi-
cantly higher response rate compared to the promise of an incentive
on completion. Against a backdrop of falling response rates to ques-
tionnaires, incentives are an effective way to increase returns.P-231
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Introduction: Meta-analyses of RCTs conducted in the context of a
systematic review aim to synthesise evidence across RCTs, similar in
population, outcome and intervention, by quantifying the pooled
treatment effect, accounting for differences between RCTs. Standard
aggregate-data methods that account for treatment heterogeneity
include random-effects meta-analysis (the average treatment effect is
estimated, assuming a distribution of treatment effects across RCTs);
subgroup analysis (separate treatment effects are estimated for each
subgroup of RCTs); and meta-regression (sources of heterogeneity
are included as study-level effect modifiers). Complex interventions
introduce further sources of between and within-study heterogeneity
as they comprise multiple, potentially interacting components, with
complicated causal pathways, and meditators and moderators of
treatment effect. Variability may exist at the patient-level due to
intervention adherence or tailoring, and at the provider-level due to
intervention delivery.
Methods: Using a planned individual-patient-data (IPD) meta-analysis
of complex interventions to reduce self-harm in adolescents (RISA-
IPD), we will discuss the benefits and challenges of using an IPD ap-
proach to handling treatment heterogeneity at the study, provider
and patient levels in systematic reviews of complex interventions.
Timing of Potential Results: The review is in set-up and anticipated
to include IPD for at least 19 RCTs; the analysis plan is expected to
written by October 2019.
Potential Relevance & Impact: IPD meta-analyses are recognised as
a way of explaining treatment heterogeneity at the patient-level (in-
cluding patient-level, in addition to study-level, effect modifiers in a
meta-regression). They provide greater scope and flexibility in ana-
lysis and the ability to appropriately handle treatment-related cluster-
ing associated with intervention delivery. However, there is little
consideration or guidance in the current literature on how to allow
for provider-level modifiers of treatment effects and limited experi-
ence of handling treatment-related clustering associated with pro-
viders. Methods for identifying study, provider and patient-level
mediators within IPD meta-analyses are also unclear.
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Sample size of four clusters-per-arm as a rule of thumb for pilot
cluster-randomised controlled trials
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Introduction: There currently exists little guidance on sample size for
pilot cluster-randomised controlled trials (cRCTs). Previous work
shows that parameter estimates from such studies, particularly the
ICC, are imprecise and problematic to use in subsequent sample size
calculations. We performed a systematic review to describe trends in
pilot cRCT sample size and illustrate the typical imprecision in ICC es-
timation. We also aimed to explore the changing precision of ICC es-
timates with increasing sample size, and establish the impact on
main trial power when imprecise ICC estimates are used to design a
main trial.
Methods: We searched PubMed and Web of Science for papers pub-
lished between 2010-2017 with the terms ‘pilot’ or ‘feasibility’ in the
title or topic, supplemented with terms to identify CRTs. We ex-
tracted sample sizes and other key information including estimation
of the ICC. Swiger’s formula was utilised to explore the precision and
impact of ICC estimates generated from different pilot sample sizes.
Results: 574 studies were returned. 81 studies were included in the
final review. These had a median of 4 planned clusters per-arm (IQR:
3,7) and 77 planned participants per-arm (IQR: 40, 240). The precision
of ICC estimates was highly varied with 95% CIs ranging from less
than 0.1 to more than 1. Analysis showed minimal gains in precision
when using more than 8 total clusters. However, inaccurate ICC esti-
mates can yield power of over 50% in a main trial when used in a
sample size calculation.
Discussion: The trend of 4 clusters-per-arm is consistent with the
minimum number of clusters suggested for pilot cRCTs in previous
work. We have shown this sample size to be a reasonable minimum
for such studies. Understanding the impact on power of utilising im-
precise ICC estimates in sample size calculations will assist re-
searchers in designing main trials.P-233
Exploring challenges in trials with surgical versus non-surgical
intervention comparators: a qualitative evidence synthesis
Loretta Davies1, David Beard1, Jonathan Cook1, Andrew Price1, Francine
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Introduction: Randomised controlled trials in surgery can be difficult
to design and conduct, especially when including a non-surgical
comparison. Only around half of initiated surgical trials reach their re-
cruitment target, and failure to recruit is cited as the most frequent
reason for premature closure of surgical RCTs.
The aim of this qualitative evidence synthesis was to identify, and
synthesise findings from qualitative studies exploring the challenges
in the design and conduct of trials directly comparing surgical and
non-surgical interventions.
Methods: A qualitative evidence synthesis using meta-ethnography
was conducted. Six electronic bibliographic databases were searched
up to the end of February, 2018. Studies that explored patients’ and
health care professionals’ experiences regarding participating in RCTs
with a surgical and non-surgical comparison were included. TheGRADE-CERQual framework was used to rate confidence in review
findings.
Results: 3,697 abstracts and 49 full texts were screened and 26 pub-
lished studies reporting experiences of patients and healthcare pro-
fessionals were included. Five themes related to challenges to these
types of trials were identified: 1. Radical choice between treatments;
2. Patients’ discomfort with randomisation: best treatment for me as
an individual; 3. Achieving balance: challenge of exploring patients’ a
priori preferences for treatment.4. Clinicians’ conflict with equipoise:
strong speciality convictions and 5. Imbalanced presentation of inter-
ventions and ‘buy-in’ of clinical specialities.
Discussion: The marked dichotomy between the surgical and non-
surgical interventions was identified in this review as making the
conduct of these types of trials particularly challenging. Consider-
ation of these five specific challenges should be made in the plan-
ning and design of future studies of this type of comparison to
optimise the delivery of these particular trials.
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Systematic review of prospective studies comparing different
monitoring strategies in clinical intervention studies
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Matthias Briel1
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Introduction: Trial monitoring is requested by Good Clinical Practice
(GCP) guidelines to ensure safety and rights of study participants as
well as data quality. Recent developments at international bodies
and regulatory agencies have supported the need for risk-based and
centralised approaches to trial monitoring. Several studies have em-
pirically assessed the effectiveness of such alternative monitoring ap-
proaches with discrepant findings. The objective of the present
systematic review is to comprehensively summarise the benefits and
disadvantages of different monitoring strategy for prospective inter-
vention studies.
Methods: We submitted a protocol to the Cochrane Methodology
Review Group and are currently systematically searching MEDLINE,
EMBASE, and CENTRAL from their inception to May 3, 2019, for all
prospective studies comparing different monitoring strategies in
intervention studies. Two authors will independently assess the
methodological quality of eligible studies using the Cochrane Risk of
Bias tool and extract information on a number of key study charac-
teristics using pre-piloted data collection forms. The primary out-
come will be the number of critical and major monitoring findings as
defined by the European Medical Association. Secondary outcomes
will include patient recruitment and retention rates, and resource
use. We will quantitatively pool results if appropriate.
Timing of Potential Results: Our electronic search yielded 3497 hits.
Title and abstract screening is currently ongoing. There are at least
five eligible studies evaluating different monitoring strategies (ADA-
MON, OPTIMON, TEMPER, START, MONITORING). At the time of the
conference we will be able to present comprehensive results from
this systematic review.
Potential Relevance & Impact: Given the large heterogeneity of
monitoring practices among research institutions, a guideline for
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tages of specific monitoring strategies is urgently needed. A new
consensus might evolve on how on-site monitoring could be effi-
ciently and judiciously used and tailored by central monitoring
findings.
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Bayesian Adaptive Design in Phase III Clinical Trials: A Gap
between Theory and Practice
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Introduction: Bayesian methods for adaptive designs have been de-
veloped in these years due to its flexibility, but it was reported to be
poorly used in practice especially in phase III clinical trials. Therefore,
we aimed at describing the current development of Bayesian adap-
tive designs and the actual use in clinical settings.
Methods: We conducted a bibliometric study by using PubMed and
Science Citation Index-Expanded databases to review the method-
ology development for Bayesian adaptive designs and actual use in
Phase III clinical trials. And we also extracted the features of Bayesian
methods in clinical practice including the characteristics of publica-
tions, trial characteristics and statistical attributions to demonstrate
the most urgent need for methodologies.
Timing of Potential Results: 30 August 2019
Potential Relevance & Impact: Although there is an increase in using
of Bayesian adaptive designs in this decade, most of these references
are still from the biostatistical teams all over the world and less was
transformed from theory into practice. Our results would indicate the
current situation of Bayesian adaptive designs in phase III clinical tri-
als, for example, most clinical trials are using non-informative priors
and few earn the benefits of Bayesian method such as trial stopping
early and sample size decreasing. It is still necessary for statisticians
to conduct more efficient designs and demonstrate its real benefit in
action.P-236
Missing Tumor Measurement (TM) Data in the Search for
Alternative TM-based Endpoints in Cancer Clinical Trials
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Introduction: Missing data commonly occur in clinical trials and may
hinder the search for alternative cancer clinical trial endpoints. We
consider reasons for missing tumor measurement (TM) data in cancer
clinicaltrials (CCT) and how missing TM data are typically handled.
We explore the potential impact of missing TM data on the predict-
ive ability of a set of tumor-measurement based endpoints.
Methods: Literature review identifies reasons for and approaches to
handling missing TM data. Data from 3 actual clinical trials were used
as an illustrative case study. A sensitivity analysis of the potential im-
pact of missing TM data was performed by comparing the predictive
ability of alternative endpoints to overall survival (OS) using observed
data and imputed data.Results: We documented several reasons for missing TM data in CCT.
Although missing TM data impacted individual objective status (e.g.
12- week status changed for 53% of patients in one imputation set),
it surprisingly only minimally impacted predictive ability of the end-
points on OS (e.g. pointwise c-indices ranged from 0.56-0.60 for
N9741, 0.55- 0.63 for N9841, and 0.51-0.66 for N0026, across ob-
served and imputed datasets).
Discussion: By understanding the reasons for missingness, we can
better anticipate them and possibly minimize their occurrence. Our
analysis suggests missing TM data may not impact predictive ability
of endpoints but may impact classification of objective status. Given
that response status is still a routine phase II endpoint in the devel-
opment of new cancer therapies (including immunotherapy), we
urge that complete TM data collection and following protocol dis-
ease evaluation as closely as possible in cancer clinical trials be a
priority.P-237
Evaluation of importance of international collaboration and data
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1Cardiff University, Cardiff, United Kingdom; 2The Christie NHS Trust,
Manchester, United Kingdom; 3University of Oxford, Oxford, United
Kingdom
Trials 2019, 20(Suppl 1):P-237
Introduction: The Less intensive-1 (LI1) trial is a study in 1000 elderly
acute myeloid leukaemia (AML) patients not suitable for intensive
chemotherapy, comparing novel agents against standard treatment
using a Pick-a-Winner design. Designed and sponsored in the UK, LI1
includes strong international collaboration. The contribution of these
international collaborations has not previously been evaluated.
Methods: Novel agents are added to the protocol via substantial
amendment and collaborative groups must seek national approval
before supporting a new protocol version. Technical, regulatory and
practical detail relating to novel agents may result in differences in
support provided by collaborative groups. Trial opened in UK Decem-
ber 2011; first patient randomised January 2012.
Results: On 30 Jan 2019, 952 patients randomised. 70 patients (7.4%)
randomised from 6 sites in New Zealand, 52 (5.5%) from 4 sites in
Denmark; collaborations with other national groups have provided
an additional 11 (1.2%) patients.
5.7% of patients in the vosaroxin-only arm (3 Denmark, 0 New Zea-
land, 53 total), 7.5% of patients in the LDAC+vosaroxin arm (2
Denmark, 2 New Zealand, 53 total) ensured data was reported to
Data Monitoring Committee 5-14 months early, dependent on ran-
domisation arm.
Published data in the control group demonstrates equivalence of pri-
mary endpoint (complete remission, CR, rate across trial 12%,
Denmark 13%, New Zealand 11%). Survival data, provided by sites,
has been entered within median 55 days (inter-quartile range, IQR
42-90 days) – UK (55 days (IQR 43-98 days)), Denmark (47 days (IQR
35-61 days)) and New Zealand (48 days (IQR 35-74 days)).
Discussion: Supportive international collaborations have accelerated
protocol accrual by 12 months over 8 years. Trial conduct and pa-
tient outcome appears equivalent across the collaborative groups
suggesting no degradation in data quality/consistency. With future
studies increasingly evaluating the diverse sub-populations of AML
such international collaborations will remain important to facilitate
timely delivery.
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A proposed review of selected clinical trial protocols and
publications to better understand the inadequate reporting of
safety data
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Introduction: The CONSORT statement for harms was introduced to
improve reporting of safety related data from randomised controlled
trials (RCT). Based on trials publications, it has been found that ad-
herence to the CONSORT guideline for harms was poor, statistical
methods were inadequately reported and varied between trials, and
safety data were not being fully utilised. Adequate reporting of safety
information was found to occur in less than 30% of trials. It is import-
ant to understand whether these deficiencies are due to inadequate
consideration of safety data at the design stage (reflected in the
protocol and CRFs, for example) or at the analysis/publication stage.
Methods: A collection of recent prominent phase III HIV and TB treat-
ment trials was identified using a clinical trials registry and key meta-
analysis publications. All publications (primary and secondary) have
been identified and trial protocols requested. A datapoint extraction
checklist has been created, based on the CONSORT statement for
harms along with additional items to gather more in-depth informa-
tion. Available information from protocols and publications will be
assessed against these criteria.
Timing of Potential Results: By September 2019 all analyses will be
completed.
Potential Relevance & Impact: To our knowledge, this will be the
first piece of research on safety data reporting that considers trial
protocols and publications in conjunction. This should help to iden-
tify the point(s) in the trial process when improvements could be
implemented.
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Introduction: Clinical trial safety data are collected as both routinely-
collected, time-specified adverse events (AEs) – usually gathered by
populating a pre-defined list - and serious adverse events (SAEs), col-
lected when sporadically occurring. However, these events are not
necessarily mutually exclusive. This was the case in ICON8, an inter-
national phase III trial which explored the efficacy of three different
chemotherapy regimens for ovarian cancer. The trial protocol stipu-
lated that SAEs on the pre-defined AE list should also be reported as
AEs. We investigated whether this was always followed.
Methods: Text searches of SAE data identified events from the pre-
defined list which should have been included in AE-led safety ana-
lyses. Categorisable SAEs were then mapped to AEs according to pre-
defined criteria: (a) SAE date matches AE assessment date +/-30
days; (b) AE assessment date between SAE onset and resolution
dates; (c) Events occurred during same chemotherapy cycle. Safety
analyses were repeated using the combined dataset.
Results: 150 patients from ICON8 were included (first 50 patients ran-
domised to each arm). Pooling AEs and SAEs not additionally re-
ported as AEs during the safety analysis period increased the
number of toxicity events by 76 from 4583 to 4659. The proportion
of patients with ≥1 G3+ AE increased in all arms; control: 10% (from
32% to 42%), experimental -1: 4% (from 56% to 60%), exeperimental-
2: 10% (from 46% to 56%). Difference in proportion of patients with
≥1 G3+ AE vs control was unaffected by data pooling: experimental-1 from 24% (5%, 43%) to 18% (-1%, 37%); experimental-2 from 14%
(-5%, 33%) to 14% (-5%, 33%), none breaching the pre-specified 15%
lower bound threshold.
Discussion: Events that meet both AE and SAE reporting criteria
should be accounted for when performing safety analyses. Mapping
is feasible and important. Methods for accurately pooling the data
should be further explored.
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Lessons learned: evaluation of a centralised system of safety blood
monitoring within a multicentre randomised placebo-controlled
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Introduction: Within placebo-controlled drug trial designs, conceal-
ing treatment allocation adequately while ensuring the robust collec-
tion and interpretation of blood safety data can present significant
methodological challenges. This evaluation assesses the use of a cen-
tralised safety blood monitoring system employed within the TOPPIC
trial, a randomised, placebo-controlled trial assessing whether mer-
captopurine (MP) prevented or delayed recurrence of Crohn’s disease
following surgical resection.
Methods: Treatment with MP causes bone marrow suppression lead-
ing to leukopenia and thrombocytopenia and, less commonly, to an-
aemia. Consistent with clinical practice, all randomised participants in
both MP and placebo arms underwent regular full blood count moni-
toring. A centralised blood monitoring system was implemented
whereby blood samples were collected and processed at participat-
ing sites, with results transferred to the central trial office by inde-
pendent staff members for entry into a web-based electronic data
capture (EDC) system. Blood values were reviewed by a blinded team
of clinical assessors, with queries and decisions fed back to site via
the EDC system.
Results: 240 participants were recruited to the TOPPIC Trial and
4,994 (67.1%) of the total projected number of 7,440 safety blood
tests were collected during the trial. Of the 4,994 collected bloods,
4,396 (88.0%) were collected within the target window with a me-
dian number of days either side of the target date of 0. Compliance
within the target window for bloods taken at GP visits was higher at
3,089 (90.9%) than those taken at scheduled study visits (81.8%). A
total of 5,088 (15.9%) sets of blood results resulted in abnormal value
alerts with a median review time by clinician assessors of 1 day.
Discussion: The TOPPIC Trial demonstrated that a centralised masked
system of safety blood monitoring can be both feasible and efficient
within a multi-site trial. The anticipated volume of messages gener-
ated should be considered when developing future systems.P-241
Provisioning, Support and Training in UK Academic Multicentre
Trials
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Background: Despite substantial research in trial conduct there re-
mains a lack of guidance for UK Clinical Trials Units (CTUs) in terms
of support for clinical sites in multicentre trials. Through surveys and
interviews this study assessed how different CTUs provide sites with
materials, training, and support prior to and during trials, and how
this is perceived by NHS staff to identify areas of unmet need.
Methods: CTUs were surveyed to obtain an understanding of current
practice. A subsequent survey was distributed to research staff at 43
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structured interviews were performed with NHS staff to discuss CTU
support and areas for improvement.
Results: Conflicts between NHS staff preference and current practice
were identified, particularly in training during the trial. In both the
survey (82%) and interviews NHS staff perceived that there was an
over-emphasis on recruitment. NHS staff registered a moderate or
strong preference for on-site initiation training (91%), although only
50% of CTUs often or always offered this. Similarly, during the trial
NHS staff preferred in-person (64%) training, although most CTUs did
not offer this (67%).
In many areas CTU practice reflected the preferences of NHS research
staff. Regular updates from the CTU trial team were identified as im-
portant in research staff interviews, and by 95% of NHS survey re-
spondents. Most CTU staff (86%) sent regular updates, with the
median being at least quarterly. Common themes identified in staff
interviews included the importance of prompt data querying.
Conclusions: The study identified divergence between CTU practice
and preferences of NHS staff, the clearest of which was between
NHS staff wanting regular, onsite training and the general CTU drive
to deliver training remotely. The study highlighted multiple themes
that could be explored through future “study within a trial” projects
to improve trial efficiency.
P-242
Trial data access: the trials and tribulations of implementing a new
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Introduction: The responsible sharing of data generated by clinical
trials and research studies is an ethical obligation, one that a growing
number of funders now mandate. However, data sharing raises vari-
ous practical issues for Clinical Trials Units (CTUs) around the mecha-
nisms for data sharing: demonstrating adequate participant consent;
ensuring the visibility of metadata, and the clarity of request pro-
cesses; the preparation of shareable datasets, and the timing of this;
resourcing data preparation, and the review process; and maintaining
adequate understanding of datasets over time. The MRC CTU at UCL
has employed a unit-wide controlled access approach, with applica-
tions reviewed by individual Trial Steering Committees (TSCs) but is
now exploring an alternative approach.
Methods: This poster provides a case study of the implementation of
a new approach to data sharing within a CTU. It details the specific
issues faced, including those presented by historical trial data. It then
discusses how changes are being made to the data access process to
resolve these issues.
Timing of Potential Results: An identified approach is under review
based on a single unit-wide Data Access Committee, servicing data
sharing post-publication into the medium term, with potential alter-
native approaches to accessing trial data much later in each trial’s
life. This approach will be finalised before October 2019.
Potential Relevance & Impact: Data sharing is becoming an increas-
ingly important issue for CTUs. This case study provides a useful view
of the issues of opening up access to clinical trial and research data
and a potential blueprint for other CTUs to follow.
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What kinds of things matter for judging how well a trial site is
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large multicentre randomised trials. We report findings from an initial
qualitative component of a wider study (Whitham et al 2018) which
aimed to identify and agree a core set of key performance metrics
and create a simple reporting tool for managing multicentre trials.
Methods: We undertook focus groups in three UK cities with stake-
holders (32 participants) holding a range of roles within clinical trial
contexts. Discussions focussed on views about the idea of monitoring
trial site performance and the kinds of things that might matter in
terms of judging how well a site is performing (and why and from
whose perspective). Discussions were recorded, transcribed and ana-
lysed thematically.
Results: Participants were supportive in principle of the need for per-
formance assessment. The process of measuring performance was
regarded as being multi-dimensional in that performance could po-
tentially vary across individuals within a site; across one site overall;
and across different sites within the same trial. In terms of what
might matter when gauging how well an individual trial site (or a
trial more generally) is doing, there was consistency across the
groups that three ‘core’ aspects were crucial: Recruitment; retention;
and the quality of outcome data collected (although there was rec-
ognition that the importance of these might vary depending on spe-
cific trial context). Participants also discussed a range of issues that
would likely impact on a site’s ability to perform well across the three
core aspects identified (e.g. quality of staff relationships etc).
Discussion: Participants identified three crucial aspects of trial per-
formance and a range of indicators that are likely to feed into these
and which could allow judgements to be made about how well a site
is likely to perform. This informed the development of our site per-
formance metric tool.P-244
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Introduction: Recruitment of participants to, and their retention in,
Randomised Controlled Trials (RCTs) is a key determinant of research
efficiency, but is challenging. Digital tools and media are increasingly
used to reduce costs, waste and delays in the conduct and delivery
of research. The aim of this UK Clinical Trials Unit (CTU) survey was
to identify which digital recruitment and retention tools are being
used to support RCTs, their benefits and success characteristics.
Methods: A survey was sent to all UK Clinical Research Collaboration
(UKCRC)-registered CTUs with a webinar to help increase completion.
A logic model and definitions of a “digital tool” were developed by
iterative refinement by project team members, the Advisory Board
(NIHR Research Design service, NHS Trust, NIHR Clinical Research Net-
works and patient input) and CTUs.
Results: A total of 24/52 (46%) CTUs responded, 6 (25%) of which
stated no prior use. Database screening tools (e.g. CPRD, EMIS) were
the tool most widely used (10/22 45%) for recruitment and were con-
sidered very effective (7/10 70%). The most mentioned success cri-
teria were saving GP time and reaching more patients. Social media
was second (6/22 27%), but estimated effectiveness varied consider-
ably, with only 17% stating very effective. Fewer retention tools were
used, with SMS / email reminders reported most (10/15 67%), but
certainty about effectiveness varied. A table of potential digital tools
to support recruitment and retention tasks, with examples and a
logic model showing relationships between the resources, activities,
outputs and outcomes for digital tools were developed.
Discussion: Database screening tools are the most commonly used
digital tool for recruitment, with clear success criteria and certainty
about effectiveness. Our detailed definition of what constitutes a
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about choices and help them identify potential tools to support re-
cruitment and retention.P-245
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Background: Pragmatic randomised controlled trials are increasingly
being used to evaluate surgical interventions, although they present
particular difficulties in regard to recruitment and retention.
Methods
This paper details the procedures and processes related to imple-
mentation of a multi-centre pragmatic surgical randomised con-
trolled trial.
Results: Forecasting consent rates based on previous similar trials en-
sured that the recruitment window was of adequate length. Ad-
equate resource was available for study procedures at multiple
clinics in each hospital due to micro-costing of study activities with
research partners ensure. A video was produced targeting recruiting
staff, which aimed to help recruiters explain the trial, randomisation
and equipoise, based on methodological work and experiences from
another study. Post-randomisation delays in delivering surgery to
one study arm were investigated by assessing the outcomes at the
time of randomisation and the day of surgery which provided confi-
dence in the baseline measure. Real-time monitoring of participant
drop-out due to delays in surgery meant we were able to extend the
recruitment window in a timely fashion. Triangulation of data sources
ensured adequate numbers of participants provided primary out-
come data.
Discussion: This paper provides a range of evidence- and
experience-based approaches which resulted in meeting our study’s
objectives and these lessons may be transferable.
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Background: Evaluating group interventions in randomised con-
trolled trials (RCTs) presents a set of practical problems which may
not be immediately obvious and are not present in RCTs of one-to-
one interventions.
Methods
Case-based approach summarising Sheffield clinical trial unit’s experi-
ence in the design and implementation of group interventions across
five randomised controlled trials.
Results: Median recruitment across the five trials was 5.8 (range 2.1-
16.0) participants per site per month. Group intervention trials can in-
volve a delay in the start of treatment whilst waiting for sufficient
numbers to start a group. There was no evidence in our trials that
the timing of consent, relative to randomisation, affected post-
randomisation attrition, but attrition was a concern for all trial teams.
Group facilitator attrition was common in studies where facilitators
were employed by the health-system rather than the by the grant
holder, and lead to the early closure of one trial. Solutions to this in-
cluded training ‘back-up’ and new facilitators. Trials specified that
participants had to attend a median of 62.5% (range 16.7% to 80%)
of sessions, in order to receive a ‘therapeutic dose’; a median of75.0% (range 34.6% to 97.8%) received a therapeutic dose. Across
the five trials, 66.4% of all sessions ran with fewer than the numbers
pre-specified as ideal. A variety of methods were used to assess the
fidelity of group interventions across the five trials.
Discussion: Investigators should expect delays / difficulties in recruit-
ing groups of the optimal size, plan for both facilitator and partici-
pant attrition and consider how group attendance and group size
affects treatment fidelity.P-247
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Introduction: Site initiation visits (SIVs) are conducted to deliver
training to sites before opening them to recruitment, though this
can be burdensome during the time-intensive trial set-up period.
There is little evidence about the best way to deliver training for sites
to perform well. Evaluating methods of training was the highest pri-
ority identified at a workshop exploring recruitment and retention of
participants to trials. Two systematic reviews investigating training in
clinical trials showed a variety of different training methods and
more research is needed to determine what kind of training and sup-
port can improve recruitment. A small retrospective study showed
that, whilst face-to-face training (either at SIV or group training ses-
sion) was associated with better recruitment than remote training
(i.e. telephone or DVD), no difference was seen between the two
types of face-to-face training.
Our objective is to compare group-based training during the trial
set-up period versus visiting the site to conduct a SIV to investigate
the impact of the training method upon key site performance met-
rics. We will embed a SWAT into the FEED1 trial, funded by the NIHR
HTA programme.
Methods: Once selected, sites will be randomised in batches to re-
ceiving their site-initiation training during a SIV or group-based train-
ing by attending a collaborators’ meeting. To allow for non-
availability of site staff, two meetings will be held. Outcomes will in-
clude recruitment and retention, data quality and protocol compli-
ance (defined as core site performance metrics) and associated costs
of each training method.
Timing of potential results: Clinical trial and SWAT results will be
available in Q1 of 2023.
Potential relevance and impact: If the intervention is shown to be
effective, there could be significant benefits to funders and trial
teams, in particular reducing the length of time it takes to set-up a
trial and open all sites.P-248
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Trials 2019, 20(Suppl 1):579 Page 72 of 141Background: Challenges to the successful conduct of ‘The Emer-
gency treatment with Levetiracetam or Phenytoin in Status Epilepti-
cus in children (EcLiPSE)’ trial were identified at the pre-trial stage.
These included practitioner anxieties about conducting research
without prior consent (RWPC), inexperience in conducting an Emer-
gency Department (ED) led trial and use of a medication that was
not usual ED practice. As part of an embedded study (the Consent
Study) we explored parent and practitioner experiences of involve-
ment in the EcLiPSE trial to inform the design and conduct of future
ED led trials.
Methods: A mixed-method study involving questionnaires and inter-
views with parents of randomised children, interviews and focus
groups with EcLiPSE practitioners and audio recorded trial
discussions.
Results: A total of 143 parents (93 mothers, 39 fathers, 11 missing in-
formation) of randomised children completed a questionnaire and 30
(25 mothers, 5 fathers) were interviewed. We analysed 76 recorded
trial discussions. Ten practitioners (4 medical, 6 nursing) were inter-
viewed, 36 (16 medical, 20 nursing) participated in one of six focus
groups. Practitioner anxieties around RWPC and changes to usual
practice were addressed by: experience of trial recruitment, including
positive responses from parents; a clinically important question; sim-
ple pragmatic trial design; and strong leadership. Lack of leadership
at a few sites negatively affected staff engagement and recruitment.
EcLiPSE completed on time, achieving its required sample size target.
Conclusions: Our study provides valuable insight into factors that
helped to facilitate successful recruitment and conduct of a challen-
ging emergency department led trial. Findings should be used to in-
form the design and conduct of future trials in this setting.P-249
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Introduction: CALIBER (NCT02070120) is a phase II study investigat-
ing intravesical chemoablation as an alternative to surgery for recur-
rent low risk non-muscle invasive bladder cancer. Eighty-two
participants were recruited from 24 NHS sites between January 2015
and September 2017. A full sample collection could not be imple-
mented from the outset due to budget restrictions. CALIBER-T was
launched in October 2016, after securing additional funding to col-
lect blood, tissue and urine samples for translational analysis.
Methods: Addition of CALIBER-T required:
•Additional regulatory approvals
•Amended site agreements
•Implementation of sample tracking system
•Streamlining of sample collection within existing patient pathways
•Reconsent of participants who joined the trial prior to implementa-
tion of CALIBER-T
•Additional central and local staff resources
Teleconferences were held with sites to discuss sample collection ob-
jectives, local patient pathway management and to promote engage-
ment. A system for per-patient reconsent reminders to sites was
setup. Systems were established with the collaborating laboratories
to enable sample reconciliation, whilst maintaining patient
confidentiality.
Results: 18/24 CALIBER sites, at which 58/82 CALIBER participants
were randomised, agreed to participate in CALIBER-T. To May 2019,
24 blood samples had been received. This is lower than originally an-
ticipated, despite reminding sites to reconsent, due to participant
scheduling issues and limited site capacity for reconsenting.
Discussion: RecommendationsSample collection should be embedded from the outset of a trial if
possible. Participating centres should be encouraged to actively en-
gage with the aims of the translational study to help facilitate collec-
tion of a robust sample set.
Conclusion: The value of implementing additional biological sample
collection during a trial can outweigh the challenges encountered in
its introduction, however it requires thorough evaluation, careful in-
tegration with existing systems and the support of key stakeholders
to ensure that sample collection can be implemented effectively.
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Introduction: UCON is an open-label randomised trial comparing uli-
pristal acetate (UPA) with the levonorgestrel-releasing intra-uterine
system in women with heavy menstrual bleeding. In February 2018,
the European Medicines Agency (EMA) issued a drug alert for UPA.
An urgent safety measure (USM) was implemented, which included
suspension of recruitment and UPA use.
We describe the impact of the USM on trial timelines.
Methods: Women take UPA for 12 weeks followed by 4 weeks off-
treatment, for 3 courses. The participant-reported primary outcome is
collected after the final off-treatment week. The USM allowed
women to complete a course, if they wanted, but not start a subse-
quent course. The original sample size 220 women including 20%
loss to follow-up: 198 participants had been randomised when re-
cruitment was suspended. On resumption, the UPA group could
complete 3 courses, subject to monthly blood tests.
Timeline
8/2/18 EMA issues drug alert with temporary recommendations that
no new patients start UPA. Urgent teleconference amongst Trial Man-
agement Group.
12/2/18 Urgent teleconference with MHRA safety scientist. Imple-
mentation of USM. Notifications to MHRA and ethics committee.
13/2/18 Sites notified and template letter for participants provided.
26/2/18 Substantial amendment submitted.
18/5/18 EMA update allows restricted UPA resumption.
8/18 Clinician and patient surveys to determine commitment to re-
cruitment and acceptability of monthly blood tests for UPA group.
7/8/18 MHRA allows UPA resumption. Restart amendment submitted.
21/08/18 Recovery plan submitted to funder. Approved 10/9/18.
18/10/18 Trial reopens to recruitment.
Impact: Sample size had to be increased by 84 to replace partici-
pants on study during USM. An extra 12 months of recruitment is re-
quired, at a cost of £199,505. Average recruitment in 5 months
before USM was 8.4/month, now 2.4/month since resumption.
Discussion: Following a USM necessitating suspension of recruit-
ment, prompt and coordinated action is required. Nevertheless, the
impact on the trial can be substantial.
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Introduction: Regular monitoring of clinical trial data is an essential
component of trial conduct to ensure data are being collected to a
high standard, intervention(s) are being administered according to
the protocol and are safe. Automated reports of data compliance,
protocol adherence and safety, tailored to the needs of the trial, are
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to monitor progress and guide decision-making.
Methods: Trial monitoring has been largely automated with the use
of modular programming, control flow and configuration files, which
allow database extracts to be validated and imported, appropriate
datasets to be derived, and specific charts, tables and listings to be
produced using the output delivery system in SAS. The input data
and output summaries required (e.g. whether summaries are re-
quired for the study as a whole, by site or by intervention), are han-
dled by optional initialisation parameters. Capabilities also include
calling Stata and R from SAS, to best use the strengths of each soft-
ware for specific and tailored monitoring; error handling; saving of
log files; and automatic backup of data extracts.
Results: Use of a modular framework has improved code mainten-
ance, extension, readability and speed. Code repositories are adapted
to different trials, with development time reducing for each succes-
sive initiation. The methodology is being successfully applied to four
large multicentre trials run through the clinical trials unit, with re-
ports being produced regularly or ad hoc.
Discussion: The upfront investment in statistical programming time
to design and set-up the automated monitoring system has been
significant, but overall time burden has reduced and the benefit to
trial teams has been substantial. Potential further developments in-
clude email notification of completed batch tasks, including alerts of
errors encountered.
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Introduction: Monitoring site performance in multicentre studies is
vital to inform the trial management group about trial conduct, aris-
ing issues, data quality, recruitment and retention. Onsite monitoring
may be conducted periodically to verify study documentation and data
collected for the study against source data. Remote central monitoring is
conducted using manual and automated reviews of data submitted to
online study databases. Increasingly, clinical trials units (CTUs) are using
remote central monitoring of multicentre studies in preference to routine
onsite monitoring, to improve efficiency. Remote central monitoring
methods vary between studies. The aim of this study is to identify which
data items are frequently monitored centrally, by what methods and the
criteria for triggering onsite monitoring across a range of studies.
Methods: We designed an online survey using SurveyMonkey and
are intending to send it to trial managers responsible for approxi-
mately 60 ongoing studies run through our clinical trials unit. The
survey will take approximately 10 minutes to complete and will col-
lect data on the following: central monitoring methods, data items
monitored (e.g. percentage eligible patients consented, protocol
compliance), effectiveness of central monitoring, how issues are iden-
tified and actions recorded (e.g. via email, minutes) and triggers for
onsite monitoring (e.g. repeated serious breaches).
Timing of Potential Results: Results of this initial survey will be avail-
able in June 2019.
Potential Relevance & Impact: The results will be used to refine the
survey before disseminating it to CTUs nationally. The data will be used
to improve methods for remote central monitoring to ensure that it is
effective in identifying data quality and conduct issues at sites.
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Do consent procedures differ when recruiting outside of the UK
versus within the UK: data from the international Tranexamic acid
for hyperacute primary IntraCerebral Haemorrhage (TICH-2) study
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Trials 2019, 20(Suppl 1):P-253Background: TICH-2 was an international randomised controlled trial
of whether tranexamic acid halts haematoma expansion and im-
proves outcome. Stroke treatments typically have greater efficacy if
given early and so delays should be avoided. However, obtaining
consent in the emergency situation is difficult since many stroke pa-
tients lack capacity. Here we assess whether consent procedures
were affected by recruiting country.
Methods: Ethics approval was obtained to allow full informed con-
sent or verbal assent (using a brief information sheet; BIS) followed
by full written consent at a later date. The BIS was used when the
therapeutic time window was short and the use of full written con-
sent would inhibit recruitment into the trial. Where patients lacked
capacity, approval for enrolment was obtained with permission from
a relative, carer or friend acting as legal representative. Permission
from legal representatives could also be given using the BIS. If no
one was available then permission could be obtained if two clinicians
(one unconnected with the trial) agreed to enrol the patient.
Results: Of 2325 enrolled participants, 1910 (82%) were recruited
within the UK and 415 (18%) were recruited outside of the UK. Over-
all, full informed consent was obtained in 1552 (67%) participants,
brief assent in 584 (25%) and independent physician assent 188
(8%). In a direct comparison, non-UK participants were more likely to
have been recruited after full informed consent had been given than
UK participants (83% versus 63%, p<0.0001). There was also a higher
rate of non-UK participants who had the capacity to give full consent
themselves (35% vs 21%, p<0.0001). Non-UK participants were also
consented by an independent clinician slightly more often than UK
participants (11% vs 8%, p=0.038).
Discussion: Non-UK participants were more likely to be enrolled after
fully informed consent (given by the participant or a relative) than
UK participants.
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Introduction: Minimisation is a widely used randomisation scheme
that ensures excellent balance between treatment groups for several
prognostic factors, even in small samples. However, extending it to tri-
als using unequal allocation ratios is challenging. Sequence balance
minimisation is a new procedure extending minimisation for trials using
unequal allocation ratios. Here we show that sequence balance mini-
misation has good treatment and factor balancing properties, and is a
valid alternative for stratified block randomisation especially in small tri-
als using unequal allocation ratios.
Methods: Treatment and factor balancing properties of sequence
balance minimisation were explored in a simulation study for a two
arm trial with 1:2 allocation ratio. Number of prognostic factors on
which to achieve balance ranged from 1 to 10 prognostic factors
with 2 levels occurring in equal probabilities. Sample size was set to
30 and 120.
Results : Including additional prognostic factors (up to 10) in the se-
quence balance minimisation had little impact on overall treatment
and factor balance; the mean and median number of allocations
achieved remained as same as the expected number, that is 10 pa-
tients 5 of whom with each factor level in sample size 30, and 40 pa-
tients 20 of whom with each factor level in sample size 120
respectively.
Treatment and factor balance performance of stratified block ran-
domisation deteriorated as the number of prognostic factors in-
cluded in the scheme increased (up to 10) with variations in
allocations achieved increasing and reaching similar levels to that of
simple randomisation.
In all scenarios, sequence balance minimisation outperformed simple
randomisation providing less variations in allocations achieved.
Discussion: Sequence balance minimisation has good treatment and
factor balancing capabilities, and is a valid alternative to stratified
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ment and factor balance across greater number of prognostic
factors.P-255
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Introduction: Trainee Research Collaboratives (TRCs) have been
established across the UK which allow surgical trainees to join large
collaborative research groups. These networks can generate new tri-
als, improve recruitment to ongoing trials and develop a research-
active future consultant workforce. How TRCs work with stakeholders
and the roles they play have not been evaluated. Understanding
them is key to maximising their potential to optimise TRCs and trial
conduct.
Methods: Semi-structured interviews with 32 TRC members and
linked personnel and observations of TRC meetings (n = 5) were
undertaken. Interviewees were purposefully sampled to include a
range of key stakeholders across different UK regions. Interviews and
observations explored experiences of participating in TRC trials and
understanding the roles of stakeholders. Interviews were audio-
recorded, transcribed and analysed thematically, alongside observa-
tion field notes. A stakeholder meeting identified key strategies to
enhance clinicians’ engagement in trials.
Results: TRCs play an important role in conducting rigorous research,
and the support of key players was needed to facilitate the success
of TRC research. Consultant surgeons are needed to champion TRCs,
provide mentorship to trainees and facilitate trainee involvement in
trials. Research nurses are needed to help support trainees and co-
ordinate trainee activity. Clinical Trials Unit (CTU) staff are needed for
methodological input and training which compliments clinician ex-
pertise. However, there are challenges to collaborative working be-
tween the groups such as unclear contact points, lack of consensus on
authorship policies and a lack of awareness of the benefits of collabora-
tive working. To overcome these challenges, there needs to be an ac-
knowledged mutually beneficial relationship between the groups, as
well as improved communication and pathways for working.
Discussion: Multi-disciplinary teams are needed to ensure the suc-
cess of TRC research. Enhancing relationships between key stake-
holders and maximising the skills and knowledge within multi-
disciplinary teams can optimise TRCs and thus trials.
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Trials 2019, 20(Suppl 1):P-256Introduction: Trials rarely recruit well or complete on time and one
contributory factor is clinician engagement. This is often worse in
surgical trials, where preferences for specific interventions are strong
and research-active senior surgeons rare. Trainee Research Collabora-
tives (TRCs) have been established across the UK which allow surgical
trainees to join large collaborative groups. TRCs have completed sev-
eral surgical trials on time and target. We aimed to understand key
elements of successful trainee engagement in trials and the role TRCs
play in facilitating this engagement and conducting successful trials.
Methods: Semi-structured interviews (n=32) explored motivation for
trainee engagement in trials, experiences of participating in TRCs tri-
als, including barriers and facilitators. Observations of TRC meetings
(n = 5), a survey (n=72) and a stakeholder meeting were also under-
taken. TRCs and linked personnel were purposefully sampled to in-
clude a range of key stakeholders and specialties across different UK
regions. Interviews were audio-recorded, transcribed and analysed
thematically, alongside observation field notes.
Results: Trainees engage with trials to progress their careers, contrib-
ute to the surgical evidence base and improve patient care. Chal-
lenges to engagement included competing clinical priorities, “trainee
fatigue”, trainee confidence, integration into traditional hierarchies,
recognition of trainee input and authorship issues. TRCs were per-
ceived to play an important role in providing a supportive infrastruc-
ture to facilitate engagement with mentoring being a key feature.
Challenges can be further overcome by engaging senior surgeon
support, conducting achievable study designs, transparency of in-
volvement and recognition, consideration of corporate authorship
policies and providing pathways and activities for training including
“on the job” training.
Discussion: Using multiple methods to understand trainee engage-
ment in trials and the role of TRCs has helped elucidate how trial
conduct and delivery can be improved. Findings could potentially
translate to other specialties.P-257
A systematic literature review of site staff training methods in
clinical trials
Athanasia Gravani, Andrew Beswick, Chris Rogers, J Athene Lane
University Of Bristol, Bristol, United Kingdom
Trials 2019, 20(Suppl 1):P-257
Introduction: Clinical trial staff must be able to demonstrate appro-
priate education and training relating to their roles to fulfil ICH Good
Clinical Practice guidelines and facilitate trial conduct. We aimed to
investigate training methods used in randomized controlled trials
(RCT) of health-care interventions.
Methods: A systematic search was undertaken of multiple databases
in November 2013 to identify articles reporting methods and prac-
tices of staff training within RCTs. Key trials journals and reference
lists of included papers were hand searched for additional references.
As data extracted was largely descriptive a meta-analysis was not
possible, so thematic categories and sub-codes were developed and
used to summarise and compare studies. An updated search re-
vealed no new systematic reviews and identification of individual pa-
pers is ongoing (November 2018).
Results: 7,471 records were screened for eligibility (full texts of 177
articles were reviewed) and 89 studies identified (46 from database
searches and 55 through manual searches). Host studies focused on
a wide range of diseases: 23 (26%) circulatory system, 15 (17%) men-
tal/behavioural disorders, 14 (16%) neoplasms and 13 (15%) endo-
crine diseases. Studies were mainly conducted in the USA (55%) or
multi-nationally (27%). Multiple methods of training were used with
different combinations of live (face-to-face and remote) and recorded
(text-based and multimedia) methods. Training was often provided
in groups (51%) by research team trainers (65%). Training costs were
only provided in four (4.5%) studies.
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discordant with the paucity of published details suggesting more stan-
dardised reporting is required. Wide variation existed in staff training
process across RCTs of various intervention types and disease areas.
Further research is needed to robustly evaluate staff training process
within RCTs, including their impact on trial conduct and costs.
This was funded by the UK MRC ConDuCT-II Hub for Trial Method-
ology Research.P-258
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Introduction: Online studies have efficiency, convenience, geograph-
ical, time and cost saving advantages. In paediatric studies, partici-
pants may also feel more in control, with less social pressure to
participate. However, risks include uncertainty around who has con-
sented, limited opportunity for participants to ask questions, technol-
ogy failure, requirement to be IT literate, and need for appropriate
web access.
Methods: Our NIHR funded study tested an adolescent online
psychological support programme intervention with Skype and
telephone support but no face-to-face contact with any re-
searcher. PenCTU delivered the online study management and
data entry system. Participants were approached by post or
email; informed consent, screening and study measures were
managed online.
Results: Trial Manager perspective: Ethical approval was straightfor-
ward; consent forms were completed correctly and receipt at PenCTU
was immediate. Participants dictated the rate of progress resulting in
some long intervals between approach, consent, questionnaire and
intervention completion. The lack of initial face-to-face contact may
have contributed to poor recruitment to the study. However, once
recruited, retention was good.
Participant perspective: Families accepted the approach and re-
ported that the online format was convenient and intuitive to fol-
low, but some technical difficulties increased participant burden.
Some families required telephone support during questionnaire
completion and would have welcomed initial face-to-face contact
with the therapist to build rapport during the intervention.
Discussion: Online consent worked well in this feasibility study, how-
ever the risks and benefits would need to be carefully balanced for a
higher risk or complicated study, and a Skype link would provide
additional reassurance for both researchers and participants.
In future online paediatric studies, we would recommend an ini-
tial face-to-face meeting, offering contact by social media, im-
proving compatibility with smartphones and incorporating
interactive or video links into participant facing documents for
further information.
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Introduction: Cluster-randomised trials (CRTs) are often used to
avoid the contamination risk inherent in individually-randomised
trials (IRTs) of many complex interventions, although they canhave other limitations including selection bias and large sample
sizes. We aimed to design and implement an IRT of a systematic
voiding programme (SVP) allowing for contamination whilst limit-
ing its potential through careful design and close monitoring of
usual care (UC) delivery.
Methods: Patients individually-randomised to receive either UC deliv-
ered by existing ward staff or SVP delivered by specifically-trained
and allocated existing ward staff, supported by a study-specific
champion.
Adjustment of effect size for contamination when calculating sample
size; development of process measures to evaluate the extent of con-
tamination; internal pilot to confirm an acceptable level of contamin-
ation. Data to evaluate contamination collected via case-note review
of care received by UC participants.
Results: Even with a 25% reduction in effect size due to contamin-
ation, the sample size for the IRT was considerably less than that for
a CRT without effect size contamination. Through discussions with
the Trial Team and the Trial Steering Committee, we developed mea-
sures of contamination:
1.Percentage of UC participants with a:
a.strategy for minimising indwelling urinary catheterisation in the
acute phase unless clinically justifiable; and
b.comprehensive continence assessment; and
c.tailored treatment plan (including behavioural approaches).
2.Percentage of UC participants receiving toileting assistance from
staff trained to deliver the SVP intervention on 50% or more
occasions.
These will be evaluated in an internal pilot: if each is <=25%, ‘green
light’ to main trial.
Discussion: An IRT can be more efficient than a CRT, even in the
presence of moderate contamination. However, it is important to
limit contamination by careful design and implementation, to moni-
tor and evaluate the extent of contamination, and to consider this
when interpreting effectiveness and cost-effectiveness.P-260
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Introduction: Conducting trials within early years community set-
tings, managed by public health teams is challenging; especially
given the fluidity in structure and organisation, and the increasing
political and economical demands.
Additionally, ensuring that routine data from research naïve environ-
ments is of high quality, sufficiently robust for research and is trans-
ferred in an appropriate manner can be time-consuming.
We will present the challenges encountered during the set-up, imple-
mentation and analysis of a public health trial, sharing the lessons
learnt and detailing the strategies developed to overcome these issues.
Methods: OFTEN is a NIHR-funded, multi-centre, two-arm, cluster ran-
domised controlled trial evaluating the effectiveness of an optimisa-
tion intervention aimed at promoting parent engagement to
‘HENRY’, a UK community-based obesity prevention intervention.
The trial was delivered in 126 children’s centres across 20 local au-
thorities; outcomes were evaluated using anonymised data, routinely
collected from each centre.
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ting underwent substantial restructuring due to austerity, resulting in
centre closures or mergers, thereby reducing research capacity. Due
to competing demands, the intervention was de-prioritised resulting
in low intervention fidelity.
The trial faced many data issues: data required for randomisation
was not consistently entered into databases; data specifications
were not initially understood therefore some data were incor-
rectly entered; and differing methods were used to show missing
data. Additionally, poor quality assurance processes led to trans-
fer of incorrect data and the deletion of some data required for
process evaluation.
Discussion: Researchers should ensure those involved in collecting
and transferring data for research in public health settings receive
training in data management and data protection. We also encour-
age the use of quality assurance checklists. Researchers can use our
practical, easy to implement strategies to overcome some of the key
challenges faced when conducting future research in public health
settings.
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Introduction: Myeloma causes profound immunodeficiency and
recurrent, serious infections. There are approximately 5,500 new
UK cases of myeloma per annum; a quarter will have a serious
infection within 3 months of diagnosis. Newly diagnosed patients
may benefit from antibiotic prophylaxis to prevent infection and
early death but this may be associated with healthcare-associated
infections
Methods: The Tackling Early Morbidity and Mortality in Myeloma trial
(TEAMM) trial was a multicentre randomised, double-blind, placebo-
controlled trial in newly-diagnosed myeloma patients randomised to
receive Levofloxacin or placebo for 12 weeks at the start of anti-
myeloma treatment. Follow-up was 4-weekly to 16 weeks and again
at 1 year. The composite primary outcome was defined as time to
first febrile episode or death in the first 12 weeks from start of trial
treatment. Secondary outcomes included overall survival at 16 weeks
up to 12 months.
Results: 977 patients were randomised (489 levofloxacin, 488 pla-
cebo). Primary events (febrile episodes, deaths, febrile episodes with
death) in levofloxacin versus placebo arms were 19% vs 27% (87, 4, 4
vs 112, 15, 7), respectively; HR=0.66 (95% CI 0.51-0.86) p=0.002. There
was a benefit in overall survival at 12 weeks (p=0.008) but not at 12
months (p=0.94).
Conclusions: The use of 12 weeks prophylactic antibiotics signifi-
cantly reduced the number of febrile episodes or deaths within the
first 16 weeks. However, this did not predict longer-term survival.
Models to adjust for additional treatments indicated that the use of
co-trimoxazole was independently associated with improved survival.
TEAMM demonstrates the need for longer-term follow-up in cancer
trials. This has influenced the design of TEAMM2 trial.P-262
Challenges of running a cancer trial with multiple primary tumour
sites – ICR-CTSU experience based on the CORE trial
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Introduction: CORE (ClinicalTrials.gov NCT02759783) is a multicentre
phase II randomised controlled trial investigating the addition of
stereotactic body radiotherapy (SBRT) to conventional care for extra-
cranial oligometastases in patients with breast, prostate and non-
small cell lung cancer. Including multiple cohorts each with a differ-
ent primary tumour site, allows efficient evaluation of safety of SBRT
and feasibility of conducting subsequent cohort specific phase III tri-
als; however this also presents several challenges for both trial de-
sign and management.
Methods and Results: Trial eligibility criteria and patient pathways
needed to be carefully considered to fit with different standard of
care pathways for each cohort, whilst allowing for a combined ana-
lysis. Expertise for each cohort during protocol development and on
oversight committees was essential. Similarly, at sites, liaising with
three different clinical teams was common, necessitating a coordi-
nated approach and more resources.
The trial design originally assumed even recruitment across cohorts,
but practically, while recruitment to breast and lung cohorts was as
predicted, recruitment to prostate exceeded expectations. With a sin-
gle recruitment target over all cohorts, the larger number of prostate
cancer patients recruited impacted on the statistical assumptions. Re-
cruitment to the prostate cohort was temporarily suspended, while
engagement with breast and lung communities was increased,
amendments to the protocol were made to improve recruitment to
these cohorts and discussions around the implications to the trial de-
sign were had with the Trial Steering Committee. The control group
progression-free survival estimate was revised based on the recruit-
ment ratio seen between the cohorts and therefore the sample size
was increased.
Discussion: Recruitment was completed in February 2019. Frequent
collaboration with the trial oversight committees and sites, and close
monitoring of recruitment, enabled effective trial design and man-
agement to maximise the information gained from the trial, includ-
ing the feasibility of subsequent phase III trials.P-263
Challenges of using electronic real time measuring devices in
randomised controlled trials
Seonaidh Cotton, Victoria Bell, Shaun Treweek, Steve Turner
University Of Aberdeen, Aberdeen, United Kingdom
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Introduction: Electronic real time measuring devices are increasingly
used in RCTs, eg to capture outcome data or as part of the interven-
tion. They are not without challenges, as we discuss for two distinct
devices in different trials.
Challenges: The first device is an adherence monitor used in RAA-
CENO (ISRCTN67875351) to measure adherence to asthma
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to using these monitors (eg children losing the monitor, uncharged
batteries). There were also unanticipated challenges (eg NHS firewalls
preventing download of adherence data; or some monitors not accur-
ately capturing medication use). The study was designed so that
monitor-reported or family-reported adherence could be used in treat-
ment decision-making. Adherence monitors were returned at 430
follow-up appointments; in 357, adherence data could be downloaded
from the monitor. Of these, 264 suggested adherence of <70% (ie non-
adherent), but based on family-reported adherence, the research team
classified 141/264 as being adherent to their asthma medication.
The second example is an activity monitor used in the EurofIT trial
(ISRCTN81935608) to objectively measure primary outcome (total
physical activity, total sedentary time). All participants also self-
reported activity and sitting time. The activity monitors had chal-
lenges: skin reactions to the adherence tape; people not wearing
them all day; and software problems. At follow-up, primary outcome
data from the activity monitor was available from approximately 83%
of participants. Some of those who did not have outcome data avail-
able from the activity monitor provided self-reported secondary out-
come data on activity levels – however in this study there were
substantial differences between objective measurement and self-
report, casting substantial doubt on the value of self-report
Discussion: Trials using devices for trial outcome data need to under-
stand both the technical challenges of implementation but also the
differences between device data and other sources of notionally
equivalent data.
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What impact does form re-design and user testing have on
consent form completion errors?
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Introduction: Consent to research requires participants to endorse
and sign a consent form, usually a printed sheet. Completion errors
may invalidate consent, requiring participants to be re-consented, in-
curring recruitment delays and researcher opportunity costs, particu-
larly in postal recruitment trials. The aim was to compare a trial
consent form with a revised version, developed through information
design (making changes to layout, appearance and navigation) and
user testing, for rates of completion errors and corrections.
Method: The two consent forms were compared in a SWAT with se-
quential groups design. The revised form was used for participants
to the ISDR trial over the last 6 weeks of recruitment. Error and com-
pletion rates were compared with rates in a sample of original ver-
sion forms, used in the first 18 months of ISDR trial recruitment.
Results: The revised form was completed by 307 participants at five
eye clinics in one city in Northern England during April-May 2016.
For the original version of the form we sampled the forms for 720
participants recruited at the same five centres over November 2014-
March 2016. Rates of completion errors were low: 7/720 (0.97%) in
original forms; 2/307 (0.65%) in revised forms (including 2/720 and 0/
307 important errors that would invalidate consent). Form correction
rates were: 82/720 (11.4%) and 18/307 (5.9%), with lower correction
rates in revised forms (Chi-square=7.48; df=1; p=.006). Most correc-
tions were minor, non-GCP corrections (61/720; 14/307) rather than
more significant, GCP corrections (21/720; 4/307).
Discussion: The revised consent form did not reduce completion er-
rors in the ISDR trial, although overall rates were low. The revised
form halved the rate of form corrections, indicating that information
design changes can impact on participants’ ease of completion. The
revised form needs evaluation in a SWAT using random allocation,
ideally in a trial using postal or other remote recruitment method.P-265
An assessment of feasibility and cost-effectiveness of remote
monitoring on a multicentre observational study
Jennifer Murphy, Margarita Durkina, Puja Jadav, Gaia Kiru
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Introduction: ICH GCP E6(R2) encourages risk-adapted approaches to
monitoring by streamlining operations in line with the risks inherent
in the protocol. The aim of this analysis is to determine the feasibility
and cost-effectiveness of a remote monitoring model for a European,
multi-centre study.
Methods: 6,000 subjects in 130+ centres across 18 countries were re-
cruited to a low-risk observational study, in which a combination of
remote and on-site monitoring was performed.
The monitoring plan required verification of 100% informed consent
forms (ICFs), source data verification (SDV) of data for 20% of sub-
jects and an investigator site file (ISF) check.
1-2 on-site visits were performed in each country and monthly moni-
toring calls were conducted for all centres. Self-compliance checklists
were employed to verify the ICFs, SDV and ISF.
Data collected as part of monitoring compliance to the monitoring
plan in an 18 month period will be analysed to determine the rates
of errors identified at on-site visits compared to self-compliance
checklists. A cost-benefit analysis will also be undertaken.
Timing of potential results: The results will be available by October
2019.
Potential relevance: This analysis will determine if self-compliance
checklists are a reliable and cost-effective tool for remotely monitor-
ing compliance to the protocol, GCP and study procedures at investi-
gator sites.P-266
50% of the participants from 20% of the recruitment sites?
Seonaidh Cotton, Anne Duncan, Karen Innes, Gordon Fernie, Tracey
Davidson, Susanne Breeman
University Of Aberdeen, United Kingdom
Trials 2019, 20(Suppl 1):P-266
Background: The phrase “50% of participants from 20% of recruit-
ment sites; 80% of participants from 50% of recruitment sites” is
often quoted as a metric about recruitment of participants into ran-
domised controlled trials, but to our knowledge there is no empirical
evidence to confirm this.
Methods: Using a sample of 10 trials from our CTU, we investigated
the proportion of participants recruited from top recruiting sites. Our
sample included completed and ongoing trials.
Results: The number of recruitment sites in the 10 trials ranged from
20 to 121. The proportion of sites that recruited 50% of participants
ranged from 8% to 42% (median 22%). The proportion of sites that
recruited 80% of participants ranged from 33% to 71% (median
48%).
Discussion: For seven of the studies, the proportions of sites recruit-
ing 50% of participants ranged between 15% and 26%. There were
three studies where the proportions were outwith this range, all of
which included primary care sites. For eight of the studies, the pro-
portion of sites recruiting 80% of participants ranged between 40%
and 60%. The two studies where the proportions were outwith this
range were studies including primary care sites.
Our initial results suggests that the metric “50% of participants from
20% of recruitment sites and 80% of participants from 50% of re-
cruitment sites” may hold true for studies in secondary care, and we
aim to confirm this in a larger sample. Identifying the sites likely to
be the best recruiters remains a challenge; using our data we will in-
vestigate whether there are any common features of these sites, for
example whether they are sites where the Chief Investigator or other
grantholders are based.
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Collaborative CTU Monitoring Survey
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Introduction: This poster reports on a selection of results from a sur-
vey of UKCRC Registered Clinical Trials Units (CTUs) regarding their
current monitoring structure and practices.
Academic CTUs undertake a range of trial types, often specialising in
therapeutic areas. Trial monitoring is a key activity undertaken as
part of trial management to ensure data integrity and subject safety.
It was evident from discussions between CTUs that there was a re-
quirement to set up a collaborative forum to include all aspects of
monitoring, lessons learned and to share experiences.
Methods: As a starting point, an online survey was created using Sur-
vey Monkey to collect details on the current monitoring set-up for
each CTU, including novel approaches and areas of interest for future
collaboration.
The survey comprises sixteen questions and five main categories.
The categories include; Trial Portfolio and Trial Types; Sponsor; Moni-
toring Structure; Training and Monitoring Processes. Initially, the sur-
vey was distributed to UKCRC Registered Oncology CTUs that were
known to have a specific interest in monitoring. To date, survey re-
sponses have been received from twenty-nine CTUs. We now plan to
approach all the remaining UKCRC Registered CTUs to provide a
much broader indication of monitoring set-up and practices across
academic units.
Timing of Potential Results: The next wave of surveys will be distrib-
uted in May with results expected by the end of June. All results will
then be analysed and presented, a selection of which will be in-
cluded in the poster.
Potential Relevance & Impact: To our knowledge, there has not
been a survey conducted previously to look specifically at monitoring
and monitoring practices in academic CTUs and this will therefore be
the first time this information has been collected and reported.P-268
Challenges of conducting trials across multiple clinical specialities
Chris A Rogers, Sarah Baos, Lucy Culliford, Maria Pufulete, Ben Gibbison
University of Bristol, Bristol, United Kingdom
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Introduction: Clinical trials are expensive and take several years to
complete. Initiatives to improve efficiency and maximise generalis-
ability of findings are actively encouraged. We describe the chal-
lenges of conducting an RCT across multiple specialties.
Methods: The NIHR-funded GAP study (ISRCTN63614165), to evaluate
the effectiveness of gabapentin vs. placebo for pain management
after surgery is being conducted in three surgical specialties (cardiac,
thoracic and abdominal) in two hospitals.
Results: Surgical specialties are led by different clinical and research
nurse teams based in different locations/departments within the hos-
pitals. Despite this, regulations permit only one local PI for each hos-
pital. This has presented logistical challenges (e.g. number of site
files to have?) and has disincentivised clinicians in some specialties.
PI delegation of responsibilities (e.g. assessing eligibility/safety) to
colleagues in other specialties has had to be much higher than usual.
Training of non-GCP-trained clinical staff has been a major undertak-
ing, facilitated with targeted training materials covering key aspects
of GCP.
Designing study materials (e.g. information leaflets, data collection
forms) that include all necessary and appropriate information for dif-
ferent patient populations and recruitment pathways (e.g. cardiac
surgery vs. cancer surgery) required careful consideration.
Adaptable study coordination and monitoring procedures are neces-
sary; allowing for different ways of working across specialties (e.g.
greenlighting the site or specialty) and enabling identification of
trends at site and specialty level. The sponsor, whilst viewing eachhospital as a single site, has monitored speciality separately. The sys-
tem for capturing local research activity does not allow recruitment
to be easily attributed to different specialties, resulting in discrepan-
cies and frustration for local teams.
Discussion: The study design, involving three surgical specialties was
chosen to maximise the value of the research for the NHS. This study
highlights that while the design is methodologically attractive, the
current regulatory structures and NHS systems make implementation
sub-optimal.
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Risk of bias and implication for sample size of an urgent safety
measure requiring trial recruitment suspension
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Daniels3
1University of Birmingham Clinical Trials Unit, Birmingham, United
Kingdom; 2University of Edinburgh, MRC Centre for Reproductive Health,
Edinburgh, United Kingdom; 3University of Nottingham Clinical Trials
Unit, Nottingham, United Kingdom
Trials 2019, 20(Suppl 1):P-269
Introduction: UCON is an open-label randomised trial comparing uli-
pristal acetate (UPA) with the levonorgestrel-releasing intra-uterine
system (LNG-IUS) in women with heavy menstrual bleeding. In Febru-
ary 2018, the European Medicines Agency issued a drug alert for
UPA. An urgent safety measure (USM) was implemented, prompting
suspension of recruitment and UPA use.
We discuss the implications of the USM on the risk of bias and sam-
ple size.
Methods: Women take UPA for 12 weeks followed by 4 weeks off-
treatment, for 3 courses. The participant-reported primary outcome is
collected after the final off-treatment week. The USM allowed
women to complete a course, if they wanted, but not start a subse-
quent course. The original sample size was 172 with primary out-
come, 220 assuming ≃20% drop-out: 198 had been randomised
when recruitment was suspended. On resumption, the UPA group
could complete 3 courses, subject to monthly blood tests.
Results: Four populations are apparent, according to status at
suspension.
A:Completed trial prior to USM, no risk of bias (44 UPA; 45 LNG-IUS).
B:Complete after USM, possible risk of bias, due to knowledge of
USM (could impact either group) or decision to stop UPA (50 UPA,
completed or discontinued 3rd course; 48 LNG-IUS)
C:In course 1 or 2 when USM implemented, high risk of bias, as UPA
group could not complete 3 courses (6 UPA, 7 LNG-IUS).
D:Future participants. Theoretically no risk of bias, but UPA group will
have monthly blood tests.
We will exclude populations B and C, both UPA and LNG-IUS, from
the primary analysis, but include in a secondary analysis. 104 more
randomisations are needed (population D).
Discussion: Following a USM, risk of bias should be considered and
assumed to apply to both groups. Recruitment may need to be in-
creased to replace impacted participants, enabling a clean primary
analysis.
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Recruiting to time and target: experiences from the ERIC-PPCI trial
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Introduction: Recruiting sufficient patients to randomised trials is a
familiar challenge. In ERIC-PPCI the ability of remote ischaemic condi-
tioning to improve outcomes in heart attack patients was examined.
The intervention and urgent clinical care had to be given
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or were in pain, which reduced their capacity to consent. This pres-
entation will discuss the measures taken to ensure the challenging
research context did not affect the delivery of patient care or ability
of the trial to recruit.
Methods: Trial treatment was automated to reduce the burden for
the research staff and patients. A delayed consent with verbal assent
model was used to expedite patient randomisation and treatment.
Full consent was taken after the patient had received clinical care
and the allocated trial treatment. Successful recruitment and con-
senting strategies were shared among participating sites throughout
the trial.
Results: ERIC-PPCI completed recruitment of the initial target of 2000
patients 12 months ahead of schedule. This enabled the sample size
to be increased to account for a slightly lower than expected event
rate. The final recruitment total of 2800 patients was reached before
the original recruitment end date.
Discussion: Integrating research pathways with care pathways makes
recruitment easier for research staff and less disruptive for patients.
Flexibility in consent models allows trials to meet the needs of the
patients, clinical setting and research question. The ease with which
patients can be randomised and the intervention can be given are
key priorities in trial design.
Investment in well-designed trials could return savings as trials would
be more able to respond to challenges and deliver definitive answers
to the key research question without costly extensions or unneces-
sary repeated research.P-271
Engaging surgical trainees in Orthopaedic, NIHR Portfolio,
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Introduction: Recruitment to surgical trials is challenging and clin-
ician engagement plays a significant role in the success of a trial.
Complexities such as rare patient population, multiple speciality in-
volvement and the use of an investigational medicinal product in an
environment where surgery is the area of interest, all raise challenges
to engagement and recruitment.
The MANTIS trial (NIHR HTA 15/39/06), has adopted alternative
methods to improve recruitment, due to these complexities. In re-
cent years, regional ‘Research Collaboratives’ have formed to improve
trainee engagement in surgical research, a resource utilised in
MANTIS.
The aim of this project is to review the engagement/involvement of
surgical trainees in NIHR Portfolio, multicentre, randomised con-
trolled trials and how this can benefit both the research community
and the professional development of surgical trainees.
Methods: A questionnaire will be circulated to trainee ‘Research Col-
laboratives’ across the UK and identified trainees already engaged at
recruiting sites participating in the MANTIS trial. Domains will cover:
•Routes of engagement
•Level of involvement in ongoing/past trials
•Accreditation and incentives for participation
•Multi-disciplinary engagement
•Recruitment strategies
Timing of potential results: The deadline for responses to the ques-
tionnaire will be the end of August 2019. The results will be collated
and analysed in September 2019.
Potential Relevance and Impact
Involving surgical trainees in clinical research has the potential to
benefit the trial management team for multicentre randomisedcontrolled trials. It could also aid the professional development of
the trainees themselves and encourage the incorporation of research
into routine clinical care and training.
If surgical trainees are engaged sufficiently early in trial development,
their involvement could improve study set-up, recruitment and re-
tention in trials. Understanding current trainee involvement (when
and how they are involved) and how to improve engagement, has
great potential to positively impact on trials going forward.
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On-site monitoring of primary outcomes is important in primary
care clinical trials: Benefits of Aldosterone Receptor Antagonism in
Chronic Kidney Disease (BARACK-D) Trial a case study
Louise Jones, Emma Ogburn, Ly-Mee Yu, Nargis Begum, Aaron Long, F
D Richard Hobbs
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Background: To assess whether remote or on-site monitoring is a
more efficient way to verify outcomes in primary care clinical trials,
we conducted a case study in the BARACK-D trial. BARACK-D is a
PROBE (Prospective Randomised Open Blinded Endpoint) trial of the
licensed drug, spironolactone in patients with moderately severe
chronic kidney disease (CKD). Patients were randomised between
spironolactone 25mg daily plus routine care, versus routine care. The
primary outcome is change in rate of combined cardiovascular
events. As with many trials, the observed primary event rate in the
early phase of the trial was lower than expected. A risk-based ap-
proach to monitoring meant that all monitoring would be done
remotely.
Method: Trial recruitment commenced in November 2013, from
January – March 2018 on site monitoring visits were conducted to
verify primary endpoints reported by the general practices, which
generally have very busy competing clinical demands. To maximise
data verification, practices were monitored where >5 participants
were recruited, and participants had >1 years trial exposure from ran-
domisation. 50 practices were visited and data relating to 598 partici-
pants verified.
Results: Prior to the source data verification 42 primary endpoints
were reported from all 250 practices (3.8% of 1112 randomised), an
incidence rate of 3.2 per 100 person-years (95% CI, 2.4 to 4.4) against
the expected rate of 12. On-site monitoring identified an extra 73 pri-
mary endpoints, the primary outcome event rate for monitored prac-
tices rose to 10.01 per 100 person-years (95% CI, 8.10 to 12.38) which
is in the region of expected rate.
Conclusions: Our data suggest that extensive on-site monitoring of
primary outcomes is important to ascertain accurate reporting, for
clinical trials in a primary care setting. This is in contrast to recent
publications stating that triggered or risk-adaptive monitoring is an
efficient way to prioritise and reduce on-site monitoring.
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Introduction: It is increasingly common in clinical trials to collect a
lot of data about patients such as genomic, imaging, data from wear-
able technologies. There is the potential for this high-dimensional in-
formation to be informative for the efficacy of a new treatment in
the situations where only a subset of patients benefits from the treat-
ment. The adaptive signature design method allows a trial to de-
velop and test efficacy of treatment in a high-efficacy patient group
(the sensitive group) using genetic data. Patients are classified to be
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quires specification of a set of tuning parameters for identifying the
sensitive group. Selection of the tuning parameters is implemented
by a time-consuming nested cross-validation procedure.
Methods: We propose a variation to the adaptive signature design
method that does not require selection of the tuning parameters.
The method is based on polygenic risk scores that utilise weighed
contribution of the gene expression levels. The sensitive group is
found by applying a nonparametric clustering procedure to the poly-
genic risk scores. We have implemented the new method in an R
package.
Results: The performance of the new method is assessed for various
sample sizes and response rates. The new method has substantial re-
duction in computational time required. In many scenarios there is a
substantial improvement in the ability to correctly identify the sensi-
tive group and the overall power of the design.
Discussion: The new method for selecting a sensitive group of pa-
tients based on the polygenic risk scores shows a superior perform-
ance and drastically improves the computational time, in comparison
to the existing one. Further research will focus on extending the
method to incorporate different types of outcomes and a variety of
types of biomarkers.P-274
Sample size estimation for Randomised Controlled Trials with
repeated assessment of patient reported outcomes: what
correlation between baseline and follow up outcomes should we
assume?
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Introduction: Patient Reported Outcome Measures (PROMs) are now
frequently used in randomised controlled trials (RCTs) as primary
endpoints. RCTs are longitudinal and many have a baseline (PRE) as-
sessment of the outcome and one or more post-randomisation as-
sessments of outcome (POST). With such designs there are several
ways of estimating the sample size and analysing the outcome data:
1)Analysis of post-randomisation treatment means (POST)
2)Analysis of mean changes from pre to post-randomisation (CHAN
GE)
3)Analysis of covariance (ANCOVA)
Sample size estimation using the CHANGE and ANCOVA methods re-
quires specification of the correlation between the baseline and
follow-up measurements. Assuming a correlation of 0.70 between
baseline and follow-up outcomes in the ANCOVA method would
halve the sample size compared with using the POST method. There-
fore, if the correlation is overestimated the study results may be
under powered. So what correlation (between baseline and follow-
up outcomes) should be assumed and used in the sample size
calculation?
Aims: To estimate the correlations between baseline and follow-up
PROMs in RCTs.
Methods: The Pearson correlation coefficients between the baseline
and repeated PROMs (Barthel, EQ-5D, EORTC-QLC-C30, SPADI, SF-36,
WOMAC etc) assessments from 20 RCTs (with 7,173 participants at
baseline) were calculated and summarised.
Results: The 20 reviewed RCTs had baseline sample sizes ranging
from 49 to 2,659. The time-points for the post-randomisation follow-
up assessments ranged from 0.25 to 24 months. 464 correlations, be-
tween baseline and follow-up, were estimated; the mean correlation
was 0.50 (SD 0.15; median 0.51, range -0.13 to 0.91).
Conclusions: There is a general consistency in the correlations be-
tween the repeated PROMs, the majority being in the range 0.41 to
0.60. A correlation of 0.5 implies that we can reduce the sample size
in a RCT by 25% if we use an ANCOVA model for the design and
analysis.P-275
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Introduction: The SAFA (Spironolactone for Adult Female Acne) RCT
compares spironolactone with placebo (in addition to standard top-
ical care) for moderate-severe persistent facial acne in adult women.
Spironolactone is licensed in the UK for indications including hyper-
tension and heart failure, but not acne. Consequently, the SAFA trial
could be classed as a Type B CTIMP (testing authorised medicinal
products according to treatment regimens outside the marketing au-
thorisation; somewhat higher than the risk of standard medical care).
However, spironolactone has been used off-license for treating acne
in women for over 30 years and the safety profile is well known. The
MHRA actively promote a risk proportionate approach to CTIMPs,
allowing methods to be adapted while still maintaining applicable
standards.
Methods: Trial risks were assessed along with their mitigating strat-
egies. Main considerations were:
-Trial dose (50-100mg spironolactone/day) is considered a low dose.
-Trial population is a much younger population than would be taking
spironolactone within its licensed indication. Consequently, they are
likely to have healthier cardiovascular and renal systems and fewer
comorbidities. Blood serum potassium (to rule out hyperkalemia) and
kidney function (eGFR) are tested at baseline. Evidence shows later
testing is not needed.
-Concerns have been raised about teratogenicity of spironolactone,
but risk of harm to the foetus is not thought to be high and is likely
to be lower than for other oral treatments for acne. Women of child-
bearing potential at risk of pregnancy must have a negative urine or
serum pregnancy test at baseline.
Results: The MHRA accepted the risk assessment; the SAFA trial is
classed as a Type A CTIMP (comparable to the risk of standard med-
ical care).
Discussion: Assessing the IMP risk category and adapting the trial
design accordingly maintains safety standards and reduces partici-
pants’ burden of taking part in a clinical trial.P-276
Continuity of researchers collecting outcome data within
randomised controlled trials - any evidence of an impact on QoL
measures?
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Introduction: Capturing changes in health and wellbeing within ran-
domised controlled trials (RCT) can be complex. The precision and
accuracy of outcome tools to measure change is crucial and consid-
eration needs to be given to potential errors when collecting these
outcomes.
Many RCTs use multiple researchers to collect data, accepting that
this can introduce variation in measurement. This study aims to iden-
tify if there is a measurable effect of using different researchers to
collect repeated assessments of Quality of Life (QoL) at different
time-points.
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iniscence therapy on participants with dementia and carer (PwD-
carer) dyads, ‘REMCARE’, was used. Data were categorised into those
where the same researcher attended all assessments and those
where different researchers undertook assessments. ANCOVA models
used in the original REMCARE analysis with the addition of the ‘re-
searcher-consistency’ variable were run on two QoL outcomes to as-
sess the importance of this distinction.
Results: 330 PwD-carer dyads were included in the analysis. Statisti-
cally significant differences were found on researcher consistency at
initial follow-up for the PwD QoL outcomes and at second follow-up
for the proxy QoL outcome and the interaction between centre and
researcher consistency for the PwD.
Discussion: These exploratory results indicate the possibility of an
impact of researcher continuity on QoL outcomes within this dataset.
Further research is required to establish causality definitively. If dem-
onstrated this would have implications for planning future research
studies and consideration of how outcome measures should be
collected.P-277
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Introduction: The Core Outcome Measures in Effectiveness Trials
(COMET) Initiative maintains a public repository of core outcome sets
(COS). Originally populated through a systematic review, annual up-
dates keep it current. It is labour intensive and costly to keep this
up-to-date. A balance is needed between managing this workload
and identifying all eligible studies.
COS are now easily accessible and the Core Outcome Set-STAndards
for Development (COS-STAD) recommendations were established to
improve the methodological approach for developing COS, and help
users assess whether a COS has been developed using a reasonable
approach.
The fifth update of this systematic review aims to:
1.utilise automatic article ranking to assess suitability for assisting fu-
ture updates to the annual systematic review of COS,
2.to apply COS-STAD to included COS and describe current COS stan-
dards of development.
Methods: Searches were carried out to identify COS (January-Decem-
ber 2018). A machine learning model, using logistic regression, was
trained and evaluated, and subsequently used to rank records. Cut-
off for screening was determined by the results of the model evalu-
ation. Full texts of potentially relevant articles were assessed for in-
clusion. COS-STAD was applied to each included COS.
Results timing: We estimate that this model of automatic ranking
can decrease the number of references that needs to be screened by
75% while identifying approximately 98% of all relevant references.
Results expected July.
Potential Relevance & Impact: We anticipate these results will dem-
onstrate that automation can successfully assist the screening
process in the annual update of the SR of COS, making it a more effi-
cient process to keep the database current.
Research in the area of COS development is becoming more preva-
lent but is still quite new; we therefore expect few COS to meet all
minimum-standards. This assessment is intended as a baseline
against which future comparisons can be made.P-278
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Introduction: There is clear systematic review evidence that meas-
urement can affect people being measured. Changes in measured
behaviour and other outcomes due to this reactivity may introduce
bias in otherwise well-conducted randomised controlled trials. Re-
searchers from Manchester, Aberdeen, Cambridge, Oxford, London
and York developed the MEasurement Reactions In Trials (MERIT)
study which was commissioned by MRC/NIHR to produce guidance
on how to minimise bias due to measurement reactivity in studies of
interventions to improve health.
Methods: Rapid systematic reviews have been conducted to estab-
lish the evidence-base for the guidance; an international Delphi pro-
cedure has been conducted to combine the views of experts on the
required scope of the guidance, and a two-day expert workshop was
then held to develop the guidance content.
Results: Systematic reviews showed that asking questions has a small
but potentially important effect on measures of health-related behav-
iour. A rapid review of trials that investigated the effects of objective
measurement on behaviour reported limited evidence, which fo-
cused mostly on physical activity.
40 experts participated in the Delphi procedure, and 23 in the expert
workshop. These suggested that aspects of study design and ap-
praisal, and selection of measurement tools and procedures, were
important components to include in the guidance.
Discussion: The final MRC-NIHR guidance stresses the importance of
considering risk of bias from measurement reactivity and theorising
around potential measurement reactions during the early stages of
trial design. It provides tools for appraising risk of bias from measure-
ment reactivity, specific guidance on aspects of trial design that can
be altered to minimise such biases, as well as guidance on trial con-
duct and analysis.P-279
Statistical challenges in designing a randomised screening trial to
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example of a Multiphase Optimisation Strategy (MOST) design
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Introduction: Complex interventions are often defined as interven-
tions containing several potentially interacting components. While
this definition recognises, they have multiple components, typically
complex interventions are treated as black boxes, with randomised
evidence built up on whether one package works relative to others.
Updated MRC guidance on developing and evaluating complex inter-
ventions explicitly includes the possibility of empirical optimisation.
Collins has argued that, in order to do this, factorial trial designs can
be used to estimate the individual and combined effects of compo-
nents of a complex intervention. Fisher claimed that one benefit of a
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components to be evaluated under a variety of contexts.
Methods: Using a trial with a fractional factorial design that aims to
optimise the outputs of National Clinical Audits (ENACT), we will de-
scribe statistical challenges in designing a randomised screening trial
under the Multiphase Optimisation Strategy (MOST) championed by
Collins. We will outline the sample size calculation, the choice of
components to evaluate, the choice of combinations of components
to include in the design, the randomisation method and the statis-
tical analysis plan.
Timing of Potential Results: The trial is expected to be ready for
analysis in June 2019.
Potential Relevance & Impact: A potential barrier to the use of fac-
torial designs in empirically optimising complex interventions is the
recommendation that factorial designs are only used in clinical trials
if it is safe to assume that there will be no interactions or if the trial
is powered to detect realistic interactions. This view grew out of the
proposal to use factorial designs as a way of providing multiple an-
swers for the price of one. The impact has been that factorial trials
are largely avoided if interactions are plausible, a situation expected
where the factors are components of a complex interventionP-280
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Introduction: The correct use of random allocation in trials removes
the risk of selection bias by ensuring researchers cannot allocate pa-
tients with certain characteristics to a particular treatment group.
Randomisation will only remove the risk of selection bias if the allo-
cation schedule is concealed from the recruiting researcher. How-
ever, some allocation concealment methods are better than others.
We assessed whether there was evidence of a relationship between
concealment quality and internal validity.
Methods: We identified 352 eligible papers. We hand searched four
major medical journals for individually randomised controlled trials
published in the years 2017 and 2018. For each article, we extracted
summary statistics on age for each treatment group, and the p-value
corresponding to the primary analysis. We categorised articles ac-
cording to whether the allocation concealment was good (227;
64.5%), adequate (66; 18.8%), inadequate (48; 13.6%) or unclear (11;
3.1%). For each category we calculated the amount of heterogeneity
in the standardised age difference between treatment groups using
the I² statistic, and graphically displayed the distribution of p-values.
We compared parametrically the likelihood of studies that used inad-
equate concealment reporting a statistically significant result to stud-
ies that used good or adequate concealment.
Results: We found that trials that used inadequate concealment were
more likely to report statistically significant findings than trials that
used good or adequate methods (OR 1.95; 95% CI: 0.95 to 4.04; p=
0.07). We found that for good, adequate and inadequate trials the
value of I² was 0%, 1.0% and 31.1% respectively.
Conclusion: We have found a relationship between concealment
quality and the p-value of the primary outcome. Trials that use inad-
equate concealment are more likely to have statistically significant p-
values compared with trials using good or adequate methods, and
there is evidence that the imbalance in age in inadequate trials is
not due to chance alone.P-281
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Introduction: Random allocation to treatment groups is a key fea-
ture of clinical trial design, used to achieve balance between
treatment groups on baseline characteristics. Several different
randomisation techniques, such as simple randomisation, stratified
randomisation, and randomisation by minimisation have been de-
veloped and are used in a variety of trial scenarios; however, it is
not always clear what the optimal randomisation strategy is for a
given trial. The optimal randomisation strategy depends on the
planned sample size, and the number of key characteristics
(stratification factors) on which we wish to ensure suitable bal-
ance. The Wound Healing in Surgical Trauma (WHIST) trial (n =
1629) used randomisation by minimisation with three stratifica-
tion factors (open versus closed wound at presentation, Injury se-
verity score ≤15 versus ISS ≥ 16, and recruitment centre). The
optimal randomisation strategy in this trial is explored.
Methods: Anticipated baseline imbalance in the WHIST trial under
different randomisation scenarios (simple randomisation, stratified
randomisation, and randomisation by minimisation) was investigated.
Simulations were conducted to explore the optimal randomisation
strategy under a variety of different scenarios including varying num-
bers of stratification factors and overall sample sizes.
Results: In the WHIST trial, randomisation by minimisation led to in-
creased balance on minimisation factors compared with simple ran-
domisation; however, the benefit of this increased balance was small
compared to the added complexity of the randomisation system re-
quired. Stratified randomisation resulted in decreased balance com-
pared to simple randomisation.
Discussion: In some instances, more complex randomisation
schemes than needed are used. At other times inappropriate ran-
domisation schemes may lead to unacceptable imbalances in base-
line characteristics. Further guidance on this is needed.P-282
Covariate constrained block randomisation for a cluster
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Introduction: Cluster randomised controlled trials require randomisa-
tion at the level of the cluster as opposed to the level of the partici-
pant. As there are fewer units being randomised than in an
individually randomised trial the risk of baseline covariate imbalance
is high. Standard methods of stratified randomisation can be
employed but are limited to categorical covariates. In an ongoing
trial we used stratified covariate constrained randomisation in order
to accommodate continuous covariates.
Methods: Clusters were identified within catchment areas, 4-6 within
each. We required balance in the trial arms for characteristics of the
area’s service user populations hence the randomisation was
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two continuous cluster level covariates; surgery quality and
deprivation. The randomisation algorithm, adapted from the work of
Carter and Hood, balanced trial arms within and across catchment
areas for these two covariates.
Results: We randomised 28 clusters from 7 catchment areas (strata).
All clusters within a stratum were supplied as a set over the course
of the randomisation period. Every time the covariate information on
clusters of a stratum became available the algorithm worked out all
possible cluster assignments within the stratum and constructed a
balancing index based on the clusters that have been randomised so
far. An assignment is then chosen at random from the best perform-
ing allocations in terms of the balancing index to avoid the algorithm
becoming deterministic.
Discussion: There were several added complexities in using this ran-
domisation technique in terms of performing the allocations as it
was a bespoke algorithm executed by the statisticians. This method
does require all cluster information within a stratum to be provided
at once which could be a limitation. Outside of this the algorithm
allowed the flexibility that was required to balance on continuous co-
variates in a reliable way.
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Introduction: Placebo-controlled trials are rarely used to evaluate in-
vasive procedures. As well as ethical issues to address, there are
methodological challenges related to their conduct. Our systematic
review examined key methodological considerations for using an in-
vasive placebo intervention in a randomised controlled trial (RCT).
Methods: Any RCT comparing an invasive procedure with a placebo
was eligible for inclusion. Articles published up to 31st December
2017 were retrieved from Ovid MEDLINE, Ovid EMBASE and CENTRAL
electronic databases, hand searching references and expert
knowledge.
Data were extracted on trial characteristics and key methodological
areas - i) rationale for using invasive placebo interventions; ii) deliv-
ery of co-interventions in the placebo group; iii) intervention stand-
ardisation and fidelity, including offering the treatment intervention
to patients randomised to placebo; v) information provision; vi) mini-
misation of risk.
Results: Identified were 113 articles reporting 96 RCTs. Most trials
were conducted in gastrointestinal surgery (n=40, 42%) and evalu-
ated minimally-invasive procedures (n=44, 46%). Over two thirds ran-
domised fewer than 100 patients (n=65, 68%) and a third were
single centre (n=21, 22%).
Approximately a third (n=33, 34%) did not report any rationale for
using a placebo. Co-interventions were inconsistently reported, but
64 trials (67%) stated that anaesthesia was matched between groups.
Attempts to standardise interventions and monitor their delivery
were reported in few trials, (n=7, 7%) and (n=4, 4%) respectively.
Treatment interventions were offered to patients randomised toplacebo in 43 trials (45%). Provision of patient information regarding
placebo use was infrequently reported (n=11, 11%). Most common
strategies to minimise patient risk were operator skill (n=22, 23%)
and independent data monitoring (n=28, 29%).
Discussion: Most placebo-controlled trials evaluated minimally-
invasive procedures. Reporting of trial methodology was inconsistent.
Standardised guidance is needed for the design, delivery and report-
ing of this type of trial to generate high quality evidence to inform
clinical practice.
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Introduction: Discontinuity of care at the child and adult mental
health service boundary is present in many European countries.
Young people of transition age (typically 16-18) who need ongoing
mental health care may be poorly served by the gap between child
and adolescent (CAMHS) to adult mental health services (AMHS), left
without adequate care or support, at a time when they are undergo-
ing great stress and change (leaving home, for example). We there-
fore developed a complex intervention, “Managed Transition”, to
improve outcomes for young people at the child and adult mental
health service (transition) boundary and undertook a cluster rando-
mised controlled trial (cRCT) to assess the clinical and cost-
effectiveness of “Managed Transition” compared to standard care.
Methods: Randomisation was 2:1 (control:intervention) and the cRCT
was embedded within a longitudinal cohort study using a novel de-
sign. The primary outcome measure was the clinician reported Health
of the Nation Outcome Scale for Children and Adolescents (HoN-
OSCA) score at 15 months post-intervention. A range of secondary
outcomes, including health and health economic measures, were
also measured at 9 and 15 months post-intervention.
Results: A total of 793 young people from 40 CAMHS in 8 countries
were recruited into the trial; 241 to the intervention and 552 to the
control arm. Follow-up was completed in September 2018 and the
findings are already being used to inform policy and service develop-
ment in Europe.
Discussion: During MILESTONE we faced many challenges. Aside
from the usual barriers, recruitment, retention, compliance and so
on, we faced a multitude of methodological problems arising from
the novel trial design and unique clinical and geographical settings.
In this presentation we share our experience of MILESTONE, using
statistical and health-economic results, to illustrate what worked well
and what did not, and to make recommendations for the design of
future studies.
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Introduction: The UNBLOCS randomised controlled trial (RCT) com-
pared the current gold standard, transurethral resection (TURP), with
a new laser technique, thulium vaporesection (ThuVARP), for benign
prostate obstruction. The trial aimed to blind patients to their
Trials 2019, 20(Suppl 1):579 Page 84 of 141surgical allocation to avoid bias in patient-reported primary and sec-
ondary outcomes.
Methods: The RCT was conducted in seven hospitals. Patients were
randomised 1:1 to TURP or ThuVARP at the point of surgery, whilst
under anaesthetic, with patients blinded until completion of follow
up. Two co-primary outcomes were measured; a patient reported
symptom score and a clinical measure at 12-months post-surgery.
Secondary outcomes included quality of life and patient satisfaction.
Results: Patient blinding was considered successful. Only 40% of pa-
tients believed they knew which operation they had received, with
58% of those predicting ThuVARP and 72% of those predicting TURP
correct. However, of those who were correct, 76% guessed.
Discussion: Blinding was achieved primarily by randomising patients
whilst under anaesthetic and blinding ward staff, with additional
measures taken for patients under spinal anaesthetic. Successful
blinding allowed the collection of robust and unbiased patient-
reported outcomes. However, there were implications for trial con-
duct. All trial surgeons had to be able to conduct either procedure,
and theatres needed to be equipped and staffed for both proce-
dures, resulting in some delayed operations. The decision to list pa-
tients as daycase or inpatient had to be taken by sites regardless of
surgical arm. This could be considered a limitation, as conversion to
daycase was a potential key advantage of the laser, but most sites
were reluctant to plan to carry out TURP as a daycase. However, in
other respects it could be considered a strength, as sites could not
apply pre-conceived ideas on the suitability of each procedure for
daycase, and ultimately length of stay was then determined by the
patient’s recovery.
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Introduction: Triple negative breast cancer (TNBC) has a high risk of recur-
rence. Previous work has demonstrated that circulating tumour DNA (ctDNA)
detection in patients who have completed treatment for early BC is highly
predictive of future relapse (Garcia-Murillas et al.Sci.Transl.Med.2015). c-TRAK-
TN is the first study to assess whether ctDNA assays have clinical utility in
guiding further therapy in TNBC patients.
Methods: c-TRAK-TN is a phase II, multi-centre, randomised trial in
moderate-/high-risk early-stage TNBC patients, with no evidence of
distant metastases, who have completed standard therapy. If tissue
screening detects a trackable mutation, patients will undergo blinded
3-monthly ctDNA surveillance, with randomisation on a 2:1 ratio to
pembrolizumab or observation triggered by detection of minimal re-
sidual disease indicated by a ctDNA positive (ctDNA+) result by
12months. Patients and their treating team will only be unblinded to
the ctDNA+ result if randomised to pembrolizumab. As discussed
and agreed with patient representatives, keeping the treating team
and patient blind to ctDNA+ results aims to avoid unnecessary anx-
iety in otherwise asymptomatic patients and avoid pressures to re-
start treatment based on, as yet, an unproven test. Primary
endpoints are ctDNA+ detection by 12months and absence of de-
tectable ctDNA or recurrence at 12months after starting pembrolizu-
mab (chosen as a surrogate of treatment efficacy, anticipated to
correlate with long-term outcome).
Timing of potential results: Recruitment will end within the next
year with results expected in 2021.
Potential relevance and impact: c-TRAK-TN adds to a growing port-
folio of studies assessing ctDNA utility, and will assess whether
ctDNA surveillance can predict recurrence and guide treatment inTNBC patients, with potential to change clinical practice. Details of
the novel trial design and its rationale, including an unconventional
use of blinding and novel endpoints, will be presented with illustra-
tions of trial innovation and efficiencies. Clinical outcome data will
not be presented.P-287
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Introduction: In randomised controlled trials (RCTs), a factorial design
compares two (or more) interventions (A, B; designed to affect the
same or different mechanisms/endpoints) to control by randomising
to control, A-only, B-only or both. Although this often requires fewer
resources/participants than (e.g.) two 2-arm RCTs, investigators con-
sidering this design need to address several issues.
Methods: We surveyed journal articles published between 2000-2018
relating to designing factorial RCTs. Issues to consider were identified
based on these and the authors’ personal experience.
Results: Factorial RCTs are more desirable if: 1) Interventions can be
easily co-administered. 2) Potential for interaction (effect of A differ-
ing when B administered) is low. 3) Eligibility criteria for A and B are
similar. 4) Recruitment is feasible, e.g. no patient preference against
B. 5) Each intervention and toxicities associated with it is unlikely to
reduce either adherence to (and hence effectiveness of) the other
intervention or overall follow-up. 6) Risk of safety issues from co-
administration above individual risks of the separate interventions is
low: i.e. an AE due to one intervention is unlikely to result in stop-
ping the other intervention. Other considerations include: 7) Blinding:
two placebos (“double-dummy”) may be necessary; this could enable
discontinuing only one intervention for a specific participant. 8)
Methodological issues: scale of analysis and statistical model (e.g. for
binary endpoints, logistic regression estimates odds ratios and ab-
sence of interaction is required on the logit scale), necessity or not of
adjustment for multiplicity, sample size inflation if necessary. 9)
Funding availability. 10) Regulatory requirements.
Discussion: These issues should be considered, especially for the pri-
mary endpoint but also for secondary endpoints when designing fac-
torial RCTs. Factorial RCTs should also be considered as alternatives
to multi (>2)-arm RCTs, and as extensions to standard 2-arm RCTs,
particularly when there may be an opportunity to address additional
management questions.P-288
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Background: Malignant Mesothelioma (MM) is a cancer caused by
exposure to asbestos arising predominantly from the parietal
pleura or peritoneal lining and is associated with predominantly
contiguous growth. In the UK, 65,000 people are expected to die
between 2001 and 2050, making MM one of the few predicted
cancer epidemics. There have been no new approved treatments
for mesothelioma for over 12 years. Currently no standard option
Trials 2019, 20(Suppl 1):579 Page 85 of 141for relapsed mesothelioma exists, despite several non-randomised
phase II trials conducted over the last 3 decades.
Aim: To enable acceleration of novel, effective, personalised therapy
for improving disease outcomes for patients with MM utilising a plat-
form design.
Methods: MiST is a British Lung Foundation funded, multi-arm
stratified therapy clinical trial for relapsed MM patients. MiST
has three stages: Stage 1 (molecular pre-screeening) aims to
enrol 120 patients, Stage 2 (treatment) aims to recruit 26 pa-
tients per arm and Stage 3 is genomic profiling. Patients are in-
cluded in each arm based on their molecular screening as
follows: Patients negative for BRCA1 and/or BAP1 and/or prior
response to platinum therapy can be allocated to rucaparib
(MiST-1); P16 negative patients can be allocated to abemaciclib
(CDKN2A) (MiST-2); Patients with any histological subtype can
be allocated to receive bemcentinib and pembrolizumab (MiST-
3) and PDL1 positive or previously treated in arms 1-3 can be
allocated to atezolizumab and bevacizumab (MiST-4).
The primary outcome is disease control rate (DCR) at 12 weeks with
secondary outcomes including DCR and objective response rate
(ORR) at 24 weeks as assessed by modified RECIST 1.1 (mRECIST1.1).
Current progress: MiST began recruitment in February 2019 with 32
screened to date and 17 entered into MiST 1. MiST 2-4 are due to
open to recruitment in the next 3-6 months.P-289
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Introduction: It is unclear how multiple treatment comparisons are
managed in the analysis of multi-arm trials. We investigated strat-
egies for managing multiple testing related to primary outcomes in
multi-arm trials.
Methods: We investigated clinical trial protocols approved by ethics
committees in the United Kingdom, Switzerland, Germany, and
Canada in 2012 and their corresponding publications. We created a
decision tool to determine the need for multiple testing procedures
(MTPs) and compared the results of the decision tool to the analysis
plan in the protocols. Pre-specified analysis plans in trial protocols
were compared to those in corresponding publications.
Results: Sixty-four protocols for multi-arm trials were identified, of
which 50 involved multiple testing. Nine of 50 trials (18%) used a
single-step MTP and 17 (38%) used an ordered sequence of primary
comparisons to control the overall type I error. In the 9 trial protocols
that used a single-step MTP, 6 (67%) considered an adjustment in
their sample size calculation to maintain statistical power and pre-
vent type II error. Based on our decision tool, 45 of 50 protocols
(90%) required use of a MTP but only 28 of the 45 (62%) accounted
for multiplicity in their analysis or provided a rationale if no MTP was
used. The remaining 5 of 50 (10%) protocols did not require MTPs
based on our decision tool. There was little difference between in-
dustry and non-industry funded trials regarding the use of MTPs
when required (Risk Ratio 1.12, 95% CI 0.57-2.22). We identified 30
protocol-publication pairs, of which 20 planned a MTP in the proto-
col. Four of these 20 trials (20%) did not perform the MTP in the pub-
lication and provided no rationale.Discussion: Strategies to reduce type I and type II errors were incon-
sistently employed in multi-arm trials. Selective reporting of analyses
occurred in publications of multi-arm trials.P-290
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Introduction: We investigated the reporting quality of randomized clinical
trial (RCT) protocols approved by Swiss research ethics committees (RECs),
before the introduction of the Human Research Act in Switzerland in 2014
and the publication of the SPIRIT guidelines in 2013, and thereafter based
on the SPIRIT checklist. We determined trial characteristics associated with
non-adherence to SPIRIT items.
Methods: We included all RCT protocols approved by Swiss RECs in
2012 and 2016. For each protocol, we extracted information on gen-
eral trial characteristics and evaluated for each of the SPIRIT checklist
items whether the respective information was reported in the RCT
protocol. We calculated the adherence to SPIRIT in terms of the pro-
portion of reported SPIRIT items per protocol and the proportion of
trial protocols reporting individual SPIRIT items.
Results: We included 183 RCT protocols approved in 2012 and 217 in
2016. No difference was found in the median proportion of reported
SPIRIT items between protocols from 2012 (median 74%, interquartile
range [IQR], 64%-80%) and 2016 (median 76%, IQR, 69%-82%). Sig-
nificant improvement was found for non-industry-sponsored proto-
cols (interaction p-value <0.01); the median proportion increased
from 65% (IQR, 56%-74%) in 2012 to 76% (IQR, 66%-83%) in 2016,
while for industry-sponsored protocols median adherence remained
on a high level (79%, IQR 75%-82% in 2012, and 77%, IQR 72%-82%
in 2016). Improvement in adherence of non-industry-sponsored pro-
tocols was due to an improvement in 23 individual SPIRIT items im-
proving by 10% or more. The following RCT characteristics were
significantly and independently associated with lower adherence to
SPIRIT: single centre, no support from CTU or CRO, non-industry-
sponsoring, and approval in 2012.
Discussion: Industry-sponsored RCT protocols were more complete
according to SPIRIT than non-industry-sponsored protocols approved
in Switzerland in 2012, but non-industry protocols showed moderate
improvement when compared to 2016, while industry protocols
remained on a high level.P-291
Maximising participation via efficient electronic processes for data
capture and consent: the TYPPEX feasibility study (NIHR
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in settings with limited research capacity, or where large sample size
makes traditional consent processes unfeasible. As an example, we
present ongoing work from the TYPPEX programme (Tailoring
evidence-based psychological therapY for People with common men-
tal disorder including Psychotic EXperiences) in the NHS Improving
Access to Psychological Therapy (IAPT) service.
The TYPPEX feasibility study will test a trial design that incorporates
electronic health record extraction/linkage, paperless consent and
online follow-up to meet the challenge of obtaining outcome data
for around 1200 participants across 12 IAPT teams in the planned
cluster randomised controlled trial.
Methods: The intervention comprises a 3-day training package de-
signed to upskill IAPT CBT therapists. The primary outcome of the de-
finitive trial will compare reliable recovery between service users
treated by therapists before and after training.
Participating Trusts will upload clinical data on all eligible service
users to Norwich Clinical Trials Unit in a pseudonymised form (a link-
ing identifier having been encrypted using a one-way secure hash al-
gorithm), obviating the need for individual consent. In parallel,
TYPPEX-trained therapists will recruit service users to complete ques-
tionnaires for health economic analysis, obtaining informed consent
and baseline questionnaire responses on a tablet device which has
been set-up for secure, unsupervised use (e.g. in a waiting room).
Follow-up is via email questionnaires issued automatically at three
and six months after baseline.
To maximise the utility of the final dataset, the secure hash algorithm
will match questionnaire responses from consented participants with
their corresponding clinical record.
Timing of Potential Results: Results from the feasibility study in Decem-
ber 2019 will inform the design of the definitive RCT opening in 2020.
Potential Relevance & Impact: The TYPPEX study demonstrates effi-
cient electronic processes that could be adapted for future clinical
trials.
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Inclusive consent processes during a clinical trial of emergency
care: The Paramedic Acute Stroke Treatment Assessment (PASTA)
Trial
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Introduction: Involving all relevant patients in clinical trials of emer-
gency care is challenging especially when trials commence pre-
hospital and patients can lack capacity or early mortality is high. The
Paramedic Acute Stroke Treatment Assessment (PASTA) trial was a
multi-centre cluster randomised controlled trial which evaluated a
pre-hospital initiated enhanced care pathway designed to facilitate
access to emergency stroke treatment. The primary outcome was re-
ceipt of intravenous thrombolysis which must be administered within
4.5 hours of stroke onset at hospital. Novel approaches to consent
were designed and used due to the trial setting, because many
stroke patients lack capacity due to effects on neurological function,
and inpatient mortality is 15%.
Methods: The study design comprised consent after hospital arrival
and administration of urgent treatments. To locate eligible stroke pa-
tients conveyed by trial paramedics, a systematic identification
process consisting of a series of questions answered for all stroke ad-
missions using routine records, was developed. Questions included
admission mode, whether the conveying paramedic was study active,
stroke onset time. To offer enrolment to all eligible patients six con-
sent procedures were designed, selected according to clinical assess-
ment of neurological impairment affecting communication or
capacity, early mortality or discharge.
Results: The trial enrolled 1214 patients using the six consent proce-
dures: standard process for patients with capacity who were able to
communicate (n=525); ‘easy access’ materials for patients with cap-
acity but stroke related communication difficulties (n=24); use of apersonal (n=327) or a professional (n=95) consultee for patients lack-
ing capacity; an ‘early mortality’ principal investigator declaration for
patients who died before consent approach (n=206); and postal con-
sent added following an amendment for patients discharged before
consent approach (n=37).
Discussion: Novel consent approaches enabled enrolment of a rele-
vant study population for evaluation of an emergency pre-hospital
intervention. This format may be useful for other pre-hospital emer-
gency trials.
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Introduction: When performing a Bayesian sample size calculation
(using assurance) or Bayesian analysis we can use a subjective prior
distribution based on expert knowledge. If we have multiple experts,
we may want to elicit individual priors and combine them into a sin-
gle distribution using an aggregation technique, for example opinion
pooling or Bayesian aggregation. Alternatively, we may want to use
group elicitation to obtain a consensus between experts and there-
fore obtain a single group prior, for example via the Delphi Method
or the Sheffield Elicitation Framework (SHELF).
Methods: We have completed the process of eliciting prior distribu-
tions from medical experts both individually and in a group setting
to apply and compare mathematical and behavioural aggregation
methods during the planning of a clinical trial looking the early diag-
nosis of Motor Neurone Disease.
Results: The behavioural aggregation technique resulted in consistently
more overconfidence than the mathematical aggregation techniques.
Under two different proper scoring rules (Brier Score and log likelihood),
the rank ordering of the accuracy of the techniques reversed.
Discussion: When conducting a prior elicitation in order determine a
sample size for a clinical trial the method used must be chosen care-
fully as it could have a large effect on the final sample size.P-294
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Introduction: Cerebral Palsy (CP) is the most common childhood phys-
ical disability, resulting in musculoskeletal deformity. Children fre-
quently receive orthopaedic surgery to improve functional outcomes
and minimise decline. Despite increasing use, there is weak evidence
on the effectiveness of surgery in improving gait and function. The
need for research is not reflected in the appetite to fund this important
area. CP clinicians in the UK have tried for 10 years to develop a study
to provide quality evidence for current surgical practices.
Aim: To explore previous funding applications to inform a strategy
for future research on surgical interventions in CP patients.
Method: We reviewed feedback from previous funding applications;
collated and explored the main points.
Results: Previous applications have included: surgical RCTs compar-
ing new surgical techniques with standard practice; and a qualitative
study exploring patient and parent perspectives on surgical treat-
ment. Challenges identified include: the cost of a trial for a relatively
Trials 2019, 20(Suppl 1):579 Page 87 of 141small patient population; ethical concerns in introducing new treat-
ments to this patient population; length of follow up, and defining
the appropriate sample to include.
The review indicated a service evaluation was required: to collate the
incidence of surgical interventions was required.
Discussion: Well-designed surgical trials are necessary in the field of
CP so evidence is available to guide current and new practices. The
challenges in doing so are varied. Attempting to provide high level
evidence in the form of an RCT was not feasible. There was insuffi-
cient information about the standard of practices and patient path-
ways that exist in the NHS, and there was no clear primary outcome
to include. Moving back along the IDEAL Framework, the initial study
needed to be an information gathering exercise. From here, an ap-
propriate, pragmatic trial design can emerge, that is attractive to
funding bodies and study stakeholders.
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Introduction: Breastmilk substitutes are consumed by 90% of Euro-
pean infants, often at very high volumes per kilogram at a critical devel-
opmental stage. In BMS trials, regulators demand high-level BMS
exposure from the first weeks of life to prove safety and it is common
practice to provide free BMS to participants. This may conflict with sup-
porting the initiation and maintenance of breastfeeding. For example,
triallists may randomise during pregnancy or in the early postnatal
days, which risks incentivising women to use BMS. We developed spe-
cific methodological guidance through a Delphi consensus project to
guide the design, conduct, analysis and reporting of BMS trials.
Methods: We conducted three Delphi rounds and a consensus meet-
ing from January to October 2018 with experts in clinical trials, breast-
feeding support, infant feeding, critical appraisal and BMS regulation.
To inform responses to the third round, we systematically reviewed a
sample of BMS trials (PROSPERO CRD42018091928) and undertook a
BMS industry consultation. Following the consensus meeting, we con-
sulted BMS trial participants and a research ethics committee.
Results: An initial 73 criteria, derived from the literature, were sent to
23 experts affiliated with institutions across Europe, North America and
Australasia. Key themes discussed at the consensus meeting were re-
search integrity, study designs and their implications for supporting
breastfeeding, and definitions of interventions and endpoints. The final
guidance contains 57 criteria, including recommendations that ran-
domisation does not occur until a participant expresses an intention to
introduce BMS, and participants are offered skilled breastfeeding sup-
port from a trained breastfeeding counsellor at this stage. Guidance for
reimbursement of BMS was developed.
Discussion: This consensus-derived guidance for the design, conduct,
analysis and reporting of BMS trials aims to better protect BMS trial
participants and better inform the infant nutrition community about
the effectiveness and safety of BMS products.
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Trials 2019, 20(Suppl 1):P-296Introduction: HALT is a phase II/III trial assessing SBRT treatment of
oligoprogressive disease (OPD) in patients with mutation+ advanced
non-small cell lung cancer. OPD is a relatively newly described pat-
tern of progression and RECIST criteria cannot be used alone to iden-
tify patients with OPD suitable for SBRT. Consistent classification of
OPD and confirmation of lesion suitability for SBRT is central to the
interpretation and success of HALT. To achieve this the team have
developed a bespoke review process allowing remote, real-time, cen-
tral eligibility assessment.
Methods: The HALT virtual multidisciplinary team (vMDT) consisting
of clinicians, radiologists and trial team members, convenes remotely
on a weekly basis. Treating clinicians may also attend. Via collabor-
ation with the CRUK National Cancer Imaging Translational Acceler-
ator (NCITA) at ICR, registered patients have anonymised radiology
and clinical history uploaded centrally to a research PACS (XNAT
image repository), which is made available remotely via a web portal.
Case review by at least two oncologists and a radiologist located
across UK, Europe and Australia occurs remotely utilising widely
available commercial software. Entry criteria are scrutinised, and
feedback provided to the referring centre.
Results: Between 05/01/2018 and 30/04/2019 30 patients have undergone
vMDT review; 23 (76%) patients confirmed eligible, 7 (23%) confirmed ineli-
gible. Reasons identified include >3 progressing lesions identified by vMDT,
lesion suitability not confirmed, alternative treatment recommended. 22 pa-
tients have been randomised to date.
Conclusion and Potential Impact: Establishing the vMDT ensures
members of the trial and participating site teams develop expertise
in identifying OPD collectively and agree the technical SBRT ap-
proach per case. Such on-trial learning will be invaluable to the inter-
pretation of results and subsequent development of the proposed
international phase III trial. Details of the vMDT rationale, develop-
ment and process will be presented and the potential impact on
international guidelines and wider clinical practice discussed.
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Introduction: Doctors and patients require relevant and reliable com-
parative effectiveness data to support shared decision making. The
Evaluating Diuretics in Normal Care (EVIDENCE) study will compare
medicines using cluster randomisation of prescribing policy and
existing clinical prescribing mechanisms. Routinely collected NHS
data will be used to link prescribing to mortality and hospitalisations.
This pilot study explores the feasibility of applying this method in
Scottish NHS General Practices.
Methods: GP practices were invited to take part in the study. Ran-
domisation was applied at practice level to allocate a prescribing pol-
icy advising first-line choice when choosing a thiazide-type diuretic
for hypertension. Existing long-term prescriptions were switched,
where necessary, to comply with randomised policy by a study
pharmacist. Patients were informed by letter of the study taking
place and the potential for a prescription change with the option to
discuss with the study team and/or opt-out of the switch.
Results: 26 practices have been randomised in 4 NHS board areas
(mean list size 6297, range 1808-12778). 5920 patients with hyperten-
sion and taking either indapamide or bendroflumethiazide were
identified (mean 228 per practice (53-556). 43% of identified patients
were male, mean age 69.8 years. Bendroflumethiazide was taken by
79% of patients (63-94% per practice). 5130 patients were suitable
for a drug switch. The study generated 139 telephone contacts with
patients regarding potential medication switches; less than 3% of pa-
tients did not accept medication switching.
Discussion: There is a lack of comparative effectiveness evidence to
guide prescribing in the NHS. The EVIDENCE methodology harnesses
Trials 2019, 20(Suppl 1):579 Page 88 of 141the potential of existing NHS prescribing and data infrastructure to
compare commonly used medicines while addressing the limitations
of observational research. This pilot study has demonstrated that the
approach is feasible and cost-efficient with minimal disruption to
existing practice workflows.P-298
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Introduction: Multi-arm clinical trial designs provide an effective
means of evaluating several treatments. Given the large number of
treatments now available for testing in many disease areas, it has
been argued that their utilisation should increase. However, for any
given clinical trial there are numerous possible multi-arm designs
that could be used and choosing between them can be a difficult
task. This task is complicated further by a lack of available easy-to-
use software for designing multi-arm trials.
Methods: To aid the wider implementation of multi-arm clinical trial
designs, we have developed a web application for sample size calcu-
lation when designing a multi-arm trial. It is built using the Shiny
package in the R programming language.
Results: The application supports sample size calculation when using a
wide selection of popular multiple comparison corrections and can control
several varieties of power. In addition, optimised arm-wise allocation ratios
can be determined. It is free to access on any device with an internet
browser and requires no programming knowledge to use.
Conclusions: The application provides the core information required
by statisticians and clinicians to review the operating characteristics
of a chosen multi-arm clinical trial design. We hope that it will assist
with the future utilisation of such designs in practice.P-299
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Introduction: The Department of Health commissioned a randomised
controlled trial to determine whether routine testing of pregnant
women for group B Streptococcus reduces the incidence of neonatal
sepsis. A cluster-randomised trial was mandated. Use of routine data
was encouraged, enabling a no-consent trial model. An objective
was to identify key process factors that maximise the impact of test-
ing. Two tests are available: antenatal microbiology or intrapartum
molecular tests, both requiring a vaginal-rectal swab.
Methods: Population: all pregnant women intending vaginal
childbirth
Intervention: Microbiology or molecular test, with maternal antibiotics given
in labour to test positive women.
Comparator: Usual care, antibiotics given to women with clinical risk factors.
Sample size for neonatal sepsis outcome: 320,000 women, from 80
maternity units
Trial design: A prospective two-arm parallel cluster RCT, with a
second-level randomisation of the testing units: 20 using microbiol-
ogy test, 20 molecular test and 40 usual care. This will allow a direct
comparison of tests. Both tests are significantly different processes,
undertaken at different gestational ages; however, both are accurate
and direct effective prophylaxis. The second-level comparison will beunderpowered for the primary outcome but will be able to detect a
realistic difference in the proportion of missed testing opportunities.
Data source: Routine datasets will be merged to determine the primary
outcome and important maternal and neonatal outcomes. However, they
do not describe whether tests were performed, antibiotics given in suffi-
cient time to be effective nor whether a woman declines the swab. A ver-
tical audit of 100 women per testing unit will collect this data.
Discussion: Trials requiring massive sample sizes can be resource in-
tensive to collect prospective data whilst routine data sources can be
more efficient, yet limited in the outcome data available. Supple-
menting routine data through a vertical audit in a subset of the sam-
ple can answer secondary objectives.
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Introduction: Randomised trials in emergency medicine are challen-
ging but vital for improving patient care. Obtaining informed con-
sent in such an environment is a particular issue and can be
controversial. The ARREST trial is assessing whether out-of-hospital
cardiac arrest patients without an obvious cause should be taken to
a specialist heart centre or the closest emergency department. This
patient group presents specific difficulties: patients lack capacity to
consent, presentation is unpredictable, care must not be delayed,
and mortality rates can be >50%.
Methods: During the set-up of ARREST we accessed the following sources
of information: 1) ARREST research team; 2) cardiovascular patient groups;
3) researchers running similar trials; 4) regulatory bodies; and, 5) published
literature on research in emergency contexts.
The information that we collected guided the design of the trial with
a focus on patient consent, documentation and follow-up.
Results: The ARREST trial uses deferred consent with remote online ran-
domisation to enrol patients without delaying care. To minimise the risk of
bias, baseline and primary endpoint data are collected on patients who die
or are discharged prior to consent. Remote follow-up using health records
reduces the burden on the patients and researchers.
Full ethical approval was received in January 2018 and the first pa-
tient was enrolled in February 2018. ARREST is recruiting to target
and is on track to finish within the projected timelines.
Discussion: Deferred consent has been key to the success of ARREST
and patients have been receptive. However, further qualitative re-
search into the experience of patients in emergency medicine trials
using deferred consent is needed to better understand when it is an
appropriate model.
There is a shortfall in high-quality research in challenging environments from
cardiac arrest care to humanitarian crisis response. Innovation in consent
methods would facilitate research and benefit patient care.
P-301
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medicines: regulatory requirements, choice of preparation, dose and
control. There is no guidance on conducting clinical trials involving
herbal products in the UK’s National Health Service, so the regulatory
requirement for each trial needs to be determined individually.
Methods : Two randomised controlled trials looking at the use of
herbal products to give symptom relief in acute infections to reduce
antibiotic use were conducted in the UK primary care setting: ATA-
FUTI (a full-scale trial of Arctostaphylos uva-ursi for acute urine infec-
tions) and HATRIC (a feasibility trial of Pelargonium sidoides for acute
bronchitis). The trial team met with Pharmaceutical Assessors from
the Clinical Trials Unit at the MHRA (Medicines and Healthcare prod-
ucts Regulatory Agency) to determine whether the herbal product
was considered a medicinal product and what documentation would
be required. Dosage was determined from a literature review. The
preparations were chosen according to availability on the market.
Results: The regulatory requirements and lessons from the trials will
be discussed. In ATAFUTI the herbal product had a marketing author-
isation in an EU member state, but was used in a different formula-
tion, and was manufactured and packaged specifically for the trial
within the UK. The placebo used was sugar beet fibre in capsules.
The herbal product used in HATRIC had been granted a Traditional
Herbal Registration certificate by the MHRA. The trial medication (ac-
tive and placebo) was supplied by the company which manufactures
and markets the herbal product in Germany. The feasibility study
was very useful in informing choice of presentation of the herbal
product for a main trial.
Discussion: Designing trials of herbal products is challenging. A deci-
sion algorithm is needed to inform the regulatory requirements for
future herbal trials. Feasibility studies help to inform the design of
larger trials.
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Introduction: Cluster randomised controlled trials are frequently used
in health services research and they are generally more difficult to
design and conduct than individually randomised studies. Puffer et al
(2003) reviewed cluster trials published between 1997-2002 and
found that 40% showed signs of bias: mainly through recruitment
bias. In a more recent, smaller review, of trials in 2008 Brierley et al
found a continuing problem of bias. Similarly, Bolzern and colleagues
(2018) noted there was evidence of a continuing problem with selec-
tion bias in cluster trials. In this review we aim to replicate the study
by Puffer and colleagues to see if more recently published cluster
randomised trials have improved their methodology. Furthermore,
we will examine statistical evidence for bias using baseline testing of
age as well as other indicators of bias.
Methods – We have searched the BMJ, Lancet, Journal of the Ameri-
can Medical Association and The New England Journal of Medicine
for cluster randomised controlled trials published between
01.01.2014 and 31.12.2018. At least two researchers have performed
study selection and data extraction independently. We will undertake
a qualitative and quantitative assessment of the likelihood of poten-
tial bias in the study samples. In preliminary results we have found
continuing evidence of bias in cluster trials.
Timing of Potential Results – We will present the full results of our
findings by September 2019.
Potential Relevance & Impact – We will compare our findings with
previously conducted studies related to bias in cluster randomised
trials, in order to identify how approaches to reducing the chance of
bias have changed over time, if at all. Our aim is that this review will
give an insightful update on current practices by summarising how
cluster randomised controlled trials are conducted and reported in
four major journals.P-304
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Introduction: Pilot and feasibility studies are necessary to answer
whether a definitive trial can be performed in a clinical area. They
are particularly beneficial in research naïve specialties, where there
are more areas of uncertainty. These studies act as important deci-
sion points for whether or not a definitive trial is practicable. One ex-
ample of this is the INDICATE study, which showed a definitive trial
was not possible.
Methods: A pilot study was undertaken to assess whether a rando-
mised trial comparing surgical decompression with a single steroid
injection in patients with moderate Carpal Tunnel Syndrome (CTS)
was possible in the NHS.
Results: The study gave evidence that it was possible to recruit and
retain participants, but not at sufficient levels to achieve a successful
definitive trial. Two of the five identified sites recruited participants
and an extension of four months was needed to complete
recruitment.
The clinical pathway exposed several significant barriers to recruit-
ment. There was a high cost of recruiting through primary care, and
Clinical Commissioning Groups were unwilling to fund one arm of
the trial. The patient pathway was varied, making it difficult to iden-
tify the study population. There was also a lack of interest within the
surgical community.
Conclusion: The results of INDICATE show patients, surgeons and
funders need to be engaged to ensure appropriate treatment arms
will be accepted, performed and paid for. INDICATE also demon-
strated the need for NHS pathways to identify patients in a way that
is conducive to research.
These lessons have impacted the design of subsequent pilot studies.
Large structural changes are not as easily circumnavigated, and
therefore unsuccessful pilots should be noted by those who aim to
make clinical care amenable to research.
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Introduction: The care home can be a challenging environment in
which to undertake multi-centre research with respect to capacity,
consultee availability, staff turnover, varying approaches to record
keeping and archiving. We report strategies used to maximise re-
cruitment and data collection in the Falls in Care Home (FINCH), a
cluster randomised controlled trial evaluating a falls prevention inter-
vention in older age care homes (CH).
Methods: Potential difficulties and risks to recruitment and data
availability were evaluated with respect to eligibility, consent, out-
come data availability within the CH and national datasets, and site
resources. Learnings from the FiCH feasibility study*, TMG, PPI and
CRN researcher feedback were considered when drafting the proto-
col, CH Manager, Resident and Consultee information sheets and
consent forms, Case Record Form and database design.
Results: Pragmatic strategies implemented included: all care home
residents were eligible except those at end of life, proxy (CH
staff) reported EQ-5D-5L and DEMQOL-P-4D for all residents irre-
spective of capacity, 3-monthly data collection by RAs; not using
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sode statistics.
Ten sites were opened. 87 CH and 1698 residents were recruited. Per
CH, an average of 20 (53%) residents (min 8 (9%) and max 65 (71%))
were recruited. For the primary outcome (falls), 100% data complete-
ness was achieved for residents who were living in the CH at time of
data collection. For the 633 residents who died or moved out of the
CH since the last data collection, falls records were accessible for 379
(59%). Imputation will be used to model missing data. Rapid archival
of resident notes was the primary reason for lack of data availability.
Discussion: Pragmatic recruitment and data collection strategies are
necessary for care home studies. Rapid archiving of paper-based resi-
dent records should be considered when designing care home
studies.
*Clin Rehabil. 2016 Oct;30(10):972-983P-306
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Introduction: Dapagliflozin is effective in managing blood glucose and
reducing weight, without risk of hypoglycaemic events, in the treat-
ment of type 2 diabetes. It is FDA/EMA approved and recommended
by NICE as a combination therapy in standard clinical practice. Whilst
dapagliflozin’s efficacy and safety have been demonstrated, traditional
trials may not fully reflect use in clinical practice or effectiveness in typ-
ical treated patient populations. DECIDE is a pragmatic trial investigat-
ing the real-world efficacy of dapagliflozin.
Methods: DECIDE utilises real-world research data and services pro-
vided by the Clinical Practice Research Datalink (CPRD), which rou-
tinely collects de-identified patient data from a network of 1,400 GP
practices across the UK. Potentially eligible patients are located by
searching the CPRD database using broad criteria. Pre-screened pa-
tient lists are sent to GP investigators for eligibility checks and subse-
quent recruitment. Following informed consent, patients are
randomised to dapagliflozin or standard of care. Electronic health re-
cords are mapped directly into the trial database, enabling combin-
ation with investigator eCRFs and patient reported outcomes.
DECIDE will enrol 872 patients and follow them for 2 years. The pri-
mary outcome is the proportion of patients achieving clinical success,
measured by a composite endpoint at 52 weeks including (1) HbA1c
reduction ≥0.5%, (2) weight loss ≥2kg, (3) no reported severe or doc-
umented hypoglycaemic events, and (4) no switching from, or add-
ing to, the treatment to which the patient was randomised.
Timing of Potential Results: The estimated study completion date is
31/12/2021.
Potential Relevance and Impact: DECIDE will demonstrate the effi-
cacy of dapagliflozin amongst real-world patients and clinical prac-
tice, potentially informing treatment guidelines. The first of its kind,
DECIDE will also confirm the efficiencies of using CPRD data and ser-
vices to inform protocol design, access a large pool of patients, tar-
get site selection, and reduce the burden and costs of producing
real-world evidence.P-307
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Introduction: Achieving high participation and retention of partici-
pants in RCTs has traditionally been difficult, and this can limit the in-
ternal and external validity of a study.
Testing of strategies to improve recruitment and retention of partici-
pants is therefore important. Rigorous testing can be completed by
nesting or embedding recruitment and retention randomised studies
within ongoing trials.
Methods: To enable testing of recruitment and retention strategies, the
PROMoting THE Use of SWATS (PROMETHEUS) programme, has been
funded by the Medical Research Council (MRC). The PROMETHEUS
programme aims to support 25 or more SWATs over the lifetime of the
study, to increase the routine embedding of SWATs, and so build the evi-
dence base in relation to participant recruitment and retention in trials.
Results: In delivering the PROMETHEUS programme, difficulties and
challenges specific to the approval, implementation and publication
of SWATs have been identified. These include: applying for and
obtaining relevant approvals and sponsorship; concerns about the
content or format of the recruitment and retention strategies; poten-
tial for contamination, resentful demoralisation or impact on other
planned trial activities; implementation of strategies; and reporting
detail requested in publications. These concerns have arisen across
the spectrum of research stakeholders including but not limited to
host trials, Research Ethics Committees, sponsors, and journal editors.
This presentation will outline the complexities related to the delivery
of recruitment and retention SWATs, and will offer possible solutions
to these problems.PS1A
- O2 Same intervention, different opinions: some challenges of
doing Study Within A Trial (SWAT) replication studies
Anne Duncan1, Kirsteen Goodman2, Suzanne Hagan2, Shaun Treweek1
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Introduction: Studies Within A Trial (SWATs) provide evidence to
support trial process decisions. We will use the example of replicat-
ing the same SWAT intervention in three different trials to illustrate
some challenges (expected and unexpected) in doing SWATs.
Methods: A theoretically informed cover letter (SWAT24) was found
to improve response rates to postal questionnaires in the IQuaD den-
tal trial by 6%. We aimed to see if the benefits of SWAT24 were repli-
cated in other trials.
The INTERVAL (dental), AMBER (MS) and OPAL (urinary incontinence)
trials replicated SWAT24, randomising participants to receive either
the theoretically informed cover letter or standard cover letter with
their follow-up questionnaires. Each trial was required to gain ethical
approval, as well as buy-in from local PIs.
Results: Approval was given for all three trials. However, review of
the same SWAT intervention led to different requirements from eth-
ical committees to gain approval. For OPAL, the committee thought
the language coercive and requested changes. There were similar
concerns from the committee handling AMBER and a local PI
thought the letter would undermine relationships with participants
and did not take part. The committee handling approvals for INTER-
VAL thought the language aggressive. Minor changes were made to
text for OPAL, AMBER and INTERVAL. To our knowledge, none of the
1432 participants receiving the SWAT24 letter in IQuaD, INTERVAL,
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crease in response rate of 4% (95% CI=0% to 8%) in favour of the
theory-informed letter.
Discussion: Replication is key to SWATs. For replication evaluations of a
SWAT, it would be efficient for committees and others to have sight of pre-
vious ethical judgements, as well as information on response from previous
participants. Trial Forge is working with the Health Research Authority on
streamlining the approvals process for SWATs in the UK.
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Introduction: Failure to collect outcome data in randomised trials is
inefficient and can result in bias and loss of statistical power. Further
evaluations of strategies to increase retention are required. We
assessed the effectiveness of two strategies for retention in a rando-
mised prevention trial using a two-by-two factorial randomised study
within a trial (SWAT [SWAT Repository ID 25]).
Methods: Parents of babies included in the host trial were rando-
mised to (1) SMS notification prior to sending questionnaires at 3, 6,
12 and 18 months versus no SMS notification and (2) £10 voucher
sent with the invitation letter for the primary follow up visit at 24
months or given at/after the visit. The two co-primary outcomes
were (1) collection of questionnaire data at interim follow-up times
and (2) collection of host trial primary outcome at 24 months during
a home/clinic visit with a research nurse.
Results: Between November 2014 and November 2016, 1394 partici-
pants were randomised: 350 to no SMS + voucher at/after visit, 345
to SMS + voucher at/after visit, 352 to no SMS + voucher before visit
and 347 to SMS + voucher before visit. Overall 75% of questionnaires
were completed in both the group allocated to the prior SMS notifi-
cation and the group allocated to no SMS notification (odds ratio
(OR) SMS v. none 1.02, 95% CI 0.83 to 1.25). Host trial primary out-
come data was collected at a visit for 566 (81%) whose parents were
allocated to receive the voucher at/after the visit and for 557 (80%)
allocated to voucher before the visit (OR before v. after 0.89, 95% CI
0.69 to 1.17).
Discussion: There was no evidence for either strategy increasing re-
tention. The Trial Forge PRIORITY 2 project is currently working to
identify the top ten unanswered questions for trial retention to pri-
oritise for future SWATs.
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Introduction: To evaluate whether text messages sent as pre-
notification or post-notification reminders improve questionnaire re-
sponse rates. This study was embedded in the UK FROST trial of
treatments for frozen shoulder in a hospital setting.
Methods: Participants were randomised at the three-month follow-
up to either text messages: pre-notification on the day of the ques-
tionnaire mail-out; or post-notification four days following question-
naire mail-out. The primary outcome was the proportion of
participants who returned a valid questionnaire. The secondaryoutcomes were time to questionnaire return and proportion of par-
ticipants requiring at least one return reminder. No formal power cal-
culation was conducted. Electronic searches of multiple databases
were undertaken to identify other similar embedded trials to perform
a meta-analyses.
Results: Of 269 embedded trial participants, 122/135 (90.4%)
returned a valid questionnaire at three months follow-up in the pre-
notification arm and 119/134 (88.8%) in the post-notification arm
(difference of -1.6%; 95% CI of difference: -8.9%, 5.7%). There was no
statistically significant difference between groups in the rate of re-
turn (chi squared test: p=0.67; adjusted regression: OR 0.93; 95% CI:
0.41, 2.08; p=0.85), time to return (median of 13 days and 14 days for
pre- and post-notification, log-rank p=0.93) or requirement of a re-
minder (47.4% and 41.0% for pre- and post-notification, p=0.29).
From the electronic searches, one embedded trial of timing of text
message reminders in patients with depression in primary care was
eligible for pooling with our embedded trial. The unadjusted pooled
odds ratio from a random effects model for response rate was 1.28
in favour of post-notification (95% CI: 0.69, 2.37; P=0.44).
Discussion: Text messaging is a simple and inexpensive strategy to
improve response rates. There was, however, no evidence from this
study of different timing of text message reminders being more ef-
fective. This is possibly due to the already high response rates.PS1A
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Introduction: One of the top three research priorities for the UK clin-
ical trial community is to address the gap in evidence-based ap-
proaches to improving participant retention to clinical trials. Despite
this, there is little evidence supporting methods to improve reten-
tion. This presentation outlines the PRioRiTy II project, a Priority Set-
ting Partnership (PSP) that identified unanswered questions and
uncertainties around trial retention and then prioritised those in col-
laboration with key stakeholders.
Methods: There were three stages: (i) an online survey consisting of
six open ended questions eliciting any questions or comments re-
spondents had about retention to clinical trials. (ii) A second online
survey where stakeholders were invited to select the questions from
the longlist they felt needed to be answered. (iii) A face-to-face con-
sensus workshop, where key stakeholder representatives finalised an
ordered priority list of unanswered research questions for methods
of retention to clinical trials.
The research project had a strong and effective patient & public in-
volvement throughout the piece.
Results: 456 respondents yielded 2,431 answers to six open ended
questions, from which 372 verbatim questions were identified. This
allowed us, through our analysis and by merging questions in con-
sultation with the steering group, to create a list of 27 questions. The
top 21 questions from the second online survey were brought for-
ward to a face-to-face consensus meeting, in which key stakeholder
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tention, which will be highlighted during this presentation.
Conclusion: The Top 10 priority list of unanswered questions about
trial retention forms an agenda for trial methods research. It can be
used by funders and researchers to ensure that focus is given to the
areas of most importance in improving retention in trials.PS1B
- O1 Nature and impact of time-to-treatment measurement error
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Background: In trials of interventions for patients at very high risk of
haemorrhaging, delays in treatment result in reduction in the effect-
iveness of the intervention. However, estimates of time to treatment
often rely on clinician assessment, which is subject to mismeasure-
ment and which may result in bias in the estimate of treatment ef-
fect (due to the interaction between delay and treatment effect). In
such situations source data verification (SDV) of the time to treat-
ment is undertaken for a sample of the trial participants. Motivated
by a large international trial involving trauma patients (CRASH-3), this
work aims to demonstrate the potential for bias due to mismeasured
covariates; available approaches for addressing mismeasurement
using SDV are discussed and the choices and assumptions necessary
for different methods are clarified.
Methods: Through simulations and analysis of the CRASH-3 trial we
describe existing statistical approaches to modelling the relationship
between outcomes, clinician reported time to treatment and SDV
time; these include regression calibration, multiple imputation for
missing data and full Bayesian analysis. Specific issues to be ad-
dressed are sampling of patients for SDV, whether there is a gold
standard measurement or not, whether the observed data is both
biased and mismeasured and the (potentially) skewed distribution of
observed times.
Timing of potential results: Patient recruitment is complete for the
CRASH-3 trial. Our analytic work is ongoing and will be completed
during summer 2019.
Potential relevance and impact: Source verification of data is expen-
sive and time consuming, especially in large multi-centre trials. The
impact of correcting for error in clinician reported time will provide
more accurate estimates of treatment effectiveness to policymakers
and clinicians and can be used to determine the amount of SDV
required.
PS1B
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Introduction: Long trial duration, composite endpoints, and complex
interventions, are all reasons for clinical trials to anticipate time-
varying effects of treatment. The exact nature of the time-
dependence of a treatment effect may be hard to anticipate at the
design stage of a trial, for example a lag to effect may be expected
but the timing of that lag may be unclear. Various analysis ap-
proaches may be pre-specified in trial protocols in this instance such
as persevering with a Cox proportional hazards model to estimate a
single overall hazard ratio, employing an accelerated failure time
model to estimate an acceleration factor, or undertaking a compari-
son of restricted mean survival time based on a parametric Royston-
Parmar model.Methods: We undertook simulation studies to quantify the extent to
which standard approaches may provide misleading insights to the
effect of treatment under different scenarios of time-dependency in
the form of a simple piecewise lag to effect. We examined the sensi-
tivity of results to the shape of the underlying hazard.
Results: We found that the timing of when events occur affects the
degree to which the methods of analysis were misleading, i.e. that
the shape of the underlying hazard function in the control group is
influential. The longer the lag to effect, the more influential was the
shape of the hazard in determining the relative merits of the differ-
ent analytical approaches that were considered.
Discussion: These results highlight the complexity of designing trials
and selecting analytical methods for pre-specification if time-
dependent effects of treatment are to be anticipated but it is not
clear exactly what form that dependency will take.PS1B
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Introduction: Randomised controlled trials are considered the ‘gold
standard’ for the evaluation of new and existing medicinal products.
Consequently, the methods to analyse and report efficacy outcomes
are well developed. This progress has not been matched for safety
data. In recent work we found that trials typically rely on simple tab-
ulations of frequencies and percentages. We aimed to identify
whether there are statistical methods available that were specifically
designed to analyse safety outcomes in trials.
Methods: We undertook a scoping review to identify such methods,
systematically searching Medline and EMBASE via OVID and Web of
Science and SCOPUS databases. Original methods or the original ap-
plication of existing methods for the analysis of AEs were included if
they incorporated a concurrent comparator group, were suitable for
parallel group trials and had undergone peer-review. A taxonomy of
methods was developed. Several of these methods were then ap-
plied and evaluated in simulated trial data.
Results: The search identified 10785 articles of which 44 were eli-
gible. Methods were grouped into those for safety outcomes that
were pre-specified in the protocol (n=9) or for safety outcomes that
emerge during the study (n=35). Methods were then further cate-
gorised as: visual summary (n=8), hypothesis test (n=11), decision-
making probability under a Bayesian framework (n=10), or estimation
technique (n=15).
Application of two of the Bayesian methods, the Gamma-Poisson
and Beta-Binomial models, in simulated datasets has shown ad-
equate power to detect signals when sample sizes exceed 400 per
group, regardless of the time of events when using non-informative
priors.
Discussion: There are many subjective and quantitative signal detec-
tion approaches available to analyse pre-specified and emerging
safety outcomes. Our review of trials published in journal articles has
previously demonstrated that these methods are not used. The rea-
sons for this are unclear and performance measures and barriers to
implementation are being explored.
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through the use of responder-based endpoints. These classify pa-
tients based on whether they meet a number of criteria; some of
these criteria are whether or not continuous variables take values
above or below a threshold. Traditional analyses estimate the propor-
tion of patients who are responders and test for differences between
arms.
An alternative method called the augmented binary method utilises
information contained within the continuous component(s) to in-
crease the power considerably (equivalent to increasing the sample
size by >30%). This method has been proposed in several methodo-
logical papers as being useful in solid-tumour oncology and rheuma-
toid arthritis. However, it could be potentially useful in a much wider
variety of disorders.
In this talk we aim to summarise the method and provide results from
a review identifying new clinical conditions where it could be used
Methods: We reviewed a database from the COMET initiative of
physiological and mortality trial endpoints recommended for collec-
tion in clinical trials of different disorders. We identified responder-
based endpoints where the augmented binary method would be
useful for increasing power.
Results: We identified 68 new clinical areas where endpoints were
used that would be more efficiently analysed using the augmented
binary method.
Discussion: The augmented binary method can potentially provide
large benefits in a vast array of clinical areas. Further methodological
development is needed to account for some types of endpoint.PS1B
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Introduction: The Hawthorne effect is a non-specific treatment effect:
an alteration in behaviour resulting from observation /assessment, lead-
ing to an overestimate of intervention effectiveness. If this effect is un-
balanced across trial arms, treatment estimates may be biased.
ASPIRE is a NIHR-funded programme evaluating interventions to pro-
mote adherence to quality indicators in general practice (GP). Imple-
mentation packages were evaluated using electronic health records in
two parallel cluster-randomised controlled trials in West Yorkshire GPs.
Methods: Balanced incomplete block designs, were chosen to equal-
ise Hawthorne effects whilst maximising power and efficiency. Trial 1
examined the effect of an intervention on adherence to diabetes
control and risky prescribing whilst Trial 2 examined blood pressure
control and anticoagulation in atrial fibrillation. Within trials, GPs ran-
domised to the intervention for one indicator, acted as control prac-
tices for the other intervention and vice versa.
A non-intervention control group was included to allow exploration
of Hawthorne effects: GPs randomised to this group received none
of the adapted interventions.
If a Hawthorne effect is present, the non-random aspect of differ-
ences in intervention effects is attributed to the fact that GPs were
aware of being observed and is not attributable to the intervention.
We expect the intervention effect in the primary analysis will be
smaller than in the secondary analysis utilising the non-intervention
control practices.
Results: ASPIRE randomised 178 GPs using opt-out recruitment; trial
1=80; trial 2=64; non-intervention control=34. The intervention re-
duced risky prescribing (OR=0.82, 97.5% CI (0.67–0.99)) but had no
statistically significant effect on other primary endpoints. Secondaryanalysis showed evidence of a Hawthorne effect; OR=0.76, 97.5% CI
(0.63-0.92).
Discussion: Balanced incomplete block designs incorporating rando-
mised non-intervention controls could inform the interpretation of
RCTs, particularly those utilising routinely collected data in imple-
mentation research.
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Introduction: The Medical Research Council (MRC) and the National In-
stitute for Health Research (NIHR) fund randomised controlled trials to
provide evidence to inform national policy decisions. Currently, these
trials have a primary focus, which dictates the choice of primary out-
come. However, there are commonly multiple outcomes of importance
to evaluate. Benefit-risk methodology can be included in trials to simul-
taneously evaluate multiple outcomes by assessing the trade-off and
allowing decisions on the most overall beneficial treatment.
Benefit-risk methodology is commonly used within the regulatory
setting with much of the available information and guidance relating
to regulatory drug trials conducted by innovator pharmaceutical
companies. In the context of MRC/NIHR trials, the studies are of
health technologies (not just drugs) and often of therapies that are
already licensed. To utilise benefit-risk in the MRC/NIHR context re-
quires consideration additionally of economic outcomes, the selec-
tion of core outcome measures and trial design features.
The MRC have funded this project as part of their Methodology
State-of-the-Art Workshops series with an aim of developing guid-
ance to include benefit-risk within MRC/NIHR funded trials. This aim
will be achieved by completing the following objectives:
1.Review current practice of benefit-risk methodology
2.Review available benefit-risk methodologies
3.Achieve expert consensus on the recommended benefit-risk
methodologies
Methods: The three objectives will be met using the following
methods:
1.Web-based survey of current practice,
2.Rapid methodological review,
3.Two-day expert consensus workshop using nominal group
technique.
Timing of Potential Results: Results from the survey and rapid re-
view plus preliminary headline results from the workshop (held early
September 2019) will be available for the ICTMC conference in
October.
Potential Relevance & Impact: This research will provide guidance
for researchers applying to MRC/NIHR funding streams to ensure re-
search is appropriate to support NHS policy decisions.PS1C
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Introduction: Health Economics Analysis Plans (HEAPs) setting out
the proposed analysis in a randomised controlled trial (RCT) currently
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tent. We aimed to develop a list of essential items to include in
HEAPs using Delphi methodology to gain consensus.
Methods: 72 potential items were extracted from existing HEAPs and
an electronic Delphi survey was developed. Expert participants were
recruited through a professional mailing list and other health eco-
nomics contacts. Respondents were asked (round 1) to rate each
item on a scale of 1–9 according to how strongly they felt the item
should be included in a HEAP, to suggest additional items and to
comment on the items. The survey results were scrutinised according
to pre-set criteria for inclusion. Round 2 included a reminder of the
participant’s own scores and summary results from the whole panel;
participants were asked to re-rate items. Consensus criteria for inclu-
sion in the final list were predefined as >70% rating an item 7-9 and
<15% rating it 1-3 after round 2. A final item-selection meeting was
held to scrutinise the results and adjudicate on items for which con-
sensus had not been reached.
Results: 62 participants completed round 1 of the Delphi survey. All
72 items were carried forward to round 2, but no new items were
added; 48 respondents (77.4%) completed round 2. The expert panel
at the final meeting (n=9) agreed that 58 items should be included
in the HEAP essential list, moved 9 items to an optional list, and
voted to drop 5 items.
Conclusions: The study generated 58 core items (e.g. measurement
of resource-use data, key assumptions) that were considered essen-
tial for inclusion within a HEAP via expert consensus opinion. These
essential items form a template HEAP that will facilitate trial-based
economic evaluations in RCTs.
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Introduction: Trial-based economic evaluations are typically performed on
cross-sectional variables, e.g. QALYs and total costs, derived from the re-
sponses for only the completers in the study, using methods that ignore
the complexities of utility and cost data (e.g. partially-observed data, skew-
ness and spikes at the boundaries of the variables’ range). This is an ineffi-
cient approach which may discard a substantial proportion of the sample
and mislead the final assessment. We present an alternative and more effi-
cient Bayesian parametric approach to handle missing longitudinal out-
comes in economic evaluations, while accounting for the complexities of
the data.
Methods: We specify a flexible Bayesian parametric model for the
observed data and partially identify the distribution of the missing
data with partial identifying restrictions and sensitivity parameters.
We explore alternative nonignorable (i.e. missing not at random) sce-
narios through different priors for the sensitivity parameters, cali-
brated on the observed data. Our approach is motivated by, and
applied to, data from a trial assessing the cost-effectiveness of a new
treatment for intellectual disability and challenging behaviour.
Results: The results show the benefits of using our approach com-
pared with a standard cross-sectional model and a considerable im-
pact of alternative nonignorable assumptions on the final decision-
making conclusions, suggesting a more cost-effective intervention
compared with the results obtained under ignorability.
Discussion: Missingness represents a threat to economic evaluations as,
when dealing with partially-observed data, any analysis makes assumptions
about the missing values that cannot be verified from the data at hand.With respect to the current practice in economic evaluations, which typic-
ally assumes ignorability of the missing data mechanism, our approach rep-
resents a considerable step forward which allows to conduct sensitivity
analysis to alternative nonignorable departures while jointly accounting for
the typical complexities of the data.
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Introduction: Hyperammonaemic (HA) disorders, including urea cycle dis-
orders (UCD), are life-limiting inborn errors of metabolism (IEMs), with long-
term consequences. The AMmonia in Breath Evaluation Research study esti-
mated the health-related quality of life (HRQoL) in children with IEMs. This
study mapped the children’s HRQoL scores to utility scores and compared
health utilities for children with and without HAs but other IEMs. Health util-
ities are used to derive quality adjusted life years (QALYs) that measure
HRQoL over time on the same scale across patient groups and conditions,
making them a useful policy tool.
Methods: Patients in four UK metabolic disease hospital clinics with
HAs (cases) and without a HAs but other IEMs (controls). HRQoL was
measured using the Paediatric Quality of Life Inventory (PedsQL), and
scores were mapped to Euroqol’s EQ-5D utility weights, using Khan
et al’s published mapping algorithms (models 5 and 6). Correlation
between the PedsQL and utility scores was studied using Spearman’s
test. Differences in utilities between patients with HAs and without
HAs but other IEMs were estimated using regression adjusting for
age, sex, and hospital site.
Results: 45 cases (mean age 12.7 years [SD=5.4 years]; 24 females
[53%]) and 46 controls (mean 12.9 years [SD 3.5]; 20 females [43%])
had complete PedsQL data. Both mapping algorithms produced very
similar distributions of utility scores (average utility of 0.76 [SD=0.21])
and correlated highly (0.93 and 0.97) with PedsQL scores. Using
Khan’s model 5 algorithm, scores ranged from -0.04 to 0.97; mean
utility was 0.70 (SD= 0.26) for cases compared with 0.82 (SD=0.14) in
controls. Health utilities in cases were lower than those without HA
(-0.146, 95%CI[-0.23, -0.06]).
Discussion: PedsQL scores can successfully be mapped into health util-
ities using Khan’s mapping algorithms. Health utilities for patients with
HAs is lower compared with patients without HAs but other IEMs.PS2A
- O1 Data Dashboards – a novel approach of accurately tracking
and monitoring electronic Case Report Form (eCRF) data return
rates and missing data items for ongoing clinical trials, using a
combination of data reporting and analysis tools capable of
drilling down to data point level
Joshua James Northey, Michael Radford, Tom Maishman, Gareth Griffiths,
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Introduction: Electronic Case Report Forms (eCRFs) are used to cap-
ture and store data collected during the course of a clinical trial. This
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easily accessed, checked and analysed. However, tracking eCRF re-
turn rates can be time-consuming and inefficient, especially on stud-
ies with large numbers of patients or clinical visits. Statisticians are
often required to present the number of eCRFs received/expected to
data monitoring committees.
The aim of this project was to develop a digital tool, which trial man-
agers can use without statistician input, to help decrease the time re-
quired to monitor eCRF return rates and ensure they accurately
reflect the status of a trial.
Methods: Using a combination of reporting tools available (Business
Objects, SAS, and Excel), the structure of the RAVE database is ex-
tracted and used to build a hypothetical list of all possible forms that
could be entered. A status for each form is derived using information
already collected and trial-specific rules. Any eCRFs not expected are
excluded whilst fields where data are expected but missing are ex-
tracted for reporting. This information is collated into a series of ta-
bles and fed into an interactive report, the Data Dashboard, which
can be dynamically filtered and used for chasing sites and highlight-
ing missing data trends.
Results: The Data Dashboard shows the number of eCRFs received/ex-
pected along with their level of completeness, broken down into categor-
ies. Performance information can be drilled down to site/subject level. The
tool is easy to interpret and does not require statistical involvement.
Discussion: Data Dashboards provide accurate and efficient ways to
monitor and track eCRFs, and highlight what expected data are miss-
ing at any time-point. Focused targeting in regards to querying and
chasing of data, at site/patient level, is possible with less time and ef-
fort required.
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Introduction: The EDNA diagnostic accuracy study is comparing five
non-invasive tests for Wet Age-related Macular Degeneration. Unlike
a trial with specified follow-up intervals, participants attended hos-
pital monitoring visits (every 1-3 months) for up to 3 years. We col-
lected routine clinical data over the monitoring period in simple case
report forms (CRFs) uploaded to the study website. Due to the vol-
ume of data expected, we took a pragmatic, semi-automated ap-
proach to data monitoring. We report our experiences over the
follow-up phase.
Methods: We used varied automated feedback to promote study
compliant behaviour for data collection. We reassessed the feedback,
including wording, timing and web-based tools, regularly after inves-
tigator meetings to maximise impact.
Firstly we provided sites with audit and feedback on data complete-
ness throughout the study using a bespoke dashboard. The dash-
board highlighted data collection forms in a visual grid using a traffic
light system – green, amber and red representing complete, missing
or absent data. Clicking the traffic light took the user straight to therelevant CRF. Sites with green dashboards were congratulated in
newsletters and investigator meetings. Site payments were only is-
sued once the dashboard display was green.
We developed further web-based monitoring tools, to confirm proto-
col adherence or track queries. Protocol compliance queries were is-
sued weekly via automated emails, highlighting problems or
congratulating the site on having no current queries.
Results: Prior to data cleaning, 7600 CRFs from 562 participants at 24
sites were logged on the study website. Less than 5% of CRFs had
missing data. Overall protocol compliance in conducting study exit
visits was 88%. Study teams found the dashboard system easy to use
and a motivating tool.
Discussion: Automated feedback to sites is essential when conduct-
ing a large scale study. This should be reassessed regularly to opti-
mise audit and feedback and involve and inform collaborators.
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Introduction: During a clinical trial, data queries frequently arise and
can be burdensome for the clinical trials unit as well as the research
sites. We aimed to improve the data cleaning process in our Clinical
Trials Unit (CTU).
Methods: A Continuous Improvement (CI) event was held focussing
on data cleaning for Data Monitoring Committee (DMC) reports. CTU
participants were data managers, statisticians and trial managers.
Clinical research nurses from research sites were also invited. Data
were gathered in advance on the number of queries raised, touch
time and elapsed time for all processes for an existing trial. Docu-
ments were collated to map a detailed timeline of events. CI lean
tools were used including ‘8 wastes’ and ‘the Kano model’. The
process was captured using ‘A3 thinking’.
Results: The process mapping highlighted the sheer volume of steps
in the process. Multiple documents led to duplication, errors and
wasted effort, with associated frustration. There was a communica-
tion gap with research sites, who were unaware of the DMC’s sched-
uling and requirements. Several agreed actions were tested and
adopted, and primarily focussed on improved communication across
the whole team. These included an infographic for sites to illustrate
the data journey throughout a clinical trial. The actions have led to a
significant reduction in the number of queries raised, improved re-
sponse rates from sites, and a reduction in workload for all. The
multidisciplinary approach was invaluable in ensuring a successful
outcome.
Discussion: High quality data are essential for reports to monitoring
committees, and this should be communicated throughout each trial.
The CTU team have worked collectively to record all data queries in
a single source and clear communication with the site research
teams has increased responses to data queries. Improved tools and
reports are now being implemented for other trials.
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Introduction: There are increasing pressures for anonymised data-
sets from clinical trials to be shared across the scientific commu-
nity, and differing recommendations on how to perform
anonymisation prior to sharing. We aimed to systematically iden-
tify, describe and synthesise existing recommendations for anon-
ymising clinical trial datasets to prepare for data sharing. This
review will inform (if applicable) the development of new
recommendations.
Methods: We systematically searched MEDLINE®, EMBASE, and
Web of Science from inception to 11 February 2019. Any publica-
tion reporting recommendations on anonymisation to enable data
sharing from clinical trials was included. Two reviewers independ-
ently screened titles, abstracts and full text for eligibility. One re-
viewer extracted data from included papers, which then was
sense-checked by a second reviewer. Results were summarised by
narrative review.
Results: 18 articles were eligible for inclusion. Three distinct con-
cepts are emerging: anonymisation; de-identification; pseudonymi-
sation. In the past there was some ambiguity about these
concepts and their differentiation. The most commonly used
anonymisation techniques are: removal of direct patient identi-
fiers (e.g. name or address); careful evaluation and modification
of indirect identifiers to minimise the risk of identification (e.g.
present age instead of date of birth); elimination of superfluous
data (e.g. database audit data). Anonymised datasets joined with
controlled access (e.g checking requesters are bona fide re-
searchers with a valid research question) was the preferred
method for data sharing.
Conclusions: There are not any standardised recommendations on
how to anonymise clinical trial datasets for sharing, however, this
systematic review shows a developing consensus on techniques
used to achieve anonymisation. Researchers in clinical trials still
consider that anonymisation techniques by themselves are insuffi-
cient to protect patient privacy and they need to be paired with
controlled access.
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Introduction: The conventional process of drug development of
testing one experimental therapy in one trial is too slow and
expensive. In Radiant-BC, the primary aims are to assess the
safety and activity of the combination of radiosurgery and im-
munotherapy with several ‘real world’ systemic therapies that a
patient’s treating physician would utilise in a real-world setting.
To do this efficiently, we implemented a flexible, adaptive
Bayesian framework to test multiple arms simultaneously, allow-
ing arms to be dropped (due to safety) or added, within a mas-
ter protocol.
Methods: Radiant-BC is a non-randomised, phase Ib/expansion co-
hort trial with 10 arms currently; non-chemotherapy based (2
arms) and chemotherapy based (8 arms). Tolerability of each
treatment arm in the non-chemotherapy based group with radio-
surgery and immunotherapy will be assessed using a multi-stage
Bayesian safety monitoring approach with up to 20 patients.
Within the chemotherapy based group, dose-escalation decisions
will be guided by the continual reassessment method (CRM) and
time-to-event CRM to obtain the recommended phase II dose
(RP2D) of the specific chemotherapy treatment, first with im-
munotherapy and then with the addition of radiosurgery. A
Bayesian decision framework is utilised to assess if there is suffi-
cient evidence of promising activity to recommend for further
testing.
Results: Visualisation tools are used to define the tailored deci-
sion criterions used in the Bayesian design. Operating character-
istics demonstrate the ability of the proposed methods to
effectively assess safety, obtain the RP2D and recommend an
active arm.
Discussion: The proposed early phase platform design is a prac-
tical, flexible, efficient approach and can be applied more widely
to other disease settings. Particularly for dose-finding where ac-
crual is often suspended at several stages to assess safety, having
other arms where patients can benefit from other novel therapies
will be attractive. This will also make recruitment more seamless
and accelerate trial delivery.
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Introduction: The scientific efficiencies of platform trial designs are
widely recognised, however operational challenges are often under-
estimated. plasmaMATCH, a multi-centre phase IIa platform trial con-
sisting of ctDNA screening and therapeutic components, designed
and conducted by the Institute of Cancer Clinical Trials and Statistics
Unit (ICR-CTSU), opened within 15 months of grant activation, re-
cruited ahead of target and will report the first 4 treatment cohorts
within 3 years of first patient first visit. Many practical challenges
were overcome to ensure the trial’s success.
Methods and results: Ensuring appropriate funding arrangements
for the original trial design and subsequent trial adaptations is vital.
plasmaMATCH’s screening platform was funded by Cancer Research
UK with individual treatment cohorts funded by pharmaceutical part-
ners, however this required complex costings and contract negotia-
tions. Reciprocal confidentiality agreements and a bespoke template
agreement with consistent terms and conditions for all pharmaceut-
ical partners ensured efficient negotiations. The lack of regulatory
framework for platform trials can cause delays in obtaining ap-
provals. Issues encountered during set-up of plasmaMATCH were
overcome through dialogue with the regulator. Earlier engagement
via a regulatory advice meeting would have been beneficial.
Greater high level project management input is required in deliver-
ing platforms trials. Within plasmaMATCH, co-ordination of the
screening platform and parallel treatment cohorts, complex amend-
ments and increased on-going site support and training increased
demands on trial management resource. Platforms trials require com-
plex data management systems, the development of which led to
challenges in meeting trial set up timeline expectations. Implement-
ing amendments has significant ramifications across multiple sys-
tems, increasing demands on data management resource. Within
plasmaMATCH a single protocol and consistent cohort assessment
schedules reduced database complexity.
Discussion: The key lesson learnt at the ICR-CTSU is that the delivery
of platform trials is resource intensive, however operational chal-
lenges can be overcome with sufficient resources and planning.
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Introduction: Platform studies that answer more than one scientific
question within a common clinical trials infrastructure provide a
methodology for efficient clinical trial design. There is evidence for
the molecular stratification of treatment for patients with mCRPC and
a growing number of putative targeted therapies.
Methods: We designed a phase II platform study in mCRPC to de-
liver multiple targeted treatments via individual, linked protocols.
MAESTRO, an overarching molecular stratification profilingprotocol, will identify potentially eligible patients with actionable
mutations, progressing on standard treatments. PERSEUS1, evalu-
ating pembrolizumab, is the first of a number of planned phase
II signal-finding studies.
Results: PERSEUS1 (NCT03506997) opened to recruitment in Novem-
ber 2018 as part of a pilot phase at the lead site, with patients mo-
lecularly characterised under a separate existing, single-centre,
ethics-approved protocol. MAESTRO is a separately funded screening
platform requiring ethics but not MHRA approval. To deliver the plat-
form study nationally, MAESTRO and PERSEUS1 will open simultan-
eously at multiple centres in 2019. Additional phase II study cohorts
are in development.
Discussion: We pragmatically separated the protocols due to the
modular funding framework and to minimise multi-stakeholder ne-
gotiations, thus allowing for simpler contractual arrangements with
multiple pharmaceutical companies/funders. In turn, this allowed nat-
ural separation of databases which facilitates simpler governance,
regulatory and reporting arrangements.
Despite the administrative burden of multiple protocols requiring ap-
proval at sites, rather than implementing new cohorts as substantial
amendments, this approach allows centres to select the downstream
phase II trials they have capacity for.
Timing the implementation of future phase II studies relative to the
rate of accrual in MAESTRO (recruitment capped by available fund-
ing) and the uptake of multiple planned downstream studies by par-
ticipating centres is crucial for efficient recruitment.
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There has been a recent surge of interest in precision medicine,
which goes beyond assessing the population-averaged effects of a
new treatment in the conventional paradigms of drug development.
A target patient population may be stratified into small subgroups
using biomarkers. Basket trials provide a framework to evaluate an
experimental therapy over the standard-of-care with respect to the
subpopulations. However, considerable criticism has been levelled
against designs of early basket trials for the low-powered stand-
alone analysis strategies. Approaches such as standard hierarchical
modelling may be limited, since the exchangeability assumption may
be too restrictive.
We propose a novel methodology for phase II basket trials with sev-
eral modules, where information from similar modules can inform
analysis of a specific module. For each parameter that underpins the
treatment effect in a module, a marginal predictive prior (MPP) is
specified using information from the other modules; specifically, it
combines one-to-one commensurate predictive priors (CPPs) that
represent information from other modules. A spike-and-slab prior is
considered for the precision parameter of each CPP. To characterise
the pairwise commensurability, we compute the Hellinger distance
between probability distributions of any two module-specific param-
eters and obtain a series of normalised weights for combining the
CPPs. This leads to a robust MPP that only information from the most
consistent modules will be borrowed. Following Bayes’ Theorem, the
MPP will be updated using the module data to a robust posterior.
We illustrate our approach using the design of a trial of primary bil-
iary cholangitis and Parkinson's disease as an example. Simulation re-
sults suggest our approach can identify consistent external modules
to implement borrowing of information, and thus improves (i) preci-
sion of estimates and (ii) statistical power. In cases of modules being
completely inconsistent, our approach gives similar results with that
of a stand-alone analysis.
Trials 2019, 20(Suppl 1):579 Page 98 of 141PS2B
- O5 Bayesian trial monitoring and power estimation in a complex
Hepatitis C treatment trial (VIETNARMS)
Leanne McCabe1, Ian R White1, Graham S Cooke2, A Sarah Walker1
1MRC Clinical Trials Unit at UCL, London, United Kingdom; 2Imperial
College London, London, United Kingdom
Trials 2019, 20(Suppl 1):PS2B
Background: Multi-arm trials combined with Bayesian monitoring
allow for many interventions to be tested simultaneously and for in-
ferior interventions to be detected early and stopped, preserving
both time and resources. However, testing multiple interventions
with unknown effects may complicate interim monitoring and affect
power. We explored methods for testing the operating characteristics
of multi-arm trials with Bayesian monitoring, using a Hepatitis C trial
exploring multiple treatment strategies as an exemplar.
Methods: VIETNARMS is a 14-arm trial that will factorially randomise
patients to two drug regimens, three strategies for shortening treat-
ment duration or control, with or without adjunctive ribavirin for
shortened treatment. It will use Bayesian monitoring at interim ana-
lyses to detect, and stop recruitment into, unsuccessful arms, defined
as >0.95 posterior probability of the true cure rate being <90%. We
tested the operating characteristics of the stopping rule, planned the
timing of the interim analyses and characterised power at the final
analysis using theory and simulation.
Results: The probability of stopping an arm incorrectly is always
maintained <0.05: arms with very low cure rates (<60%) are very
likely (>90% chance) to stop after ~25% patients are recruited and
arms with slightly lower than anticipated cure rates (80%) are likely
to stop (70% chance) by the end of recruitment. The timings of in-
terim analyses, based on the probability of stopping an arm with
cure rate 60-90%, will take place 7, 10, 13, and 18 months after re-
cruitment starts. Assuming an overall cure rate of 95% gives >90%
power for almost all intervention cure rates and comparisons.
Discussion: The operating characteristics of the stopping rule are ap-
propriate and interim analyses can be timed to detect failing arms at
various stages. Bayesian monitoring can be effective in complex
multi-arm trials.PS2C
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Introduction: The power of a large clinical trial can be adversely af-
fected by low recruitment, follow-up and adherence rates. External
pilot trials, conducted before a planned definitive trial but on a
smaller scale, can be used to estimate these parameters and identify
any issues. Pilot trials commonly specify decisions rules which use
these estimates to determine if the definitive trial is feasible and
should go ahead, but there is little methodological research under-
pinning how they, or the pilot sample size, should be chosen.
Methods: We argue that recruitment, follow-up and adherence rates are
of interest primarily in how they affect the power of the definitive trial, and
use this power as a quantitative measure of feasibility in a hypothesis test
of pilot data. Considering a two-arm parallel group definitive trial with a sin-
gle normally distributed primary endpoint, we show how appropriate hy-
potheses for this test can be defined. We suggest a test statistic and
provide its sampling distribution, thus defining type I and II error rates, and
show how these can be used to inform the choice of pilot trial sample size
and stop/go decision rule.
Results: We use our method to re-design the TIGA-CUB trial, a pilot trial
comparing a psychotherapy with treatment as usual for children with con-
duct disorders. Our results show that error rates around the conventional
levels of 0.05 (type I) and 0.2 (type II) can be obtained using typical pilot
sample sizes of between 30 and 50 participants per arm. In comparison tothe proposed method, the standard approach of using several independent
progression criteria leads to a substantial loss of efficiency.
Discussion: A formal hypothesis testing approach to the design and
analysis of external pilot trials could lead to improved decision mak-
ing without requiring any substantial increase in pilot sample size.PS2C
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Introduction: This study reports recruitment challenges in a demand-
ing breast cancer trial (OPTIMA prelim) involving a ‘less treatment
arm’ and describes strategies employed to successfully overcome
them.
Methods: A mixed-methods recruitment intervention (the ‘QuinteT Re-
cruitment Intervention’, QRI) was employed to investigate recruitment
difficulties and feed-back iteratively findings to inform changes to re-
cruitment processes during the trial. Quantitative site-level recruitment
data, qualitative interviews (n=22) with healthcare professionals, audio-
recorded recruitment discussions between oncologists and patients (n=
36) and patient-facing documentation were analysed using descriptive,
thematic, and conversation analyses. The findings were triangulated to
inform a ‘plan of action’ to optimise recruitment.
Results: Despite belief and enthusiasm for OPTIMA prelim, some on-
cologists’ routine practices and perceptions of equipoise appeared to
unwittingly inhibit recruitment. A reluctance to deviate from the
usual practice of recommending chemotherapy according to tumour
clinicopathologic features meant that not all eligible patients were
approached. Audio-recorded discussions with eligible patients also
revealed how ingrained routine practices undermined recruitment in
subtle ways, as some oncologists justified chemotherapy provision
before explaining the RCT, and often encountered difficulties in con-
veying uncertainty/equipoise. To tackle these challenges, individual
and group feedback was given to oncologists, using data from their
appointments to illustrate communication issues and vignettes to air
issues around approaching patients. More general ‘tips’ documents
with suggestions on how to structure discussions, and convey
equipoise were disseminated to all recruiters, alongside revisions to
the Patient Information Sheet. The recruitment target was achieved,
and a before/after analysis showed that the strategies improved
recruitment.
Conclusions: This is the first study to illuminate the tension between
routine practice and the requirements of recruiting to an RCT. Nego-
tiating clinical and research roles is challenging, particularly in cancer
trials involving less/no treatment. Iterative investigation and feedback
on clinicians’ practices can help to overcome these challenges as tri-
als are underway.
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Introduction: Despite an ageing population and rising prevalence of
conditions associated with cognitive impairments, adults who lack
capacity to consent are under-represented in research. Trials involv-
ing adults who lack capacity raise a number of ethical and practical
challenges. Participants who are unable to consent require a family
member to act as a proxy decision-maker, however, families can ex-
perience an emotional and decisional burden as a result. Despite nu-
merous innovations to improve informed consent processes, there
are no interventions for proxy decision-makers. We have developed a
decision support tool which aims to support families making deci-
sions about research participation on behalf of an adult who lacks
capacity to consent.
Methods: The intervention was developed using the MRC guidance
for the development of complex interventions, which recommends a
phased approach using available evidence and theoretical principles.
The intervention was informed by a systematic review, analysis of
existing information provision, qualitative interviews with families
who had acted as proxies, and the development of a theoretical
framework. The intervention was iteratively developed in conjunction
with lay advisors and relevant stakeholders.
Results: Utilising our previous research findings, and applying decision-
support development frameworks, we identified the complex interven-
tion components. We developed a decision-support tool which in-
cludes information about the proxy’s role and the basis for their
decision, and uses values clarification and decision-support methods.
This is supported by a brief training intervention for the researcher/clin-
ician seeking consent. We conducted acceptability testing with a group
of stakeholders which found high levels of acceptability.
Discussion: Ensuring the inclusion of under-represented or vulner-
able groups in randomised trials is a priority area. A novel interven-
tion has been developed to support families making proxy decisions
about research. The decision-support tool is acceptable to users but
requires feasibility testing and establishment of outcome measures
prior to any future evaluation of its effectiveness.PS2C
- O4 Why is the early intervention development phase for complex
health care interventions important? An overview of new guidance
Alicia O'Cathain2, Elizabeth Croot2, Edward Duncan1, Nikki Rousseau1,
Katie Sworn2, Katrina Turner3, Lucy Yardley3, Pat Hoddinott1
1University Of Stirling, Stirling, United Kingdom; 2University of Sheffield,
Sheffield, UK; 3University of Bristol, Bristol, UK
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Introduction: Good research ideas often do not produce the antici-
pated results.[1] It is unknown which intervention development pro-
cesses lead to real world impact on health outcomes as they are
seldom published. Is this a missed opportunity for learning? Could
there be avoidable waste? The UK Medical Research Council and Na-
tional Institute of Health Research funded INDEX study aimed to pro-
duce guidance for researchers on how to develop and report complex
interventions to improve health or health care outcomes.
Methods: Evidence was triangulated from: two systematic reviews, qualita-
tive interviews and e-Delphi studies, guided by two international stake-
holder workshops. Systematic reviews of i) published methodological
approaches to intervention development ii) international primary researchstudies reporting intervention development, published in 2015-16, to iden-
tify and categorise practices. In parallel, qualitative interviews with a diverse
sample of developers (clinicians, academics, social scientists) and wider
stakeholders (public representatives, funders, journal editors) were analysed
iteratively, inductively and thematically. Data triangulation generated 85
items for two e-Delphis with i) experts in intervention development, ii)
wider stakeholders, to measure consensus and explore reasons for diver-
gence. All data fed into a logic model and final guidance on intervention
development and reporting.
Results: An overview of the guidance will be presented. Key princi-
ples include: iterative cycles of development with stakeholder input
at each cycle; integrate creativity with scientific methods; be open to
failure, change, and consider unintended consequences; look ahead
to future evaluation and real-world implementation. Novel qualitative
insights include: ways to meld the art and the science of design; the
meanings and drivers of “success” and understanding divergence of
opinion.
Conclusions: The guidance provides a comprehensive tool for consider-
ation when undertaking intervention development. Reporting intervention
development processes will promote transparency so that in future re-
searchers can link early design decisions to trial outcomes.
Reference
1. Chalmers et al, Lancet, 2014: https://doi.org/10.1016/S0140-6736(13)62229-1
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Introduction: Addressing recruitment and retention challenges in tri-
als are important priorities for methodological research, but navigat-
ing this growing literature is difficult and time consuming. In 2016,
ORRCA (www.orrca.org.uk) launched a free, online, searchable, data-
base of recruitment research that is currently being updated with re-
cent publications and extended to include retention research
(ORRCA2). We report the latest results including a mapping exercise
of trial recruitment and retention literature, assessment of the data-
base impact and lessons learnt from conducting an international, col-
laborative, methodology project.
Methods: Search strategies from relevant Cochrane reviews were
tailored to the trial recruitment and retention objectives and to
the databases: MEDLINE(Ovid), WoS, Scopus, CINAHL, PyscINFO,
and the Cochrane Library. An international team of reviewers
were trained and quality assurance approaches introduced. Fol-
lowing abstract screening, full texts were retrieved for potentially
eligible articles. Studies evaluating or reporting recruitment or re-
tention strategies and case reports were included. Eligible articles
are being mapped against an agreed framework of recruitment
or retention domains and categorised by evidence type (e.g. ran-
domised or non-randomised evaluations, studies without
evaluation).
Results: 68,900 abstracts and 6,028 full texts have previously been
reviewed for ORRCA, identifying 3,555 eligible articles. Screening of
an additional 14,465 abstracts for ORRCA and 69,740 abstracts for
ORRCA2 by 31 reviewers from six countries is nearly complete. Pre-
dicted number of articles for full text review are 860 and 3,600
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ORRCA2 will be prioritised and results presented.
Relevance and Impact: The database allows identification of effective
recruitment and retention solutions tailored to specific trial designs
and patient populations. It has supported several publications includ-
ing two systematic reviews. The recruitment and retention frame-
works allow neglected areas to be highlighted for future targeting of
research resources. Lessons learnt will help development of other
large-scale methodological projects.
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- O1 Agreeing outcomes that matter to patients – co-production of
an animation to explain core outcome sets
Heather Bagley1, Sarah Gorst1, Rosemary Humphreys2, Rebecca Craven2,
Christine Vial2, Paula R Williamson1, Bridget Young1, Nicola Harman1,
Elizabeth Gargon1
1University of Liverpool, Liverpool, United Kingdom; 2Public contributor,
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Introduction: The development of standardised core outcome sets
(COS), for all trials of effectiveness in a particular condition, can
facilitate the comparison of trials and increase the relevance of
research. COMET brings together people interested in the devel-
opment and application of COS and seeks to facilitate the opti-
mal input of patients, members of the public as key stakeholders
in COS development. However, engaging patients and other
stakeholders in COS development can be challenging. To help
stakeholders to understand what COS are, COMET developed a
plain language whiteboard animation.
Methods: Three public contributors and 5 researchers co-designed
the animation, including the narrative approach, scripting, graphics
and the evaluation question.
Results: The 3-minute animation, which will be screened as part of
this presentation, explains from a patient perspective what COS are,
why they are needed and how they are developed. The public con-
tributors emphasised the need for the animation to be presented
through a patient voice and the group decided to focus on asthma
as an exemplar commonly recognised condition.
The animation (http://www.comet-initiative.org/resources/PlainLan-
guageSummary) has had over 1000 views. Of the 49 people currently
responding to our evaluation question: “How well did this video ex-
plain core outcome sets to you?” all responded positively. The anima-
tion is available with subtitles and has so far been translated into
French, Portuguese and Dutch.
Discussion: Involving patients in co-designing our animation helped
ensure COS were explained in an accessible way. A dissemination strat-
egy for the animation aims to ensure it is used by COS developers and
patient organisations to promote meaningful participation in COS.
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conduct. Patients and/or lay members of the public are increas-
ingly included in oversight committees, influenced by inter-
national patient and public involvement (PPI) initiatives to
improve research quality and relevance. However, guidance on
undertaking PPI in trial oversight is lacking. We explore how PPI
functions in oversight committees and provide recommendations
to optimise PPI in future trials as part of a larger study investigat-
ing the role and function of oversight committees in trials facing
challenges.
Methods: Using an ethnographic study design, we observed over-
sight meetings of eight UK trials and conducted semi-structured in-
terviews with members of their trial steering committees (TSCs) and
trial management groups (TMGs) including PPI contributors, trial
sponsors and funders. Thematic analysis of data was undertaken,
with findings integrated to provide a multi-perspective account of
how PPI functions in trial oversight.
Results: Eight TSC and six TMG meetings from eight trials were
observed. 52 purposively sampled oversight group members, in-
cluding three PPI contributors, were interviewed. PPI was re-
ported as beneficial in trial oversight, with PPI members
contributing a patient voice and advocacy role. However, PPI con-
tributors were not always active at meetings and were sometimes
felt to have a tokenistic role, with trialists reporting a lack of un-
derstanding of how to undertake PPI. Interviewees highlighted
the importance of planning effective strategies to recruit PPI con-
tributors, considering the level of oversight and stage(s) of trial
to include PPI, and regular support for PPI contributors by the
trial team.
Discussion: Consideration should be given at trial design stage on
how to recruit and involve PPI contributors within trial oversight,
and support and mentorship for both PPI contributors and trial-
ists (in how to undertake PPI effectively). This study further
strengthens the evidence base on facilitating meaningful PPI
within clinical trials.
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Introduction: The delivery of platform trials presents many chal-
lenges, particularly where designs are complex, challenge patient
pathways, require multiple biopsies or lack direct patient benefit. The
Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-
CTSU) has found the involvement of patient advocates essential in
overcoming some of these challenges, including patient acceptability
of trial design and explanation of the complex trial in plain English
as exemplified by plasmaMATCH and PHOENIX, complex platform tri-
als in breast cancer.
Methods and results: Patient and public involvement (PPI) in trial de-
sign was sought at an early stage, with an extensive consultation
process undertaken across multiple patient advocate groups and in-
volving targeted forums and NCRI Dragons Den events. This provided
invaluable feedback, ensuring alignment of the trial design with the
patient pathway and providing reassurance of patient acceptability
of the complex designs, collection of multiple tissue and blood sam-
ples (a key component of trial design in both plasmaMATCH and
PHOENIX) and around issues of patient benefit and recruitment. PPI
in patient information sheets and the consent process has been vital
in ensuring the complex designs are effectively described in simple
language.
Consumer representatives as named collaborators on grant applications
has ensured continued engagement throughout trial development,
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search ethics committees meetings has proved to be a valuable tool in
assisting communications about the proposed research, highlighting to
regulators and ethics committees the acceptability and importance of
the novel trial design to patients. The inclusion of consumer members
on Trial Management Groups ensures continued PPI as the trials evolve,
which is crucial in platform trials given the dynamic nature of these
trials.
Discussion: PPI input from an early stage and throughout the life-
time of the trial is vital in designing and delivering complex and in-
novative platform trials.
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Introduction: The Health Research Board – Trials Methodology Re-
search Network (HRB-TMRN) in Ireland celebrates International Clinical
Trials Day with the help of the younger members of our community
through the network’s START programme www.startcompetition.com
START is an outreach initiative that incorporates both a competition
for primary schools and also a fun activity day https://www.youtube.-
com/watch?v=zNdhQhWh5Jk
Launched in 2016, START asks children (8-12 years old) to simulate
and report their ‘very own’ randomised trial.
Aim: To explore the START initiative from the perspective and experi-
ences of participating children and their teachers.
Methods: Using a qualitative descriptive study we conducted eight in-
terviews with teachers and eight focus groups with 63 children. Inter-
views were recorded, transcribed and analysed using template analysis.
Results: Data were grouped into six broad themes; i) START – it
caught our attention; ii) it was doing science not just reading about
it; iii) we created our trial; iv) we know about trials now; v) START –
it’s relevant across the primary school curriculum; vi) improving
START. The children shared their understanding of trial processes,
the “scientific knowledge” they had gained. They spoke of communi-
cating their learning to other children and with their families. START
was identified as having the potential to contribute substantially to
key aspects of the broader school curriculum. Working in a team, the
children were able to see each other’s strengths in delivering the
trial; a trial they held, with pride, as their own.
Discussion: It is accepted across the trial community that taking part
in trials can be beneficial for healthcare, but when there is a lack of
public understanding around trials, this means recruitment and over-
all acceptance of trials is limited. By educating young children about
the importance of trials, the outreach initiative of the HRB-TMRN
(START), contributes to efforts to address this problem.
PS2D
- O5 Complexities of informed consent in an emergency, perinatal,
cluster-randomised pilot study: The experience of developing the
ACROBAT study (Administering Cryoprecipitate in Obstetric
Bleeding at an Earlier Time)
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Introduction: The ACROBAT study (ISRCTN12146519) is a pilot
cluster-randomised trial of early cryoprecipitate administration inmajor obstetric haemorrhage requiring blood transfusion. ACROBAT
introduces a number of complexities around consent. The relative
rarity of the condition and urgency of treatment questions the practi-
cality of advance consent. The cluster design, introduced to ensure
uniformity of treatment in a highly multidisciplinary setting, limits
women’s options to opt out. Development of the consent model re-
quired in-depth patient and public involvement (PPI).
Methods: We developed and discussed the consent model in collabor-
ation with ‘Katie’s Team’, a women’s health PPI group, across four meet-
ings between February and December 2018. Discussions centred on:
-Timing of consent including the level of information deemed appro-
priate for antenatal discussion
-Content of study materials including antenatal information leaflets,
posters and participant information sheets (PIS)
-Opinions on handling data for participants losing capacity
-Content and setting for qualitative research interviews
Results: Most members accepted full meaningful consent is only feas-
ible post-intervention. However, some suggested that a very generic
advance consent might be appropriate; with a few preferring not to be
given any information at all, especially in an emergency setting.
Members gave valuable input on wording and presentation of infor-
mation, including a graphical representation of the intervention and
helping to organise the PIS in a more patient-centred way. PPI mem-
bers were strongly against delegation of consent to a partner where
capacity is lost.
Recruitment to the ACROBAT study began in March 2019 and is on-
going. Learning points from the recruitment process will be
presented.
Discussion: Research in emergency clinical situations can highlight a
wide range of opinions among PPI members on key issues, which de-
velop over time and can be highly emotive. This requires thoughtful,
iterative engagement and feedback from the trial team to develop
practical, acceptable solutions.PS3A
- O1 QuinteT Recruitment Intervention in the By-Band-Sleeve
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Introduction: The By-Band-Sleeve (BBS) randomised controlled trial
(RCT) (NIHR-HTA-09/127/53) was set up to compare gastric band, gas-
tric bypass and sleeve gastrectomy operations for complex obesity.
Recruitment was anticipated to be difficult and the QuinteT Recruit-
ment Intervention (QRI) was aimed at optimising recruitment.
Methods: In phase 1 of the QRI, we conducted in-depth semi-
structured interviews with healthcare professionals; audio-recorded
and observed recruitment consultations; scrutinised screening logs;
and analysed data primarily using qualitative research methods. In
phase 2, we provided confidential and supportive recruitment feed-
back/training to recruiters, aimed at collaboratively developing and
implementing a plan of improvement.
Results: We conducted 35 interviews with healthcare professionals,
received audio-recordings of ~2500 patients’ consultations, observed
19 consultations, provided 110 feedback/training sessions (29 site-
specific, 77 recruiter-specific, four research nurse sessions) and dis-
seminated recruitment tips documents. The feedback/training, along-
side tremendous commitment from surgeons and nurses in the
centres and the Trials Unit, enabled recruitment in all 12 centres.
Randomisation rates varied from 20%-60% of eligible patients. Lower
levels of recruitment occurred in centres that encountered insur-
mountable organisational barriers and when recruiters struggled to
implement QRI training, for example to address patients’ preferences.
Recruitment is now close to completion, but a 15-month costed
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1341. Many lessons were learnt to improve future QRIs: spreading
good practice from leading recruiters to others, better targeting of
recruitment training in higher-volume centres, focusing support on
particular recruiters rather than on all, and the need for close integra-
tion with the Trials Units.
Discussion: BBS has recruited the largest number of participants for
a bariatric RCT. Notwithstanding the measures used to optimise re-
cruitment, an extension was required to complete recruitment. The
QRI continues to evolve and lessons from BBS have added to the
knowledge base on recruitment and will enhance future QRIs.PS3A
- O2 TRCPAD: Accelerating Participant Recruitment in AD Clinical
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Introduction: Trial Ready Cohort for Preclinical/Prodromal Alzheimer's
Dementia (TRCPAD) aims to develop a large, well-characterized,
biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment
into AD prevention trials. In current trials, screening evaluation, which
often includes amyloid PET imaging and disclosure of results, is an
expensive and time-consuming process. Preclinical Alzheimer’s stud-
ies have had more than a 2/3rd amyloid screen fail rate, resulting in
prolonged and expensive recruitment.
To achieve our aim we have set 3 objectives:
1)Build an efficient and sustainable recruitment system in order to
enroll an initial TRCPAD Cohort.
2)Optimize an innovative, adaptive algorithm to identify the appro-
priate trial participants.
3)Develop and validate web-based cognitive and functional outcome
measures for future clinical trials.
Methods: To reduce recruitment time and costs we have developed
a web-based registry https://www.aptwebstudy.org/. Individuals
complete online cognitive assessments in an unsupervised context
to assist in evaluating eligibility for in-person screening and estab-
lishment of a trial-ready cohort (TRC). ApoE genotype may be deter-
mined from blood or salivary samples collected from the
participants. Eligible participants with increased risk for developing
AD are referred to affiliated clinical sites for amyloid PET and other
assessment and, depending on results, will have the opportunity to
participate in AD prevention clinical trials. Enrolment and preliminary
longitudinal information from this cohort can be used as run-in data
for new trials and will minimize the screen fail rates and the enroll-
ment timeline for new trials.
Results: APT webstudy was launched on December 22nd, 2017. Our
recruitment rate stands at ~1,000 consented participants per month,
with participation throughout the US.
Discussion: Participant identification and enrollment into TRC in-
clinic assessments are on target to begin before end of 2019. In this
presentation, we will describe the approach used to establish this co-
hort and provide some data on the current status.PS3A
- O3
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Suzanne Hartley1, Jessica Pool1, Lauren Moreau1, Emma McNaught1,
Chris P Gale1, Alison Blenkinsopp2, Peter Gardner1, Jonathan Silcock2,
Beth Fylan2, Yvonne McGill1, Amanda Farrin1
1University Of Leeds, Leeds, United Kingdom; 2University of Bradford,
Bradford, United Kindgom
Trials 2019, 20(Suppl 1):PS3A
Introduction: Delivery of large, multicentre trials is complex and des-
pite significant resources, many require extensions to recruit to tar-
get. Potential recruitment barriers are often not fully understood at
trial inception. Reasons for poor recruitment are multifaceted and it
is challenging for central trial teams to unpick underlying causes. We
describe our experience of using centralised nurse peer support as a
strategy to maximise recruitment in a multi-centre cluster rando-
mised controlled trial (cRCT).
Methods: ISCOMAT, a NIHR research programme, includes a cRCT to
evaluate an intervention to optimise medicines use for heart failure
patients following hospital discharge, with target sample size of
2,100 patients from 42 NHS Trusts. Trial recruitment commenced
June 2018, with variable recruitment rates observed across sites. Vari-
ation appeared unrelated to size of ward; throughput of patients; or
differences in patient pathways and staffing structures. In February
2019, we appointed an experienced cardiology research nurse, based
with the central team, to provide peer support to sites. Support is
provided by phone, email and site visits where required. Details of
contact is documented.
Results: Engagement with the peer support has been high and well
received by research nurses at sites. Immediate benefits of providing
peer support included:
•Greater engagement with the recruiting teams;
•Recruitment barriers identified;
•Reduced time to recruit first participant at each site;
•Increased monthly recruitment rates for sites open to recruitment;
•Improvements in other aspects of trial performance resulting from
higher engagement.
Discussion: Embedding an experienced nurse within a central trial
team has been a positive experience, improving engagement be-
tween the central trial team and sites. It allows for identification of
how local issues impact on trial performance. It should be considered
as a cost effective strategy in large multi-centre trials where patient
recruitment is complex and variable.PS3A
- O5 Achieving high-volume, low-cost participant screening and
enrolment through automation and centralisation: experiences
from the T4DM diabetes prevention trial
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Introduction: Recruitment to diabetes prevention trials is challenging
and expensive, involving screening large numbers with low rates of
screening success. The T4DM study is a recently completed Austra-
lian trial of testosterone to prevent Type II diabetes in high-risk men
aged 50 – 74 years. We had to screen a large number of volunteers
at few sites and with a low screening budget per participant. We
therefore adopted and evaluated a semi-automated approach to
screening and enrolment.
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mented: i) web-based pre-screening, ii) laboratory screening through
a network of third-party pathology centres, and iii) final on-site
screening. Online data collection, computer-driven eligibility check-
ing, and automated, email-based communication with prospective
participants were used. Participant screening status, and associated
costs and resource use were centrally tracked.
Results: Of 19,022 screened participants, 1,007 were randomised.
Nearly all (95%) participants chose online over phone-based pre-
screening. At peak, 1,403 participants were pre-screened in a single
day. On average, 11 staff hours were required for each participant
randomised. Screening costs, including both direct and staffing costs,
were AUD$1,420,909 (£782,228) in total (AUD$75 (£41) per subject
screened and AUD$1,411 (£777) per participant randomised).
Discussion: A screening process incorporating centralised, online and
automated elements achieved high-volume, low-cost participant
screening. Compared to similar, previous trials, screening savings are
conservatively estimated at AUD$5,899,126 (£3,247,543); equivalent
to 76% of the entire T4DM study budget. Our approach could be
adapted for use in other trials seeking to screen large numbers of
participants.
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Introduction: Designing and delivering placebo surgical interventions
for use in randomised controlled trials (RCTs) is complex. An in-depth
understanding of the constituent components of the treatment inter-
vention (to ascertain what should, and should not, be delivered as
part of the placebo intervention) is needed. Furthermore, assessment
of potential risk to patients and utilisation of strategies to ensure the
placebo effectively mimics the treatment are required. To date no
guidance exists for the design of placebo surgical interventions.
This study aimed to develop a framework to optimise the design and
delivery of placebo interventions in surgical RCTs.
Methods: A preliminary framework was developed by expanding the
scope of an existing typology that facilitates the deconstruction of
surgical interventions into their constituent components. Then, strat-
egies to optimise placebo interventions were identified from pub-
lished RCTs. Finally, the framework was refined after consultation
with key stakeholders in surgical trial methodology, medical ethics
and consensus methods.
Results: The resultant DITTO framework consists of five stages: Stage 1
- Deconstruct treatment intervention to produce a comprehensive list
of components and co-interventions; Stage 2 - Identify critical element
believed to provide therapeutic benefit; Stage 3 - Take out critical elem-
ent; Stage 4 - Think risk, feasibility, and role of placebo in trial whenconsidering inclusion of remaining intervention components; and Stage
5 - Optimise placebo and ensure effective blinding of trial persons, e.g.
by use of auditory masking.
Discussion: The DITTO framework provides a structure for the design
of placebo surgical interventions. It facilitates in-depth analysis of the
treatment intervention. It also outlines key considerations regarding
the composition of the placebo intervention, including potential risk
to patients and the use of placebo optimisation strategies.
PS3B
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Introduction: The optimal design for a clinical trial using value of in-
formation (VoI) methods is the point at which it becomes more
costly to collect additional data than the value gained from that data.
This requires prior distributions for trial outcomes, either based on
past trials or expert opinion. However, a proposed trial cannot typic-
ally be expected to produce data consistent with earlier studies. The
aim of this study was to demonstrate the utility of using pharmaco-
metric clinical trial simulation (CTS) to address key limitations of
current VoI approaches to phase III clinical trial design using gout
treatments as a case study.
Methods:The methods consist of four principal stages: a CTS to pre-
dict the distribution of treatment response rates for a given sample
size; a payer model that links a rate of treatment response to an esti-
mate of the maximum reimbursement price a payer would be willing
to pay to access the drug; a model of the pharmaceutical company
return on investment linking drug prices to sales revenue; and an
analysis of the sensitivity of the optimal decision to the uncertainty
in specific model parameters using expected value of partial perfect
information (EVPPI).
Results:The optimal sample size for a single trial comparing febuxo-
stat 80 mg and allopurinol 300 mg once daily was estimated to 500
patients per arm, given assumptions on the incidence of patients
and a minimum launch price. EVPPI for each uncertain model param-
eters indicated that uncertainty in parameters for drug adherence, ra-
ther than drug pharmacology, dominated the uncertainty regarding
the optimal sample size decision.
Discussion: Using clinical trial simulation to generate distributions of
trial outcomes removes a key limitation of value of information ap-
proaches to trial design, the requirement for prior distributions on
outcomes, and EVPPI may focus efforts to reduce uncertainty to spe-
cific areas.
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Introduction: Two-stage adaptive enrichment designs are efficient
for trials in stratified medicine. In stage 1 patients are recruited from
the full population while in stage 2, recruitment is restricted to a
biomarker-driven subgroup that is selected based on the interim
analysis of stage 1 data. Confirmatory analysis in the selected sub-
group consists of stages 1 and 2 patients. The aim of this work was
to develop appropriate point and interval estimators for survival out-
comes which are common in oncology, where subgroup analysis is
common. Such estimators do not exist.
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totic distribution for the log hazard ratio. We have proposed the
asymptotic normal distribution of the score statistic as it aligns with
the log-rank test. Another challenge was how to include stage 2 data
from patients with censored observations in stage 1 in estimation
without inducing correlation between stages 1 and 2. To achieve ap-
proximate independent increment structure, we have proposed fix-
ing the number of events from each of the following, patients used
in the interim analysis, patients with censored observations at the in-
terim analysis and patients recruited in stage 2. This enabled borrow-
ing the group sequential ideas that assume independent increment
structure. After addressing the two challenges, we extended methods
for normally distributed outcomes to derive an approximate asymp-
totic uniformly minimum variance conditional unbiased estimator
(UMVCUE) and a new confidence interval for the log hazard ratio.
Results: Using simulations, the approximate UMVCUE has negligible
bias and does not have substantially bigger root mean squared error
than the naive estimator. Further, unlike the naïve confidence interval,
the new confidence interval has the desired coverage probability.
Discussion: Naive estimators following two-stage adaptive enrich-
ment clinical trials have undesirable properties. Therefore, we recom-
mend the approximate UMVCUE and the new confidence interval.PS3B
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Introduction: Despite significant progress in scientific stem cell re-
search there are still very few novel cell therapies licensed for clinical
use. Clinical trials have been identified as one of the main transla-
tional challenges for cell therapies, and issues such as length of time
to complete, under-funding and manufacturing challenges have
been the subject of much discussion amongst policy-makers, regula-
tors, clinicians, methodologists and commercial developers. Although
there has to date been some engagement with the trials community
this has tended to focus on specific clinical areas (e.g. oncology). This
paper examines some of the challenges experienced in designing
and conducting cell therapy trials in the UK with a view to identify-
ing opportunities to help overcome these challenges.
Methods: Mixed methods study including a quantitative analysis of
all current UK trials of novel cell therapies (n=44), 17 semi-structured
interviews with clinicians, cell manufacturers and scientific re-
searchers involved in current trials and an ethnographic case study
of a musculoskeletal cell therapy trial.
Results: Three meta-themes were identified which appear to be par-
ticularly challenging for trials:
1)Uncertainty: difficult to design trial protocols and interpret results
because basic science, mechanism of action and ideal treatment
protocol often poorly understood.
2)Complexity: treatments involve a number of components (e.g. surgical
procedures, manufacturing processes) which are highly context specific.
3)Variability: both between trials (e.g. clinical area, cell type) and
within trials (e.g. site expertise and resources, heterogeneity in cell
batches, effective dose, patient response).
Discussion: These findings suggest that cell therapies should be
treated as complex interventions. The MRC Complex Interventions
Evaluation Framework and the IDEAL framework for surgical trials
offer useful guidance that could be adapted to address the particular
challenges of cell therapies. Methodological opportunities to improve
the efficiency of trials include adaptive and factorial designs, rando-
mised registry trials and embedded process evaluations.PS3C
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Introduction: Given the high cost and failure rate of single-arm
phase II oncology trials, it is of interest to reduce the expected sam-
ple size, allowing efficacious treatments to be found more quickly
and minimising the number of patients receiving an inefficacious
treatment. Simon’s design uses a single interim analysis to reduce ex-
pected sample size. However, further reductions can be achieved
using curtailment. Curtailment is stopping when the final go or no-
go decision is certain, so-called non-stochastic curtailment, or likely,
known as stochastic curtailment.
We reduce the expected sample size by proposing designs that in-
corporate stochastic curtailment for either a go or no-go decision.
Methods: We obtain optimal stopping boundaries by searching over
a range of potential conditional powers, beyond which the trial will
stop for a go or no-go decision. This search is novel: firstly, the
search is undertaken over a range of values unique to each possible
design realisation. Secondly, these values are evaluated taking into
account the possibility of early stopping. Finally, each design realisa-
tion’s operating characteristics are obtained exactly.
The proposed designs are compared to existing designs in a real
data example. They are also compared under three scenarios, both
with respect to four single optimality criteria and using a loss
function.
Results: Using the real data, the proposed designs approximately
halve the sample size. Comparing designs across the three scenarios,
the proposed designs are superior in almost all cases. Optimising for
the expected sample size under either the null or alternative hypoth-
esis, the saving compared to the popular Simon's design ranges from
22% to 55%.
Discussion: We have proposed designs for phase II, single-arm, bin-
ary outcome clinical trials, and augmented them with a number of
approaches for finding better design realisations. These designs,
combined with the proposed approaches, are shown to be superior
to existing designs.
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Introduction: Two-stage single-arm designs remain the most com-
mon design in phase II oncology. Consequently, much research has
been conducted on how to analyse such trials. However, it is not
clear that recommended methods are regularly utilised, and there-
fore many trials may report results that are biased or have inflated
type-I error-rates. We present a review that quantifies the degree of
this problem.
Methods: PubMed was used to identify phase II oncology trials con-
ducted between 2013-2017. Each extracted record was assessed to
identify trials that utilised a two-stage single-arm design with a bin-
ary primary outcome, for subsequent inclusion in the review. In-
cluded trials were evaluated against a variety of quality of reporting
criteria. Wherever possible, the design parameters were matched
against reported operating characteristics for each trial. Those trials
that proceeded to stage two were also assessed on whether they (a)
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(b) accounted for any design deviation. For trials that did not con-
form to (a) or (b), the final analysis was replicated using recom-
mended inferential procedures to assess quantities such as the bias
in the final point estimate.
Results: Over 5000 records were extracted from PubMed, leading to
more than 500 included trials. Key design parameters and resultant
operating characteristics were well reported. However, few trials that
proceeded to stage two adjusted their inference to account for the
interim analysis. Similarly, despite design deviation being common,
almost no studies accounted for this in their reported analyses.
Conclusions: Two-stage single-arm designs can efficiently weed-out
inactive anti-cancer agents, but their value is reduced when infer-
ence is not performed in the recommended manner. Currently, few
trials conform to established recommendations. Future two-stage
single-arm trials should utilise adjusted analysis procedures, so that
they conform to their desired type-I error-rate, and do not over-
estimate response rates.
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The endpoints for immunotherapy and targeted therapy are often
complicated, making conventional phase II trial designs or commonly
used basket designs inefficient and disfunctional. We propose a flex-
ible Bayesian optimal phase II (BOP2) design that is capable of hand-
ling simple (e.g., binary) and complicated (e.g., ordinal, nested and
co-primary) endpoints under a unified framework. We use a Dirichlet-
multinomial model to accommodate different types of endpoints. At
each interim, the go/no-go decision is made by evaluating a set of
posterior probabilities of the events of interest, which is optimized to
maximize power or minimize the number of patients under the null
hypothesis. Unlike most existing Bayesian designs, the BOP2 design
explicitly controls the type I error rate, thereby bridging the gap be-
tween Bayesian designs and frequentist designs. In addition, the
stopping boundary of the BOP2 design can be enumerated prior to
the onset of the trial. These features make the BOP2 design access-
ible to a wide range of users and regulatory agencies, and particu-
larly easy to implement in practice. Simulation studies show that the
BOP2 design has favorable operating characteristics with higher
power and lower risk of incorrectly terminating the trial than some
existing Bayesian phase II designs. The software to implement the
BOP2 design is freely available at www.trialdesign.org
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Introduction: In rare cancers or subtypes of common cancer a com-
parison of multiple promising treatments may be required. The se-
lected treatment can then be assessed against the standard of care
(if it exists) or used as backbone for combinations with new, possibly
targeted, agents. There could be different experimental therapies or
different doses of the same therapy, and either done in combination
with standard treatments.
In practice a “pick-the-winner” design is often used, focusing only on
efficacy to select the most promising treatment. Recent selection tri-
als have modified the pick-the-winner rule in an ad-hoc manner to
make decisions in case of equal/similar observed responses.There is a need to formalise how a treatment with a slightly lower ef-
ficacy compared to another treatment may actually be preferred if it
has a better toxicity profile, is easier to administer, or cheaper.
Methods: We define at the design stage a margin of practical equiva-
lence, which corresponds to the extent by which a superior treat-
ment needs to be to be selected based on efficacy only.
Considering binary outcomes, we used exact probabilities to calcu-
late the required sample size for two- and three-arm selection trials
incorporating a margin for a large variety of design inputs. The sam-
ple size is obtained by making sure that the probability of selecting
the superior treatment, assuming it exists among the options consid-
ered, is above a threshold, often 80% or more.
Results: We developed a free user-friendly web application for sam-
ple size calculation. The application also derives the probability of
selecting the superior treatment for a given sample size.
Discussion: There is a need to improve the design of selection trials.
The application will facilitate the adoption of the margin of practical
equivalence, which formalises the flexibility required compared to
the strict pick-the-winner rule.PS3C
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Introduction: Treatment-as-usual (TAU) is often used as a comparator
in behaviour change trials. Its characteristics are poorly described in
published manuscripts but are highly heterogeneous and can influ-
ence trial outcomes. Guidelines for reporting of behavioural trials
offer little guidance on which elements of TAU should be reported.
This study identifies which TAU characteristics are critical in behav-
iour change trials and should be routinely reported.
Method: A three-round modified Delphi study was conducted with
an international panel (N = 25) of health psychology practitioners
and research experts in trials methodology, primary care, TAU and
behavioural interventions. Participants rated the importance of 60
possible items, organised under eight categories (the reporting of
health behaviours, active content, tailoring of active content, setting,
provider, treatment time, fidelity of delivery and therapeutic alliance)
in Rounds 1 and 3 on a 9-point scale (1-3: not important; 4-6: recom-
mended; 7-9: critical). Participants also rated how detailed the report-
ing should be. Round 2 was a 2-week online discussion forum
amongst participants to discuss items. Consensus in Round 3 was
established using pre-determined thresholds.
Results: Experts agreed that 19 TAU characteristics (organised under
health behaviours, active content and tailoring, provider’s profession,
treatment time, setting and fidelity of delivery) are critical to report
at a general level. All these characteristics were also recommended
to be reported in more detail.
Discussion: This study adds to the existing reporting guidelines by
specifying which individual TAU characteristics are critical when
reporting behaviour change trials with TAU comparators, and how
detailed their reporting should be. Further research is needed to as-
sess how feasible it would be to collect these data.PS3D
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address statistical multiplicity in pragmatic RCTs, and b) whether ap-
proaches should vary according to the taxonomy of the situation
and context of research questions. The first step is to collate informa-
tion from three sources:
a)Systematic literature review around opinions, guidelines and
methods used
b)Survey of practice within UK based Clinical Trial Units (CTUs)
c)Survey of the methods used in pragmatic RCTs recently published
in high impact medical journals
Methods: A key objective is the creation of a conceptual framework
to synthesise the information obtained from the three sources. We
are extracting data from relevant papers into nVivo software in order
to generate themes and visualise findings graphically, e.g. compari-
son diagrams and concept maps. These findings will also be used to
inform the design of both surveys, which will include factual ques-
tions about specific approaches and open-ended questions to cap-
ture alternative methods.
Provisional results: Provisional systematic review findings suggest
varying opinions/guidelines on the approach to multiplicity, and that
methods used range from simple Bonferroni adjustment through to
more complicated procedures, e.g. hierarchical/gatekeeping proce-
dures. Once results from all three sources are available the synthe-
sised findings will be triangulated to inform the rest of the research;
the first step of which is planned to be empirical studies comparing
probabilities of Type I and II errors when applying different methods
to different multiplicity situations.
Potential relevance and impact: This research will provide guidance
on recommended approaches to address multiplicity for methodolo-
gists designing pragmatic RCTs and health professionals interpreting
RCT findings. The overall results have potential to be applied to most
RCTs commissioned by the NIHR, hence influencing evidence-based
changes in practice in the UK NHS across many disease areas.
This research is funded by the NIHR and the NIHR disclaimer applies.
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Introduction: The CONSORT Statement says that early stopping of a
clinical trial weakens the conclusions from the trial. The GRADE
guidelines go further, saying that early stopping is a study limitation
carrying the risk of bias, and recommending systematic reviewers
conduct sensitivity analyses omitting such studies. Our aim is to as-
sess methodologies for conducting these sensitivity analyses and to
make recommendations about interpretation of the guidelines.
Methods: We began by reviewing and summarising the range of
possible impacts of early stopping on treatment effect estimation in
single studies and meta-analyses. We then used simulation studies to
evaluate the performance of various approaches to meta-analysis
when early stopping is present. Our primary focus was early stopping
for benefit and we investigated the performance of meta-analyses
where treatment effect estimates were adjusted for the interim moni-
toring using the statistical method of conditional maximum likeli-
hood estimation.
Results: Early stopping at the first interim analysis leads to overesti-
mation of treatment effects but at subsequent interim analyses the
effect is unpredictable, and may lead to overestimation, underestima-
tion or even unbiased estimation. Interim monitoring that does not
stop the study early leads to underestimation. Importantly, these ef-
fects do not translate into biased meta-analyses, because the under-
estimation and overestimation balance each other in multiple
studies. In contrast, exclusion of studies stopped early always leads
to underestimation in meta-analyses. However, if treatment effect es-
timates are adjusted for the interim monitoring, prior to conducting
the meta-analysis, the underestimation is rectified.Discussion: We recommend against sensitivity analyses that simply
exclude studies that stopped early from meta-analyses. If a sensitivity
analysis is conducted in accordance with GRADE, we recommend
that treatment effect estimates are first adjusted for the interim mon-
itoring. To facilitate this, we recommend specific information that
should be reported in adhering to the CONSORT reporting standards
on early stopping.
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Introduction: The Consolidated Standards of Reporting Trials (CON-
SORT) statement was introduced in 1996 and revised in 2010. It pro-
vides a checklist for reporting details of the study design/results of
randomised controlled trials (RCTs). We aimed to survey RCTs pub-
lished in 1996, 2006 and 2016 to determine whether reporting stan-
dards of key methodological details had changed over time.
Method: We used MEDLINE to obtain a random sample of published
RCT articles from each year. There was no restriction on journal. Titles
and abstracts were screened, and full text of potentially eligible stud-
ies assessed for inclusion. We collected information on the journal,
number of treatment arms, whether a CONSORT flow diagram and
power calculation were included and how randomisation methods
and baseline data were reported.
Result: 252/603 studies were considered eligible for inclusion. Just
over a third provided a CONSORT flow diagram. A table of baseline
characteristics was provided in 83% of studies, but over half of these
also provided p-values for baseline data. Details of a power calcula-
tion were included for 47% of studies. The method used to generate
the random sequence and method of allocation concealment was
unclear/not reported in 70% and 65% of studies respectively. Over
time, the proportions including CONSORT diagrams, power calcula-
tions and baseline tables increased. Reporting of randomisation
methods also improved; permuted blocks and sealed envelopes
remained the most common methods for sequence generation and
concealment.
Discussion: Our survey was not restricted to high impact journals
and showed that reporting standards have improved between 1996
and 2016, but despite the existence of CONSORT, there is still poor
reporting of key methodological aspects of RCTs. Notably, over half
of articles reported significance tests for baseline characteristics, con-
trary to current recommendations, and the method of randomisation
was either unclear or not reported in over half of the studies.
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Introduction: Randomised clinical trials (RCTs) need to be reported in a
way that enables robust and reliable interpretation of their results. Here
we review how well current publications of RCTs report binary primary
outcomes and appropriate sensitivity analysis for missing data.
Numerous different statistical approaches exist for the analysis of
binary data, some of which have been shown to be suboptimal.
Guidelines, including the Consolidated Standards of Reporting Trials
(CONSORT), stipulate that analyses of binary outcomes should
present estimates for both absolute and relative effects, together
with confidence intervals. Where some primary outcome data are
missing, sensitivity analysis should investigate the effect of changes
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certain what is typically done.
Methods: We searched MEDLINE for primary publications of RCTs
published in January 2019, and identified those that reported a bin-
ary primary endpoint. Data to be extracted include the study size,
loss to follow-up by trial arm, statistical analysis methods (principal
and secondary) for the primary endpoint, together with whether or
not absolute as well as relative effects and their confidence intervals
were reported. Details of sensitivity analyses performed will be ex-
tracted, and reporting of the results will be considered
Timing of Potential Results: The search and study assessment
process is in progress and data extraction and synthesis will take
place over the summer. Around 200 trials are anticipated to be
included.
Potential Relevance & Impact: Current practice on how RCTs with
binary primary endpoints are analysed, and how well the results are
presented will be summarised. Presentation of both relative and ab-
solute effects, as well as the use of appropriate sensitivity analysis
are assessed. This will be useful to both authors and reviewers of
RCT reports and contribute to improving reporting standards, as well
as identifying potential areas for improvement.
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Background: When designing a randomized clinical trial (RCT), unlike
power and alpha which can be set at conventionally accepted values
(usually 90% or 5%, respectively), assumptions about the event rate
of the primary endpoint and the targeted difference (or minimal clin-
ically important difference) for the sample size calculation are often
based on prior knowledge from empirical studies or expert opinion.
Overestimation of event rates and target difference can have a detri-
mental impact on the power of an RCT. In this study, we aim to sys-
tematically investigate the prevalence and extent of overestimation
of event rates and targeted difference. We will then examine their
impact on trial conclusions.
Methods: We are planning to perform a cross-sectional survey review
of phase II-III RCTs published in seven high impact medical journals
from January 2015 to January 2019.
Timing of Potential Results: This study is part of an ongoing clinical
trials survey. It will include approximately 200 two-arm, parallel and su-
periority trials with a single binary outcome. In a pilot review of the first
68 RCTs, we have found that 34 (50.0%) had an overestimated primary
event rate (i.e. smaller than the lower limit of the 95% CI of observed
event rate) and 31 (45.6%) had a larger than targeted difference (i.e.
outside the 95% CI of the actual treatment difference). However,
among those 41 studies either having overestimation of event rate or
target difference, 10 of them drew a positive conclusion.
Potential Relevance & Impact: We think that many trials may be
underpowered due to higher event rates or aiming to detect unreal-
istic treatment effects. If this is the case the results from these stud-
ies should be interpreted with caution and not in isolation. This is
particularly important for trials with positive conclusion.PS4A
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Introduction: Running an internal pilot can help to optimise
methods for a trial. The literature provides recommendations for the
design of internal pilots, however, information is lacking regarding
the designs used and the process of review against progression cri-
teria. The aim of this research is to provide an overview of current
practice.
Methods: A cohort of clinical trials, extracted in 2017, comprised
those with an internal pilot having undergone the progression re-
view stage, funded by the National Institute for Health Research
Health Technology Assessment programme. Data about the design
and assessment of the internal pilots were abstracted from: project
descriptions; summary of changes from the first stage application;
funder/reviewer feedback about the full application; funder monitor-
ing notes; progress report history and trial protocols.
Results: Fifty-seven studies were reviewed. The majority of internal
pilots were first proposed in the initial stages. The Trial Steering
Committee was mostly commonly involved in the review process,
alongside the funder. Progression criteria included: target number for
recruitment, rate of randomisation, retention/primary outcome ascer-
tainment rate, rate of treatment adherence and consent rate. All
studies but one continued to the main trial, however a quarter did
not strictly meet their progression criteria. Actions taken for studies
which did not meet their progression criteria included a second re-
view, recovery plan and close monitoring. Changes were made to
the design of the main trial for 25% of the studies; these were pri-
marily to do with conduct of recruitment.
Discussion: We provide insight into the process of designing and
assessing internal pilot trials. Progression criteria are sometimes not
met; however, committees involved in the reviewing process will
generally support continuation to the main trial, usually accompan-
ied by a second review or close monitoring. We make recommenda-
tions to optimise the decision-making process.PS4A
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External pilot and feasibility (PAF) trials are an essential part of
trial preparation, particularly for the planning of complex inter-
ventions. However, they rarely published, and the ones that are
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odological focus. There are also misunderstandings about the
purpose of PAF trials including confusion about the definitions of
the terms “pilot trial” and “feasibility trial”. In this presentation,
we discuss: 1) some key challenges with past practice in the con-
duct and reporting of external PAF trials; 2) progress on address-
ing some of the challenges that include providing the framework
for defining PAF studies; and the CONSORT extension to PAF tri-
als focusing on those conducted in preparation for a randomised
controlled trial (RCT); and 3) future plans to address important,
unresolved uncertainties in design, conduct, analysis and report-
ing of external pilot and feasibility studies. These will include de-
veloping guidelines for sample size estimation, writing study
protocols for external PAF trials, and guidance for reporting of
external PAF studies which are not randomized controlled trials.PS4A
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Introduction: Pilot randomized clinical trials (RCTs) inform the de-
sign, planning, and conduct of full-scale RCTs. We reviewed the
start-up activities of an ongoing international rehabilitation RCT
(NCT03471247) examining early in-bed cycling in critically ill pa-
tients comparing the pilot with the main RCT.
Methods: We included all sites that participated in the pilot
(CYCLE Pilot RCT, CYCLE Vanguard) and those in the main RCT
which initiated ethics, contracts, or personnel training as of April
30, 2019. We extracted time to ethics and contracts approval,
number of training sessions and personnel trained on the proto-
col, and time from last activity (approvals or training) to the date
of first patient enrolment.
We hypothesized: 1.Shorter time to ethics approval for the full RCT.
2.No difference in time to contract approval. 3.No difference in time
to first patient enrolment. We calculated mean and standard devi-
ation (SD) or median and interquartile ranges [Q1, Q3] for data that
were not normally distributed. We conducted an unpaired t-test or
Mann Whitney-U Test, as appropriate. We used p<0.05 for statistical
significance.
Results: We included 10 pilot (8 Canada, 1 US, 1 Australia) and 14 full
RCT sites (11 Canada, 2 US, 1 Australia). Of these, 9 sites (7 Canada, 1
US, 1 Australia) participated in both the pilot and full RCT. There was
a shorter time to ethics approval in the full RCT (18 vs 68 days,p=
0.007), but no differences in time to contracts approval (64 vs 81
days,p=0.805) or first patient enrolment (39 vs 26 days,p=0.389)
(Table 1).
Discussion: Experiences and knowledge gained from the CYCLE pilot
RCT were instrumental in informing and planning start-up activitiesof our main RCT that led to faster ethics approval. Future studies
examining the generalizability of our results to other rehabilitation or
critical care trials are needed.
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Introduction: Although ethical issues related to consent in an exter-
nal pilot study (PS) or a feasibility study (FS) resemble those in a de-
finitive randomized controlled trial (RCT), there are important
differences in emphasis.
Analysis: Consent is given, or withheld, based on an understanding
of the study’s nature and purpose, and an appraisal of its potential
benefit; participants may altruistically shoulder the burden of partici-
pation for the sake of generating knowledge. Whilst the direct bene-
fit of a full RCT relates to clinical practice, the direct benefit of a PS
or FS relates to whether or not to conduct a full RCT; clinical benefit
is indirect, and uncertain, given that a full RCT may not ultimately
occur. As a randomized PS may outwardly resemble a main RCT, par-
ticipants may mistake its true purpose. Thus, the intended and the
perceived value of the study may differ, creating a different variety
of what is known as ‘therapeutic misconception’ from that arising in
a definitive RCT. The quality of consent will diminish accordingly.
Additionally, consent may be undermined by participants’ tendency
to overestimate the benefits, and underestimate the risks, of taking
part (referred to as ‘therapeutic misestimation’). This tendency may
raise specific concerns in a PS or FS: i) the nature and/or intensity of
an intervention being refined in a FS will not yet be fully optimized;
ii) participants in a randomized PF may not benefit from the superior
treatment until the completion of the main RCT very much later; iii)
if a subsequent main RCT is not in fact undertaken, no such clinical
benefit will accrue.
Conclusion: Ethical issues associated with consent in a PS or FS are
similar to those in a main RCT but require a different focus. This
should be reflected in the consent process and in the associated con-
sent documentation.
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Introduction: The current CONSORT guidelines for reporting of pilot
trials do not recommend hypothesis testing of clinical outcomes on
the basis of a pilot trial being under-powered to detect such differ-
ences and this being the aim of the main trial. It states that primary
evaluation should focus on descriptive analysis of feasibility or
process outcomes (e.g. recruitment, adherence, treatment fidelity).
Whilst the argument for not testing clinical outcomes is justifiable,
the same does not necessarily apply to feasibility/process outcomes,
where differences may be large and detectable with small sample
sizes. Moreover, there remains much ambiguity around sample size
for pilot trials.
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progression to the main trial determined by a set of criteria set up a
priori. We can set up a hypothesis-testing approach focused around
this system that tests against being in the RED zone (unacceptable
outcome) based on an expectation of being in the GREEN zone (ac-
ceptable outcome).
Results. For example, in relation to treatment fidelity, if we assume
the upper boundary of the RED zone is 40% and the lower bound of
the GREEN zone is 70% (designating unacceptable/acceptable treat-
ment fidelity, respectively), the sample size required for analysis
given 90% power and one-sided 5% alpha would be n=22 (interven-
tion group alone). A larger sample size would increase the power to
reject the RED signal in favour of potential progression.
Discussion: In general, more than one key process outcomes are
assessed for progression to a main trial; a composite approach would
be to appraise the rules of progression across all these key outcomes.
This methodology begins to provide a formal framework for
hypothesis-testing and sample size indication around process out-
come evaluation for pilot RCTs.PS4B
- O1 Considerations concerning the use of health economics in the
design and analysis of adaptive clinical trials – a qualitative study
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Introduction: Both adaptive designs and health economics offer in-
novative approaches to efficient research and decision making.
Adaptive designs allow data to be examined as a trial progresses to
inform changes to that trial. The methods of health economics aim
to maximise the health gained for the money spent. Methods for
evaluating cost-effectiveness could be incorporated into the design
and analysis of adaptive clinical trials, to give innovative and efficient
trials.
Methods: A qualitative study explored the attitudes of key stake-
holders – including researchers, decision makers and members of the
public - towards the use of health economics in the design, monitor-
ing and analysis of adaptive clinical trials. Data were collected using
interviews and focus groups. Framework analysis was used to analyse
the data and identify themes.
Results: Twenty-nine participants took part in the study. Partici-
pants considered that answering the clinical research question
should be the priority in a clinical trial, despite their awareness
that cost-effectiveness was important for decision making. Con-
cerns raised by participants included: handling the volatile nature
of cost data at interim cost-effectiveness analyses; implementing
this approach in global trials; resourcing the development of
adaptive trial designs that use health economics in their design
and analysis and training stakeholders in these methods so that
they can be implemented by researchers and appropriately inter-
preted by decision makers.
Conclusion: The use of health economics in the design and analysis
of adaptive clinical trials has the potential to increase the efficiency
of health technology assessments worldwide. However, careful con-
sideration is needed to ensure the statistical methods reflect the im-
portance of clinical effectiveness and adequate training and
resources are provided to facilitate the implementation of this
approach.PS4B
- O2 Stopping a clinical trial early based on the probability that
cost-effectiveness is unlikely: An extension of conditional power
computations to economic evaluation
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Introduction: Conditional power (CP) is a well-established method
for conducting futility analyses in clinical trials to stop a trial early for
lack of efficacy using observed data at some interim point. However,
despite futility criteria not being met, a trial may continue with mod-
est efficacy gains that are unlikely to be cost-effective. Treatment ef-
fects from such trials may not offer value for money to tax payers
because the cost per quality adjusted life year (QALY) can be much
higher than acceptable thresholds. Stopping a trial based on the
joint criteria of efficacy and costs have not been examined in detail.
Objectives: We extend the conditional power computations and
examine the probability of cost-effectiveness conditional on the data
observed at some interim point when applied in practice.
Methods: Expressions for the conditional power based on efficacy for
the two sample case (1:1 allocation) are extended to cost-
effectiveness. The incremental net benefit (INB), willingness to pay
(WTP) threshold, interim and final sample sizes, variabilities and cor-
relations between costs and effects are examined. Data from several
clinical trials are used to examine the operating characteristics of the
conditional power of cost-effectiveness (CPCE).
Results (TBC): Both CP and CPCE agree in general, about 70% of the
time for a CP threshold of 80%. CPCE conclusions will differ and can
be much lower 30% of the time, depending on the WTP. Hence, trials
may continue based on clinical efficacy, despite interventions being
unlikely to be cost-effective. Value of information methods (VOI) and
Bayesian predictive power results provide consistent conclusions
with CPCE.
Conclusions: CP based on cost-effectiveness is feasible and a useful
tool during IDMC meetings (where health economists are increas-
ingly involved) for decision making, especially where clinical effects
are modest or small. CPCE uses more information than standard CP
methods and is more informative.
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- O3 Cost-Effective Clinical Trial Design: Application of a Bayesian
Sequential Stopping Rule to the ProfHER Pragmatic Trial
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Introduction: We investigate value-based, sequential, clinical trial de-
sign by applying a Bayesian decision-theoretic model of a sequential
experiment to data from the ProfHER pragmatic trial. The work repre-
sents the first applied analysis of this value-based, sequential, design
to retrospective data from a completed clinical trial.
Methods: We take information on the research cost profile from the
trial and incorporate information on the accumulation of evidence
on cost-effectiveness to obtain a stopping boundary. We compare
this with the accumulation of data in the trial itself and use a boot-
strap analysis to study the stopping rule's operating characteristics.
Results: We show that the model's stopping policy would have
stopped the trial early, saving about 5% of the research budget
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trial's expected sample size could have been reduced by approxi-
mately 40%, saving an expected 15% of the budget, with 93% of
resampled paths making a decision consistent with the result of the
trial itself. Hence we show how substantial benefits to trial cost stew-
ardship may be achieved by accounting for research costs in defining
the trial's stopping policy and active monitoring of trial data as it
accumulates.
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- O4 Dealing with unavoidably high loss to follow-up in care home
trials - The DCM-EPIC trial
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Introduction: Conducting cluster-randomised controlled trials (cRCTs)
in care homes is challenging and resource intensive. Significant but
unavoidable loss to follow-up is to be expected due to the frailty and
age of the population. High loss to follow-up can lead to an under-
powered trial, biased results and uncertain conclusions due to miss-
ing data.
Methods: DCM-EPIC was a cRCT evaluating the effectiveness and
cost-effectiveness of staff-implemented Dementia Care Mapping (an
observational tool to support the implementation of person-centred
care) for people with dementia living in care homes in England. The
primary outcome was the level of agitation in residents 16-months
following care home randomisation.
Results: In DCM-EPIC, we faced ~50% at 16-months in clusters whose
size is fixed by the care home size/beds.
Discussion: Typically there are two trial design options: a closed-
cohort or a cross-sectional cRCT. DCM-EPIC was originally designed
as a closed-cohort cRCT but the loss to follow-up meant a design
change was required to maintain statistical power. A theoretically at-
tractive alternative that addresses the high loss to follow-up, termed
an ‘open-cohort’ or ‘dynamic-cohort’ cRCT design, can be considered
a hybrid between closed-cohort and cross-sectional designs, but is
presently not a widely recognised choice for cRCTs. Using DCM-EPIC
as an example, we will describe the rationale for using an open-
cohort design in this setting, the possible implications for the scien-
tific elements of the research (sample size, bias and analysis) as well
as study implementation elements (additional researcher resource to
recruit further residents, data collection and management consider-
ations), when compared to traditional alternatives.PS4B
- O5 To fund or not to fund a paediatric severe asthma trial: that is
the question
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Introduction: Clinical Trial Unit teams (CTUs) work closely with investi-
gators to develop funding applications for trials. The last 5 years have
seen an increase in the detail and reassurances funders request prior to
confirming funding success. When novel or adaptive designs are pro-
posed these iterations and reassurances can be even harder to navi-
gate. We share our experience and learning on a three year journey
from first submission to award of a small population paediatric trial.
Methods: In 2016 the NIHR released a commissioned call for “Difficult
to Treat Severe Asthma” encouraging novel approaches to make a
step-change in treatment. A national collaboration of investigators
identified priority research questions for the subset of children with
severe treatment resistant asthma.Feasibility work confirmed a maximum achievable sample size of 150
over 3-years and PPI work established a placebo arm would only be
acceptable for a short period. In order to answer three research ques-
tions and achieve the efficiency required, a non-standard design of
two interlinking trials was selected using a continuous primary out-
come, within-participant variability, and inclusion of placebo arm to
allow efficacy assessment and bio-marker validation.
The design presented challenges in terms of achieving blinding due
to complexity of the treatments and it was considered too complex
by the funder.
Results: With funder engagement the applicants re-examined the re-
search questions and undertook a radical re-design leading to an
open-label non-inferiority comparison of two treatments, using a
Bayesian approach with clinician elicited prior. Operational complex-
ity was reduced by the removal of blinding but Industry were less
keen to support and cost increased due to longer duration.
Discussion: Effective collaboration between Investigators, CTU staff,
PPI experts and funder is essential to ensure the right questions are
addressed and trial design is acceptable in small population settings.
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Introduction: CRYOSTAT-2 is an on-going Phase III trial recruiting
1568 trauma patients with major haemorrhage from 23 major trauma
centres in the UK and planned recruitment at level 1 US trauma
units. The intervention is early infusion of cryoprecipitate (a blood
component), alongside the standard major haemorrhage protocol,
which must be started within 90 minutes of arrival at the Emergency
Department (ED).
Methods: Learning from two feasibility trials it was clear that the trial
needed to be pragmatic to maximise recruitment in a challenging
and time critical environment. There were several challenges to over-
come including participant consent, randomisation method, timely
preparation and delivery of cryoprecipitate from blood banks to ED,
and comprehensive follow-up, as patients may abscond from hos-
pital, be returned to custody or suffer ongoing emotional trauma. Re-
cruitment out of hours was also considered crucial to recruit
representative patients and meet recruitment targets.
Results: A waiver of consent process enables rapid recruitment when
patients are often incapacitated, followed by personal and/or profes-
sional consultees and participant informed consent for continuation
in the study. Randomisation uses simple physical envelopes, and is
conducted by blood bank at some sites to reduce the burden on the
ED team. The trial is pragmatic to enable recruitment out of hours
and 29% of participants have been recruited between 8pm and 8am
so far. In those who receive the intervention, 83% receive it within
90 minutes, up from 79% in the first six months of the study. Section
251 approval is being sought from the Confidentiality Advisory
Group to enable complete follow-up.
Table 1 (abstract PS4A - O3). See text for description.
Pilot RCT
N=10 sites
Main RCT
N=14 sites
p-value
Time to ethics approval, median [Q1, Q3] (days) 68 [30, 106] 18 [14, 36]a 0.007
Ontario sites participating in pilot and main RCT (n=7)* 69 [28, 113] 16 [13, 18] 0.018
Time to contracts approval, median [Q1, Q3] (days) 81 [42, 119] 64 [38, 141]b 0.805
Time to first enrollment, mean ± SD (days) 26±31 39±25c 0.389
Training sessions across all sites, n
Cycling 14 15d -
Outcome measures 12 13e -
Research coordinator 12 13f -
Personnel trained
Cycling, n 52 44d -
Cycling, median [Q1, Q3] (people per site) 6 [3, 6] 3 [2,4]d -
Outcome measures, n 83 74e -
Outcome measures, median [Q1, Q3] (people per site) 10 [6, 10] 6 [4, 7]e -
Research coordinator, n 32 28f -
Research coordinator, median [Q1, Q3] (people per site) 2 [2, 3] 2 [1,3]f -
Abbreviations: RCT: Randomized clinical trial; Q=quartile; SD = standard deviation. *In the Main RCT, Ontario
instituted a central REB. Sample sizes for Full RCT sites varied, based on completed activities as of April 30,
2019: aTime to REB approval: n=12; bContracts approval: n=11; cFirst enrollment n=8; dCycling: n=13 sites;
eOutcome measures: n=12 sites; fResearch coordinators: n=12 sites
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ticularly in the context of a trauma call, but can be successfully deliv-
ered through pragmatic study design, a high quality multidisciplinary
team approach, and ongoing review and support from the lead in-
vestigators and dedicated Clinical Trials Unit.PS4C
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Introduction: Over 34 surgical Trainee Research Collaboratives (TRCs)
have been established across the UK which allow surgical trainees to
join large collaborative research groups focused either geographically
or by clinical speciality. These networks can generate new trials, im-
prove recruitment to ongoing trials and develop a research-active
consultant workforce. TRCs have completed several surgical trials, in-
cluding the ROSSINI trial in 21 UK centres led by the West Midlands’
collaborative. The reasons for TRC successes have not been evaluated
but understanding them is key to potential wider translation to other
clinical specialities.
Methods: Semi-structured interviews on experiences of participating in
surgical trials involving TRCs, including barriers and facilitators, and ob-
servation of trial and TRC meetings (n = 5) were undertaken. TRCs and
linked personnel were purposefully sampled to include a range of keystakeholders and surgical specialties across different geographical loca-
tions in the UK. 32 interviews were audio-recorded, transcribed and
analysed thematically, alongside observation field notes. Findings were
synthesised and presented at an external stakeholder meeting in 2018
with 13 experienced trialists, nurses and surgeons. The meeting identi-
fied key strategies to enhance clinicians’ engagement in trials across
specialities and inform post-graduate training.
Results: Analysis revealed four main themes: trainee motivations and
barriers to engaging with trials, perceived benefits, and challenges to
TRCs and overcoming these challenges. The most important strat-
egies identified were: identifying a Consultant champion to support
TRCs, conducting a “flagship” study over a relatively short duration to
promote the TRC and motivate trainees, transparency about what is
involved for trainees, facilitating trainees to generate study ideas and
becoming Co-CIs or Co-PIs, increasing research training and working
more closely with trial methodologists.
Discussion: If implemented these strategies could overcome the chal-
lenges identified and enhance clinician engagement and trial conduct
within surgery and other specialties. Further work is exploring this impact.PS4C
- O4 Design of Vaccine Efficacy Trials for Priority Emerging and
Epidemic Diseases
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Introduction: Vaccine efficacy (VE) trials use clinical trial frameworks
yet are not “clinical” trials: where disease natural history in patients
drives clinical trial design, understanding infectious disease transmis-
sion in populations underpins VE trials. Design of VE trials can be fur-
ther complicated by the sporadic nature and uncertain duration of
epidemics, alongside occurrence in resource-poor settings, and public
health imperatives to rapidly end transmission.
The NIHR-funded Vaccine Efficacy Evaluation for Priority Emerging
Diseases (VEEPED) project builds on the investigators’ experience in
responding to Ebola in West Africa, including in the design of the
WHO’s novel ring vaccination cluster randomised trial which demon-
strated efficacy for the rVSV-ZEBOV vaccine in Guinea.
VEEPED aims to determine appropriate VE trial designs for priority
emerging infectious diseases and to make recommendations to triallists
and policymakers on factors determining the feasibility or otherwise of
VE trials under different trial designs and epidemic circumstances.
Methods: VEEPED applies epidemiological evidence review and
transmission modelling to high-pathogenicity infectious diseases
which have been prioritised by the UK Vaccine Network and the
WHO R&D Blueprint. Through consideration of epidemic dynamics
and application of practical findings from studies such as the Ebola
ring vaccination trial, VEEPED evaluates VE trials designs to assess
those which may most feasibly demonstrate efficacy for novel vac-
cine candidates and appropriateness of different control strategies.
The project considers both specific priority diseases as well as
broader design principles based on epidemiological characteristics.
Timing of Potential Results: Preliminary findings of the VEEPED pro-
ject will be available in October 2019. Full findings will be available
in late 2020.
Potential Relevance & Impact: Inappropriate VE trial designs divert
resources and delay determination of efficacy for candidate vaccines.
Addressing VE trial design in the inter-epidemic periods strengthens
the prospect of rapid VE evaluation and deployment of effective
vaccines.
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Introduction : A standalone external pilot explores the feasibility of
performing a definitive RCT, with outcome data not routinely com-
bined with data from the subsequent RCT. An internal pilot is de-
signed and conducted as the first phase of an RCT, with outcome
data included in the main analysis. When to perform an internal or
external pilot is poorly understood. Qualitative work is needed to ex-
plore the views and perceptions of funders regarding how, when
and why to choose an external or internal pilot study design.
Methods: Purposive sampling identified participants from UK funding
panels including NIHR (HTA/RfPB/EME/PGfAR) CRUK, CSO and ARUK.
Maximum variation sampling ensured inclusion of multiple character-
istics, including chair/deputy chair/member positions on different
funding panels and various methodological roles. Semi-structured in-
terviews performed face-to-face or by telephone using a topic guide
explored participants’ views and practices of funding pilot work. Data
analyses were conducted according to principles of thematic analysis,
in an iterative and cyclical process as further interviews were con-
ducted and until no new themes emerged or evolved.
Results: Of 27 participants contacted, 19(70%) consented and were
interviewed in three iterative phases (mean duration 59minutes, range
30-88). Most participants agreed an external pilot design should be
chosen when substantial uncertainty exists about one or more design
parameters. Of these parameters, a stable, deliverable and acceptable
intervention was perceived by most as essential for proceeding to a
main trial. Some discussed how staged funding for external pilot stud-
ies progressing to a feasible main trial could improve efficiency and
limit waste, through avoiding conduct of studies with little hope of
main trial funding. Others felt an open ended funding strategy pre-
sented significant logistical difficulties, despite it’s appeal.
Conclusion: Future work will focus on developing recommendations
for when to do an external pilot, and establishing whether a flexible
design model is possible.
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common preventable reasons for poor trial recruitment. Exploring
treatment preferences during trial consultations entails eliciting and
acknowledging the reasons for a patient’s preference and providing
information to balance treatment views. Doing so can improve in-
formed consent, trial recruitment and retention. We examined how
trial recruiters respond to treatment preferences during consultations
and recruiters’ views about exploring treatment preferences.
Methods: Transcribed audio-recordings of 128 trial consultations from
97 patients and semi-structured interviews with 53 trial recruiters (sur-
geons, oncologists, and nurses) from two multicentre trials (CONTRACT
ISRCTN15830435; ROAM/EORTC-1308 ISRCTN71502099). Data analysis
was thematic.
Results: Initially, few recruiters elicited treatment preferences but fol-
lowing training they increasingly did so. However, contrary to the train-
ing, recruiters’ exploration and balancing of preferences tended to be
asymmetrical - they particularly avoided exploring and balancing pref-
erences when the patient’s preference aligned with the recruiter’s own
preference. In one of the trials, this often resulted in the patient declin-
ing to participate. Recruiters spoke of being reluctant to explore and
balance preferences and some attributed this to concerns about unduly
influencing patients to participate. Some thought preference explor-
ation would take too much time or would conflict with their clinical re-
sponsibilities to advise patients about treatments.
Discussion: Despite trial communication training, recruiters were
hesitant to explore patient treatment preferences. Consequently,
patients will often be relying on suboptimal information about
treatments to inform their decisions about trials. Emphasising that
preference exploration, regardless of the recruiter’s own prefer-
ence, is consistent with a supported and informed approach to
decision-making could help to overcome recruiters’ concerns. Evi-
dence on the perspectives of patients on treatment preference
exploration would inform recruiter training and practice. Trialists
also need to consider the potential impact of recruiter biases on
trial communication when designing future trials that compare
markedly different treatments.PS5A
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Introduction: Trials within Cohorts (TwiCs) is an innovative approach
to the design and conduct of multiple randomised controlled trials
(RCTs) (Relton et al, 2010). This approach utilises an observational co-
hort to recruit trial populations and obtain short and longer term
outcomes. We describe what is currently known about the use of this
design approach.
Methods: An extension of the 2010 Consolidated Standards of
Reporting Trials (CONSORT) Statements for RCTs using cohorts and/
or routinely collected health data is in development, supported by a
scoping review that includes publications of methods or reports of
protocols or results from RCTs using cohorts, registries, electronic
health records and administrative databases. Data sources for this
scoping review included Medline and Cochrane Methodology Regis-
ter and were limited to English language.
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methods or reports of protocols or results from RCTs that use cohorts
to recruit identified in the scoping review. This is supplemented with
information from topic experts.
We report: (i) types of cohorts (setting, population, condition/ disease
area), (ii) how the cohorts are utilised (identifying potential trial par-
ticipants, recruitment, randomisation, process and outcome data col-
lection including bespoke and/or routine health record data, types of
trials conducted/ planned), (iii) approaches to informed consent, e.g.
staged approach (Young-Afat et al, 2016), and (iv) any purported
and/or real study design (in)efficiencies.
Timing of Potential Results: Early results indicate 75+ eligible full
text articles, including 23 trial protocols and 23 articles reporting the
results of trials using cohorts. Full results will be available in August
2019 and presented at the conference.
Potential Relevance and Impact: Standard approaches to trial design
are often costly and frequently fail to recruit sufficiently large or rep-
resentative samples. This review will help provide information on the
use and potential (in)efficiency of the TwiCs approach.PS5A
- O4 Using a Discrete Choice Experiment to Examine the Factors
Influencing Clinical Trial Participation
Michelle Queally1,2, Declan Devane3, Matthew Griffin2, Paddy Gillespie1,2
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Introduction: Understanding the key factors within individuals’ deci-
sion making process with respect to clinical trial participation has the
potential to improve both the efficiency of recruitment for clinical tri-
als and their management. Currently little known about the relative
importance of the different factors influencing individuals’ decisions
regarding clinical trial participation. The objectives of this study were
to use a discrete choice experiment (DCE) to: (1) identify key factors
important to individuals regarding participation in clinical trials, (2)
better understand how individuals’ value and trade-off between
these factors; and (3) estimate willingness-to-pay for these factors.
Methods: A literature review, four focus groups, two consultations
with a public and patient involvement (PPI) group and three consul-
tations with expert groups of clinicians and researchers were con-
ducted to select attributes and levels for the DCE. The Nominal
Group Technique (NGT) which is a structured, multistep, facilitated
group meeting technique was used to elicit and prioritize responses
to identify the most important attributes in clinical trial participation.
Timing Potential Results: Six attributes ranked most important re-
garding clinical trial participation were identified: (1) Communication,
(2) Knowledge, (3) Risk, (4) Benefit, (5) Incentive; and (6) Follow up
time of the trial. A Bayesian efficient DCE design to include twelve
choice sets was piloted (n=45). The main survey will be administered
(May 2019) to a nationally representative sample in Ireland (n=500).
Potential Relevance and Impact : To the best of our knowledge, this
is the first study to utilise a DCE to measure and quantify preferences
of individuals regarding factors influencing clinical trial participation.
The incorporation of choice task questions will enable trial researchers
to elicit how individuals weigh up their choices and consider trade-offs
between the attributes. This study will also be the first to include a PPI
panel throughout the DCE design and development.PS5A
- O5 Physical Rehabilitation Core Outcomes in Critical Illness
(PRACTICE): a secondary modified thematic analysis characterising
reasons for change in rating importance of outcomes for physical
rehabilitation trials
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Introduction: Trials of physical rehabilitation in critical illness across the
continuum of recovery are challenged by outcome heterogeneity.
PRACTICE is an international, mixed-methods study designed to de-
velop a core outcome set (COS) for such trials. Following completion of
stage one of PRACTICE, where outcomes for inclusion in the core set
were agreed, we sought to explore participant reasons for changing
scoring of outcome importance during the consensus process.
Methods: A preliminary secondary analysis of a two-round modified
Delphi consensus process involving multiprofessional researcher and
clinician, and patient/caregiver stakeholder groups, in which partici-
pants rated the importance of 30 outcomes for inclusion in the COS
using a 9-point scale (1-3, not important; 4-6, important but not crit-
ical; 7-9, critical). Feedback from scoring in the first round was pro-
vided in the second round, presented for overall participants and per
stakeholder group. Where a participant changed their rating of an
outcome resulting in subsequent change in importance category,
they were prompted to provide a reason for that change. Changes
were classified as ‘positive’ or ‘negative’ indicating either an increase
or decrease in outcome importance, respectively. A modified the-
matic analysis was conducted to characterise reasons for change.
Results: 301 participants completed both rounds of the consensus
process. In total, 832 reasons for change were provided (n=627 posi-
tive, n=205 negative). Fourteen themes characterising reasons for
change were identified, the most common of which were i) ‘Consid-
ering the impact on other outcomes’ (n=179, 21.5%), ii) ‘Being influ-
enced by the patients’ responses’ (n=174, 20.9%), and iii)
‘Reconsideration’ (n=107, 12.9%).
Discussion: Multiple factors influenced rating of outcome importance
for inclusion in the PRACTICE COS. That patient opinion featured
heavily in decision-making highlights the value of their contribution
to the COS development process, and may also infer the importance
of patient involvement in primary study design.PS5B
- O1 Open-cohort designs in institutional settings: findings from a
literature review of cluster-randomised trials and epidemiological
studies
Laura Marsden1, Rebecca Walwyn1, Andrew Copas2, Claire Surr3, Amanda
Farrin1
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in institutions such as care homes, schools, hospitals, prisons, and
whole communities. These institutions can be defined as ‘open co-
horts,’ as individuals join and leave the cluster over the study period.
Two accepted designs currently exist for CRTs. Closed-cohort designs
follow the same individuals over time, allowing us to assess interven-
tion effects on individuals. As care home CRTs suffer unavoidably
high drop-out rates, mainly due to death, use of a closed-cohort de-
sign can result in substantial missing data, introducing bias and lead-
ing to questionable conclusions. Alternatively, cross-sectional designs
collect data from different groups of individuals at the start and end
of a trial. Whilst unaffected by drop-outs, this design only permits
analysis of change at the population-level, not on individuals.
We propose an ‘open-cohort design’ which accounts for migration
and uses data from all individuals present in the cluster between
baseline and follow-up, allowing us to generalize at both individual-
and cluster-level and assess long-term effects. Whilst open-cohort de-
signs are not currently widely recognised as an alternative for clinical
trials, open-cohort studies are conducted in epidemiology.
Methods: A review of epidemiological studies and CRTs in care
homes, schools, hospitals and other settings was conducted. We ex-
plore the extent to which open-cohort designs have, or could have,
been used across these settings. Practical challenges arising in imple-
mentation and analysis, generally or specific to setting, are
investigated.
Timing of potential results: The review is underway and expected to
be completed by June 2019.
Potential relevance and impact: Open-cohort designs have obvious
advantages; fewer clusters would need to be recruited, reducing
costs, and research questions targeting all those exposed to the
intervention during the study period could be addressed. However,
research is needed to determine how this design complicates the
conduct, analysis and interpretation of CRTs.PS5B
- O2 Power calculations for Cluster Randomised Trials (CRTs) with
truncated Poisson-distributed outcomes: A motivating example
from a malaria vector control trial
Lazaro M. Mwandigha1, Keith J. Fraser1, Amy Racine2,3, Samer
Mouksassi3,4, Azra C. Ghani1
1MRC Centre for Global Infectious Disease Analysis, Imperial College
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Background: Cluster-randomised trials are increasingly used to study
the efficacy of interventions targeted at the population level. Whilst
formulae exist to calculate sample sizes taking into account the intra-
cluster correlation, they assume that the outcome under consider-
ation covers the full range of allowable values. This assumption is fre-
quently violated in epidemiological trials in which counts of infection
episodes are truncated due to practical constraints on the number of
times a person can be tested.
Methods: Motivated by a malaria vector control trial with right-
truncated Poisson-distributed outcomes, we investigated the effect
of truncation on power using Monte Carlo simulations.
Results: The results demonstrate that the adverse impact of trunca-
tion is directly proportional to the magnitude of the event rate λ
with estimates of power being overestimated in instances where the
truncation was not accounted for. The severity of the adverse impact
of truncation on power increased with magnitude of the intra-cluster
correlation (ICC) but decreased the further the truncation point was
from zero.Discussion: Potential truncation should therefore be accounted for in
the estimation of sample size requirements and power at the study
design stage.
PS5B
- O3 Comparison of different randomisation methods in a cluster
randomised vaccine effectiveness trial: a simulation study using
real-world data
Xinxue Liu1, Merryn Voysey1, K Zaman2, Farhana Khanam2, Firdausi
Qadri2, Andrew Pollard1, John Clemens2
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford,
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Background: Cluster randomised controlled trials (CRCTs) of vaccine
effectiveness randomly allocate all individuals in a geographically-
defined cluster to receive either the test vaccine or a control vaccine
according to their cluster of residence. Randomisation by cluster ra-
ther than by individual can result in the baseline characteristics of in-
dividuals being imbalanced between the treatment groups. The lack
of balance at baseline will increase the variance of the estimated ef-
fect and thus reduce the efficiency of the study.
Methods: We conducted a simulation study using census data from
a CRCT (Typhoid Vaccine Acceleration Consortium-Bangladesh,
TyVAC-Bangladesh) to compare three randomisation methods (sim-
ple block randomisation, stratified block randomisation, and re-
stricted randomisation) in three different scenarios: all 150 clusters in
TyVAC-Bangladesh, or a subset of 50 or 20 randomly selected clus-
ters. For each randomisation method, we generated 1000 randomisa-
tion lists allocating each cluster to either typhoid vaccine or control.
For each baseline characteristic, imbalance was defined as ≥10% dif-
ference between the two arms. We assessed the performance of
each randomisation method by comparing the proportion of simu-
lated randomisation lists with that were imbalanced for each se-
lected baseline characteristics.
Results: For individual-level continuous normally distributed vari-
ables, such as age, all randomisation methods achieved perfect bal-
ance. For continuous cluster-level variables (such as the number of
male participants in the cluster), the performance of the randomisa-
tion method depended on the variable’s distribution. For highly
skewed variables, most methods had imbalance proportions >70%.
However, when restricted randomisation was used with the skewed
variable as a design variable, the imbalance proportion dropped to
20%. Scenarios with large numbers of clusters were less likely to be
imbalanced.
Conclusion: Choosing the right design variables for cluster random-
isation is important to achieve good baseline balance in CRCTs. Out-
come predictors with highly skewed distribution at cluster-level
should to be incorporated as a design variable.PS5B
- O4 Common concerns about the feasibility of stepped-wedge
cluster randomised trials and issues encountered during trials of
this design: findings of an online questionnaire
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1Health Sciences, University of Leicester, Leicester, United Kingdom;
2Institute of Applied Health Research, University of Birmingham,
Edgbaston, United Kingdom
Trials 2019, 20(Suppl 1):PS5B
Introduction: Stepped-wedge cluster randomised trials (SW-CRTs) are
a complex design with features that may increase the likelihood of
Trials 2019, 20(Suppl 1):579 Page 115 of 141the trial encountering issues that may impact its feasibility. The aim
of this work was to determine the common issues affecting the feasi-
bility of SW-CRTs.
Methods: An online questionnaire, consisting of closed questions
and free-text responses, asked respondents about their involve-
ment in SW-CRTs, concerns about the feasibility of the trial and
any problems encountered. Participants were also asked about
any concerns they had about SW-CRTs in general. Potential par-
ticipants were identified from the authors of published SW-CRTs,
list of delegates at conferences about SW-CRTs, panel member
pages of funders’ websites, and the websites of clinical trials
units and the Research Design Service. Recipients were encour-
aged to forward their email invitation onto anyone that might be
interested in participating. Open invitations were posted on Twit-
ter. A descriptive analysis was conducted.
Results: Email invitations were sent to 403 individuals, 154(38%)
responded, mostly trialists (66%) and funding panel members (16%).
Most participants had been involved with a SW-CRT (82%) and had
concerns about some aspect of the design (94%). Some of the most
common concerns related to the staggered implementation: not hav-
ing all clusters ready when the trial starts; clusters not willing or able
to start the intervention when randomised to; when to inform clus-
ters of when they’ll start the intervention; and retention of the last
clusters to start the intervention.
Discussion: There are features of the SW-CRT design which have the
potential to impact the feasibility of the trial. In particular, the stag-
gered implementation of the intervention, although often one of the
main reasons for choosing this design, can cause problems. The add-
itional challenges of staggering the implementation of the interven-
tion need to be weighed against the potential benefits.PS5B
- O5 Optimal incomplete stepped wedge trials with continuous
recruitment
Richard Hooper1, Andrew Forbes2, Jessica Kasza2
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Introduction: We consider the problem of optimal design for a
stepped wedge trial with continuous recruitment. Suppose we recruit
from a fixed number of clusters where eligible participants present
continuously over a fixed duration, and suppose we have a fine de-
gree of control over the timing of cross-over in each cluster. Suppose
also that we want to minimise the number of participants, leading us
to consider “incomplete” designs (which do not recruit for the entire
duration at every cluster). How should we schedule recruitment and
cross-over at different clusters to achieve given precision with the
fewest participants?
Methods: The optimality of incomplete designs is poorly understood.
Time here is continuous, and the time effect modelled as a polyno-
mial, but to simplify we assume that eligible participants present at
regular intervals. Without exploring every possible design there is no
guarantee of finding a global optimum, but an iterative algorithm
which makes slow, steady modifications may come close. We demon-
strate one such approach. At each iteration (starting from a complete
design) a single participant – the participant making the least impact
on precision – is removed, and then small changes preserving the
total sample size are made repeatedly to improve precision until no
further improvement is possible. This continues until further itera-
tions would compromise the desired precision. To triangulate the so-
lution the algorithm restarts with a very sparse design, adding a
participant at each iteration until the desired precision is achieved.Results: Unusual and striking shapes emerge. Solutions tend to focus
recruitment and cross-over on the leading diagonal of the cluster-by-
time diagram, but in some scenarios clusters become organised into
distinct steps or phases.
Discussion: There is evidently much to be learned about optimal trial
design in this setting. Algorithmic searches could offer a practical ap-
proach to trial design in complex settings.
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Pragmatic randomised trials aim to provide evidence to support deci-
sions by stakeholders in healthcare systems (patients, clinicians, fun-
ders, policy makers). The typical pragmatic trial recruits participants
who provide data for the trial using purpose built data collection sys-
tems. At the end of the trial – all is disbanded. This approach is costly
and frequently fails to recruit sufficiently large or representative
samples.
Since the advent of electronic data, pragmatic trials are increasingly
using routine health data collected from administrative, clinical and
patient sources. A new group of trial designs have emerged which
we describe as ‘Health System Trials’. These include Registry-based
Randomised Controlled Trials (RRCTs), Electronic Health Record (EHR)
Trials, Administrative Data (AD) Trials and Trials within Cohorts
(TwiCs). These four designs purposefully utilise existing and/or newly
created health system data structures for one or more trial activities:
identifying potential trial participants, recruitment, randomisation,
process and outcome data collection, etc. The process of informed
consent is often spread out (staged) as occurs in routine healthcare
especially with TwiCs designs.
By utilising populations within health systems and the data that de-
rives from their healthcare encounters, these trials efficiently recruit
large representative populations and obtain both short and longer
term outcomes. These designs reduce the effort and cost of trials
whilst improving the applicability of the trial results for decision
makers in health systems.
We discuss the opportunities for these types of trial designs to be in-
tegrated within health systems, enabling the continuous generation
of knowledge that is an essential feature of learning health systems.
CONSORT Reporting guidelines for Trials Using Cohorts and Routine
Health Data are currently being developed. Drawing on development
work for these guidelines we describe real world examples of ‘Health
System Trials’, including examples of both nascent vertical (disease
focused) and horizontal (e.g. practice based) learning health systems.
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NCT01852123) was a randomised controlled trial, enrolling 48,282 pa-
tients between 2013 and 2016. The trial’s objective was to determine
if implementation of a new high-sensitivity troponin assay would im-
prove outcomes in patients presenting with suspected acute coron-
ary syndrome to hospital emergency departments across Scotland.
The trial was unusual in making use of routine electronic healthcare
data in unconsented patients. This presented a number of data man-
agement and governance challenges.
Methods: The trial accessed routine electronic healthcare data
sources from ten hospitals in two NHS health boards in Scotland. Par-
ticipant data were linked across twelve distinct data sources using
the participant CHI (Community Health Index) number as a unique
identifier.
Data extraction was supported by the NHS Safe Haven of each health
board and eligible patients were assigned a unique study ID prior to
removing identifiable participant data. De-identified data were trans-
ferred to a secure analysis platform and combined into a single data-
base for statistical analyses, accessible only to approved individuals.
The study had ethical and local management approval for record
linkage.
Results: Reporting of the trial presented challenges not encountered
in conventional randomised controlled trials. Data linkage was com-
plex – collection of the correct data during the correct timeframe
from multiple data sources was challenging. Creation of a ‘meta data-
base’ whilst ensuring data accuracy was made possible by drawing
on a number of securely linked raw NHS data sources.
Discussion: The High-STEACS trial successfully reported on a large
number of patients via routinely collected healthcare data. Using
data from electronic health records without individual patient con-
sent required adherence to rigorous data governance processes. This
approach enabled all patients to be identified, rather than limiting
findings to a selected, possibly unrepresentative, group which would
have been the case in a traditional clinical trial setting.
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Background: Trials within implementation laboratories involve col-
laborations between healthcare systems and research teams to ad-
dress health systems’ priorities and produce generalisable knowledge
about factors—context, intervention design, and delivery—that could
influence effectiveness of feedback interventions. Sequential head-
to-head trials can compare various consecutive refinements of feed-
back interventions with embedded process evaluations to examine
mechanism of action and effect modifiers. Such incremental im-
provements could lead to faster changes in policy, address health-
care system priorities, and advance improvement science.
Primary care data sources for feedback interventions include large-
scale databases (General Practice Research Database), high-level na-
tionally gathered databases (OpenPrescribing.com) or data extracted
directly from electronic health records (EHR). Different sources of
data have implications for implementation laboratory trial design.Methods: The Campaign to Reduce Opioid Prescribing is a primary
care feedback intervention that has led to a deeper understanding of
the utility and challenges of primary care data sources.
316 practices in West Yorkshire were provided with bimonthly feed-
back on opioid prescribing for non-cancer pain. Effectiveness of this
enhanced feedback intervention was assessed using an interrupted
time-series design.
Results: High-level, nationally gathered data showed opioid prescrip-
tion rates fell significantly in intervention practices during the post-
intervention period compared to control practices (0.05 prescriptions
per 1,000 patients (95%CI -0.10, -0.01)). Locally extracted EHR data
gives a more in-depth analysis by reducing ‘noise’ (exclusion of opi-
oids prescribed for palliative care), potential unintended conse-
quences (increased referrals) and demonstrates changes in clinically
relevant sub-groups, however data extraction was complex and iden-
tified challenges in collection.
Discussion: UK primary care data sources are heterogeneous, with
different purposes, structures and collection methods. The utility of
data sources have implications for conducting pragmatic trials that
will have consequences for methodological advances in the develop-
ment of ‘implementation laboratories’ and will be integral to the de-
sign of future trials in this field.
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Introduction: There is growing interest in identifying how core out-
come sets (COS) might fit into the different stages of the healthcare
research and delivery ecosystem, and how this might be facilitated. It
has been suggested that COS may be used to inform clinical guide-
lines, audit, quality standards (QS) and quality indicators (QI) (1). If so,
the potential of electronic health records (EHR) to facilitate compara-
tive effectiveness research by providing a readily available source of
data would be greatly enhanced as the outcome data being col-
lected in routine practice and the outcomes chosen for this type of
research would be the same.
Methods: We will compare COS for research with COS for routine
care, matched by condition. We will present a ‘proof of concept’ case
study in type 2 diabetes (T2D), mapping outcomes across COS, QS,
QI, and EHR.
Results: To date, 275 COS studies (333 COS) for research and an add-
itional 32 COS studies (35 COS) for both research and routine prac-
tice have been published (2). Of 257 ongoing COS registered in the
COMET database, 131 are for research and 10 for routine care, with
the remaining 116 being developed for both research and routine
care. Sixteen (89%) of the 18 core outcomes included in the SCORE-
IT T2D COS (3) were represented within the ICHOM diabetes set for
routine care (4), all were recorded within CPRD, and 13 (72%) and 14
(78%) featured in the NICE QS (5) and QI set (6) for T2D respectively.
Discussion: This talk will focus on the importance of and opportunity
for choosing outcomes to measure that matter to patients and
decision-makers, and the barriers and facilitators for core outcomes
to be incorporated into routine data collection.
References
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Introduction: Translational failure from pre-clinical animal studies to
clinical trials has been noted in a number of disease areas. Whilst
multiple contributory factors including poor study conduct and
reporting have been acknowledged, little attention has been given
to whether outcomes measured in pre-clinical studies are relevant to
those considered important in clinical trials. Core Outcome Sets
(COS) aim to reduce waste in research by defining a minimum set of
outcomes to be used in all trials of a particular condition. However,
these have been developed for phase 3/4 effectiveness trials and
their utility in pre-clinical research is unknown.
Methods: To better understand the translatability of outcomes a sys-
tematic review of outcomes used in preclinical pharmacological inter-
ventions for type 2 diabetes in mouse models will be completed. We
will extract exact descriptions of outcomes and categorise these ac-
cording to the COMET taxonomy. The list of outcomes will then be
compared to outcomes identified in a systematic review of phase 3/4
trials of glucose lowering interventions. Preclinical outcomes will also
be reviewed against the outcomes considered most important, and
recently included in a COS, by people with type 2 diabetes, health-
care professionals, researchers, and policymakers.
Timing of Potential Results: Results of the pre-clinical systematic re-
view and extracted outcomes will be presented. The core outcome
set for glucose lowering interventions for type 2 diabetes and sys-
tematic review of phase 3/4 studies have been completed.
Potential Relevance & Impact: This review of pre-clinical studies will
enable better understanding of the outcomes measured at different
phases of research and the translatability of COS. The use of estab-
lished COS in pre-clinical studies may also provide a way for patients
to influence pre-clinical research to make it more relevant to their
needs and contribute to the refinement of animal studies and overall
reduction of animals in research.PS5D
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Introduction: In trials in surgery, post-operative length of hospital
stay (LoS) is often used as a proxy for early outcome. However, blind-
ing of surgeons is typically not possible, which leads to potential for
bias, as the surgeon decides when a patient is ready for discharge.This has led us to investigate how routinely collected clinical mea-
sures during the first 24 hours and complications that occur through-
out the post-operative stay could be used to develop a more
objective measure of early outcome.
Methods: Measurements routinely collected during the first 24 hours
after surgery have been extracted from hospital electronic records
and combined with trial data for a cohort of patients who have pre-
viously participated in a cardiac surgery RCT. Relationships between
six measurements (summarised over the first 24 hours) and LoS have
been investigated to identify early indicators of poor outcome. The
six measures were chosen in discussion with clinician colleagues.
Provisional results: A total of 808 patients who had participated in
one of 7 trials were included. Initial univariable and multivariable
analyses suggest higher arterial mean blood pressure and higher
minimum haemoglobin were significantly associated with shorter
LoS, while higher maximum lactate and maximum potassium were
associated with longer LoS. Heart rate and temperature were not as-
sociated with LoS. Effect estimates were attenuated for all measure-
ments in the multivariate analysis. We will also describe the
association between these measures and complications and how
these are being combined, alongside patient and clinician “ratings”
of complication severity, to develop of an objective measure of early
outcome.
Potential relevance and impact: Supplementing clinical trial data
with routinely collected measurements provides more detailed infor-
mation on early outcome at minimal additional cost. The method-
ology to develop this measure is applicable in other clinical areas.PS5D
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Introduction: Core outcome sets (COS) improve the consistency and
relevance of outcomes in trials but these benefits will only arise if tri-
alists use them. Our first aim was to assess the extent to which trial-
ists followed a funder’s recommendation to search for a COS. Our
second aim is to explore trialist’s views on COS.
Methods: In January 2012, the NIHR HTA programme updated their
guidance to recommend that applicants search for a COS when pre-
paring a funding application for a trial. We examined 95 researcher-
led applications submitted to the NIHR HTA from then to December
2015 for evidence of such a search and other rationale for outcome
choice. We also surveyed applicants to explore their use of COS and
choice of outcomes. Our next step is to conduct semi-structured in-
terviews with researchers working on NIHR HTA clinical trials. Purpos-
ive sampling from the NIHR portfolio of research projects will identify
participants whose experiences can inform our understanding of out-
comes in trials. We will seek data saturation and our analysis will
draw on thematic approaches.
Results: Results of the qualitative interviews will be available for pres-
entation at the conference but our document-based work showed
that 18 of the 95 NIHR HTA applications (19%) stated that a search
for a COS had been done. Of the 77 (81%) applications that did not
mention COS, our survey of applicants found that 18 had searched
for a COS. Some applicants who did not search for COS gave reasons
for their choice of outcomes.
Discussion: A funder can have an impact on COS uptake by encour-
aging a search for a COS, but more actions are needed to increase
this impact. Our interviews with researchers will provide further infor-
mation on the barriers and facilitators to COS uptake, which will in-
form such strategies to improve uptake of COS.
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Introduction: Core outcome sets (COS) represent the minimum out-
comes that should be measured and reported in all clinical trials in a
specific condition. Input from patients in COS development, and sub-
sequent uptake of COS, will ensure that future studies provide users
of research with relevant knowledge regarding interventions. A 2017
survey found that Delphi surveys are being utilised in 89% of on-
going COS with patient participants. It is unclear how patients experi-
ence Delphi surveys as part of COS development and whether these
methods are suitable for facilitating patient participation. The object-
ive of this study was to explore participants views of the Delphi sur-
vey used for COS development.
Methods: Patients and health professionals who participated in a
Delphi survey as part of a COS study took part in semi-structured
qualitative interviews which explored participants’ understanding of
COS and their experiences of the Delphi survey. Analysis was inter-
pretative and thematic.
Results: Twenty-four participants from 7 COS studies were inter-
viewed. They varied in how accurately and fully they understood the
purpose of COS and the Delphi survey, which influenced their partici-
patory experience. They also differed in how easily they interpreted
and subsequently used the written guidance provided to COS partici-
pants. Some participants wanted guidance regarding whose perspec-
tive to take into account when scoring outcomes and on how to
apply the scoring system. Participants’ motivation for taking part in-
cluded the international and expert consensus aspects of the Delphi
survey. A small number of participants raised the positive and nega-
tive emotional impact of participation when reviewing outcomes and
stakeholder feedback.
Discussion: The findings identify ways of improving information for
COS Delphi participants to enhance their experience of participation
and make the process more meaningful for them.PS5D
- O4 The impact of patient-reported outcome (PRO) data from
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Background: Patient-reported outcomes (PROs) are commonly col-
lected in clinical trials and should provide impactful evidence on the
effect of interventions on patient symptoms and quality of life. How-
ever, the different types of research impact associated with PRO trial
results, appropriate impact metrics and barriers and facilitators are
not well defined. Objectives: i) to determine the range of potential
impacts from PRO trial data, identify potential PRO impact metrics
and identify barriers/facilitators to maximising PRO impact; and ii) to
examine real-world evidence of PRO impact based on Research Ex-
cellence Framework (REF) 2014 impact case studies.Methods: Two independent investigators searched MEDLINE, EMBASE,
CINAHL+, HMIC databases from inception until December 2018. Articles
were eligible if they discussed research impact in the context of PRO trial
data. In addition, the REF 2014 database was systematically searched for
case studies incorporating a trial in which PRO data were collected.
Results: Nine types of PRO trial impact were identified; the most frequent
of which centred on PRO data informing clinical decision-making. The in-
cluded publications identified several barriers and facilitators centred
around PRO trial design, conduct, analysis and reporting. Twelve (17%) REF
case studies outlined demonstrable PRO trial impact; including changes to
international and national guidelines, influencing cost-effectiveness analysis
and contributing to drug approvals.
Conclusions: PRO trial data may potentially lead to a range of im-
pacts and benefits for patients and society, which can be measured
through impact metrics. However, in practice, there is relatively lim-
ited evidence demonstrating directly attributable real world PRO-
related research impact. In part, this is due to the wider challenges
of measuring the impact of research and PRO-specific issues around
design, conduct, analysis and reporting. Adherence to existing inter-
national guidelines is essential to maximise the use of PRO trial data,
facilitate impact and minimise research waste.
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Introduction: Dementia research uses multiple measures due to the
complexity of the condition. Limited dementia-specific scales exist
and generic measures are used in their absence. Problems such as
the acceptability of responses and respondent fatigue, as well as the
use of retrospective recall in a population with recall difficulties are
challenges to effective outcome assessment in dementia research.
Aims: To explore the limitations of the outcome measures used in a
randomised controlled trial of a complex intervention for persons
with early stages of dementia.
Objectives
-Use retrospective analysis of study data and outcome assessor comments
recorded during data collection to identify potentially problematic items or
scales and explore participant difficulties in completing the outcome
measures.
-To report on the effectiveness of the measures used and make rec-
ommendations for future dementia measure development.
Setting: ‘Journeying through Dementia’ is a randomised controlled
trial of a community-based self-management intervention for people
with early stages of dementia and their carers. 480 people with de-
mentia took part in the trial, and outcome measures were collected
face-to-face at baseline, 8-, and 12-month intervals. We selected de-
mentia specific outcome measures based upon recommendations for
research across Europe and used general measures where dementia-
specific scales were not available.
Methods: A retrospective secondary analysis of 8-month follow up
data from the trial. Quantitative analysis of missed item responses,
missed scales and drop-out points identified potentially problematic
items and measures. A narrative review of comments made by out-
come assessors explored why participants had trouble in responding
to outcome measures.
Timing of Potential Results: Potential results will be available in July
2019.
Potential Relevance and Impact: We report on the problems experi-
enced using outcome measures in a large scale RCT for dementia.
Learning from the Journeying through Dementia trial may guide fu-
ture trial conduct and outcome measure development.
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Background: Poor retention is common. It reduces statistical power
and can bias the estimates of intervention effect, especially with dif-
ferential loss-to-follow across trial arms. Given the sparsity of evi-
dence from randomised evaluations of effective retention strategies,
we performed a systematic review to synthesise evidence from non-
randomised evaluations to supplement existing evidence.
Methods: We searched MEDLINE, Embase, and Cochrane CENTRAL from
2007 to 2017 for studies that compared two or more strategies to increase
retention in randomised trials, but did not use randomisation for allocation.
The retention trials had to be nested in real ‘host’ trials.
Abstract and text screening was done in duplicate. Two investigators
independently rated the risk of bias of included studies using the
ROBINS-I tool and determined the certainty of evidence using
GRADE.
Results: We identified 7609 abstracts and included 14 studies in the
review. Most retention strategies were targeted at increasing ques-
tionnaire response rate rather than face-to-face appointments. Six
strategies suggested a promising increase in questionnaire response
rates: telephone follow-up compared to postal questionnaire comple-
tion; electronically-transferred monetary incentives compared to cash
incentives; cash versus no incentive; reminders to non-responders;
shortened versus longer questionnaires; online questionnaire follow-
up compared to postal questionnaire [absolute increase in retention
ranged from 10-40%]. However, each retention strategy was evalu-
ated in a single observational study, which together with risk of bias
concerns meant that GRADE certainty was low or very low for all in-
cluded studies.
Conclusions: This systematic review provides low or very low cer-
tainty evidence on the effectiveness of retention strategies evaluated
in non-randomised studies. Despite the uncertainty, some of the re-
ported effect sizes were substantial and would remain large even if
greatly reduced. Further evaluation in randomised studies (particu-
larly telephone follow-up) would be helpful to provide a more cer-
tainty around the actual effect size.
Keywords: Clinical trials; Drop-outs; Non-randomised evaluations;
Retention
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Background: Issues around retention, especially those issues re-
ported by trial participants, have not received the same scrutiny in
the literature as trial recruitment. This is a mistake. Poor retention is
just as important for trial validity and is quite capable of fatally
undermining a trial. Our aim was to undertake a meta-ethnographic
synthesis of findings from primary qualitative studies that have ex-
plored factors influencing trial participant drop-out.
Methods: A systematic search of Embase, Ovid MEDLINE, PsycINFO,
Cochrane CENTRAL, SSCI, CINAHL and ASSIA covering papers pub-
lished from 1946 to August 2018 was conducted. Meta-ethnography
was utilised to synthesise findings from eligible papers that con-
tained qualitative data from trial non-retainers.
Results: We identified 11 studies reporting qualitative data from
13 trials. The studies were undertaken between 2008 and 2018.Each study included between 3 and 40 people who had dropped
out from a trial, with findings from 168 people in total reported
across the papers. Emergent from our synthesis was the signifi-
cance of trial non-retainers’ perceptions around the personal ‘fit’
of key aspects of the trial with their personal beliefs, preferences,
capabilities or life circumstances. These related to their own
health state; preferences for receiving trial ‘care’; individual cap-
abilities; beliefs about or experiences of trial medication; and con-
siderations whether trial participation could be accommodated
into their broader lives. All these factors raise important issues
around the extent to which initial decisions to participate were
fully informed.
Conclusions: To improve retention in clinical trials, researchers
should work to reduce the burden on trial participants both through
the design of the intervention itself as well as through simplified
data collection processes. Providing more detail on the nature of the
trial interventions and what can be expected by ‘participation’ at the
consenting stage may prove helpful in order to manage
expectations.PS6A
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Yin Mo1,2,3, Cherry Lim1,2, James Watson1,2, Ben Cooper1,2
1Mahidol-Oxford Research Unit (MORU), Thailand; 2Nuffield Department
of Medicine, University of Oxford, Oxford, United Kingdom; 3National
University Hospital, Singapore
Trials 2019, 20(Suppl 1):PS6A
Non-adherence in non-inferiority trials increases the risk of falsely
claiming non-inferiority, enabling consecutively worse treatments
to be accepted into clinical practice. We performed a simulation
study to i) explore the impact of various patterns of non-
adherence and analysis methods on trial estimates; ii) quantify
the risk of falsely claiming non-inferiority (type I error) under rea-
sonable assumptions in a typical non-inferiority trial, iii) propose
alternative analysis methods, and vi) provide a tool for trial inves-
tigators to design non-inferiority trials using intuitive parameters.
We simulated a hypothetical two-arm non-inferiority randomized
controlled trial with a binary outcome and incorporated patient
characteristics as confounders which may influence both the like-
lihood of taking up the allocated intervention and the primary
outcome. Different scenarios of non-adherence, both random and
driven by confounders, were considered. Using the intention-to-
treat analysis, the trial estimates (given by treatment effect of the
experimental treatment – treatment effect of the control treat-
ment) drift towards 0 with increasing degree of non-adherence.
The bias in the trial estimate derived by the per-protocol analysis
increases with the strength of correlation between confounders
and non-adherence behaviour. The risk of committing type I error
can be as high as 10% even with relatively high levels of adher-
ence (90%). Modified per-protocol analysis with inverse probabil-
ity weighting was able to provide unbiased estimates provided
that confounders are conditioned on. Instrumental variable esti-
mation overcomes this limitation and gives unbiased estimates in
all scenarios of non-adherence but requires a large sample size.
We propose that trial investigators should consider the pattern
and degree of expected non-adherence, causal relationships be-
tween the confounders and the outcomes, and the primary ana-
lysis method in power calculations during the planning stage of
a non-inferiority trial. Modified per-protocol analysis with inverse
probability weighting can be considered as a primary analysis
method in non-inferiority trials with non-adherence.
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Introduction: Results of clinical trials depend upon the statistical
methods used for analysis. Modifications to the planned analysis ap-
proach can introduce bias if based upon trial data. Transparent and
accurate reporting of planned and conducted analyses is necessary
to allow for appropriate evaluation of methods.
Methods: We conducted two separate reviews of published rando-
mised trials in order to evaluate transparency around the statistical
methods. The first review included 101 trials published in six high-
impact medical journals. The second included 100 trials published in
all journals indexed in PubMed. We evaluated the number of trials
with a publicly available pre-specified analysis approach for the pri-
mary outcome, how often changes to the pre-specified approach
were made, whether reasons for changes were given, and informa-
tion around the blinding status of trial statisticians in relation to data
access.
Results: Across the two reviews we found that pre-specified analysis
methods were often not publicly available, and when available were
often dated after recruitment to the trial began. Most trials with an
available pre-specified approach had discrepancies between the
planned and conducted analysis, which were often not explained or
justified. In many cases, incomplete reporting of statistical methods
made it impossible to evaluate whether discrepancies occurred. Very
few trials reported the blinding status of statisticians in relation to
data access, prohibiting evaluation of whether changes to the statis-
tical methods were made based on unblinded trial data.
Discussion: Investigators frequently made changes to their pre-
specified analysis approach during the course of a trial. However,
evaluation of whether such changes may have introduced bias was
hampered by the limited availability of pre-specified analysis ap-
proaches, lack of explanation around the reasons for changes, and in-
complete reporting of the statistical methods used.PS6A
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Introduction: Participants in clinical trials often do not reflect the
populations in which treatments are needed or will be used. Enhan-
cing representation of underserved groups in clinical research is im-
portant to ensure that research findings are widely applicable.
Methods: The project used a multicomponent workstream led by the
UK NIHR Clinical Research Network Cluster E Specialty Team. We
undertook: a) literature review by NIHR Innovation Observatory to
identify previous work, underserved groups, and barriers to inclusion;
b) surveys of professional stakeholders and participant representativegroups involved in research delivery to refine these initial findings
and identify example of innovation and good practice; and c) a series
of workshops bringing together key stakeholders from funding, de-
sign, delivery and participant groups to reach consensus on defini-
tions, barriers and a roadmap for future work.
Results: ‘Underserved groups’ was identified as the preferred term.
Three-quarters of stakeholders felt that a clear definition did not cur-
rently exist; definition was challenging and context-specific but 17
exemplar groups were identified as underserved. Barriers to success-
ful inclusion of underserved groups grouped into communication be-
tween research teams and participant groups; how trials are
designed and organised; differing agendas of research teams and
participant groups; and lack of trust in the research process. Exam-
ples of good practice included long-term engagement with partici-
pant groups, the use of co-design, research champions within
underserved communities, and removal of unnecessary trial exclusion
criteria and processes. The consensus for future work was to develop
toolkits to address these barriers, including generic advice and advice
targeted for those working with specific groups, and engaging re-
searchers, funders, research users and others working with under-
served groups.
Conclusions: The work of the group over the next 12 months will
build on these findings by generating resources customised for dif-
ferent underserved groups to improve the representativeness of trial
populationsPS6B
- O1 Covariate adjustment in individually randomised trials
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Introduction: While an unadjusted analysis of a randomised trial is
unbiased, adjusting for measured pre-randomisation characteristics
can increase statistical power. Guidelines regarding best practice for
covariate adjustment in trials typically recommend adjusting for a
small number of covariates, not including interactions of covariates
with randomised arm, and the pre-specification of both the adjust-
ment variables and the model.
These guidelines are often at odds with theoretical literature. Bias in-
troduced by misspecifying an adjustment model in a trial can often
be avoided by including interactions between covariates and trial
arm. Promising new statistical approaches may not allow the pre-
specification of the model or adjustment variables.
Whether and how to perform covariate adjustments in trials remains
contentious.
Methods: Using simulations, we explore the statistical properties of a
number of covariate adjustment methods in a range of settings
based on real clinical trials. These include settings with few highly
prognostic pre-specified adjustment variables, and those with large
numbers of measured covariates that may be desirable to adjust for.
We compare traditional covariate adjustment, inverse-probability-of-
treatment-weighting, doubly robust methods, and targeted max-
imum likelihood estimation. We investigate continuous, count, binary,
and time-to-event outcomes.
We illustrate key findings using the ViDiAs trial, a randomised con-
trolled trial of vitamin D3 supplementation for the prevention of
asthma exacerbation and URI. 250 adults were randomised to a
course of vitamin D3 or placebo over a year. For URI, the primary
analysis found no effect (Hazard Ratio 0.87, 95% confidence interval
0.62, 1.16, p=0.34), after adjusting for stratification factors. However,
a number of other pre-randomisation variables showed imbalance
between arms.
Timing of Potential Results: Simulation results will be finalised this
summer.
Potential Relevance & Impact: The results of these simulations, and
application to key exemplar trials, will provide practical guidance for tri-
alists regarding how to plan and perform covariate adjustment in trials.
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Introduction: It is advisable to account for baseline covariates in the
analysis of randomised trials for two reasons: 1) To increase power
and 2) To obtain valid estimates of error when covariates have been
balanced in the randomisation procedure. There are several different
methods of accounting for covariates beyond simple covariate ad-
justment, and the choice of method is not straightforward outside
standard linear regression models.
Methods: We work through how we choose a method at the point of
writing a statistical analysis plan. Considerations include the outcome
type (e.g. quantitative or binary), the possibility of non-convergence of
adjusted models, and the estimand of interest (e.g. marginal risk ratio
or conditional odds ratio, where conditional applies to specific covariate
values and marginal is averaged across these). We illustrate the choices
for each using the Vietnarms trial, considering three broad methods: re-
gression adjustment, marginal standardisation and inverse-probability-
of-treatment weighting (IPTW).
Results: When the estimand is a risk ratio or risk difference, regres-
sion adjustment carries a high risk of non-convergence and should
not be used. Regression adjustment is also unsuitable for non-
collapsible quantities when the estimand of interest is marginal. Mar-
ginal standardisation cannot currently be used to estimate a mar-
ginal hazard ratio, though methods are in development.
Discussion: Regression adjustment is suitable for estimation of condi-
tional mean differences, conditional odds ratios and conditional haz-
ard ratios. Surprisingly, IPTW seems to be the unifying method
suitable for any marginal estimand, and is simple to implement. The
disadvantage is that closed-form variance formulas are not available
for hazard ratios, forcing a reliance on the bootstrap. Further work
will include exploring further estimands, such as the difference in re-
stricted mean survival time; considering more efficient methods; and
developing the missing closed-form variance formulas.
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Introduction: Randomised trials are increasingly applied to complex
interventions such as surgery and behavioural therapies. These inter-
ventions are characterised by two main features, multiple compo-
nents and clustering of outcomes due to healthcare provider or
group settings. Moreover, they are usually evaluated in open-label,
pragmatic trials, allowing flexibility in delivery of the intervention, as
well as differential use of co-interventions. Heterogeneity in the treat-
ments delivered complicates evaluation but provides an opportunity
to explore mechanisms of action.
Our aim is to demonstrate the use of mediation in this context, using
the AMAZE trial as an illustration.
Methods: AMAZE was a trial of atrial fibrillation (AF)-surgery as an
addition to planned cardiac surgery to treat irregular heart rhythm.
The primary outcome (binary) was return to normal heart rhythm at
12 months. A binary co-intervention (removal of the left atrial ap-
pendage) was undertaken at the surgeon’s discretion. Using logistic
models with surgeon as a random effect, the contribution of this co-
intervention to the total treatment effect was explored.
Results: Of the 280 patients with outcomes at 12 months post-
surgery, 67/143 (47%) controls and 84/137 (61%) AF-surgery patients
returned to normal heart rhythm. Left atrial appendage removal was
more likely in AF-surgery patients than controls (55% versus 30%).Adjusting for baseline confounders, the difference in probability of
return to normal rhythm (total effect) was 17% (8%, 27%), with aver-
age mediated effect of 13% (3%, 24%) and indirect effect via left
atrial appendage removal of 4% (0.4%, 8%). Sensitivity to presence of
unknown confounders was further assessed.
Discussion: Although heterogeneity of delivery complicates interpret-
ation of complex interventions, it provides an opportunity to explore
potential mechanisms of action in a quantitative (rather than qualita-
tive) way. Interpretation must be cautious since methods require
strong assumptions.
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Objective: Intention-to-treat (ITT) is the recommended statistical method
for analysing randomized control trials (RCTs). However, given that trial par-
ticipants often do not fully adhere to the treatment protocol, research
teams often also report a per-protocol (PP) analysis. Naive PP (i.e. compar-
ing participants who achieved a minimum level of treatment with control
participants) is known to break random allocation and may therefore result
in a biased treatment effect estimate. Nevertheless, the level of bias associ-
ated with the naïve PP method is not well understood. The aim of this
meta-epidemiological study is to quantify this bias.
Methods: We will identify RCTs (published between April, 2017 and March,
2019) across 5 major journals (Lancet, NEJM, BMJ, JAMA, Annals of Internal
Medicine) that report both ITT and PP estimates for the primary outcome.
Our pilot of 25 trials shows that we require 79 RCTs to detect ≥6% differ-
ence between ITT and PP at 90% power. Given that we are pooling RCTs
across populations and treatments, we will use random effects meta-
analysis to compare the ITT and PP treatment estimates reported for the
primary outcome. Treatment effect across studies will be converted to the
common metric of log of odds ratio (OR).
Timing of potential results: Our pilot study of 25 trials indicate that
PP estimates were an average 4% higher than ITT estimates (OR:
1.04, 95% CI: 0.94 to 1.06, p = 0.14). The full study is ongoing and re-
sults will be ready before September, 2019.
Potential relevance and impact: Treatment non-adherence is a prob-
lem that besets virtually all RCTs and, as result, the reporting of treat-
ment estimate using ITT alone may not be completely informative.
This study seeks to quantify the level of bias associated with naïve
PP method and whether the PP reporting is a useful supplement
alongside the traditional ITT estimate.PS6B
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Factorial designs are an under-used but potentially important design
in the evaluation of more than one medical intervention within a sin-
gle trial. However, the design of such trials is often misunderstood
and the analysis, reporting and interpretation inappropriate.
Systematic reviews and meta-analyses, at their best, can be a vital
tool to bring together the worldwide evidence from randomised tri-
als assessing the impact of particular treatments or interventions.
However, the data are often poorly understood and results misrepre-
sented and misinterpreted, for example, through the handling of
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can lead to delays in effective treatments for patients and can be a
barrier to further research opportunities.
These issues will be illustrated through the example of the factorial
design REPAIR trial and subsequently published meta-analysis. The
REPAIR trial evaluated the impact of remote ischaemic pre-
conditioning in patients undergoing living donor kidney transplant-
ation indicating improved short and long-term effects on estimated
glomerular filtration rate. The meta-analysis used data that were ex-
tracted and reported incorrectly and despite subsequent changes
the published report remains inadequate. This is due mainly to the
misunderstanding of the factorial design and the subsequent misrep-
resentation of the results through the use of random effects meta-
analysis. This has led to a potentially effective intervention being de-
nied to patients, delays in publication of long-term REPAIR results,
and prevented further research in kidney transplantation. The trial
design and published results from REPAIR will be presented together
with the reported results from the meta-analysis to allow informed
conclusions to be made. In addition the 5 year outcomes from RE-
PAIR will be presented.
We encourage measures to improve the acceptance and understand-
ing of factorial trials as well as caution in over-interpreting the results
from random effects meta-analyses from randomised trials.PS6C
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Introduction: Patient Reported Outcome Measures (PROMs) are a
widely used method of collecting both primary and secondary out-
come data. Completion of PROMs can be via the traditional paper
questionnaire or online via a link which directs the participant to an
electronic version of the questionnaire that they can complete via
their smart phone /computer.
“What are the most effective ways of collecting information from par-
ticipants to increase retention?” has just been published as item 7 in
the top 10 priorities for research into trial retention. We explored this
by giving participants the option to choose between paper and elec-
tronic methods in two trials.
Methods: In two large multicentre trials (TOPSY and OPAL), partici-
pants (women with prolapse and urinary incontinence respectively)
were given the option of completing their follow-up questionnaires
via paper or online. We measured;
1.What proportion of participants prefer each method?
2.Is the method of completion influenced by socio-demographic
characteristics?
3.Is there a difference in a) the return and b) the completion rate for
the two methods?
Timing of potential Results: The OPAL trial is complete and the
TOPSY trial is ongoing (complete mid 2021). We will present data on
participant preference for mode of completion; differences for partic-
ipants with different socio-demographic characteristics for the differ-
ent modes of completion; percent of paper and email return rates
and extent of completion at different time points overall and for dif-
ferent sociodemographic characteristics.Potential relevance and Impact: The results have the potential to in-
fluence future trial design by informing researchers about likely ben-
efits, and potential drawbacks, of different methods of questionnaire
administration for different participants. There is also the potential to
set up one or more SWATs to collaborate with other trialists to pro-
spectively gather evidence to answer item 7 in the top 10 priorities
for retention research.
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Introduction: Patient reported outcomes (PROs) are used to evaluate
the effectiveness of an intervention by the patient measuring their
own health and quality of life. It is not uncommon for PROs to be
used for primary outcome data in primary care clinical trials or stud-
ies. From previous research it is not clear whether paper data capture
(pDC) or electronic data capture (eDC) is most efficient when it
comes to completeness of data. Some say adherence to pDC is
higher (Blondin et al., 2010) and others that adherence to eDC is
higher (Hufford et al., 2002). Previous studies have focused on time
efficiency, error rate and cost. This study will investigate the com-
parative completion rates of PROs from pDC and eDC (forms com-
pleted via computer/mobile by patient).
Methods: Completed studies are included in this project if they meet
the following inclusion criteria: (1)randomised clinical trial or observa-
tional study; (2)Primary Care Clinical Trials Unit (PC-CTU), University
of Oxford involved in study management; (3)data management car-
ried out by PC-CTU; (4)both pDC and eDC options were available for
PROs.
Analysis: The first analysis will compare the number of forms per trial
that were completed via pDC or eDC. The second analysis will sum
the number of required missing fields, these will then be compared
within the trial (pDC vs. eDC) and across the selected trials using
tests of significance (t-test, ANOVA). We will also perform secondary
analyses looking at (1)age range (2)number of times participant
asked to complete a PRO and (3)whether or not reminders were sent
to participants.
Timing of potential results: August 2019.
Potential relevance and impact: The outcome of this study will help
to inform which method of data capture will provide the highest
completion rates for collecting PROs.
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Introduction: Spin (distorted reporting of research results) consists in
presenting research results as being more positive or significant than
proved by experiments. In randomized controlled trials (RCTs), spin
consists in exaggerating the beneficial effects (efficacy, safety) of the
studied intervention. Spin results in overestimation of the interven-
tion by clinicians and induces unjustified positive presentation of the
intervention in press releases and health news.
Recent studies (2016-2019) showed that spin is prevalent in articles
on RCTs with non-significant primary outcome in various domains,
e.g. surgery (40%), cancer (47%), obesity (46.7%), otolaryngology
(70%), anaesthesiology (32,2%) and wound care (71%). Spin often re-
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from benevolent desire to present the most important results). Thus,
our aim is to provide spin detection assistance to authors and
reviewers.
Methods: We propose a machine learning algorithms and tools for
spin detection developed in collaboration with experts in clinical tri-
als. It uses Natural Language Processing (NLP) and machine learning
(BERT neural embeddings) to extract spin-related items (primary and
reported outcomes, patient population, significance levels) and rela-
tions between them to detect potential spin. The system flags the
phenomena of interest in the text and generates a report. It was
evaluated on manually annotated corpora. The tool set includes a
spin detector in Python and a graphic interface (TkInter library) to an-
notate new training data.
Results: Our algorithms achieved operational performance for detect-
ing relevant phenomena (F-measure from 76,2 to 97.8%). The most
difficult task is extracting reported outcomes, where our system
achieves an F-Measure of 76,2%, outperforming existing algorithms.
Discussion: The proposed tool can be used by both authors and re-
viewers to detect potential spin, helping to improve the quality of re-
search results reporting. The tool and the annotated dataset will be
freely available.PS6C
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Introduction: Frequent follow-up data collection may be desirable in
RCTs as it allows greater longitudinal assessment, and increased
power and accuracy by reducing attrition bias, which undermines
the intention-to-treat (ITT) principle. Short message service (SMS)
using mobile telephones offers an alternative way to enhance out-
come data collection to postal, online, or telephone-call follow-up
processes.
Methods: Data from an RCT (SCOPiC trial ISRCTN75449581) evaluat-
ing stratified care in patients with sciatica in primary care were used
to examine the rate of responses for primary outcome data collected
largely through SMS over 12 months.
Results: Data were received and evaluated from 476 trial partici-
pants. The primary outcome was time to resolution of sciatica
symptoms from baseline, assessed on a 6-point ordinal scale col-
lected using SMS (with reminder SMS processes and an alterna-
tive of brief phone calls). Data were collected weekly for weeks
1-16, then either monthly for weeks 17-48 or until two consecu-
tive responses of ‘completely recovered’/’much better’ were re-
ceived. In total, 426/476 (89.5%) of participants opted for SMS
follow-up. Overall response was 89.3% (9467 responses from
10,601 attempts); 90.2% via SMS and 81.9% via phone-call. Re-
sponse rate was higher over the earlier ‘weekly’ period at 93.9%
than for the later ‘monthly’ period at 84.7%. SMS choice (versus
phone-call) was significantly associated with lower age (mean,
50.5 years v 65.2) and currently working (73% v 35%). Partici-
pants with incomplete follow-up lived in significantly more de-
prived neighbourhoods. There were no strong associations with
baseline and follow-up health status variables.Discussion: Within this low back pain population in primary care
(and likely more broadly), SMS follow-up of key outcome data can be
successful, particularly when targeting younger and/or working pop-
ulations. It offers an accessible and robust way of enhancing follow-
up, improving the quality of statistical analyses and reducing data
collection costs.PS6C
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Introduction: Advances in technology mean the collection of
digital images of wounds taken by patients themselves after leav-
ing hospital is increasingly more accessible. Images may supple-
ment patient-reported data and facilitate research and routine
follow-up (e.g. remote, blinded assessment of problems/healing).
The Selfi wound study (self-taken images of surgical wounds)
aimed to develop and pilot a method for collecting images of
wounds after patients leave hospital following surgery, and ex-
plore its potential use for remote outcome assessment of
wounds.
Methods: Existing guidelines for wound photography (e.g. medical
illustration documents, study protocols/manuals) informed instruc-
tions for patients to take images using their own mobile devices.
Cognitive interviews (n=16 patients) were conducted to pre-test
and refine the instructions and test a system for transmitting im-
ages to a study database. A further group (n=61 patients) under-
going abdominal or vascular surgery tested the method remotely,
selectively sampled for a range of ages, surgery types and wound
locations. Data were collected on experience with technology,
time taken to photograph wounds and whether help was
needed. Response rates, participant burden, and image quality
were examined.
Results: Key considerations for photographing wounds (e.g. lighting,
camera angle) informed provisional instructions for patients. Cogni-
tive interviews demonstrated acceptability and capability for taking
and uploading images, with some modifications to the instructions
required. Images were received from 34/61 (56%) patients testing
the method remotely with 14 (41%) needing a reminder. Median
time to respond was four days (range 0 to 24). Photographing
wounds took <5 minutes for the majority (84%) of responders. Im-
ages were predominantly clear and of suitable quality for assessing
the wound.
Conclusions: Remote collection of digital images of surgical
wounds from patients using their own mobile devices after leav-
ing hospital is feasible, practical and acceptable to patients. Fur-
ther evaluation of the method for facilitating outcome
assessment in trials is planned.PS7A
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Introduction: Data collection consumes a large proportion of trial re-
sources. Each data item requires time and effort for collection, pro-
cessing and quality control procedures. Generally speaking, more
data equals a heavier burden for trial staff and participants. It also in-
creases the cost of the trial. Data is generally collected for 3 broad
reasons:
•To answer the main research question (a primary outcome is speci-
fied and drives sample size calculations).
•Secondary outcomes to supplement the primary outcome.
•Additional data to monitor safety, maintain quality and for regula-
tory and data management needs.
Here we report the results of a collaborative Trial Forge project
which measured the proportion of data fitting these three broad
categories, across 18 trials run from 5 institutions in Ireland and
the UK.
Methods: We developed a standard operating procedure to cat-
egorise data. We categorised all variables collected on trial data
collection forms from 18, mainly publically-funded Randomised
Controlled Trials, including clinical trials of an investigational me-
dicinal product and surgical trials. Categorisation was done inde-
pendently in pairs: one person having in-depth knowledge of the
trial, the other independent of the trial. Disagreement was re-
solved through reference to the trial protocol and discussion,
with the project team being consulted if necessary.
Results: Primary outcome data accounted for 11.2% (mean) and 5%
(median) of all data items collected. Secondary outcomes constituted
a mean of 42.5% (median: 39.9%) of data items. Non-outcome data
represented a mean of 36.5% (median: 32.4%) of data items
collected.
Discussion: Our study highlights the proportion of data collected to
answer the main research question is minimal in comparison with
other data collected, and that much of this is non-outcome data. We
discuss implications including whether such data collection is exces-
sive or has detrimental effects on a trial.PS7A
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Introduction: RCTs have been criticised for lacking external validity.
A sizeable body of meta-epidemiological evidence has shown RCT
participants can often differ from wider patient populations, eitherthrough entry criteria restrictions or through selective uptake (“volun-
teer bias”). RCTs may struggle to convince a clinical community of
their merit if they do not represent the patients they themselves see.
We assessed whether a trial in type I diabetes mellitus (T1DM) mir-
rored the wider patient population, and applied sample-weighting
methods to derive a treatment effect projected onto a more repre-
sentative T1DM population. We describe how to apply these
methods, their limitations, and their impact on our trial's findings.
Methods: The REPOSE (Relative Effectiveness of insulin Pump Over
MDI and Structured Education) trial was nested within a large UK-
based cohort of patients with T1DM. The database captured detailed
demographic, clinical and QoL data for T1DM patients undergoing
structured diabetes-specific education. We firstly assessed whether
our RCT participants were comparable to this cohort using propen-
sity score modelling. Following this we re-weighted the trial popula-
tion to better match the wider cohort, and re-estimated the
treatment effect from this.
Results: Our trial patients differed from those of the cohort in
regards to sex, weight, HbA1c and also QoL and satisfaction with
current treatment. Nevertheless, the treatment effects derived from
alternative model weightings were similar to that of the original RCT.
Discussion: We found our RCT recruited a non-random set of partici-
pants but that the main results were unaffected by re-weighting. We
advocate researchers to take steps to address criticisms of generalis-
ability, including these analyses. Doing so is nevertheless problem-
atic: external data is difficult to obtain and may contain information
is too limited to make informative adjustments. Analyses can be sus-
ceptible to model misspecification, especially in smaller trials.PS7A
- O4
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Introduction: York Trials Unit (YTU) has gained valuable experience
through working with the Police. We present here key learning out-
comes from a co-production project in mental health, attempts to
set up a trial related to speeding offences and a trial of a youth
offending intervention.
Methods: YTU’s experience comes from:
Co-production with North Yorkshire Police (NYP) of a series of sys-
tematic reviews to improve the evidence base related to mental
health, and an RCT of training for police officers to improve their
handling of situations where members of the public they are in con-
tact with are experiencing mental ill health.
Developing a proposal for a trial with the Traffic division of NYP to
improve the response rate to conditional offers for speeding
offences.
An on-going NIHR funded project with the University of Southamp-
ton and Hampshire Constabulary to undertake an RCT, with eco-
nomic and qualitative evaluation of Gateway, an out-of-court,
community-based intervention aimed at improving life chances for
18-24 year old offenders and reducing reoffending.
Results: Four systematic reviews were completed and the cluster RCT
involving 12 police stations and 249 officers receiving the bespoke
training, showed it may have a positive effect on recording of
incidents.
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no way of linking data between two NPY information systems.
Recruitment to the Gateway trial has been delayed for various
reasons.
Discussion: Police Forces are enthusiastic collaborators and keen to
underpin their working practices with robust evidence. Conducting
pragmatic, health related trials within the police setting is feasible
and acceptable. However, even simple evaluations need to be de-
signed with care to fit in with existing work practices, in particular
Police IT systems, the Police legal framework, and the rapidly evolv-
ing political and social environment. Close collaboration between po-
lice and academia is key.
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Introduction: Bayesian adaptive designs can improve the efficiency
of trials, and can produce high quality evidence more quickly, with
fewer patients and lower costs than traditional methods. The aim of
this work was to determine how Bayesian adaptive designs can be
constructed for multi-arm phase III clinical trials, and to assess the in-
fluence that Bayesian designs would have on trial efficiency and
study results.
Methods: We re-designed the Collaborative Ankle Support Trial
(CAST) using Bayesian adaptive design methods, to allow for the pos-
sibility of response adaptive randomisation (RAR), arm dropping, and
early stopping for efficacy or futility. We constructed several alterna-
tive Bayesian designs and studied their operating characteristics via
simulation. We then virtually re-executed the trial by implementing
the Bayesian adaptive designs using the CAST data to demonstrate
the practical applicability of the designs.
Results: We constructed five alternative Bayesian adaptive designs,
each of which had high power and recruited fewer patients on aver-
age than the original design. The virtual executions showed the
Bayesian adaptive designs with RAR and/or arm dropping allocated
more patients to better performing arms, but did not stop the trial
early for efficacy or futility.
Discussion: Researchers and funders have recognised the need for
trials to become more efficient, yet the overwhelming majority of tri-
als continue to use traditional methods, particularly with fixed de-
signs. Whilst Bayesian adaptive designs have proved to be popular
for early phase studies, their use in phase III trials remains limited.
Using the CAST trial as an example, this case study found that Bayes-
ian adaptive designs can be constructed for phase III multi-arm trials
using clinically relevant decision criteria. These designs demonstrated
that they can potentially generate earlier results and allocate more
patients to better-performing arms. We recommend the wider use of
Bayesian adaptive approaches in phase III clinical trials.
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Introduction: A key design challenge for trials in rare diseases and
subgroups of special interest is a restricted sample size. Standard
frequentist-based approaches to power trials based on large sample
theory are not always suitable. To obtain robust high-quality evi-
dence alternative approaches are required. This challenge hasrecently come to the forefront and has motivated new activity on
how best to design and evaluate treatments when sample size is re-
stricted. A bold framework adopting a pragmatic approach to design-
ing trials for small populations was proposed by Parma et.al. 2016.
More recently recommendations have been produced by the Inter-
national Rare Diseases Research Consortium Small Population Clinical
Trials Task Force, and the FDA with guidance for adaptive designs.
Methods for specific acceptable approaches are lacking.
Methods: We present the development and design of two NIHR
funded small population trials. The evaluation of a new biological
drug for pustular psoriasis, a rare and debilitating condition in adults,
and a new treatment option for paediatric severe treatment resistant
asthma (STRA).
Results: No validated measure of pustular psoriasis exists and there
was minimal safety data for the drug in this population. A novel two-
stage adaptive placebo-controlled trial was designed to evaluate two
potential disease measures for the primary outcome, check proof of
concept and safety in stage one. Efficacy assessment, requiring a
sample size of 64 (90% power, two-sided 5% significance level), oc-
curs in stage two.
In STRA, placebo was not allowed for ethical reasons. With a fixed
sample size of 150 a Bayesian approach with an informative prior dis-
tribution will be used to assess non-inferiority of treatment. The pre-
dicted probability of non-inferiority demonstrates the value of
undertaking this study.
Discussion: Novel and bold approaches can be used to design trials
that will provide robust randomised evidence which would not be
possible using standard approaches.
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Introduction: Several sequential multi-arm trial designs have now been
presented. This includes multi-arm multi-stage (MAMS) designs that
allow futile treatments to be dropped, or efficacious treatments to be
identified, at each interim analysis. Whilst this approach can be highly
efficient, the actual sample size required by a MAMS design is difficult
to predict. Consequently, a multi-stage drop-the-losers design, with a
fixed total required sample size, was recently described. In many sce-
narios though, this design will be less efficient than its MAMS analogue.
Here, we present a possible compromise between these approaches; a
class of MAMS designs with fixed stage-wise sample sizes.
Methods: We examine MAMS designs in which the sample size allo-
cated to each arm, in each stage, is dependent on the number of ac-
tive arms. In particular, the operating characteristics of our new
designs are contrasted to a variety of possible sequential multi-arm
designs, using design parameters motivated by oncology, HIV, and
orthostatic hypotension MAMS trials. To facilitate the use of such de-
signs in practice, we also present an online web application for iden-
tifying sequential multi-arm designs.
Results: In many instances, at a small cost to the expected sample size,
the variation in the sample size required by our novel MAMS designs
may be easier to handle in practice. A loss function can be utilised to
choose between the available approaches. The presented web applica-
tion is able to contrast each of the designs in an efficient manner.
Conclusions: The design used by a sequential multi-arm clinical trial
should be chosen carefully. In particular, key expected sample sizes
and possible variations in the required sample size should be taken
in to consideration at the design stage. Fixing the stage-wise sample
size may offer a compromise between conventional MAMS and drop-
the-losers designs.
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Introduction: Implementing multi-arm, multi-stage (MAMS) designs
have proven to be efficient and effective for assessing new treat-
ments with survival outcomes. MAMS designs are yet to be applied
in studies assessing different durations of treatment. This simulation
study aimed to evaluate the efficiency and effectiveness of a MAMS
design for testing the optimal duration of Herceptin in treating early
breast cancer.
Methods: Non-inferiority (NI) properties were explored in six Hercep-
tin duration trials. Simulations were used to assess performance of
implementing a four arm three stage MAMS NI trial with 12 months
of Herceptin as the control arm (standard care) versus experimental
arms of six months, three months and nine weeks of Herceptin. Inter-
mediate and primary outcomes, ranges of NI margins and survival
outcome rates based on trials were investigated.
Results: Simulations showed that implementation of a four arm three
stage MAMS design is more efficient than performing each trial sep-
arately as the required sample size and duration of the study was re-
duced. The most efficient and effective MAMS design proved to be
when five year disease-free survival of 81% was used as the inter-
mediate and primary outcome with a 3% NI margin. Emphasis was
placed on ensuring that the family-wise error rate (FWER) remained
below 5%.
Conclusion: A MAMS design should be considered when implement-
ing a new therapy into a disease area as it allows different treatment
duration to be explored as well as the efficacy of the treatment. Sim-
ulations showed that a MAMS design for the Herceptin duration
question in early breast cancer would have identified the optimal
treatment duration quicker.
Implementation of MAMS designs in practice requires input from
clinical stakeholders to determine the appropriate timing for ran-
domisation and the minimum amount of follow-up required once pa-
tients have completed the course of treatment before performing an
interim analysis.
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Background: The Trials within Cohorts (TWiCs) recruit trial participants
from an existing cohort. This pragmatic design allows robust
generalizability to routine healthcare, avoids disappointment bias, aids
recruitment and assessment of longer-term outcomes.
Despite their theoretical advantages, implementation and conduct can be
demanding. Here, we share our experiences of setting up our first TWICs.
Methods: MONITOR is a multicentre TWiCs cohort assessing the ef-
fectiveness of a treat-to-target approach in psoriatic arthritis. Cur-
rently, two RCTs are set up within our cohort study.
Results: Detailed explanations of methodology were essential for ap-
provals by funders, sponsors and regulators unfamiliar with this
novel design. Separate protocols were required for the cohort and
each RCT. While this resulted in duplication, increased administration
and additional approval processes, it allows for set-up and amend-
ment of individual trials while the cohort continues.
The use of routinely collected data ensures the efficient collection of
high-quality data. However, it necessitated the use of separatedatabases, resulting in additional programming to collate data, and
more complex data checks.
Our TWICS design required a two-stage eligibility check for random-
isation, and additional safety reviews for the interventional arms only.
Close collaboration with our programming team allowed us to adapt
existing systems and minimise patient burden.
Safety reports are identical for all included RCTs, and can therefore
automated easily and will be presented to a joint committee, redu-
cing workload and the number of independent oversight committee
members required.
Statistical considerations include the potential for differential take-up
of the intervention between the trial arms, and the potential for dif-
ferential missing data rates.
Discussion: TWICS can be challenging to set-up, and require careful plan-
ning involving all trial team members and relevant external agencies. When
implemented successfully, they are a very efficient design to facilitate a
multitude of trials in a specific patient population.
Funding statement
Dr Laura Coates is funded by a National Institute for Health Research (NIHR)
Clinician Scientist Award for this research project. This presentation presents
independent research funded by the National Institute for Health Research
(NIHR). The views expressed are those of the authors and not necessarily
those of the NHS, the NIHR or the Department of Health and Social Care.PS7C
- O1 Outcome assessment by central adjudicators versus site
investigators in randomised stroke trials: A systematic review and
meta-analysis
Peter J Godolphin1, Philip M Bath2, Alan A Montgomery1, NA on behalf
of the Adjudicating Outcomes in Stroke Trials Collaboration NA3
1Nottingham Clinical Trials Unit, University of Nottingham, Nottingham,
United Kingdom; 2Division of Clinical Neuroscience, University of
Nottingham, Nottingham, United Kingdom; 3No affiliation, group
authorship, NA, NA
Trials 2019, 20(Suppl 1):PS7C
Background: In randomised stroke trials, central adjudication of a trial’s pri-
mary outcome is regularly implemented. However, recent evidence ques-
tions the importance of central adjudication in randomised trials. The aim
of this review was to compare outcomes assessed by central adjudicators
with outcomes assessed by site investigators.
Methods: We included randomised stroke trials where the primary
outcome had undergone assessment by site investigators and central
adjudicators. We searched MEDLINE, EMBASE, the Cochrane Central
Register of Controlled Trials, Web of Science, PsycINFO and Google
Scholar for eligible studies. We extracted information about the
adjudication process as well as the treatment effect for the primary
outcome, assessed both by central adjudicators and by site investiga-
tors. We calculated the ratio of these treatment effects (RTE) so that
an RTE > 1 indicated that central adjudication resulted in a more
beneficial treatment effect than assessment by site investigator. A
random-effects meta-analysis model was fitted to estimate a pooled
effect.
Results: Fifteen trials including 69,560 participants were included.
The primary outcomes included were stroke (8/15, 53%), a composite
event including stroke (6/15, 40%) and functional outcome after
stroke measured on the modified Rankin Scale (1/15, 7%). The major-
ity of site investigators were blind to treatment allocation (9/15,
60%). On average, there was no difference in treatment effect esti-
mates based on data from central adjudicators and site investigators
(pooled RTE=1.02, 95% C.I: [0.95, 1.09]).
Discussion: We found no evidence that central adjudication of
the primary outcome in stroke trials had any impact on trial con-
clusions. This suggests that potential advantages of central adju-
dication may not outweigh cost and time disadvantages in stroke
studies if the primary purpose of adjudication is to ensure valid-
ity of trial findings.
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Introduction: The evidence available to inform trial process decisions is
thin. This leads to research waste. One way of improving the evidence base
is to evaluate trial process alternatives in a Study Within A Trial (SWAT).
SWATs are gaining traction, especially in the UK and Ireland, with SWAT
funding streams from the National Institute for Health Research (NIHR) and
the Health Research Board (HRB) in Ireland.
The problem ahead: NIHR, HRB and others see a problem ahead: how
do we avoid contributing to research waste ourselves by funding or doing
SWATs that have, in fact, already answered their questions?
Developing criteria to make sensible judgements: Trial Forge (https://
www.trialforge.org) brought together a group of 28 trialists, methodologists,
clinicians, patients, research funders and research governance staff from the
UK, Ireland and Switzerland to develop a set of criteria to make decisions
about when doing another evaluation of a SWAT is needed.
I will present our five criteria. The criteria consider the evidence coming
from the cumulative meta-analysis of all evaluations of the SWAT, the cer-
tainty we have in that evidence judged using GRADE, the contexts in which
the SWAT has been evaluated, and the balance of benefit and disadvan-
tages for a) participants and b) the host clinical trial. I will present worked
examples of how the criteria apply to two SWATs, one in recruitment, one
in retention. I will also discuss how these criteria can be used to not only
make decisions about whether a SWAT needs further evaluation but to
guide the selection of the types of trials in which to embed future SWAT
evaluation.
Conclusion: To avoid research waste, decisions about which SWATs
to evaluate, how and where needs a coordinated and structured ap-
proach. The criteria we have developed are the start of such an
approach.
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ing surgical interventions are especially challenging. Training trial re-
cruiters is the top priority topic for recruitment research for UK
Clinical Trials Unit Directors. There is currently no evidence-based
training for staff recruiting patients into surgical RCTs.
The University of Bristol’s Qualitative research integrated within Trials
(QuinteT) team have developed a one-day ConDuCT-II training
course for staff recruiting into surgical RCTs. This training looks prom-
ising for increasing confidence with recruitment, raising awareness of
hidden challenges, and impacting positively on recruitment practice.
Aim: To evaluate the feasibility of undertaking a Studies Within A
Trial (SWAT) of the recruiter training intervention on participant re-
cruitment into surgical trials.
Methods: A cluster randomised SWAT design. Surgical trials recruit-
ing participants were invited to be host trials. Staff recruiting partici-
pants to the host trials in UK hospitals were asked about their
interest in attending a training workshop. Interested sites were ran-
domised 1:1 to be offered the training (intervention group) or no
training (usual recruitment practice; control group). Outcomes in-
clude: percentage of staff randomised, numbers attending training,
collection of recruitment data and recruitment rate.
Timing of potential results: To date four surgical randomised con-
trolled trials have been recruited: DISC (ISRCTN18254597); PROFHER 2
(ISRCTN76296703); IntAct (ISRCTN13334746); and START:REACTS
(ISRCTN17825590). 27 recruiting sites have been randomised, involv-
ing 57 recruiting staff. The training for the intervention group will
take place on 10th May 2019. By the time of the conference we will
present other outcome data such as recruitment rates.
Potential relevance & impact: This SWAT demonstrates that it is
feasible to test the same recruitment intervention across multiple tri-
als simultaneously, speeding up evidence generation using SWATs. If
successful, training staff will help teams recruit more quickly, and im-
prove staff confidence in doing so.PS8A
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Introduction: Statisticians are fundamental in ensuring clinical tri-
als are conducted with quality, transparency and integrity. Con-
duct of clinical trials according to Good Clinical Practice (GCP), an
internationally recognised, ethical and quality standard, is a regu-
latory requirement. Statisticians are required to undertake training
on GCP but existing training is generic and, crucially, does not
cover statistical activities. This results in statisticians undertaking
training mostly unrelated to their role and variation in awareness
and implementation of relevant regulatory requirements with
regards to statistical conduct. The need for role-relevant training
is recognised by the HRA, MHRA and MRC as well as the UKCRC
Registered CTU and NIHR Statistics Groups. Here we discuss an
NIHR funded project to develop and deliver a role-specific GCP
training tailored to statisticians.
Methods: A scoping survey of the UKCRC Registered CTU Statis-
tics Group identified an obvious need for relevant GCP training.
User preference was for a stand-alone, face-to-face course with
online training also available for interim completion. Training
Trials 2019, 20(Suppl 1):579 Page 128 of 141materials have been developed based on MHRA GCP and cover
legislation and guidance for best practice across all clinical trial
processes with statistical involvement, incorporating existing
UKCRC guidance on analysis plans, validation of statistical pro-
gramming and data sharing. The course contains exercises and
real-life scenarios to bridge the gap between theory and practice.
Comprehensive feedback from initial pilot work has been
incorporated.
Timing of Potential Results: Further pilot work with UKCRC CTU and
NIHR Statisticians is underway. Refinement and input from NIHR and
MHRA will be completed prior to release, expected October 2019.
Potential Relevance & Impact: This project will result in accessible,
comprehensive, piloted training with relevance to all statisticians
working in the clinical trials arena for national and international
adoption. This training will encourage best practice, leading to trans-
parent and reproducible statistical activity as required by regulatory
authorities.PS8A
- O3 Career development for Trial Managers: a survey of UK-based
trial management professionals
Eleanor Mitchell1, Natalie Wakefield1, Suzanne Hartley2, Alison
McDonald4, Shelley Rhodes5, Jodi Taylor6, Kirsteen Goodman7, Helen
Meadows8, Helen Hickey9, Barbara Farrell3, on behalf of the UK Trial
Managers’ Network
1Nottingham Clinical Trials Unit, University Of Nottingham, Nottingham,
United Kingdom; 2Clinical Trials Research Centre, University of Leeds,
Leeds, United Kingdom; 3University of Oxford, Oxford, United Kingdom;
4The Centre for Healthcare Randomised Trials, University of Aberdeen,
Aberdeen, United Kingdom; 5Exeter Clinical Trials Unit, University of
Exeter, Exeter, United Kingdom; 6Bristol Randomised Trials Collaboration,
University of Bristol, Bristol, United Kingdom; 7NMHAP Research Unit,
Glasgow Caledonian University, Glasgow, United Kingdom; 8Institute of
Clinical Trials and Methodology, University College London, London,
United Kingdom; 9Clinical Trials Research Centre, University of Liverpool,
Liverpool, United Kingdom
Trials 2019, 20(Suppl 1):PS8A
Introduction: Effective trial management is essential to the suc-
cessful delivery of high quality trials and appointing a dedicated
trial manager has been shown to be a factor in trials that re-
cruited more successfully. It’s also acknowledged that once trial
funding has been awarded, “the most important members of the
team are not the Profs and investigators but the trial managers”.
Trial Managers often come from a diverse range of backgrounds
with no recognised career pathway and often learn “on the job”.
Groups such as the UK Trial Managers’ Network (UKTMN) aim to
support the career development of trial managers, however there
is structural inequality within the field of clinical trials and trial
managers deserve a recognised career structure. The aim of this
study was to survey UKTMN members to understand what is im-
portant to them with respect to their own career development.
Methods: We sent an online survey link to all UKTMN members, who
are actively working in trial management roles within the UK-setting.
A mixture of quantitative and qualitative questions were included.
Responders were asked to describe their experience, opportunities
and barriers to progression, and what factors are considered import-
ant for career development. Quantitative data will be analysed and
presented descriptively and free-text responses will be reviewed for
themes.
Timing of potential results: Results from this survey will be pre-
sented at the conference.
Potential relevance and impact: Trial Managers play a vital role in
the delivery of clinical trials and a key priority for the UKTMN is to
support trial managers, providing opportunities to enhance career
development. Survey results will demonstrate what is important to
trial managers themselves and will be disseminated to significant
stakeholders (e.g. funders, CTUs, universities) with the aim of devel-
oping a more standardised career structure.PS8A
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Introduction: While recommended as good practice, timely reporting of
trial results to participants is rare, perhaps in part because of uncertainties
about “what” should be shared, “how”, “by whom” and “when”. This study
aimed to identify what content different trial stakeholder groups consider
important and why. The work is part of the REporting Clinical trial results
Appropriately to Participants (RECAP) project, which aims to develop guid-
ance for researchers to enable feeding back trial results.
Methods: Q-methodology was used to explore the relative import-
ance to stakeholders of informational items for inclusion in feedback
to trial participants. Candidate items (n=28) were identified from
current guidance on trial feedback.
Participants were sampled purposefully from six trial stakeholder
groups: Members of the public with trial experience; NHS Research
Ethics Committee Members; Sponsor Representatives; Regulator Rep-
resentatives; Funder Representatives; Trialists.
Participants were asked to arrange the 28 items in order of import-
ance on a Q-sort grid (whilst undertaking “think aloud”). Quantitative
ratings will be analysed using principal components analysis (PCA)
with varimax rotation to identify relationships between rankings and
different viewpoints. Thematic analysis of the ‘think aloud’ data will
aid interpretation of the PCA findings.
Timing of Potential Results: All data have been collected and inter-
views transcribed. PCA analysis, and qualitative data describing and
explaining the viewpoints will be ready in September. Full findings
will be presented at the conference.
Potential Relevance and Impact: Researchers and trialists sometimes
assume they know what information participants want to know
about trial results. However, trial participants can have different per-
spectives and expectations, and the nature and context of the trial
findings might also affect what is considered important content.
Well-informed guidance on how to feedback trial results to partici-
pants should help trial teams align practice with the ethical impera-
tive to disseminate findings to those who contributed.PS8A
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Introduction: Clinical research is increasing in the UK. In 2018, over
700,000 patients were recruited across 99% of the NHS trusts in the
UK. With this growing trend in clinical research, there is a need for
better public engagement and trust. A key factor in achieving this is
promoting transparency through the dissemination of trial results to
participants. In 2015, The Health Research Authority (HRA) published
guidelines, recommending that all researchers communicate results
to their study participants. However, this is not legally binding and
the act of communicating results to participants varies greatly. There-
fore, we conducted an audit of what research teams said they would
do versus what they actually did in practice with regard to feeding
back trial results to participants.
Methods: The Integrated Research Application System (IRAS) will be used
to investigate how researchers report their intention and means of inform-
ing patients of Phase III trial results through questions in the submitted eth-
ics application form. Post-study confirmation of dissemination of results is
reported in the end of study ethics report which is accessed through the
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searchers said they would do on IRAS will be compared to what was actu-
ally reported as recorded through HARP and presented as frequencies. We
will also present data on the reported involvement of patients in trials as re-
corded in the IRAS form.
Timing of Results: This audit is a part of the RECAP study. Undertaken as
an MSc project, it is scheduled to be completed in July 2019.
Potential Relevance and Impact: There Is currently a lack of data re-
garding the compliance to the 2015 HRA guidelines in the UK. The re-
sults of this audit will hopefully give a baseline to measure the impact
of any potential future measures designed to increase compliance.
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Objectives: Surgeons’ learning curves may bias trials for new proce-
dures, but methods to estimate learning curves lack precision. We in-
vestigated whether repeated Bayesian analysis is a useful alternative.
Methods: We applied repeated Bayesian inference to a dataset (415
cases) from an experienced surgeon learning laparoscopic gastrec-
tomy. We developed methods to predict the point probability of
learning phase completion, and to estimate power for this
prediction.
Through literature review, we identified learning curve effects for op-
eration time, number of retrieved lymph nodes and postoperative
complications, and derived prior probabilities for each indicator. We
calculated the probability density function assuming a “normal”
probability distribution, and used repeated Bayesian inference for
each indicator and for combinations to identify when 80%, 95% and
99% predicted the probability of learning curve completion was
achieved.
Results: The method successfully modelled the probability of com-
pleting the learning curve in real operative data, achieving a degree
of precision suitable for practical use. Curve completion varied widely
depending on the single indicator used: 95% probability was
achieved at case 14 (operative time) 277 (complications) and 415
(Lymph node yield). Combining all three indicators, 95% probability
was achieved at case 38 (80% at case 35 and 99% at case 44).
Discussion: Evaluating real surgical learning curves is challenging be-
cause surgeons modify their technique and indications as they learn,
producing a multi-peak curve. Single estimators give very different
estimates of curve completion, ranging from 14 to over 400 in this
series, and are therefore poor guides training or clinical research de-
cisions. The Bayesian analysis allowed precise estimation of learning
curve completion using a combination of estimators, giving a more
clinically meaningful figure for learning curve completion than single
estimators. It also permits real-time updating of probability estima-
tion and confidence. Great care is required in selecting appropriate
priors, to ensure credible conclusions.
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treatment is not inferior to the standard treatment at a certain pre-
defined margin, for a pre-defined set of assumptions. NI trials are
particularly appropriate when a new treatment is thought to offer
greater safety or convenience, or less expense, while providing simi-
lar efficacy to a standard. However these trials need careful monitor-
ing and interpretation.
Methods: PERSEPHONE is a 4000-patient prospective, multicentre,
phase 3 randomised trial that tested the hypothesis that 6 months of
trastuzumab therapy is non-inferior to the 12 month standard in pa-
tients with HER2 positive early breast cancer. Prior to the set-up of
the trial, there was consensus from the trial management group and
the patient and public involvement group, that an absolute reduc-
tion up to 3% in 4-year disease-free-survival (DFS) for the 6-month
treatment group was acceptable. Assumptions for the 4-year DFS
rate expected in PERSEPHONE were based on results from previous
studies.
Results: The control arm 4-year DFS at the time of analysis was
89.8% which was higher than the original estimate of 80% which
had an effect on the NI margins. Following the procedures set out in
the SAP and agreed by the DMC, the HR limit for NI was set at 1.32
and findings were that 6 months trastuzumab was NI to 12 months
trastuzumab (HR=1.07 (90%CI 0.93-1.24), p for NI=0.01).
Discussion: In a comparator trial there is a certain level of flexibility
around the timing of analyses and the relaxing of assumptions. How-
ever, in a NI trial the assumptions and pre-specified criteria on which
to base the interpretation of NI are crucial and have to be monitored
with care. Our experience with the interpretation of the PERSEPHONE
trial has highlighted a requirement for consolidated reporting in-
structions for NI trials.
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Introduction: “Target trial” emulation means applying the design
principles from randomised controlled trials (RCTs) to the analysis of
observational data. The ADAPTT study (ISRCTN ISRCTN76607611) is
using routinely-collected health data to emulate four pragmatic “tar-
get RCTs” to quantify associations between different regimens of
dual antiplatelet therapy (DAPT) and bleeding events in four popula-
tions: i) acute coronary syndrome (ACS) undergoing percutaneous
coronary intervention (PCI); ii) stable angina undergoing PCI; iii) cor-
onary artery bypass grafting (CABG); and iv) ACS treated conserva-
tively (medication only).
Methods: We defined eligibility criteria, treatment strategies, assign-
ment to interventions and follow up using clinical input and review
of the DAPT literature. We applied the eligibility criteria and identi-
fied our populations from fully anonymised, linked Hospital Episode
Statistics (HES) and Clinical Practice Research Datalink (CPRD) data.
To emulate random assignment to different DAPT regimens at
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using literature review, interviews with clinicians and short surveys
with additional clinicians) to allow description of comparability of
groups at baseline and adjustment for these factors. Bleeding events
were identified from GP consultations (CPRD) and inpatient stays
(HES) in the year after “assignment” to DAPT interventions.
Results: Preliminary analyses show variation in bleeding risk consist-
ent with expectation based on the characteristics of the DAPT regi-
mens. For example, in the ACS PCI population, bleeding occurred in
10% of patients receiving more potent DAPT versus 8% in patients
receiving less potent DAPT (adjusted hazard ratio 1.38, 95% confi-
dence interval 1.16 to 1.64). We are unable to control for some con-
founding factors that were identified.
Discussion: Detailed consideration of eligibility criteria, treatment as-
signment, start and end of follow-up period and potential confound-
ing factors, along with an intention-to-treat analysis strategy, will
hopefully avoid the common pitfalls of observational studies.PS8B
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Introduction: Visual analytics covers the use of graphical displays to
communicate data effectively. In the clinical trial setting, graphics
can provide an efficient means to convey and interpret large
amounts of emerging adverse event (AE) data. This view is supported
by guidelines, such as the CONSORT extension on harms and recom-
mendations from journal editors and the pharmaceutical industry.
We aimed to identify, appraise and demonstrate the use of graphical
displays proposed specifically to analyse safety outcomes in clinical
trials.
Methods: A scoping review was undertaken to identify articles that
proposed graphical displays for pre-specified and non-specific emer-
ging events. We systematically searched Medline and EMBASE data-
bases via OVID and Web of Science and SCOPUS databases. We also
searched the reference lists of eligible articles to identify any articles
the database search may have missed. Information on methods were
extracted and applied to trial data.
Results: The review identified eight papers published between 2001-
18 proposing 20 unique plots to display safety data. Examples of
these plots will be provided and appraised for binary AEs, continuous
laboratory (e.g. bloods) and vital signs (e.g. pulse-rate) data. We will
contrast the visual summary from two of these plots, the volcano
and dot plot, with AE data presented in published articles, including
data from Whone et al. 2019’s Parkinson’s study. Both the volcano
and dot plot provide visual summaries of the incidence of emerging
AEs.
Discussion: Graphical approaches offer an efficient means to sum-
marise large amounts of emerging AE data from RCTs and many
have been proposed. Statistical software eases the implementation
of graphical displays, however; previous work identified only a small
proportion of journal reports incorporating graphics into the AE ana-
lysis. We have demonstrated the benefits of graphical displays and
share newly developed Stata code for implementation to promote
the wider uptake of such methods.PS9A
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Introduction: Clinical trial registries are being increasingly used as
data providers in trials methodology research. The objective of this
study is to demonstrate how we can use the information from mul-
tiple data providers registered with the World Health Organisation-
International Clinical Trials Registry Platform (WHO-ICTRP) to evaluate
the uptake of a core outcome set (COS), and to discuss the advan-
tages and challenges of this approach. As a motivating example we
examine how to assess the uptake of the well-known rheumatoid
arthritis COS.
Methods: An observational review was carried out on clinical trials of
rheumatoid arthritis that were indexed on the WHO-ICTRP from in-
ception to 9th November 2018. Four measures of uptake were calcu-
lated in order to assess the reliability of results when considering
data from both trial registries which includes ongoing trials, trial pub-
lications from completed trials and a combination of both sources.
As part of the assessment we evaluate the efficiency, reliability and
geographic diversity of using clinical trial registries in trials method-
ology research.
Results and Discussion: A total of 341 unique trials were eligible for
the evaluation of COS uptake which were taken from 13 out of the
17 data providers listed on the WHO-ICTRP search portal. The four
uptake statistics that estimated the proportion of trialists that
intended to measure and/or report the full COS ranged from 70-79%.
The highest level of uptake came from trials with published results
while the lowest uptake rate was based on planned trial outcomes
that came from trial registry data. Use of the WHO-ICTRP identified
eligible trials from all major continents and in this application pro-
vided a reliable and efficient estimate of COS uptake without the
need to find, obtain and read trial publications. However, the quality
of trial registry data may be lower due to reporting deficiencies.
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Context: Clinical trials are expensive investments that aim to evaluate
the efficacy of new treatments on patients. When there are several
new treatments available for testing at different times, a platform
trial approach can be considered. This trial approach allows for add-
ing new arms to an existing trial that has similar objectives and set-
tings. This feature of adding arms is appealing to practitioners
because of the efficiencies from running one trial instead of several.
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ing trial may reduce the resources for testing the initial treatments,
and prolong the overall duration to establish the treatment benefits.
On the contrary, the decision to not add may reduce the chances of
patients getting better treatments earlier.
Methods: To support the decision of adding or not adding a new
treatment arm to an existing trial, this work proposes a decision-
theoretic framework. Two ways of defining utility are considered in
the framework: one for trials that aim to maximize the number of
rejected hypotheses; the other for trials that would declare a success
when at least one hypothesis is rejected from the study. Within a
two-stage trial setting, the framework provides an optimal decision
based on the observed data from an initial stage.
Results: The marginal benefits of adding arms vary according to the
utility considered in the framework and the design of the trials. The
decision to add a new treatment is optimal under two scenarios:
when the initial treatments are not more efficacious than the control
treatment, and when the initial treatments are considerably more ef-
ficacious than the control treatment.
Discussion: Adding a new treatment arm to an on-going trial when
it becomes available is not always optimal. The progress of the initial
treatment arms shall not be ignored.PS9A
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ing conducted using existing sources of data, such as cohorts, admin-
istrative databases, disease registries and electronic health records.
RCTs conducted using existing data sources require additional infor-
mation to be reported. This reporting guideline is an extension of
the 2010 version of the Consolidated Standards of Reporting Trials
(CONSORT) Statement for RCTs using cohorts and routinely collected
health data.
Methods: A long-list of potential items for the checklist was identi-
fied through two methods: firstly, modifications to the current CON-
SORT checklist were generated using existing reporting guidelines,
including the Reporting of Observational Studies in Epidemiology
(STROBE) and REporting of studies Conducted using Observational
Routinely-collected health Data (RECORD) statements. Secondly, a
scoping review of RCTs conducted in the last decade using cohorts
and routinely collected health data facilitated the modification and
identification of other potential items. Using the long-list, a three-
stage Delphi exercise was conducted to assess the importance of
each item for inclusion in the final extension checklist, which was
finalised at a face-to-face meeting of experts.
Results: A long-list of 27 items was created and 125 experts regis-
tered for the three-round Delphi exercise (92, 77 and 62 experts par-
ticipated in each round respectively). Consensus was reached on 21
out of 27 items. The results of the Delphi exercise informed a face-
to-face consensus meeting in May 2019; core items to be included in
the extension checklist were finalised at this meeting. Corresponding
explanations of extensions and new items with examples of good
reporting were developed subsequently.
Conclusion: The guideline checklist can facilitate transparent report-
ing of RCTs using cohorts and routinely collected health data, to as-
sist evaluations of rigour and reproducibility, enhance understanding
of the methodology, and make the results more useful for clinicians,
journal editors, reviewers, guideline authors, and funders.PS9A
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Introduction: Evidence-based trial recruitment strategies would
benefit patients, trialists and health research. This talk summarises
the 2018 update to the Cochrane review of strategies to improve re-
cruitment to randomised trials.
Methods: Randomised evaluations of recruitment interventions em-
bedded within a host randomised trial were eligible. Six databases,
including MEDLINE were searched. Abstract screening, full text as-
sessment, data extraction, risk of bias and GRADE assessments were
conducted independently by two reviewers. Risk difference and 95%
confidence interval (CI) were calculated. Meta-analysis was done
where appropriate. Protocols for evaluation of interventions consid-
ered priorities for replication studies were developed.
Trials 2019, 20(Suppl 1):579 Page 132 of 141Results: 24,432 abstracts were screened and 68 studies included, in-
volving over 74,000 people. We found 72 interventions; only three
were GRADE High certainty:
1.Open trials rather than blinded, placebo trials. Risk difference: 10%
(95% CI 7% to 13%).
2.Telephone reminders to people who do not respond to a postal in-
vitation. Risk difference: 6% (95% CI 3% to 9%).
3.Using a bespoke, user-tested participant information leaflet. Risk
difference: 1% (95% CI -1% to 3%).
Eight other interventions had GRADE Moderate certainty with cer-
tainty generally being reduced because of only having a single
evaluation. Only seven interventions had been evaluated more
than once and the uncertainty around most interventions in the
review has not changed in a decade. Further evaluations of tele-
phone reminders, text messages and financial incentives were
considered priorities because of remaining uncertainty combined
with their potential for widespread use and evaluation protocols
provided as part of the review.
Discussion: The evidence base to support trial recruitment is poor.
Where evaluations have been done a combination of design flaws,
solitary evaluations and poor precision mean we can conclude little
from the bulk of them. Prioritised and coordinated approaches to
generating recruitment evidence are needed to avoid another dec-
ade without progress.PS9B
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Introduction: Patients lacking capacity are frequently excluded
from research populations. The results of research carried out
without these patients, may not be generalisable and patients
lacking capacity could miss out on access to evidence-based
treatment. The reasons for excluding patients based on capacity
vary, but it has been suggested that recruiting and collecting
outcomes is difficult, and that researchers are unsure of the eth-
ical implications.
Lack of capacity has been reported in 30- 40% in hip fracture pa-
tients. The World Hip Trauma Evaluation (WHiTE) trials, investigating
this patient group, are amongst the largest studies to include pa-
tients without capacity.
Aim: This paper describes the process used by WHiTE to recruit pa-
tients lacking capacity, the retention of patients and success of
follow-up.
Method: Patients lacking capacity are usually enrolled by a profes-
sional consultee (PrC) before surgery. After surgery, if appropriate,
patients will either be asked to consent to continuing participation
or a personal consultee (PeC) will be approached. We recorded data
on pre- and post-enrollment consent types, withdrawals, and 120-
day retention rate.
Results: 2,146 patients enrolled between June 2016 and April 2019 -
1,461 (68%) were enrolled using consultee agreement. After surgery,
of the 1,384 patients enrolled by PrC, 25% continued under patient
consent, 36% under PeC agreement and 18% under continued PrC
agreement. Only 7% of patients/PeC declined to continue with the
study. 71% of patients initially enrolled by Consultees provided 120-
day follow-up, compared to 89% of those enrolled under patient
consent.Conclusion: Recruiting and collecting data from a frail patient
group lacking capacity is feasible. The vast majority of partici-
pants who regained capacity agreed to continue participating.
Whilst retention rates for patients who initially lacked capacity were
slightly lower than those for patients who provided consent, inclu-
sion of this data increased the overall generalisability of the data.
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Introduction: Predicting the recruitment of patients in clinical trials is
challenging. Participation rates may be lower than expected due to
several factors, which may include unrealistic recruitment rates.
However, approaches used to predict and monitor recruitment re-
main frequently unreported. Various deterministic and stochastic
statistical models have been developed and published to model the
process.
We aimed to determine how recruitment is predicted and monitored
and whether the methods developed are being utilised in practice.
Methods: A survey was developed to identify current practice and
knowledge of available methodology. The survey was piloted and
then circulated across the UKCRC registered CTU Statistics Group and
the European Clinical Research Infrastructure Network (ECRIN). We
aimed to seek their opinions and experiences in relation to predic-
tion and monitoring of recruitment.
Results: Responses were received from 50/51 across the UK CRC net-
work and from 19/53 across ECRIN. 81% (56/69) believed that a stat-
istician should be involved in prediction and monitoring of
recruitment to provide a more realistic estimate of recruitment tar-
gets and accrual periods.
However, the majority of responders 90% (62/69) did not recognise
recruitment as a stochastic process in the approaches used. 42% (29/
69) stated a preference for using simple approaches, with 36% (25/
69) being unconvinced of the value of implementing the models
identified.
Simple approaches were also used for monitoring accrual, where in-
vestigators use tables (83%, 57/69) and graphs (87%, 60/69) showing
the expected and actual recruitment rates. When participants were
asked whether they would use a web application implementing the
models mentioned, 55% (38/69) responded that they would use it
for both prediction and monitoring.
Discussion: Recruitment is a stochastic process, however, statisticians
are not utilising statistical distributions within the approaches used
to predict or monitor recruitment. The value of implementing these
complex models needs to be demonstrated prior to adoption.PS9B
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acute trauma situation poses a unique set of challenges in terms of
recruitment and consent. Patients who are incapable of giving con-
sent are an established exception to the general rule of informed
consent in clinical trials and in such situations it is neither practicable
nor ethical to embark on lengthy recruitment screening and random-
isation exercise.
Uncontrolled haemorrhage (bleeding) is responsible for approxi-
mately one-third of trauma deaths. Temporary aortic occlusion can
limit haemorrhage and maintain blood flow to the heart and brain
thereby improving patient survival odds. REBOA (Resuscitative Endo-
vascular Balloon Occlusion of the Aorta) is a novel technique
whereby a percutaneously inserted balloon is deployed in the aorta,
providing a relatively quick means of temporarily controlling haemor-
rhage (via aortic occlusion) until definitive control can be attained.
The National Institute for Health Research (NIHR) Health Technology
Assessment (HTA) funded UK-REBOA trial aims to establish the clin-
ical and cost-effectiveness of REBOA, as compared with standard
treatment alone, for the management of uncontrolled torso haemor-
rhage caused by injury.
Methods and Discussion: In this paper we describe the decision
making process behind establishing the most effective and effi-
cient randomisation and consent pathways for the UK- REBOA
trial. We will discuss the pros and cons of different approaches
to randomisation considered as well as describe the bespoke ran-
domisation service which was eventually developed. Additionally,
we will also describe the ‘consent’ models considered and explain
the reasoning for the approach finally chosen.
Results: All decisions we had to make were influenced not only
by similar trials practice, but also heavily by legal requirements,
ethics and the practical capacity of the trial staff involved. It is
likely that lessons from the UK REBOA Study experience will be
both valuable and applicable to other similar emergency care
studies.PS9B
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Introduction: Alternatives to prospective informed consent have en-
abled the conduct of paediatric emergency medicine (PEM) trials. Re-
search without prior consent (RWPC) involves practitioners
approaching parents after the trial intervention has been given and
seeking consent for their child to continue in the trial. As part of an
embedded study in ‘The Emergency treatment with Levetiracetam or
Phenytoin in Status Epilepticus in children’ (EcLiPSE) trial (across 30hospital sites in the UK) we aimed to explore how the trial and RWPC
was described by practitioners during recruitment discussions, and
how well this information was understood by parents.
Methods: Qualitative analysis of audio recorded (i) trial discussions
and (ii) telephone interviews with parents within two months of hos-
pital discharge. Thematic analysis drew upon the Realpe et al (2016)
model for successful trial recruitment.
Results: We obtained 76 recorded trial discussions between parents
and EcLiPSE trial recruiters, and conducted 30 parent telephone in-
terviews. For 19 parents we had both recorded trial discussion and
interview data, which were matched for analysis. Parental under-
standing of the EcLiPSE trial was enhanced when practitioners: pro-
vided a comprehensive description of trial aims; explained RWPC;
discussed uncertainty about which intervention was best; gave a bal-
anced description of each intervention; provided a clear explanation
about randomisation; and provided an opportunity for questions. We
present an adapted six step model to inform recruitment and RWPC
discussions in future PEM trials.
Discussion: This study provides a framework to help enhance recruit-
ment and parent understanding of PEM trials involving RWPC. Fur-
ther testing of this model in PEM trials is required.PS9C
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Introduction: In oncology, new combined treatments make it difficult
to order dose levels with increasing toxicity to satisfy the monoton-
icity assumption. New dose-finding designs that take into account
uncertainty in dose levels ordering were compared to classical de-
signs through simulations with monotonicity assumption violation.
We give recommendations for the choice of dose-finding design.
Methods: Motivated by a combination-schedule clinical trial for pa-
tients with high-risk neuroblastoma in which several combinations
could not be ordered prior to the trial, we considered both designs
that require a monotonicity assumption, the Bayesian continual re-
assessment method (CRM), the modified toxicity probability interval
(mTPI), and designs that allow to adapt dose level ordering during
the trial the Bayesian partial ordering CRM (PO-CRM) and the no
monotonicity assumption (NMA). We considered 8 scenarios includ-
ing monotonic and non-monotonic dose-toxicity relationships among
6 dose levels.
Results: For monotonic scenarios, the CRM resulted in the highest
proportion of correct selections (PCS). However, the CRM failed to
identify the target dose level if the monotonicity assumption is vio-
lated and tends to recommend either underdosing or highly toxic
levels. While the designs relaxing monotonicity assumption, NMA,
and PO-CRM, were able to identify the target dose level in mono-
tonic scenarios, they also resulted in the highest PCS in non-
monotonic scenarios, nearly 20% higher than alternatives designs.
Discussion: The violation of the monotonicity assumption has dra-
matic effects on the performance of dose-finding designs, we recom-
mend the consideration of designs that can relax this assumption
like the NMA or the PO-CRM. The choice of the design must be
guided by comprehensive simulations.
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Introduction: Dose-finding trials commonly seek to identify a max-
imum tolerable dose. Common experimental designs include the
rule-based 3+3, and the model-based continual reassessment
method (CRM, O’Quigley, 1990). Each assumes that the probabilities
of toxicity and efficacy increase monotonically as dose is increased. If
this assumption is violated, these methods may recommend inappro-
priate doses.
Methods: We collated a dataset to investigate the appropriateness of
these assumptions. Chiuzan et al. (2017) conducted a systematic
methodology review of oncology dose-finding trials between 2008
and 2014. We extracted dose-level response and dose-limiting tox-
icity (DLT) outcomes from 122 manuscripts in their sample. We then
analysed the series individually using simple logistic regression
models, and collectively using hierarchical Bayesian models.
Results: DLT outcomes were collected for 131 series of fully-ordered
doses. Several manuscripts yielded more than one series. DLT out-
comes convincingly had a positive gradient with respect to dose for
many treatment classes, including chemotherapy, inhibitors, and
radiotherapy. Monotonicity was less certain for monoclonal anti-
bodies, although sample size was small.
Response outcomes were collected for 77 series. Evidence was weak
that the probability of response increased with dose in all treatment
types. Generally, the odds of toxicity increased faster than odds of
response.
Conclusions: Rationale dictates that subtherapeutic doses exist. In re-
cent dose-finding trials, these data suggest that escalations have
tended to coerce greater toxicity risk without commensurate in-
creases in efficacy. This asymmetry suggests that trialists should
avoid relying unduly on establishing a maximum tolerable dose and
instead focus on identifying a dose that offers an attractive trade-off
between toxicity and response. Use of so-called seamless phase I/II
designs could help achieve this goal, including EffTox (Thall & Cook,
2004) and Wages & Tait (2015).
Availability of materials: full dataset is available at: http://edata.bha-
m.ac.uk/337/1/Database.xlsx
This article and accompanying analyses are available at: https://
github.com/brockk/dosefindingdata/tree/master/docs/ICTMC2019PS9C
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Introduction: Most dose-finding designs have multiple enrollment
suspensions as they require each cohort of patients to have
complete evaluation of occurrence of dose-limiting toxicity (DLT) be-
fore new patients can be recruited. The time-to-event Continual Re-
assessment Method (TITE-CRM), which uses a weighted measure
based on DLT follow-up period, has the attractive feature of not re-
quiring enrollment suspension while patients are still being observed
for DLT (Cheung & Chappell 2000). However, questions that puzzle
trialists during its implementation include: At any given time, how
much information is required before the TITE-CRM will recommend a
dose escalation? Our aim is to create an implementation tool to help
trialists understand how the TITE-CRM works for the immediate next
patient(s) and to decide when one should impose a waiting window
to allow for better informed decision.Methods: Extending previous work on Dose-Transition Pathways
(DTP) by Yap et al 2017 (based on complete information only), we
provide a simple tool, TITE-DTP, to aid trialists to decide whether one
should enrol the next available patient(s) per the TITE-CRM’s current
recommendation, or one should wait for additional information from
patients still being followed for DLT. Data visualization tool will be
used to help the trialists understand how additional information will
affect the recommendation.
Results: Without any imposed waiting, one might dose too many pa-
tients at the current dose due to insufficient information for the model
to recommend a change. We illustrate the usefulness of TITE-DTP as a
tool to guide the conduct of TITE-CRM in two ongoing cancer trials.
Conclusions: Though it is attractive to have continuous enrolment
using TITE-CRM to expedite trial delivery, it might sometimes be
worthwhile to wait to accumulate more safety information. This
would allow more patients to be treated at higher doses if safe,
which is particularly useful when patient numbers are limited.PS9C
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Introduction: Model-based designs for dose-finding studies such as
the Continual Reassessment Method (CRM) are now becoming more
commonplace amongst clinicians, statisticians and trial management
staff. Complexities and challenges in developing and delivering trials
using these methods have slowed down their implementation, albeit
suitable guidance is now emerging to make the process of trial de-
sign and set-up easier and more efficient [1].
In radiotherapy trials, toxicities can occur a long time after treatment
has finished. Consequently, the lifetime of such trials may become
extremely long with most standard phase I designs. The Time-to-
Event CRM (TiTE-CRM), a modification to the original CRM, accounts
for the time to event of late-onset toxicities and results in shorter
trial duration.
Methods: The TiTE-CRM encapsulates the dose-toxicity relationship
with a statistical model, taking into account the observed toxicities
and a weight for the proportion of completed follow-up of patients
without toxicity. This model uses all available data to determine the
next patient’s dose and subsequently declare the maximum tolerated
dose.
Results: We present some practicalities in designing, setting-up and
running TiTE-CRM trials. In particular, we describe the properties that
need to be defined at the design stage, especially time-related pa-
rameters such as the toxicity observation window, discuss issues and
propose solutions with regard to the grant application and suggest
ways of conducting the trial efficiently, without additional burden
e.g. timely collection of data when a dose allocation needs to take
place.
Discussion: Model-based designs can be complex but we found they
are both feasible and worthwhile. Sharing experience and knowledge
is key and by doing so, we aim to demystify the conduct of dose
finding trials using the TiTE-CRM.
Reference
[1]: Wheeler, G. M., et al. (2019). “How to design a dose-finding study using
the continual reassessment method.” BMC Medical Research Method-
ology 19(1): 18.
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Introduction: Premature infants in neonatal intensive care receive
many painful procedures a day. Although morphine is often used for
sedation, its analgesic efficacy is unclear. Poppi was a blinded rando-
mised placebo-controlled trial investigating the efficacy of morphine
analgesia for procedural pain in premature infants. A stopping
boundary was required to monitor safety with respect to incidences
of apnoea requiring intervention, for review by an independent data
monitoring committee (DMC) after every 25 infants. Specifying this
boundary was a challenge due to a lack of existing methodology for
one-sided stopping boundaries for safety.
Methods: A pragmatic approach was taken to defining the most ap-
propriate stopping boundary. A range of hypothetical trial scenarios,
whereby the frequencies of safety events were varied across the trial
arms, were discussed with the trial investigators. Their decisions were
plotted, and three equivalent possible stopping boundaries identi-
fied. These were based on an assumed average event rate of 7% in
the placebo group and an average tolerated difference of 12% be-
tween the groups. The DMC were consulted to select a single
boundary.
Results: A gamma spending function, with a type I error rate of 0.2
and 81% power was chosen. This would allow changes to be made
part-way through the trial, for instance, to the frequency of analyses.
The trial was stopped after the stopping boundary was crossed, with
3/15 events in the morphine group and 0/15 in the placebo group.
Discussion: We took a pragmatic approach to defining this safety
stopping boundary, using the clinical expertise of the investigators.
This was essential to ensure that the boundary would alert the DMC
to potential harm at the right time. It was a useful tool that enabled
an informed decision to be made about stopping the trial, in consid-
eration with other trial data.PS9D
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Introduction: Qualitative research is increasingly used to enhance
the conduct of randomised controlled trials (RCTs) - particularly re-
cruitment. The QuinteT Recruitment Intervention (QRI) investigates
recruitment issues in ‘real-time’ to inform tailored solutions as the
trial proceeds. Qualitative research may also be conducted at the
pre-trial stage to understand anticipated recruitment issues. Wecombined pre-trial and ‘real-time’ (QRI) investigation of recruitment
issues in the Prepare for Kidney Care RCT: a challenging trial compar-
ing the (cost)-effectiveness of ‘preparing for dialysis’ or ‘conservative
care’. This methodological sub-study aimed to compare the insights/
actions generated from each stage of qualitative work, to examine if/
how findings could be used to enhance the efficiency of addressing
recruitment challenges.
Methods: Pre-trial work: observations of introductory site-visits
and interviews with clinical professionals (n=16) from forthcoming
recruiting sites. ‘Real-time’ investigation included audio-recordings
of recruitment discussions between recruiters/patients (n=38),
interviews with recruiters (n=16), and descriptive analyses of
screening-log data.
Findings: The pre-trial investigation highlighted professionals’ con-
cerns around patients holding treatment-preferences, as many sites
advocated ‘future-treatment-planning’ earlier in the disease trajec-
tory relative to the point at which patients became eligible. Profes-
sionals also anticipated that patients/relatives may be concerned
about forgoing dialysis. This informed refinements to the presenta-
tion of the trial arms, whilst issues less amenable to change (e.g. eli-
gibility criteria) became focal points for the ‘real-time’ investigation.
The ‘real-time’ investigation confirmed that recruiters were reluc-
tant to approach patients with ‘future-treatment-plans’, which was
addressed through specific training/guidance disseminated early
on. Unanticipated issues also arose: patients generally held prefer-
ences for conservative care, although audio-recorded recruitment
discussions indicated this could be shaped by recruiters’ informa-
tion provision. Communication-related feedback/training and guid-
ance around approaching was delivered iteratively, coinciding with
improved recruitment per site/month over time.
Conclusion: Combining pre-trial and ‘real-time’ qualitative research
can provide an effective means of optimising, through a blend of
pre-emptive and responsive actions.
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Introduction: Trials of complex interventions typically include partici-
pant and researcher contacts for process and outcome measurement.
Relationships develop but their interaction with trial interventions,
procedures and outcomes has received little attention. Our aim was
to examine how researcher-participant relationships contributed to
the overall findings of the Game of Stones randomised feasibility trial
for weight loss in men.
Methods: 105 men with obesity were randomised at two Scottish
sites to three groups: text messages with financial incentives (SMS+I),
text messages (SMS only), and waiting list control. Weight, behav-
iours and acceptability outcomes were assessed by a site researcher
at 3, 6 and 12-month face-to-face appointments (intervention
groups) and 12 months only (control). The same researchers con-
ducted qualitative interviews at 3 months (n=51/55; intervention
groups only) and at 12 months (n=33/78; all groups). Qualitative, re-
tention and survey acceptability data were analysed thematically
with matrices constructed by trial group, guided by the Framework
approach.
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and trial outcomes were: valuing continuity of relationships with re-
searchers; a trusting non-judgemental rapport, feeling listened to
and supported. Some expressed disappointment with brief assess-
ments at 6 months (no qualitative interview) and with researcher dis-
continuity when assessor blinding was assessed. More men in the
control group (83%) attended at 12 months: SMS only (79%); SMS+I
group (64%). Retention related themes were: not wanting to disap-
point the good lad/nice lass researchers, the potential for weight-
gain-shame, research altruism and understanding science.
Conclusion: Participant-researcher relationships can have positive
and negative consequences for a trial and supportive accountability
was evident. Consideration of relationships in trial design and evalu-
ation is important because there may be unintentional interactions
between the intervention, outcomes, qualitative interviews, engage-
ment or retention strategies. This has within and beyond trial impli-
cations, including how interventions are translated, implemented
and sustained in practice.PS9D
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Introduction: MRC guidelines for the development and evaluation of
complex interventions identify the importance of process evaluation
in this cycle. Moreover, recent addition has stressed the relevance of
theoretically informed evaluation; realist evaluation is one such the-
oretically informed approach which is popular in applied health
research.
FinCH is a multi-centre cluster randomised controlled trial which
evaluates the “Guide to Action Care Home” (GtACH) fall prevention
programme in care homes. FinCH has recruited more than 1500 par-
ticipants across 50+ sites, a realist evaluation in 6 settings has consid-
ered the delivery of GtACH.
Methods: The process evaluation has incorporated observation of
training, observation of implementation, stakeholder interviews
(managers, staff, residents), and staff focus groups. Outcome data re-
lating to falls and injury has also been reviewed.
Results:
Context-mechanism-outcome (CMO) configurations have been gen-
erated to illustrate those circumstances and individual/organisational
responses which enable or inhibit GtACH. CMOs which are repeated
across multiple sites are identified.
Discussion: Despite philosophical foundations which might suggest
otherwise, authors have debated the potential for “realist randomised
controlled trials” and have advocated the use of realist methods in
the development/evaluation cycle.
The FinCH experience has exposed a number of areas where realist
methods and randomised controlled trials might sit uneasily.
The iterative nature of sampling in realist evaluation might be com-
promised by randomisation – the realist wants to carefully select
sites so as to explore certain contexts, randomisation might not serve
this. Realists also want to complete data collection and analysis prior
to commencing a new site, trial recruitment opportunities might not
facilitate this.
Realists might value early release of outcome data to support CMO
generation, trial protocols might not allow this.
Realist methods have lots to offer in understanding complex inter-
ventions, their delivery alongside randomised controlled trials is pos-
sible but requires significant planning and preparation.PS9D
- O4 Experiences of providing and receiving sham treatment – the
LiTEFORM trial (A Randomised Controlled Trial of the Clinical and
Cost Effectiveness of Low Level Laser in the Management of Oral
Mucositis in Head and Neck Cancer Irradiation)
Nikki Rousseau1, Lyndsay Lindley1, Tim Rapley2, Holly Fisher1, Linda
Sharp1, Jenn Walker1, Janet Wilson1, Jo Patterson3, Mike Nugent3
1Newcastle University, Newcastle upon Tyne, United Kingdom;
2Northumbria University, Newcastle upon Tyne, United Kingdom; 3City
Hospitals Sunderland NHS Trust, Sunderland, United Kingdom
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Introduction: Delivery of sham treatment of non-pharmacological
medical technologies may be invasive and arduous for patients. Add-
itionally, procedures to maintain blinding of those delivering the inter-
vention can be complex and demanding. The LiTEFORM trial was a
double blind randomised controlled trial of Low Level Laser therapy
(LLLT) in the management of oral mucositis in patients undergoing
radiotherapy for head and neck cancer. An embedded qualitative study
aimed to explore patient and health professional perspectives and ex-
periences of trial participation, including of sham treatment.
Methods: Participants attended for LLLT treatment three times a week,
timed to coincide with radiotherapy treatment. LLLT took about 30 mi-
nutes, with the experience being comparable to a dental examination.
Blinding was achieved with the use of randomly allocated sham/active
settings on the device, and special glasses for both patients and those
administering the LLLT. Qualitative interviews were conducted with
staff and with patients shortly after recruitment and at follow up, and a
sample of recruitment conversations were recorded.
Timing of potential results: Recruitment to the trial is complete, data
collection is now in the follow up phase and analysis will be
complete by October. Preliminary results suggest that the sham
treatment arm did not limit willingness of patients to participate, and
that patients felt that even a placebo effect was worth having. How-
ever sham treatment was associated with challenges for patients and staff
and some patients cited the possibility that they might be receiving sham
treatment as a factor in their decision to discontinue LLLT.
Potential relevance and impact: Ethical and practical concerns limit
the use of sham treatment arms in non-pharmacological studies.
Relatively little is known about experiences of sham treatments. Find-
ings from this study will help other researchers to anticipate and
overcome challenges and may lead to more robust evaluations of
non-pharmacological health technologies.PS9D
- O5 Unique challenges and proposed solutions for designing and
conducting pilot and feasibility work to optimise surgical trials
Katherine Fairhurst1, Shelley Potter1, Jane Blazeby1, Carrol Gamble2, Kerry
Avery1
1Centre for Surgical Research & Medical Research Council (MRC)
ConDuCT-II (Collaboration and innovation for Difficult and Complex
randomised controlled Trials In Invasive procedures) Hub for Trials
Methodology Research, Bristol Medical School, Department of
Population Health Sciences, University of Bristol, United Kingdom;
2Department of Biostatistics & Medical Research Council (MRC) NWHTMR
(North West Hub for Trials Methodology Research), University of
Liverpool, United Kingdom
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Introduction: The value of robust pilot and feasibility studies (PFS) to
inform RCTs in surgery is increasingly recognised by funders. Surgical
PFS, however are relatively rare, sub-optimal in design and remain
poorly reported and disseminated. Qualitative work is needed to ex-
plore the challenges and barriers to performing surgical PFS and con-
sider solutions to improve research practice.
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involved in designing, funding, conducting and publishing PFS for
surgical trials in the UK. Semi-structured interviews performed face-
to-face or by telephone using a topic guide, explored experiences
and perceptions of surgeons, methodologists, funders and journal
editors, around challenges and barriers to undertaking PFS in sur-
gery. A thematic approach to data analysis was performed in an it-
erative and cyclical process as interviews were completed, until no
new themes emerged and/or established themes ceased to evolve.
Results: Of 33 contacted, 27 (81%) participants consented and were
interviewed in 3 iterative phases: 11 (40%) surgeons, 16 (60%) experi-
enced trial methodologists (mean duration 58minutes, range 27-101).
Three quarters (20, 74%) also had current/recent experience on fund-
ing body panels. Both surgeons and methodologists acknowledged
PFS as vital to address the multiple challenges unique to surgical tri-
als. In contrast to methodologists, surgeons valued PFS more in prag-
matic terms (e.g. for gaining main trial funding) and methodological
conceptualisations of the types/purpose of PFS were rarely acknowl-
edged. Both groups identified current methodology (e.g. access to
CTUs)/funding infrastructure as an obstacle to efficient and timely
completion of PFS. Proposed improvements include accessible,
funder-endorsed guidance, wider dissemination of PFS findings
through efficient funder-driven reporting systems, and methods for
enhancing surgeon/methodologist collaborations.
Discussion: Differences in understanding exist regarding the purpose
and value of PFS for optimising surgical trials. Educating surgeons
about PFS and developing guidance to address the unique chal-
lenges of PFS to optimise surgical trials are needed.
PS10A
- O1 “I was meaning to read that, but…” – An international
qualitative study of how time-poor trialists choose their
recruitment strategies
Heidi Gardner, Shaun Treweek, Katie Gillies
University Of Aberdeen, Aberdeen, United Kingdom
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Introduction: Participant recruitment to trials is challenging. To date
research has focussed on recruitment once the trial has started, ra-
ther than planning strategies to support it e.g. developing informa-
tion leaflets with user feedback. We aimed to explore if people
involved with participant recruitment have explicit strategies, and if
so, how these are developed, and if not, what barriers prevent effect-
ive planning.
Methods: Design: One-to-one qualitative semi-structured interviews.
Data were analysed using a framework approach, themes were linked
through comparison of data within and across stakeholder groups.
Participants: 23 trialists; 11 self-identifying as ‘Designers’; those re-
sponsible for designing recruitment methods, and 12 self-identifying
as ‘Recruiters’; those who recruit participants. Interviewees’ experi-
ence with interventions, clinical areas, and recruitment expertise
were diverse.
Setting: UK NHS primary, secondary and tertiary-care sites involved in
trials, academic institutions (UK, the Netherlands, Canada) and con-
tract research organisations supporting pharmaceutical companies
(UK, South Africa, Italy).
Results: To varying degrees, respondents had prospective strategies
for recruitment. These were never explicitly based on evidence of re-
cruitment benefit.
Two main themes encapsulated barriers to strategy development:
1)Timing of grant applications; time-pressures due to tight deadlines
often result in rushed planning followed by an ‘amendment cascade’
after recruitment commences.
2)Research governance; trialists are often over-burdened with admin-
istrative tasks resulting from this amendment cascade.Themes relating to the types of environments needed to facilitate
successful recruitment also emerged; communication and
relationship-building within and across teams involved in multi-
centre trials; recruitment support, and trialists’ workload.
Discussion: Respondents from all countries considered limited prep-
aration times and disproportionate approvals processes as major
structural challenges to recruitment planning. Poor planning is a mis-
take that trial teams live with throughout the trial. Effective recruit-
ment requires strategies to increase the time available for trial
planning, as well as access to evidence-based strategies that can be
straightforwardly implemented.PS10A
- O2 Do investigator meetings improve recruitment into clinical
trials? – A retrospective review of data from nine trials
Eleanor Mitchell, Garry Meakin, Kirsty Sprange, Peter Godolphin
Nottingham Clinical Trials Unit, University of Nottingham, Nottingham,
United Kingdom
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Introduction: Clinical trials often fail to recruit to time and target. A
study reviewing strategies to enhance recruitment into clinical trials
reported that holding meetings with collaborators is common, offer-
ing opportunities for sites to network, receive trial updates, re-train,
and share good practice with other sites. Our aim was to investigate
the impact of an investigator meeting upon recruitment.
Methods: We compared recruitment and investigator meeting data
from nine clinical trials managed by Nottingham Clinical Trials Unit,
recruiting between 2014-2018. Sites were eligible if UK-based and open
to recruitment at least 8 weeks before and after the meeting. Data was
collected using a data collection form and from trial databases.
Mixed-effects models were fitted with 16 weeks of recruitment data
per site to estimate the change in recruitment after an investigator
meeting. Models were fitted for all eligible sites, and only for sites
that attended their investigator meeting.
Results: Most trials recruited adults only (6/9, 67%) with a median
sample size of 269 (1st quartile: 180, 3rd quartile: 517). Meetings oc-
curred throughout the year with at least one in each quarter. The
nine trials included 121 sites, 81 were eligible of which fifty-nine
(73%) attended their investigator meeting.
There was insufficient evidence to suggest that holding an investiga-
tor meeting increased recruitment (weekly recruitment increase per
site: 0.07, -0.13 to 0.28). For the 59 sites that attended the investiga-
tor meeting, the increase in recruitment was marginally higher
(weekly recruitment increase per site: 0.10, -0.17 to 0.37).
Discussion: Investigator meetings may improve recruitment in the
eight-week period thereafter, with sites that attended seeing one
additional participant randomised per 10 sites p/week. However, vari-
ability around this estimate may suggest the result is due to chance.
A larger study including more trials as well as looking at costs would
be useful to investigate further.PS10A
- O3 SWATs at scale: meta-analysis of the results of the first co-
ordinated programme of SWATs exploring improvements to
patient information in trials
Vichithranie Madurasinghe1, Peter Knapp3, Sandra Eldrige1, Peter Bower2,
on behalf of the START Group
1Queen Mary University London, London, United Kingdom; 2The
University of Manchester, Manchester, United Kingdom; 3University of
York, York, United Kingdom
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for recruitment to trials is poor. Studies-within-a-trial (SWATs) represent
a rigorous method of testing recruitment strategies and improving the
evidence-base. The recent NIHR HTA SWAT funding mechanism was a
welcome stimulus. However, rapidly and rigorously testing recruitment
interventions requires a co-ordinated effort to deliver SWATs across
multiple studies. Here, we report the completion of the first co-
ordinated SWAT programme (START), funded by the MRC.
Methods: We identified a recruitment intervention of high priority
for testing - patient information sheets optimised by a process of re-
design and testing with patients. We recruited 8 trials to test the re-
cruitment intervention using SWAT methodology. We meta-analysed
the data to assess the overall impact on recruitment rates, and to ex-
plore the degree to which effectiveness varied over different trials
Results: 8 trials were recruited from 2014, but only 7 actually deliv-
ered data, with one trial reporting two separate comparisons. These
were a mix of trials in adults, including both screening and treat-
ment, and physical and mental health. The final data set was not de-
livered until 2019. Meta-analysis of 28,476 patients across 7
comparisons showed that optimised patient information sheets were
associated with an effect of odds ratio = 1.03 (95% CI 0.90 to 1.19).
Other outcome measures (responding positively to an invitation, re-
tention) will be presented at the conference.
Discussion: Optimised patient information sheets were not associ-
ated with improved recruitment. The MRC START programme
showed that co-ordinated programmes of SWATs are feasible, al-
though there are major challenges to recruiting trials quickly and en-
suring that data are delivered and analysed in a timely fashion to
inform decision-making. We discuss the implications of the START
programme for the next phase of SWAT development and delivery.
PS10A
- O4 Evaluation of the validity and reliability of the DevPIC tool for
measuring quality of informed consent discussions during trial
recruitment
Julia Wade1, Elka Humphrys2, Alba Realpe1, Jenni Burt2, Miss Daisy
Gaunt1 , OPTiMISE Study group2,3, QuinteT research group1
1University of Bristol, Bristol, United Kingdom; 2University of Cambridge,
Cambridge, United Kingdom; 3University of Oxford, Oxford, United
Kingdom
Trials 2019, 20(Suppl 1):PS10A
Introduction: Evidence suggests that discussion is essential for effect-
ive information provision for informed consent during trial recruitment.
Measures to evaluate information provision assess recruiter information
provision or patient information recall of information but not the qual-
ity of the interaction or evidence of patient understanding emerging
during discussion. The DevPIC tool assesses the quality of information
provision as evidenced in recruitment consultations and includes evalu-
ation of patient contributions during the interaction. Initial evaluation
of DevPic shows promising validity and reliability applied to an initial
set of consultations from secondary care trials.
We are proposing to evaluate the validity and reliability of the Dev-
PIC applied to audio recordings of trial recruitment consultations in
the OPTiMISE trial within primary care in collaboration with col-
leagues not involved in the original tool development. It is part of a
programme of work to determine whether it is a practical method to
evaluate informed consent in recruitment conversations.
Methods: This is a mixed methods study. 18 primary care consulta-
tions from OPTIMISE will be analysed using both the published ver-
sion of the PIC and a parallel thematic analysis. Findings from the
two analyses will be used to establish a coding manual to guide ap-
plication of the measure. This coding manual will be applied in
evaluation of a further set of consultations sampled from a pool of
60. Findings will report the feasibility, validity, reliability and stability
of the tool.Timing of potential results and potential relevance: Findings re-
ported in October 2019 will report on validity and reliability and how
the measure can be used to evaluate the quality of informed consent
discussions during recruitment to trials and potential future applica-
tion to evaluate recruiter training.PS10A
- O5 Why do patients take part in research? An overview of
systematic reviews, and mapping to theory and trial recruitment
research
Peter Knapp1, Rebecca Sheridan2, Petr Bower3, Adwoa Parker2, Jackie
Martin-Kerry2, Joanna Hudson4
1University Of York & The Hull York Medical School, United Kingdom;
2University of York, United Kingdom; 3University of Manchester, United
Kingdom; 4King's College London, United Kingdom
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Introduction: Understanding why people take part in health research
is critical to improve trial efficiency and generalisability. The aim of
this overview of systematic reviews was to identify psychosocial de-
terminants of participation and map them to psychological theory
and empirical trial recruitment research, to identify effective strat-
egies to increase participation.
Methods: Qualitative and quantitative systematic reviews were iden-
tified systematically. Methodological quality was rated using AMSTAR
and poor quality reviews were excluded. Psychosocial barriers and fa-
cilitators were coded to psychological theory (Theoretical Domains
Framework) and empirical trial recruitment research (interventions
subjected to SWAT evaluation and included in Treweek et al, 2018,
Cochrane review).
Results: We included 22 systematic reviews (345 primary studies),
covering a wide range of populations and settings. We identified five
groups of facilitators, of which three were dominant (potential for
personal benefit; altruism; trust) and relevant across research setting
and design. We identified nine groups of barriers, which were more
dependent on the particular study (context, population and design).
Two determinants (participant information; social influences) were
found to be both barriers and facilitators. Barriers and facilitators
could be coded to the Motivation and Opportunity components of
the Theoretical Domains Framework; only one was coded to a Cap-
ability component. There was limited overlap between psychosocial
determinants and empirical trial recruitment research, and some bar-
riers and facilitators had not been tested at all.
Discussion: Our synthesis of the main psychosocial determinants of
research participation is useful knowledge for clinicians, researchers
and research ethics organisations. Identifying barriers and facilitators
should make it possible for adjustments to be made to trial design
to anticipate them. Mapping determinants to theory offers the po-
tential for greater understanding of decision-making and opportun-
ities for intervention design. The current lack of overlap between
some psychosocial determinants and empirical research also offers
the potential to guide intervention development.PS10B
- O1 Health informatics (HI) innovations in randomised trials and
clinical cohorts - Identification, screening, stratified care and data
collection during primary care consultations
Simon Wathall1,2, Nadine Foster1, Jonathan Hill2, Kika Konstantinou2,3,
Sarah Lawton2, Sara Muller2
1Keele Clinical Trials Unit, Keele University, UK; 2Primary Care Centre
Versus Arthritis, Research Institute for Primary Care & Health Sciences,
UK; 3Midlands Partnership NHS Foundation Trust, Staffordshire, UK
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main challenges for clinical research, particularly for primary care stud-
ies undertaken at point-of-care where consultation time is pressured.
The Health Informatics (HI) team at Keele Clinical Trials Unit (CTU)
has developed tools which are embedded into GP clinical IT systems,
to facilitate the conduct of trials and cohort studies in real-time GP
consultations.
Methods: HI clinical system protocols were developed to efficiently util-
ise patients’ electronic primary care medical record to automate pro-
cesses such as patient identification and eligibility screening whilst
remaining as unobtrusive as possible for the clinician end-user.
Protocols and templates are developed to embed stratified care tools
into the consultation to guide treatment decision-making, and auto-
mate coding of patient eligibility, consent and outcome/trial data
into patients’ primary care records.
Results: Automated coding facilitates efficient and accurate data re-
cording for a number of clinical research studies. Regular audits allow
the level of GP engagement and efficiency with recruitment and the
study intervention to be assessed. Three exemplar studies will be
presented, all of which had bespoke point-of-care HI templates that
have facilitated research delivery in busy GP consultations.
Arthritis Research UK funded PMR Cohort Study (Polymyalgia Rheu-
matica – a low incidence condition):
386 GP practices, suitable for invitation n=739
NIHR HTA funded SCOPiC Trial (SCiatica Outcomes in Primary Care):
42 GP practices, HI protocol fires n=19,375, eligible n=3,963, suitable
for invitation n=2,677
NIHR PGfAR funded STarT MSK Pilot trial:
8 GP practices, HI protocol fires n=3,063, eligible n=1,653, suitable for
invitation n=1255.
Discussion: Utilising GP clinical IT systems to embed HI research tem-
plates has resulted in efficient recruitment to randomised trials and
cohort studies. Consideration needs to be given to clinical coding,
training of clinical end-users, consultation styles and auditing system
usage behaviour to ensure these HI solutions are successful.
PS10B
- O2 Utility of routine electronic health records used as outcome
measures in UK randomised trials: a systematic review
Sharon Love1, Sarah Lensen1, Archie Macnair1, Graham Powell3, Victoria
Yorke-Edwards1, Elizabeth Williamson2, Matthew R Sydes1, James
Carpenter1,2
1MRC Clinical Trials Unit at UCL, London, United Kingdom; 2The London
School of Hygiene and Tropical Medicine, London, United Kingdom;
3University of Liverpool, Liverpool, United Kingdom
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Introduction: There is a wave of interest in, and resources for,
unleashing the potential for routine electronic health records (EHR)
to support medical research. In the context of randomised controlled
trials, EHR data can be used to supplement or replace established
data collection procedures. We undertook a systematic review of tri-
als accessing EHR data in the UK, to characterise these trials and the
ways they are using (or planning to use) these data.
Methods: Potential sources of EHR were defined as health databases/
sets held by national organisations, registries or audits that are not
involved in direct patient care; such as CPRD and NHS Digital. A list
of all trials accessing these EHR between 2013-2018 was developed
through screening public release registers, database websites, and
direct contact with database staff. Trials were eligible if the released
data was pertaining to individuals randomised to a trial; for example,
data access solely to identify eligible patients for recruitment was ex-
cluded. Information was sought on trial characteristics (e.g. sample
size, disease area), the EHR data received (registry source, datasets
accessed) and how the data was used, from all available sources (e.g.
publication, trial websites). Data were extracted onto a piloted formand entered into a Macro database. All screening and data extraction
was undertaken in duplicate, independently with analyses done in
Stata. PROSPERO: CRD42019123088.
Timing of Potential Results: Data extraction ongoing Mar-2019 to
Jun-2019. Results available from Aug 2019.
Potential Relevance and Impact: There are many efforts and re-
sources directed towards increasing the accessibility and quality of
“big data” in healthcare, however the extent to which UK trials are
using this data has not been described. This review will characterise
the current use of EHR in UK trials to supplement or replace trial out-
come data, and explore the scope for use in future trials.
PS10B
- O3 Routinely-collected hospital datasets can be used to identify
endpoints predictive of overall survival outcomes in randomised
controlled trials (RCT): a prostate cancer study within the
STAMPEDE protocol (NCT00268476)
Harriet P Mintz1,7, Helen M Parsons1, Prashant Patel2,7, Claire Amos3,
Rachael Brannan4, Christopher Brawley3, Joanna Calvert3, Melissa R
Gannon5, Luke Hounsome4, Fiona Ingleby3, Sean McPhail4, Mahesh KB
Parmar3, Mary Rauchenberger3, Haiyan Wu6, Matthew R Sydes3, Nicholas
D James2,7
1Warwick Medical School, University of Warwick, Coventry, United
Kingdom; 2Institute of Cancer and Genomic Sciences, University of
Birmingham, Birmingham, United Kingdom; 3MRC Clinical Trials Unit at
UCL, Institute of Clinical Trials & Methodology, UCL, London, United
Kingdom; 4Public Health England, London, United Kingdom;
5Department of Health Services Research and Policy, London School of
Hygiene and Tropical Medicine, London, United Kingdom; 6HDR UK, UCL
Institute of Health Informatics, London, United Kingdom; 7University
Hospitals Birmingham NHS Foundation Trust, Birmingham, United
Kingdom
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Introduction: Validated endpoints that appear earlier, and are more
information rich than overall-survival (OS), are desirable for oncology
RCTs e.g. progression, metastases, failure-free survival and skeletal-
related events (PFS, MFS, FFS, SRE). We present work, embedded in a
large multi-arm multi-stage trial, STAMPEDE, using routine data to
test alternative RCT analyses.
Methods: An algorithm using routine data (Hospital Episode Statis-
tics: HES) was developed using iterative training and validation, creat-
ing a HES-derived endpoint predicting OS benefits. Intense note
review was undertaken during training, (N=47) and the HES-derived
endpoint was compared to the STAMPEDE-endpoints, which was also
undertaken during validation (N=46). Standard survival analysis
methods compared interventions (+/-docetaxel) (N=93). Multi-site
validation is near completion (N=2,949).
Results: The algorithm was based on HES-derived cancer-related
event activity, over 8-week time periods. We could not reliably iden-
tify individual endpoint events but identified a composite activity-
based endpoint. During validation (N=46), 36/46 patients experi-
enced a confirmed MFS, FFS or PFS event, reported in the trial. In 30/
36, the HES algorithm corresponded to at least one trial endpoint, in-
cluding 14/33 FFS, 23/29 PFS and 22/28 MFS events. Docetaxel ef-
fects were similar to the traditional STAMPEDE endpoints (N=93)
with the HES-activity endpoint: HES-HR=0.59 (95%CI: 0.33-1.03);
STAMPEDE-FFS-HR=0.51 (95%CI: 0.29-0.89); based upon 66/93 HES
and 67/93 STAMPEDE-FFS events occuring. The final multi-site valid-
ation on 2,949 patients will be presented at the meeting.
Discussion: Although traditional endpoints could not be identified,
we developed a novel HES-activity-based endpoint: “hospital activity-
free survival”. This identified trial events and some unreported events
and enabled estimation of treatment effects. If validated, routine
data is feasible for analysis, reducing costs, resources, and patient/
clinician follow-up burden, increasing efficiency. Our novel activity-
Trials 2019, 20(Suppl 1):579 Page 140 of 141based efficacy indicator may be desirable to patients (e.g. identifying
burdensome healthcare interactions) and could correlate with health-
related quality-of-life; further work is investigating this.
PS10B
- O4 Getting animated about routine data: Using animations to
inform and engage future trial participants about linkage to
routinely collected data to aid recruitment
Fiona Lugg-widger, Lianna Angel, Peter Gee, Jeremy Segrott, Mike
Robling
Cardiff University, United Kingdom
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Introduction: The use of routinely held health, social care and other
public health records has become an important feature of the re-
search landscape and offers significant potential to advance know-
ledge across a wide range of clinical and public health domains. The
involvement and engagement of this topic input with the public is
key if we are to be successful in recruiting to studies using routine
data/data linkage.
The aim of this work is to co-produce with members of the public an
‘animation package’ that researchers can use to increase public (in-
cluding future trial participants) understanding of and engagement
in research using routine data including aiding recruitment.
Methods: We have developed an animation by working with a group
of young mothers and a group of 14-25 year olds in the South Wales
area. The next step is to test and improve the animation through
wider engagement with stakeholders including users of and receivers
of the animation package. A number of stakeholder groups have
been formed: 1) those who recruit participants; 2) Trial managers; 3)
study lay representatives and 4) members of the public. They will
provide input on their understanding of the key concepts described
in the animation, its utility as a trial recruitment tool to enable in-
formed consent when using routine data and the best format/media
for its use over the long-term.
Timing of Results: The animation package will be finalised in Au-
tumn 2019 and the feedback, utility and final product will be
presented.
Relevance & Impact: The outputs from this work will be available
and accessible for researchers to use as part of the information pro-
vided at study registration to facilitate recruitment when using rou-
tinely collected data and data linkage.
PS10B
- O5 Does regulation of routine data sharing pose a risk for
Individual Patient Data (IPD) meta-analysis? A review of some key
challenges in a UK context
Michael Robling, Fiona Lugg-Widger, Fergus Macbeth, Jo Smith, Richard
Adams
Cardiff University, Cardiff, United Kingdom
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Introduction: Maximising primary research outputs through greater
sharing of trial data is a key element of the Open Research agenda.
Similarly, UK policy interest in routine data includes greater use of
routine data in trials. Meanwhile key providers of routine data (eg
NHS Digital) have modified their approaches to data sharing driven
by regulatory requirements. But, how well do these developments sit
alongside each other to promote access? We focus on use of shared
routine data for individual participant data (IPD) meta-analyses. We
aim to identify current challenges and where these may be address-
able through organisational change.
Methods: Using a case study approach we sampled studies from our
Centre that sourced routine data and plan to share individual level
data further. This includes both secondary analysis and IPD meta-
analysis. For each we clarify how legal requirements and organisa-
tional governance serves to support or hinder further sharing ofroutine data. We identify what options exist for researchers intending
to contribute trial data and apparent pros and cons of these ap-
proaches. We talk with data providers and investigators to elicit their
understanding of the issues and potential solutions.
Timing of potential results: Completed case studies will be ready for
presentation in autumn 2019.
Potential relevance and Impact: Mapping organisational and regula-
tory challenges to IPD for trials using routine data will identity weak-
nesses in the evolved architecture for data sharing. This will help
researchers better plan for data sharing (eg drafting participant infor-
mation sheets, primary data sharing agreements) including alterna-
tive sources of primary data (eg hospital sites rather than data
centres). Current experiences of data sharing for IPD involved re-
searcher uncertainty, high access costs and significant delays in ac-
cess. For IPD still to be an effective and deliverable tool under
current regulations requires dialogue with providers and regulators,
acknowledging barriers and developing solutions.
PS10C
- O1 Estimating treatment effects in the presence of informative
missingness
Ruwanthi Kolamunnage-Dona
University of Liverpool, United Kingdom
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Introduction: In many clinical trials with longitudinal outcome data,
a common situation is where some patients withdraw or dropout
from the trial before completing the measurement schedule but the
dropout may be non-ignorable or informative. However, the standard
methods for analysing longitudinal outcome data ignore the reasons
for dropout, which could result in a biased comparison between the
treatment groups.
Methods: Joint modelling of longitudinal and event-time outcome
processes has gained its popularity in last decade as they yield more
accurate and precise estimates. However, adopting this framework in
clinical trials has been limited. We explore the impact of informative
dropout on the evaluation of treatment effect in the MAGNETIC trial;
the largest randomised placebo-controlled study to date comparing
the addition of nebulised magnesium sulphate to standard treatment
in acute severe asthma in children.
Results: The primary outcome of the MAGNETIC trial was Yung
Asthma Severity Score (ASS). It was measured at baseline and 20, 40,
60, 120, 180 and 240 minutes following randomisation, and the
amount of missingness was over 5%. The reasons for missingness
were sometimes clearly related with study withdrawal due to good
or poor prognosis of the child, but in many instances these reasons
were unclear. The results from simple approaches such as complete
case analysis and the proposed joint modelling are compared in the
context of evaluating the treatment effect.
Discussion: Ignoring the informative nature of the missing outcome
data could result in inaccurate estimation of treatment effect in clin-
ical trials. We emphasise the importance of undertaking an appropri-
ate statistical analysis accounting for such missing outcome data. The
joint modelling is proposed as a general approach for evaluating the
sensitivity of conclusions to assumptions regarding missing data in
clinical trials with longitudinal outcomes.
PS10C
- O2 Reference-based multiple imputation for data missing not-at-
random in cost-effectiveness analysis
Baptiste Leurent1, Manuel Gomes2, Suzie Cro3, Nicola Wiles4, James
Carpenter1,2
1London School of Hygiene and Tropical Medicine, London, UK;
2University College London, London, UK; 3Imperial College London,
London, UK; 4University of Bristol, Bristol, UK
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lyses (CEA) of randomised trials, and are often addressed under the
‘Missing-at-random’ (MAR) assumption. However, this assumption is
untestable and sensitivity analyses are required to assess the implica-
tions of departures from MAR. Reference-based multiple-imputation
(MI) is an attractive approach which formulates the departures from
MAR by imputing from a specific reference group. For example, a
plausible not-at-random mechanism in a placebo-controlled trial
would be to assume that participants in the experimental arm who
drop out and stop taking their treatment, have similar outcomes to
those in the placebo arm.
Methods: We extended the reference-based MI approach to jointly
accommodate missing cost and effectiveness data in a multivariate
MI framework, implemented in Stata. The approach allows for differ-
ent missing data assumptions for cost versus effectiveness endpoints.
We illustrated the approach using data from the CoBalT trial, which
evaluated the cost-effectiveness of cognitive behavioural therapy
(CBT) in addition to usual care for primary care patients with
treatment-resistant depression.
Results: The trial enrolled 469 participants and 101 (22%) had miss-
ing cost or effectiveness (QALY). Under MAR, the difference in QALY
between the CBT and usual care arm was 0.088 (95%CI: 0.035 to
0.142), and difference in cost £996 (£802 to £1,190). When we as-
sumed that patients in the active arm behaved similarly to those in
the control arm after dropping-out, the differences were reduced to
0.079 (0.025 to 0.134) and £813 (£630 to £996) respectively, but CBT
remained more cost-effective than usual care (at £20,000/QALY). This
was confirmed under a range of other missing data assumptions, in-
cluding ‘baseline-mean-carried-forward’ which assumed participants
jumped back to the baseline mean level, after drop-out.
Discussion: This study extends reference-based MI to trial-based CEA,
and illustrates its flexibility and accessibility for conducting sensitivity
analysis to departures from MAR in this context.PS10C
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Introduction: Missing data are an inevitable challenge in Rando-
mised Controlled Trials (RCTs). Methodological guidance recom-
mends that studies should undertake sensitivity analyses which
recognise that data may be ‘missing not at random’ (MNAR), and
these can be informed by elicited expert opinion. However, few pub-
lished trials plan and undertake the required elicitation exercises. The
aim of this research is to provide a framework that anticipates and al-
lows for MNAR data in the design and analysis of clinical trials.
Methods: The framework was developed and critically examined
within the POPPI trial, which investigated whether a preventive, com-
plex psychological intervention, commenced early in ICU, would re-
duce the development of patient-reported post-traumatic stress
disorder symptom severity, and improve health-related quality of life.
In particular, we performed and used expert elicitation to frame sen-
sitivity analyses for the missing outcome data. This required address-
ing key practical challenges that arise when adopting this approach
in trials: the criteria for identifying relevant experts, the outcomescale for presenting data to experts, the appropriate representation
of expert opinion, and the evaluation of the elicitation results.
Results: The framework includes the following steps: defining the
scope of the elicitation exercise, developing the elicitation tool, elicit-
ing expert opinion about the missing outcomes, evaluating the elicit-
ation results, and analysing the trial data. For the POPPI trial, 113
experts were asked to participate in the elicitation exercise, providing
59 usable responses. The sensitivity analyses found that the results
from the primary analysis were robust to alternative MNAR mecha-
nisms, based on a range of pooled and individual expert opinion.
Discussion: Future studies can adopt this framework to embed ex-
pert elicitation within the design of clinical trials. This will provide
the information required for MNAR sensitivity analyses that examine
the robustness of the trial conclusions to alternative, but realistic as-
sumptions about the missing data.
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Introduction: The area under the curve (AUC) is used to summarise
longitudinal outcomes in RCTs. When follow-up time points are
(nominally) anchored to time zero by randomisation, within-person
missing data is easily handled. In the OPEN trial, comparing two sur-
gical options for men with ureteral stricture, additional outcome data
was collected at time points anchored to index surgery and/or re-
intervention that varied from participant to participant. Missing data
at these “floating” time points is more challenging to deal with.
Methods: In OPEN the primary outcome was the AUC of ICIQ col-
lected at fixed (baseline, 18, 24-months post-randomisation) and
floating time points (pre-surgery, 1-week post catheter removal, 3, 6,
9, 12, and 24-months post-surgery). The analysis strategies were: 1)
any available data (at least two ICIQ); 2) minimal data (one early and
one late ICIQ measure, extrapolating between observed time points);
3) multiple imputation (MI) at the participant level; 4) MI at time-
point using different auxiliary models for fixed and floating measures.
We used linear regression in Stata 15. Simulation work will assess the
statistical properties of each strategy.
Results: Participants were randomised to urethroplasty (108) or ure-
throtomy (112); 104 vs 93 participants had at least two ICIQ and 90
vs 69 had minimal data. The complete case estimate of difference in
AUC was -0.51 95% CI (-1.89, 0.87). For minimal data it was -0.36 95%
CI (-1.74, 1.02); MI at the participant level -0.33 95% CI (-1.74, 1.09);
MI at time-point level -0.69 95% CI (-2.11, 0.72).
Discussion: A range of analyses to deal with missing data in the
OPEN trial produced similar results with comparable precision. Our
simulation work is ongoing to explore how these approaches per-
forms in a range of scenarios.
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